{"PMC7541054": [["IntroductionIn infectious diseases and clinical microbiology, the term \u201ctoxin\u201d typically refers to molecules that are produced by microorganisms that may affect cells in the infected host.", [["cells", "ANATOMY", 161, 166], ["infectious diseases", "DISEASE", 15, 34], ["cells", "CELL", 161, 166], ["clinical microbiology", "TEST", 39, 60], ["infected host", "OBSERVATION", 174, 187]]], ["Knowledge surrounding toxin production and release, interaction with and entry into host target cells, mechanisms of action and of relevance, and clinical significance historically has been limited.", [["cells", "ANATOMY", 96, 101], ["cells", "CELL", 96, 101], ["host target cells", "CELL_TYPE", 84, 101]]], ["With increasing utilization of genomics and proteomics techniques, however, there is a greater understanding of microbial pathogenesis and their role in clinical disease.IntroductionThere is a spectrum of importance in detecting bacterial toxins for diagnostic purposes.", [["proteomics techniques", "TEST", 44, 65], ["microbial pathogenesis", "PROBLEM", 112, 134], ["clinical disease", "PROBLEM", 153, 169], ["bacterial toxins", "PROBLEM", 229, 245], ["diagnostic purposes", "TEST", 250, 269], ["increasing", "OBSERVATION_MODIFIER", 5, 15]]], ["Definitive diagnosis of some diseases requires toxin detection.", [["toxin", "PROTEIN", 47, 52], ["some diseases", "PROBLEM", 24, 37], ["toxin detection", "TEST", 47, 62], ["some", "OBSERVATION_MODIFIER", 24, 28], ["diseases", "OBSERVATION", 29, 37]]], ["Alternatively, for some diseases, the identification of an organism's toxin may help guide decision making, and for others, detection of a toxin provides little benefit.", [["some diseases", "PROBLEM", 19, 32], ["an organism's toxin", "PROBLEM", 56, 75], ["a toxin", "PROBLEM", 137, 144]]], ["Toxins from many clinically relevant bacteria exist that clinical microbiology laboratories do not routinely screen for, either because their detection would not yield actionable information or because their importance is not well understood; detection of these toxins in microbiology laboratories may be important for diagnostic purposes, patient management, infection prevention and control, or public health.", [["infection", "DISEASE", 360, 369], ["patient", "ORGANISM", 340, 347], ["patient", "SPECIES", 340, 347], ["many clinically relevant bacteria", "PROBLEM", 12, 45], ["clinical microbiology laboratories", "TEST", 57, 91], ["these toxins", "TEST", 256, 268], ["microbiology laboratories", "TEST", 272, 297], ["diagnostic purposes", "TEST", 319, 338], ["patient management", "TREATMENT", 340, 358], ["infection prevention", "TREATMENT", 360, 380]]], ["This article provides an overview of clinically important bacterial toxins, highlighting their history, disease epidemiology, pathogenesis, and clinical presentation and the management of toxin-associated infections, and finally, it discusses the usefulness of toxin detection.", [["infections", "DISEASE", 205, 215], ["toxin", "PROTEIN", 261, 266], ["clinically important bacterial toxins", "PROBLEM", 37, 74], ["pathogenesis", "PROBLEM", 126, 138], ["toxin-associated infections", "PROBLEM", 188, 215], ["toxin detection", "TEST", 261, 276], ["infections", "OBSERVATION", 205, 215]]], ["A summary of key toxins is provided in Table 1.Panton-Valentine leukocidin ::: Toxins Produced by Frequently Isolated Bacteria", [["Panton-Valentine leukocidin", "CHEMICAL", 47, 74], ["Panton-Valentine leukocidin", "SIMPLE_CHEMICAL", 47, 74], ["Isolated Bacteria", "PROBLEM", 109, 126], ["Bacteria", "OBSERVATION", 118, 126]]]], "f1bc4ef86fedbffa0c0ddd1e467e0d1e4ad3a7f9": [["IntroductionFor nearly 100 years, physicians and scientists have appreciated the unique immunological status of the brain.", [["brain", "ANATOMY", 116, 121], ["brain", "ORGAN", 116, 121], ["brain", "ANATOMY", 116, 121]]], ["The notion that the CNS is completely isolated from the periphery and lacks immune responses was supported by early experiments demonstrating a diffusion barrier between the blood and the brain and later by the lack of tissue graft rejection, the latter of which was proven incorrect (Barker and Widner, 2004) .", [["CNS", "ANATOMY", 20, 23], ["periphery", "ANATOMY", 56, 65], ["blood", "ANATOMY", 174, 179], ["brain", "ANATOMY", 188, 193], ["tissue graft", "ANATOMY", 219, 231], ["CNS", "ANATOMICAL_SYSTEM", 20, 23], ["blood", "ORGANISM_SUBSTANCE", 174, 179], ["brain", "ORGAN", 188, 193], ["tissue graft", "TISSUE", 219, 231], ["a diffusion barrier between the blood and the brain", "PROBLEM", 142, 193], ["tissue graft rejection", "PROBLEM", 219, 241], ["CNS", "ANATOMY", 20, 23], ["periphery", "ANATOMY_MODIFIER", 56, 65], ["blood", "ANATOMY", 174, 179], ["brain", "ANATOMY", 188, 193], ["tissue", "OBSERVATION", 219, 225], ["graft rejection", "OBSERVATION", 226, 241]]], ["The presence of the blood brain barrier (BBB), which isolates the central nervous system (CNS) parenchyma from circulating immune cells and antibodies, and the lack of identifiable lymphatics originally contributed to the designation of the CNS as an immune privileged site (Barker and Widner, 2004; Medawar, 1948; Wilson et al., 2010) .", [["blood brain barrier", "ANATOMY", 20, 39], ["BBB", "ANATOMY", 41, 44], ["central nervous system", "ANATOMY", 66, 88], ["CNS", "ANATOMY", 90, 93], ["parenchyma", "ANATOMY", 95, 105], ["immune cells", "ANATOMY", 123, 135], ["lymphatics", "ANATOMY", 181, 191], ["CNS", "ANATOMY", 241, 244], ["blood brain barrier", "MULTI-TISSUE_STRUCTURE", 20, 39], ["BBB", "MULTI-TISSUE_STRUCTURE", 41, 44], ["central nervous system", "ANATOMICAL_SYSTEM", 66, 88], ["CNS", "ANATOMICAL_SYSTEM", 90, 93], [") parenchyma", "TISSUE", 93, 105], ["circulating immune cells", "CELL", 111, 135], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 181, 191], ["CNS", "ANATOMICAL_SYSTEM", 241, 244], ["circulating immune cells", "CELL_TYPE", 111, 135], ["antibodies", "PROTEIN", 140, 150], ["the blood brain barrier (BBB)", "PROBLEM", 16, 45], ["circulating immune cells", "PROBLEM", 111, 135], ["antibodies", "TEST", 140, 150], ["identifiable lymphatics", "PROBLEM", 168, 191], ["blood brain", "ANATOMY", 20, 31], ["central", "ANATOMY_MODIFIER", 66, 73], ["nervous system", "ANATOMY", 74, 88], ["CNS", "ANATOMY", 90, 93], ["parenchyma", "ANATOMY_MODIFIER", 95, 105], ["circulating immune cells", "OBSERVATION", 111, 135], ["lymphatics", "OBSERVATION", 181, 191], ["CNS", "ANATOMY", 241, 244]]], ["The concept of immune privilege has been questioned (Carson et al., 2006; Galea et al., 2007) and has evolved to incorporates the neurovascular unit (NVU), the blood-cerebrospinal fluid (CSF) barrier, and the presence of CNS lymphatics that allow leukocyte egress (Aspelund et al., 2015; Louveau et al., 2015; Weller et al., 2009) .", [["neurovascular unit", "ANATOMY", 130, 148], ["NVU", "ANATOMY", 150, 153], ["blood", "ANATOMY", 160, 165], ["cerebrospinal fluid", "ANATOMY", 166, 185], ["CNS lymphatics", "ANATOMY", 221, 235], ["leukocyte", "ANATOMY", 247, 256], ["neurovascular unit", "MULTI-TISSUE_STRUCTURE", 130, 148], ["NVU", "CANCER", 150, 153], ["blood", "ORGANISM_SUBSTANCE", 160, 165], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 166, 185], ["CSF", "ORGANISM_SUBSTANCE", 187, 190], ["CNS lymphatics", "MULTI-TISSUE_STRUCTURE", 221, 235], ["leukocyte", "CELL", 247, 256], ["the blood-cerebrospinal fluid (CSF) barrier", "TEST", 156, 199], ["CNS lymphatics", "PROBLEM", 221, 235], ["immune privilege", "OBSERVATION", 15, 31], ["neurovascular", "ANATOMY", 130, 143], ["blood", "ANATOMY", 160, 165], ["cerebrospinal", "ANATOMY", 166, 179], ["fluid", "OBSERVATION", 180, 185], ["CNS", "ANATOMY", 221, 224], ["lymphatics", "OBSERVATION", 225, 235]]], ["The detection of small numbers of leukocytes, particularly memory T cells, within newly identified lymphatics and in the CSF, is in accord with reports that low numbers of T cells in the CNS promote normal neurological function, including processes involved in cognition (Kipnis et al., 2012; Schwartz and Kipnis, 2011) .", [["leukocytes", "ANATOMY", 34, 44], ["memory T cells", "ANATOMY", 59, 73], ["lymphatics", "ANATOMY", 99, 109], ["T cells", "ANATOMY", 172, 179], ["CNS", "ANATOMY", 187, 190], ["neurological", "ANATOMY", 206, 218], ["leukocytes", "CELL", 34, 44], ["memory T cells", "CELL", 59, 73], ["lymphatics", "MULTI-TISSUE_STRUCTURE", 99, 109], ["CSF", "GENE_OR_GENE_PRODUCT", 121, 124], ["T cells", "CELL", 172, 179], ["CNS", "ANATOMICAL_SYSTEM", 187, 190], ["leukocytes", "CELL_TYPE", 34, 44], ["memory T cells", "CELL_TYPE", 59, 73], ["T cells", "CELL_TYPE", 172, 179], ["The detection", "TEST", 0, 13], ["small numbers of leukocytes", "PROBLEM", 17, 44], ["memory T cells", "PROBLEM", 59, 73], ["low numbers of T cells", "PROBLEM", 157, 179], ["small", "OBSERVATION_MODIFIER", 17, 22], ["numbers", "OBSERVATION_MODIFIER", 23, 30], ["leukocytes", "ANATOMY", 34, 44], ["memory T cells", "OBSERVATION", 59, 73], ["lymphatics", "OBSERVATION", 99, 109], ["CSF", "ANATOMY", 121, 124], ["CNS", "ANATOMY", 187, 190], ["normal", "OBSERVATION", 199, 205], ["neurological function", "OBSERVATION", 206, 227]]], ["Nevertheless, the most common manifestation of neuroinfectious diseases is the recruitment of inflammatory cells which are critical to mediate local resistance to a variety of viral, bacterial, and parasitic organisms within distinct compartments of the CNS (see Table 1 for a list of CNS compartments targeted by neurotropic pathogens).", [["inflammatory cells", "ANATOMY", 94, 112], ["compartments", "ANATOMY", 234, 246], ["CNS", "ANATOMY", 254, 257], ["CNS compartments", "ANATOMY", 285, 301], ["inflammatory cells", "CELL", 94, 112], ["CNS", "ANATOMICAL_SYSTEM", 254, 257], ["CNS compartments", "MULTI-TISSUE_STRUCTURE", 285, 301], ["inflammatory cells", "CELL_TYPE", 94, 112], ["neuroinfectious diseases", "PROBLEM", 47, 71], ["inflammatory cells", "PROBLEM", 94, 112], ["viral, bacterial, and parasitic organisms", "PROBLEM", 176, 217], ["neuroinfectious diseases", "OBSERVATION", 47, 71], ["recruitment", "OBSERVATION_MODIFIER", 79, 90], ["inflammatory cells", "OBSERVATION", 94, 112], ["viral", "OBSERVATION", 176, 181], ["CNS", "ANATOMY", 254, 257]]], ["Multiple studies have highlighted the adverse consequences of immune exclusion and the importance of immune activity to control infections in the brain.", [["brain", "ANATOMY", 146, 151], ["infections", "DISEASE", 128, 138], ["brain", "ORGAN", 146, 151], ["Multiple studies", "TEST", 0, 16], ["immune exclusion", "TREATMENT", 62, 78], ["immune activity", "TREATMENT", 101, 116], ["infections in the brain", "PROBLEM", 128, 151], ["infections", "OBSERVATION", 128, 138], ["brain", "ANATOMY", 146, 151]]], ["Many of these responses are associated with alterations in the biology of resident neural cell populations which not only amplify protective activities but can also impact on neuronal survival and function and lead to life-threatening pathology (Streit et al., 2005) .", [["neural cell", "ANATOMY", 83, 94], ["neuronal", "ANATOMY", 175, 183], ["neural cell populations", "CELL", 83, 106], ["neuronal", "CELL", 175, 183], ["resident neural cell populations", "CELL_TYPE", 74, 106], ["neural cell populations", "OBSERVATION", 83, 106]]], ["The aim of this article is to consider the host-pathogen interactions that influence neurotropic infections and to review advances in understanding the innate and adaptive mechanisms that balance protective and pathological inflammation, which determine the outcome of CNS infection.IntroductionPrimary and Acquired Immune Deficiencies Associated with Susceptibility to CNS Infection There are numerous clinical approaches such as chemotherapies, bone marrow transplantation, or immunosuppressive drugs that interfere with overall immune function and predispose to neuroinfectious diseases (Britt et al., 1981) .", [["CNS", "ANATOMY", 269, 272], ["CNS", "ANATOMY", 370, 373], ["bone marrow", "ANATOMY", 447, 458], ["neurotropic infections", "DISEASE", 85, 107], ["inflammation", "DISEASE", 224, 236], ["CNS infection", "DISEASE", 269, 282], ["Susceptibility to CNS Infection", "DISEASE", 352, 383], ["neuroinfectious diseases", "DISEASE", 565, 589], ["CNS", "ANATOMICAL_SYSTEM", 269, 272], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 447, 458], ["neurotropic infections", "PROBLEM", 85, 107], ["pathological inflammation", "PROBLEM", 211, 236], ["CNS infection", "PROBLEM", 269, 282], ["Acquired Immune Deficiencies", "PROBLEM", 307, 335], ["CNS Infection", "PROBLEM", 370, 383], ["chemotherapies", "TREATMENT", 431, 445], ["bone marrow transplantation", "TREATMENT", 447, 474], ["immunosuppressive drugs", "TREATMENT", 479, 502], ["neuroinfectious diseases", "PROBLEM", 565, 589], ["CNS", "ANATOMY", 269, 272], ["infection", "OBSERVATION", 273, 282], ["Immune Deficiencies", "OBSERVATION", 316, 335], ["CNS", "ANATOMY", 370, 373], ["Infection", "OBSERVATION", 374, 383], ["numerous", "OBSERVATION_MODIFIER", 394, 402], ["bone", "ANATOMY", 447, 451], ["marrow transplantation", "OBSERVATION", 452, 474]]], ["The AIDS epidemic revealed that T cells protect the brain from neurotropic opportunistic pathogens such as Cryptococcus neoformans, Toxoplasma gondii, Mycobacterium tuberculosis, cytomegalovirus (CMV), and John Cunnigham (JC) virus (Bowen et al., 2016) .", [["T cells", "ANATOMY", 32, 39], ["brain", "ANATOMY", 52, 57], ["AIDS", "DISEASE", 4, 8], ["opportunistic pathogens", "DISEASE", 75, 98], ["Cryptococcus neoformans", "DISEASE", 107, 130], ["Toxoplasma gondii", "DISEASE", 132, 149], ["Mycobacterium tuberculosis", "DISEASE", 151, 177], ["cytomegalovirus (CMV), and John Cunnigham (JC) virus", "DISEASE", 179, 231], ["T cells", "CELL", 32, 39], ["brain", "ORGAN", 52, 57], ["Cryptococcus neoformans", "ORGANISM", 107, 130], ["Toxoplasma gondii", "ORGANISM", 132, 149], ["Mycobacterium tuberculosis", "ORGANISM", 151, 177], ["cytomegalovirus", "ORGANISM", 179, 194], ["CMV", "ORGANISM", 196, 199], ["John Cunnigham (JC) virus", "ORGANISM", 206, 231], ["T cells", "CELL_TYPE", 32, 39], ["Cryptococcus neoformans", "SPECIES", 107, 130], ["Toxoplasma gondii", "SPECIES", 132, 149], ["Mycobacterium tuberculosis", "SPECIES", 151, 177], ["Cryptococcus neoformans", "SPECIES", 107, 130], ["Toxoplasma gondii", "SPECIES", 132, 149], ["Mycobacterium tuberculosis", "SPECIES", 151, 177], ["CMV", "SPECIES", 196, 199], ["John Cunnigham (JC) virus", "SPECIES", 206, 231], ["The AIDS epidemic", "PROBLEM", 0, 17], ["T cells protect the brain", "PROBLEM", 32, 57], ["neurotropic opportunistic pathogens", "PROBLEM", 63, 98], ["Cryptococcus neoformans", "PROBLEM", 107, 130], ["Toxoplasma gondii", "PROBLEM", 132, 149], ["Mycobacterium tuberculosis", "PROBLEM", 151, 177], ["cytomegalovirus", "PROBLEM", 179, 194], ["brain", "ANATOMY", 52, 57], ["Cryptococcus neoformans", "OBSERVATION", 107, 130], ["Mycobacterium tuberculosis", "OBSERVATION", 151, 177]]], ["Similarly, children with hyper-immunoglobulin M (IgM) syndrome, a group of primary immune deficiency disorders characterized by altered CD40 signaling that results in defects in cell mediated immunity and reduced antibody class switching, exhibit increased susceptibility to encephalitis due to enteric cytopathic human orphan (ECHO) virus, CMV, and T. gondii (Subauste, 2006; Winkelstein et al., 2003) .", [["cell", "ANATOMY", 178, 182], ["hyper-immunoglobulin M (IgM) syndrome", "DISEASE", 25, 62], ["primary immune deficiency disorders", "DISEASE", 75, 110], ["encephalitis", "DISEASE", 275, 287], ["children", "ORGANISM", 11, 19], ["hyper-immunoglobulin M", "GENE_OR_GENE_PRODUCT", 25, 47], ["CD40", "GENE_OR_GENE_PRODUCT", 136, 140], ["cell", "CELL", 178, 182], ["human", "ORGANISM", 314, 319], ["ECHO) virus", "ORGANISM", 328, 339], ["CMV", "ORGANISM", 341, 344], ["T. gondii", "ORGANISM", 350, 359], ["IgM", "PROTEIN", 49, 52], ["CD40", "PROTEIN", 136, 140], ["children", "SPECIES", 11, 19], ["human", "SPECIES", 314, 319], ["T. gondii", "SPECIES", 350, 359], ["human", "SPECIES", 314, 319], ["CMV", "SPECIES", 341, 344], ["T. gondii", "SPECIES", 350, 359], ["hyper-immunoglobulin M (IgM) syndrome", "PROBLEM", 25, 62], ["primary immune deficiency disorders", "PROBLEM", 75, 110], ["altered CD40 signaling", "PROBLEM", 128, 150], ["defects in cell mediated immunity", "PROBLEM", 167, 200], ["reduced antibody class", "PROBLEM", 205, 227], ["increased susceptibility to encephalitis", "PROBLEM", 247, 287], ["enteric cytopathic human orphan", "PROBLEM", 295, 326], ["ECHO", "TEST", 328, 332], ["virus", "PROBLEM", 334, 339], ["CMV", "PROBLEM", 341, 344], ["immune deficiency", "OBSERVATION", 83, 100], ["defects", "OBSERVATION", 167, 174], ["increased", "OBSERVATION_MODIFIER", 247, 256], ["encephalitis", "OBSERVATION", 275, 287]]], ["The recent advances in whole-genome sequencing technology have intensified the investigation into the prevalence and causes of neuroinfectious diseases in patients with primary immunodeficiencies (Joshi et al., 2009) .", [["neuroinfectious diseases", "DISEASE", 127, 151], ["primary immunodeficiencies", "DISEASE", 169, 195], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["neuroinfectious diseases", "PROBLEM", 127, 151], ["primary immunodeficiencies", "PROBLEM", 169, 195], ["neuroinfectious diseases", "OBSERVATION", 127, 151]]], ["In pediatric patients with herpes simplex virus (HSV) encephalitis, these approaches have led to the identification of loss of function mutations in multiple innate immune genes including Unc-93 homolog B1 (UNC93B), Toll-like receptor (TLR)3, TIR-domain-containing adaptor-inducing interferon-b (TRIF), TNF receptor-associated factor (TRAF)3, signal transducer and activator of transcription (STAT)1, NF-kB essential modulator (NEMO), and TRAF family member-associated (TANK)-binding kinase 1 (TBK1), (Casrouge et al., 2006; Guo et al., 2011; Herman et al., 2012; P\u00e9 rez de Diego et al., 2010; Sancho-Shimizu et al., 2011; Zhang et al., 2007) .", [["herpes simplex virus (HSV) encephalitis", "DISEASE", 27, 66], ["patients", "ORGANISM", 13, 21], ["herpes simplex virus", "ORGANISM", 27, 47], ["HSV", "ORGANISM", 49, 52], ["Unc-93 homolog B1", "GENE_OR_GENE_PRODUCT", 188, 205], ["UNC93B", "GENE_OR_GENE_PRODUCT", 207, 213], ["Toll-like receptor (TLR)3", "GENE_OR_GENE_PRODUCT", 216, 241], ["TIR-domain-containing adaptor-inducing interferon-b", "GENE_OR_GENE_PRODUCT", 243, 294], ["TRIF", "GENE_OR_GENE_PRODUCT", 296, 300], ["TNF receptor-associated factor (TRAF)3", "GENE_OR_GENE_PRODUCT", 303, 341], ["signal transducer and activator of transcription (STAT)1", "GENE_OR_GENE_PRODUCT", 343, 399], ["NF-kB", "GENE_OR_GENE_PRODUCT", 401, 406], ["NEMO", "GENE_OR_GENE_PRODUCT", 428, 432], ["TRAF family member-associated (TANK)-binding kinase 1", "GENE_OR_GENE_PRODUCT", 439, 492], ["TBK1", "GENE_OR_GENE_PRODUCT", 494, 498], ["innate immune genes", "DNA", 158, 177], ["Unc-93 homolog B1", "DNA", 188, 205], ["UNC93B", "DNA", 207, 213], ["Toll-like receptor (TLR)3", "PROTEIN", 216, 241], ["TIR-domain-containing adaptor-inducing interferon-b", "PROTEIN", 243, 294], ["TRIF", "PROTEIN", 296, 300], ["TNF receptor-associated factor (TRAF)3", "PROTEIN", 303, 341], ["signal transducer and activator of transcription (STAT)1", "PROTEIN", 343, 399], ["NF-kB essential modulator", "PROTEIN", 401, 426], ["NEMO", "PROTEIN", 428, 432], ["TRAF family member-associated (TANK)-binding kinase 1", "PROTEIN", 439, 492], ["TBK1", "PROTEIN", 494, 498], ["patients", "SPECIES", 13, 21], ["herpes simplex virus", "SPECIES", 27, 47], ["herpes simplex virus", "SPECIES", 27, 47], ["HSV", "SPECIES", 49, 52], ["herpes simplex virus (HSV) encephalitis", "PROBLEM", 27, 66], ["loss of function mutations", "PROBLEM", 119, 145], ["Unc", "TEST", 188, 191], ["Toll-like receptor (TLR)", "TREATMENT", 216, 240], ["adaptor", "TREATMENT", 265, 272], ["interferon-b (TRIF)", "TREATMENT", 282, 301], ["TNF receptor", "TREATMENT", 303, 315], ["signal transducer", "TEST", 343, 360]]], ["Advances in the use of human induced pluripotent stem cells (IPSC) to generate different neural cell types means that these populations can be used alone or within three-dimensional models of CNS function and combined with gene editing to dissect the basis for susceptibility.", [["pluripotent stem cells", "ANATOMY", 37, 59], ["IPSC", "ANATOMY", 61, 65], ["neural cell", "ANATOMY", 89, 100], ["CNS", "ANATOMY", 192, 195], ["human", "ORGANISM", 23, 28], ["induced pluripotent stem cells", "CELL", 29, 59], ["IPSC", "CELL", 61, 65], ["neural cell", "CELL", 89, 100], ["CNS", "ANATOMICAL_SYSTEM", 192, 195], ["human induced pluripotent stem cells", "CELL_LINE", 23, 59], ["IPSC", "CELL_LINE", 61, 65], ["neural cell types", "CELL_TYPE", 89, 106], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["human induced pluripotent stem cells (IPSC)", "TREATMENT", 23, 66], ["susceptibility", "PROBLEM", 261, 275], ["pluripotent stem cells", "OBSERVATION", 37, 59], ["neural cell types", "OBSERVATION", 89, 106]]], ["This approach has already been utilized to examine the contribution of TLR3-mediated mechanisms of resistance to HSV in different neuronal populations (Lafaille et al., 2012) .IntroductionThe increased use of biologically based therapies to target inflammatory processes has led to the emergence of a new cohort of patients susceptible to many of the infections described above.", [["neuronal", "ANATOMY", 130, 138], ["infections", "DISEASE", 351, 361], ["TLR3", "GENE_OR_GENE_PRODUCT", 71, 75], ["HSV", "ORGANISM", 113, 116], ["neuronal populations", "CELL", 130, 150], ["patients", "ORGANISM", 315, 323], ["TLR3", "PROTEIN", 71, 75], ["patients", "SPECIES", 315, 323], ["HSV", "SPECIES", 113, 116], ["HSV", "PROBLEM", 113, 116], ["biologically based therapies", "TREATMENT", 209, 237], ["target inflammatory processes", "PROBLEM", 241, 270], ["the infections", "PROBLEM", 347, 361], ["increased", "OBSERVATION_MODIFIER", 192, 201], ["inflammatory", "OBSERVATION", 248, 260], ["infections", "OBSERVATION", 351, 361]]], ["An important example is the reactivation of the ubiquitous JC virus, which leads to a potentially fatal CNS infection that causes progressive multifocal leukoencephalopathy (PML) (Berger and Koralnik, 2005) .", [["CNS", "ANATOMY", 104, 107], ["CNS infection", "DISEASE", 104, 117], ["leukoencephalopathy", "DISEASE", 153, 172], ["PML", "DISEASE", 174, 177], ["JC virus", "ORGANISM", 59, 67], ["CNS", "ANATOMICAL_SYSTEM", 104, 107], ["JC virus", "SPECIES", 59, 67], ["the ubiquitous JC virus", "PROBLEM", 44, 67], ["a potentially fatal CNS infection", "PROBLEM", 84, 117], ["progressive multifocal leukoencephalopathy", "PROBLEM", 130, 172], ["ubiquitous", "OBSERVATION_MODIFIER", 48, 58], ["JC virus", "OBSERVATION", 59, 67], ["potentially", "UNCERTAINTY", 86, 97], ["fatal", "OBSERVATION_MODIFIER", 98, 103], ["CNS", "ANATOMY", 104, 107], ["infection", "OBSERVATION", 108, 117], ["progressive", "OBSERVATION_MODIFIER", 130, 141], ["multifocal", "OBSERVATION_MODIFIER", 142, 152], ["leukoencephalopathy", "OBSERVATION", 153, 172]]], ["This pathogen has continued to rise in prominence with the advent of the humanized monoclonal antibody therapies natalizumab (anti-a4integrin) (Berger and Koralnik, 2005) and rituximab (anti-CD20) (Jelcic et al., 2015) , to treat multiple sclerosis, B cell malignancies, and encephalitis due to autoantibodies against the N-methyl-D-aspartate (NMDA) receptor.", [["B cell malignancies", "ANATOMY", 250, 269], ["natalizumab", "CHEMICAL", 113, 124], ["anti-a4integrin", "CHEMICAL", 126, 141], ["rituximab", "CHEMICAL", 175, 184], ["multiple sclerosis", "DISEASE", 230, 248], ["B cell malignancies", "DISEASE", 250, 269], ["encephalitis", "DISEASE", 275, 287], ["N-methyl-D-aspartate", "CHEMICAL", 322, 342], ["NMDA", "CHEMICAL", 344, 348], ["N-methyl-D-aspartate", "CHEMICAL", 322, 342], ["NMDA", "CHEMICAL", 344, 348], ["natalizumab", "SIMPLE_CHEMICAL", 113, 124], ["anti-a4integrin", "SIMPLE_CHEMICAL", 126, 141], ["rituximab", "SIMPLE_CHEMICAL", 175, 184], ["CD20", "GENE_OR_GENE_PRODUCT", 191, 195], ["B cell malignancies", "CANCER", 250, 269], ["N-methyl-D-aspartate", "SIMPLE_CHEMICAL", 322, 342], ["NMDA", "SIMPLE_CHEMICAL", 344, 348], ["CD20", "PROTEIN", 191, 195], ["autoantibodies", "PROTEIN", 295, 309], ["N-methyl-D-aspartate (NMDA) receptor", "PROTEIN", 322, 358], ["This pathogen", "PROBLEM", 0, 13], ["the humanized monoclonal antibody therapies natalizumab (anti-a4integrin)", "TREATMENT", 69, 142], ["Koralnik", "TREATMENT", 155, 163], ["rituximab (anti-CD20)", "TREATMENT", 175, 196], ["multiple sclerosis", "PROBLEM", 230, 248], ["B cell malignancies", "PROBLEM", 250, 269], ["encephalitis", "PROBLEM", 275, 287], ["autoantibodies", "PROBLEM", 295, 309], ["D-aspartate (NMDA) receptor", "TREATMENT", 331, 358], ["rise", "OBSERVATION_MODIFIER", 31, 35], ["prominence", "OBSERVATION", 39, 49], ["multiple", "OBSERVATION_MODIFIER", 230, 238], ["sclerosis", "OBSERVATION", 239, 248], ["B cell malignancies", "OBSERVATION", 250, 269]]], ["The use of another anti-integrin antibody, efalizumab (anti-aLintegrin), to treat psoriasis, is also associated with increased incidence of PML (Molloy and Calabrese, 2009) and has been withdrawn from the market.", [["efalizumab", "CHEMICAL", 43, 53], ["anti-aLintegrin", "CHEMICAL", 55, 70], ["psoriasis", "DISEASE", 82, 91], ["PML", "DISEASE", 140, 143], ["anti-integrin antibody", "GENE_OR_GENE_PRODUCT", 19, 41], ["efalizumab", "SIMPLE_CHEMICAL", 43, 53], ["anti-aLintegrin", "SIMPLE_CHEMICAL", 55, 70], ["anti-integrin antibody", "PROTEIN", 19, 41], ["another anti-integrin antibody", "TREATMENT", 11, 41], ["efalizumab (anti-aLintegrin)", "TREATMENT", 43, 71], ["psoriasis", "PROBLEM", 82, 91], ["increased incidence of PML", "PROBLEM", 117, 143], ["psoriasis", "OBSERVATION", 82, 91], ["PML", "OBSERVATION", 140, 143]]], ["The broad impact of this type of intervention is illustrated in studies in which blockade of a4 integrin compromises protective immunity in the CNS to T. gondii, simian immunodeficiency virus (SIV), and Bornavirus (Planz et al., 1995; Sasseville et al., 1994; Wilson et al., 2009) .", [["CNS", "ANATOMY", 144, 147], ["simian immunodeficiency virus", "DISEASE", 162, 191], ["a4 integrin", "GENE_OR_GENE_PRODUCT", 93, 104], ["CNS", "ANATOMICAL_SYSTEM", 144, 147], ["T. gondii", "ORGANISM", 151, 160], ["simian immunodeficiency virus", "ORGANISM", 162, 191], ["SIV", "ORGANISM", 193, 196], ["a4 integrin", "PROTEIN", 93, 104], ["T. gondii", "SPECIES", 151, 160], ["simian immunodeficiency virus", "SPECIES", 162, 191], ["T. gondii", "SPECIES", 151, 160], ["simian immunodeficiency virus", "SPECIES", 162, 191], ["SIV", "SPECIES", 193, 196], ["intervention", "TREATMENT", 33, 45], ["a4 integrin compromises", "TREATMENT", 93, 116], ["simian immunodeficiency virus", "PROBLEM", 162, 191], ["broad", "OBSERVATION_MODIFIER", 4, 9], ["CNS", "ANATOMY", 144, 147]]], ["There is considerable clinical experience with anti-tumor necrosis factor (TNF) therapies to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and Crohn's disease.", [["ulcerative", "ANATOMY", 159, 169], ["necrosis", "DISEASE", 58, 66], ["rheumatoid and psoriatic arthritis", "DISEASE", 99, 133], ["ankylosing spondylitis", "DISEASE", 135, 157], ["ulcerative colitis", "DISEASE", 159, 177], ["Crohn's disease", "DISEASE", 183, 198], ["anti-tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 47, 73], ["TNF", "GENE_OR_GENE_PRODUCT", 75, 78], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 159, 177], ["TNF", "PROTEIN", 75, 78], ["anti-tumor necrosis factor", "PROBLEM", 47, 73], ["TNF) therapies", "TREATMENT", 75, 89], ["rheumatoid and psoriatic arthritis", "PROBLEM", 99, 133], ["ankylosing spondylitis", "PROBLEM", 135, 157], ["ulcerative colitis", "PROBLEM", 159, 177], ["Crohn's disease", "PROBLEM", 183, 198], ["considerable", "OBSERVATION_MODIFIER", 9, 21], ["anti-tumor", "OBSERVATION_MODIFIER", 47, 57], ["necrosis", "OBSERVATION", 58, 66], ["rheumatoid", "OBSERVATION_MODIFIER", 99, 109], ["psoriatic", "OBSERVATION_MODIFIER", 114, 123], ["arthritis", "OBSERVATION", 124, 133], ["ankylosing spondylitis", "OBSERVATION", 135, 157], ["ulcerative", "OBSERVATION_MODIFIER", 159, 169], ["colitis", "OBSERVATION", 170, 177], ["Crohn's disease", "OBSERVATION", 183, 198]]], ["These therapies can also lead to infections with pathogens that exhibit tropism for the CNS that include Listeria monocytogenes, Nocardia species, Histoplasma capsulatum, T. gondii, Cryptococcus neoformans, Mycobacterium tuberculosis, and CMV (Ali et al., 2013) .IntroductionThese clinical examples illustrate that treatments which negatively impact immune surveillance and effector function can lead to severe infections of the CNS.", [["CNS", "ANATOMY", 88, 91], ["CNS", "ANATOMY", 429, 432], ["infections", "DISEASE", 33, 43], ["Listeria monocytogenes", "DISEASE", 105, 127], ["Nocardia species", "DISEASE", 129, 145], ["Histoplasma capsulatum", "DISEASE", 147, 169], ["Cryptococcus neoformans", "DISEASE", 182, 205], ["Mycobacterium tuberculosis", "DISEASE", 207, 233], ["infections of the CNS", "DISEASE", 411, 432], ["CNS", "ANATOMICAL_SYSTEM", 88, 91], ["Listeria monocytogenes", "ORGANISM", 105, 127], ["Nocardia species", "ORGANISM", 129, 145], ["Histoplasma capsulatum", "ORGANISM", 147, 169], ["T. gondii", "ORGANISM", 171, 180], ["Cryptococcus neoformans", "ORGANISM", 182, 205], ["Mycobacterium tuberculosis", "ORGANISM", 207, 233], ["CMV", "ORGANISM", 239, 242], ["CNS", "ANATOMICAL_SYSTEM", 429, 432], ["Listeria monocytogenes", "SPECIES", 105, 127], ["Histoplasma capsulatum", "SPECIES", 147, 169], ["T. gondii", "SPECIES", 171, 180], ["Cryptococcus neoformans", "SPECIES", 182, 205], ["Mycobacterium tuberculosis", "SPECIES", 207, 233], ["Listeria monocytogenes", "SPECIES", 105, 127], ["Histoplasma capsulatum", "SPECIES", 147, 169], ["T. gondii", "SPECIES", 171, 180], ["Cryptococcus neoformans", "SPECIES", 182, 205], ["Mycobacterium tuberculosis", "SPECIES", 207, 233], ["CMV", "SPECIES", 239, 242], ["These therapies", "TREATMENT", 0, 15], ["infections", "PROBLEM", 33, 43], ["pathogens", "PROBLEM", 49, 58], ["tropism", "PROBLEM", 72, 79], ["the CNS", "TEST", 84, 91], ["Listeria monocytogenes", "PROBLEM", 105, 127], ["Nocardia species", "PROBLEM", 129, 145], ["Histoplasma capsulatum", "TEST", 147, 169], ["T. gondii", "TEST", 171, 180], ["Cryptococcus neoformans", "PROBLEM", 182, 205], ["Mycobacterium tuberculosis", "PROBLEM", 207, 233], ["CMV", "PROBLEM", 239, 242], ["immune surveillance", "TEST", 350, 369], ["severe infections of the CNS", "PROBLEM", 404, 432], ["Listeria monocytogenes", "OBSERVATION", 105, 127], ["Cryptococcus neoformans", "OBSERVATION", 182, 205], ["Mycobacterium tuberculosis", "OBSERVATION", 207, 233], ["severe", "OBSERVATION_MODIFIER", 404, 410], ["infections", "OBSERVATION", 411, 421], ["CNS", "ANATOMY", 429, 432]]], ["Moreover, when combined with the experiences with patients with acquired immune deficiencies, they suggest that immune surveillance of the CNS occurs in the absence of overt inflammation and protects from the consequences of reactivation of persistent infections.The Consequences of Microbial NeurotropismFor many of the micro-organisms that exhibit tropism for the CNS, their presence at this site has little obvious benefit in promoting their life cycle and is frequently catastrophic for the host.", [["CNS", "ANATOMY", 139, 142], ["CNS", "ANATOMY", 366, 369], ["immune deficiencies", "DISEASE", 73, 92], ["inflammation", "DISEASE", 174, 186], ["infections", "DISEASE", 252, 262], ["patients", "ORGANISM", 50, 58], ["CNS", "ANATOMICAL_SYSTEM", 139, 142], ["CNS", "ANATOMICAL_SYSTEM", 366, 369], ["patients", "SPECIES", 50, 58], ["acquired immune deficiencies", "PROBLEM", 64, 92], ["the CNS", "PROBLEM", 135, 142], ["overt inflammation", "PROBLEM", 168, 186], ["persistent infections", "PROBLEM", 241, 262], ["the micro-organisms", "PROBLEM", 317, 336], ["tropism", "PROBLEM", 350, 357], ["the CNS", "PROBLEM", 362, 369], ["inflammation", "OBSERVATION", 174, 186], ["persistent", "OBSERVATION_MODIFIER", 241, 251], ["infections", "OBSERVATION", 252, 262]]], ["For example, the presence of C. neoformans or ListeriaCNS CompartmentMeninges Ventricular System Parenchyma monocytogenes in the brain might allow these organisms access to an environment that protects from the peripheral immune system, but without treatment they can cause fatal disease.", [["brain", "ANATOMY", 129, 134], ["peripheral immune system", "ANATOMY", 211, 235], ["C. neoformans", "ORGANISM", 29, 42], ["ListeriaCNS CompartmentMeninges Ventricular System Parenchyma monocytogenes", "ORGANISM", 46, 121], ["brain", "ORGAN", 129, 134], ["peripheral immune system", "ANATOMICAL_SYSTEM", 211, 235], ["C. neoformans", "SPECIES", 29, 42], ["Parenchyma monocytogenes", "SPECIES", 97, 121], ["C. neoformans", "SPECIES", 29, 42], ["Parenchyma monocytogenes", "SPECIES", 97, 121], ["C. neoformans", "PROBLEM", 29, 42], ["Parenchyma monocytogenes in the brain", "PROBLEM", 97, 134], ["treatment", "TREATMENT", 249, 258], ["fatal disease", "PROBLEM", 274, 287], ["C.", "OBSERVATION_MODIFIER", 29, 31], ["neoformans", "OBSERVATION", 32, 42], ["Parenchyma", "ANATOMY_MODIFIER", 97, 107], ["monocytogenes", "OBSERVATION", 108, 121], ["brain", "ANATOMY", 129, 134], ["peripheral immune", "OBSERVATION", 211, 228]]], ["Under these circumstances there is no obvious evolutionary advantage for these organisms that we can discern.", [["these organisms", "PROBLEM", 73, 88], ["no obvious", "UNCERTAINTY", 35, 45]]], ["In contrast, a limited subset of pathogens that includes HSV, African trypanosomes, T. gondii and Ebola, the ability to persist in neural tissues can directly aid in transmission or provide a sanctuary from which the pathogen can emerge to continue its infectious life cycle (Jacobs et al., 2016; Swanson and McGavern, 2015) .", [["neural tissues", "ANATOMY", 131, 145], ["T. gondii", "DISEASE", 84, 93], ["Ebola", "DISEASE", 98, 103], ["HSV", "ORGANISM", 57, 60], ["African trypanosomes", "ORGANISM", 62, 82], ["T. gondii", "ORGANISM", 84, 93], ["Ebola", "ORGANISM", 98, 103], ["neural tissues", "TISSUE", 131, 145], ["T. gondii", "SPECIES", 84, 93], ["HSV", "SPECIES", 57, 60], ["T. gondii", "SPECIES", 84, 93], ["pathogens", "PROBLEM", 33, 42], ["HSV", "PROBLEM", 57, 60], ["Ebola", "PROBLEM", 98, 103], ["pathogens", "OBSERVATION", 33, 42], ["neural tissues", "ANATOMY", 131, 145]]], ["This principle might be relevant to HIV, which persists in microglia and astrocytes and could re-emerge, although this has yet to be proven.", [["microglia", "ANATOMY", 59, 68], ["astrocytes", "ANATOMY", 73, 83], ["HIV", "ORGANISM", 36, 39], ["microglia", "CELL", 59, 68], ["astrocytes", "CELL", 73, 83], ["microglia", "CELL_TYPE", 59, 68], ["astrocytes", "CELL_TYPE", 73, 83], ["HIV", "SPECIES", 36, 39], ["HIV", "PROBLEM", 36, 39], ["HIV", "OBSERVATION", 36, 39]]], ["Another consideration is that for many important infections of the CNS, humans are considered dead end hosts and the evolutionary basis for neurotropism in this host is unclear.", [["CNS", "ANATOMY", 67, 70], ["infections", "DISEASE", 49, 59], ["CNS", "ANATOMICAL_SYSTEM", 67, 70], ["humans", "ORGANISM", 72, 78], ["humans", "SPECIES", 72, 78], ["humans", "SPECIES", 72, 78], ["neurotropism", "PROBLEM", 140, 152], ["infections", "OBSERVATION", 49, 59], ["CNS", "ANATOMY", 67, 70]]], ["Thus, West Nile Virus (WNV) and the flavivirus, Zika virus can cause acute and autoimmune encephalitides in adults and severe neurodevelopmental abnormalities in human fetuses.", [["fetuses", "ANATOMY", 168, 175], ["West Nile Virus (WNV) and the flavivirus", "DISEASE", 6, 46], ["Zika virus", "DISEASE", 48, 58], ["acute and autoimmune encephalitides", "DISEASE", 69, 104], ["neurodevelopmental abnormalities", "DISEASE", 126, 158], ["West Nile Virus", "ORGANISM", 6, 21], ["WNV", "ORGANISM", 23, 26], ["Zika virus", "ORGANISM", 48, 58], ["human", "ORGANISM", 162, 167], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 168, 175], ["West Nile Virus", "SPECIES", 6, 21], ["Zika virus", "SPECIES", 48, 58], ["human", "SPECIES", 162, 167], ["West Nile Virus", "SPECIES", 6, 21], ["WNV", "SPECIES", 23, 26], ["Zika virus", "SPECIES", 48, 58], ["human", "SPECIES", 162, 167], ["West Nile Virus (WNV", "PROBLEM", 6, 26], ["the flavivirus", "PROBLEM", 32, 46], ["Zika virus", "PROBLEM", 48, 58], ["acute and autoimmune encephalitides", "PROBLEM", 69, 104], ["severe neurodevelopmental abnormalities in human fetuses", "PROBLEM", 119, 175], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["autoimmune encephalitides", "OBSERVATION", 79, 104], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["neurodevelopmental", "OBSERVATION_MODIFIER", 126, 144], ["abnormalities", "OBSERVATION", 145, 158], ["human fetuses", "OBSERVATION", 162, 175]]], ["Neither of these viruses appears to spread from mammals back to mosquitoes and it is difficult to make a case that neurotropism in humans is critical for their success.", [["humans", "ORGANISM", 131, 137], ["humans", "SPECIES", 131, 137], ["humans", "SPECIES", 131, 137], ["these viruses", "PROBLEM", 11, 24], ["viruses", "OBSERVATION", 17, 24]]], ["Conversely, WNV is neurotopic in almost all birds (the natural host) and while it is asymptomatic in many species, its spread into new avian hosts indicated that those with CNS involvement generally succumb to infection (Gamino and H\u00f6 fle, 2013).", [["CNS", "ANATOMY", 173, 176], ["infection", "DISEASE", 210, 219], ["WNV", "ORGANISM", 12, 15], ["CNS", "ANATOMICAL_SYSTEM", 173, 176], ["WNV", "SPECIES", 12, 15], ["WNV", "PROBLEM", 12, 15], ["neurotopic", "PROBLEM", 19, 29], ["asymptomatic", "PROBLEM", 85, 97], ["WNV", "OBSERVATION", 12, 15], ["infection", "OBSERVATION", 210, 219]]], ["The underlying molecular basis for these types of events is illustrated by the finding that glycosylation in the E protein of WNV results in increased peripheral viremia and virulence for birds and neuroinvasiveness in rodents (Shirato et al., 2004) .", [["peripheral viremia", "DISEASE", 151, 169], ["neuroinvasiveness", "DISEASE", 198, 215], ["E", "GENE_OR_GENE_PRODUCT", 113, 114], ["WNV", "ORGANISM", 126, 129], ["E protein", "PROTEIN", 113, 122], ["WNV", "SPECIES", 126, 129], ["WNV", "PROBLEM", 126, 129], ["increased peripheral viremia", "PROBLEM", 141, 169], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["peripheral viremia", "OBSERVATION", 151, 169]]], ["It is plausible that strategies that promote neurotropism in a primary hosts provides an evolutionary advantage, which in an aberrant host results in disease.Pathogen Interactions with Blood and CerebrospinalFluid Barriers and Access to the CNS In the face of evolving (or accidental) neurotropism among pathogens that affect distinct compartments of the CNS (see Table 1 ), the presence of a barrier that limits microbial entry would have a significant selective advantage (Bundgaard and Abbott, 2008) .", [["Blood", "ANATOMY", 185, 190], ["CNS", "ANATOMY", 355, 358], ["Blood", "ORGANISM_SUBSTANCE", 185, 190], ["CNS", "ANATOMICAL_SYSTEM", 355, 358], ["disease", "PROBLEM", 150, 157], ["Blood and CerebrospinalFluid Barriers", "TREATMENT", 185, 222], ["accidental) neurotropism among pathogens", "PROBLEM", 273, 313], ["CNS", "ANATOMY", 241, 244], ["CNS", "ANATOMY", 355, 358]]], ["Indeed, the evolutionary conservation of the chemoprotective properties of the BBB and its role as a physical barrier to pathogen entry might indicate that its role in immune privilege evolved secondarily to these functions.", [["BBB", "MULTI-TISSUE_STRUCTURE", 79, 82], ["immune privilege", "TREATMENT", 168, 184]]], ["In lower vertebrates and invertebrates this barrier is exclusively formed by glial cells.", [["glial cells", "ANATOMY", 77, 88], ["glial cells", "CELL", 77, 88], ["glial cells", "CELL_TYPE", 77, 88], ["lower vertebrates", "ANATOMY", 3, 20], ["glial cells", "OBSERVATION", 77, 88]]], ["In higher vertebrates, it is established by polarized endothelial cells and the blood-cerebrospinal barrier (BCFB) and BBB exclude blood borne pathogens from the meninges, CNS parenchyma and ventricular system.", [["endothelial cells", "ANATOMY", 54, 71], ["blood-cerebrospinal barrier", "ANATOMY", 80, 107], ["BCFB", "ANATOMY", 109, 113], ["BBB", "ANATOMY", 119, 122], ["blood", "ANATOMY", 131, 136], ["meninges", "ANATOMY", 162, 170], ["CNS parenchyma", "ANATOMY", 172, 186], ["ventricular system", "ANATOMY", 191, 209], ["endothelial cells", "CELL", 54, 71], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["cerebrospinal barrier", "MULTI-TISSUE_STRUCTURE", 86, 107], ["BCFB", "MULTI-TISSUE_STRUCTURE", 109, 113], ["BBB", "MULTI-TISSUE_STRUCTURE", 119, 122], ["blood", "ORGANISM_SUBSTANCE", 131, 136], ["meninges", "MULTI-TISSUE_STRUCTURE", 162, 170], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 172, 186], ["ventricular system", "MULTI-TISSUE_STRUCTURE", 191, 209], ["polarized endothelial cells", "CELL_TYPE", 44, 71], ["the blood", "TEST", 76, 85], ["cerebrospinal barrier", "TEST", 86, 107], ["blood borne pathogens from the meninges, CNS parenchyma and ventricular system", "PROBLEM", 131, 209], ["higher vertebrates", "OBSERVATION", 3, 21], ["polarized endothelial cells", "OBSERVATION", 44, 71], ["cerebrospinal", "ANATOMY", 86, 99], ["meninges", "ANATOMY", 162, 170], ["CNS", "ANATOMY", 172, 175], ["parenchyma", "ANATOMY_MODIFIER", 176, 186], ["ventricular system", "ANATOMY", 191, 209]]], ["The basis for this enhanced barrier function is the formation of specialized inter-epithelial and inter-endothelial tight junctions .", [["inter-epithelial", "ANATOMY", 77, 93], ["inter-endothelial tight junctions", "ANATOMY", 98, 131], ["inter-epithelial", "CELL", 77, 93], ["inter-endothelial", "CELLULAR_COMPONENT", 98, 115], ["tight junctions", "CELLULAR_COMPONENT", 116, 131], ["this enhanced barrier function", "TREATMENT", 14, 44], ["specialized", "OBSERVATION_MODIFIER", 65, 76], ["inter-epithelial", "ANATOMY_MODIFIER", 77, 93], ["inter-endothelial", "ANATOMY_MODIFIER", 98, 115], ["tight junctions", "OBSERVATION", 116, 131]]], ["Intercellular tight junctions (TJs) composed of claudins and occludins join meningeal and choroid plexus (CP) epithelial cells, presumably limiting the ability of blood borne pathogens that cross their fenestrated endothelium from gaining access to the CNS.", [["Intercellular tight junctions", "ANATOMY", 0, 29], ["TJs", "ANATOMY", 31, 34], ["meningeal", "ANATOMY", 76, 85], ["choroid plexus", "ANATOMY", 90, 104], ["CP) epithelial cells", "ANATOMY", 106, 126], ["blood", "ANATOMY", 163, 168], ["endothelium", "ANATOMY", 214, 225], ["CNS", "ANATOMY", 253, 256], ["Intercellular tight junctions", "CELLULAR_COMPONENT", 0, 29], ["TJs", "CELLULAR_COMPONENT", 31, 34], ["claudins", "GENE_OR_GENE_PRODUCT", 48, 56], ["occludins", "GENE_OR_GENE_PRODUCT", 61, 70], ["choroid plexus (CP) epithelial cells", "CELL", 90, 126], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["endothelium", "TISSUE", 214, 225], ["CNS", "ANATOMICAL_SYSTEM", 253, 256], ["TJs", "CELL_TYPE", 31, 34], ["claudins", "PROTEIN", 48, 56], ["occludins", "PROTEIN", 61, 70], ["meningeal and choroid plexus (CP) epithelial cells", "CELL_TYPE", 76, 126], ["claudins and occludins join meningeal and choroid plexus (CP) epithelial cells", "PROBLEM", 48, 126], ["blood borne pathogens", "PROBLEM", 163, 184], ["tight junctions", "OBSERVATION", 14, 29], ["join meningeal", "ANATOMY", 71, 85], ["choroid plexus", "ANATOMY", 90, 104], ["epithelial cells", "OBSERVATION", 110, 126], ["fenestrated endothelium", "OBSERVATION", 202, 225], ["CNS", "ANATOMY", 253, 256]]], ["In contrast, parenchymal capillaries and venules exhibit both TJs and adherens junctions (AJs), which prevent permeation of solute, cells, and pathogens through paracellular routes.", [["parenchymal capillaries", "ANATOMY", 13, 36], ["venules", "ANATOMY", 41, 48], ["TJs", "ANATOMY", 62, 65], ["adherens junctions", "ANATOMY", 70, 88], ["AJs", "ANATOMY", 90, 93], ["cells", "ANATOMY", 132, 137], ["paracellular", "ANATOMY", 161, 173], ["parenchymal capillaries", "TISSUE", 13, 36], ["venules", "MULTI-TISSUE_STRUCTURE", 41, 48], ["TJs", "CELL", 62, 65], ["adherens junctions", "CELLULAR_COMPONENT", 70, 88], ["AJs", "CELLULAR_COMPONENT", 90, 93], ["cells", "CELL", 132, 137], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 161, 173], ["TJs", "CELL_TYPE", 62, 65], ["solute, cells", "PROBLEM", 124, 137], ["parenchymal", "ANATOMY_MODIFIER", 13, 24], ["capillaries", "ANATOMY_MODIFIER", 25, 36], ["venules", "ANATOMY", 41, 48], ["both", "OBSERVATION_MODIFIER", 57, 61], ["TJs", "OBSERVATION", 62, 65], ["adherens junctions", "OBSERVATION", 70, 88]]], ["Mammalian BBB TJs and AJs connect BBB endothelial cells to each other and to cytoskeletal actin filaments.", [["BBB TJs", "ANATOMY", 10, 17], ["AJs", "ANATOMY", 22, 25], ["BBB endothelial cells", "ANATOMY", 34, 55], ["cytoskeletal", "ANATOMY", 77, 89], ["filaments", "ANATOMY", 96, 105], ["BBB TJs", "CELL", 10, 17], ["AJs", "CELL", 22, 25], ["BBB endothelial cells", "CELL", 34, 55], ["actin", "GENE_OR_GENE_PRODUCT", 90, 95], ["filaments", "CELLULAR_COMPONENT", 96, 105], ["Mammalian BBB TJs", "CELL_TYPE", 0, 17], ["AJs", "CELL_TYPE", 22, 25], ["BBB endothelial cells", "CELL_TYPE", 34, 55], ["BBB TJs", "ANATOMY", 10, 17], ["endothelial cells", "OBSERVATION", 38, 55], ["cytoskeletal", "OBSERVATION", 77, 89], ["actin filaments", "OBSERVATION", 90, 105]]], ["As in peripheral vascular beds and the gut, the lengths of actin fibers, which determine the integrity of TJs and AJs at the BBB, are regulated by Rho GTPases (Cetin et al., 2004; Huveneers et al., 2015; Daniels et al., 2014) .", [["peripheral vascular beds", "ANATOMY", 6, 30], ["gut", "ANATOMY", 39, 42], ["actin fibers", "ANATOMY", 59, 71], ["TJs", "ANATOMY", 106, 109], ["AJs", "ANATOMY", 114, 117], ["BBB", "ANATOMY", 125, 128], ["peripheral vascular beds", "MULTI-TISSUE_STRUCTURE", 6, 30], ["gut", "ORGANISM_SUBDIVISION", 39, 42], ["actin", "GENE_OR_GENE_PRODUCT", 59, 64], ["fibers", "CELLULAR_COMPONENT", 65, 71], ["TJs", "CELLULAR_COMPONENT", 106, 109], ["AJs", "CELLULAR_COMPONENT", 114, 117], ["BBB", "MULTI-TISSUE_STRUCTURE", 125, 128], ["Rho GTPases", "GENE_OR_GENE_PRODUCT", 147, 158], ["actin", "PROTEIN", 59, 64], ["TJs", "CELL_TYPE", 106, 109], ["AJs", "CELL_TYPE", 114, 117], ["Rho GTPases", "PROTEIN", 147, 158], ["peripheral vascular beds", "TREATMENT", 6, 30], ["actin fibers", "TREATMENT", 59, 71], ["peripheral", "ANATOMY_MODIFIER", 6, 16], ["vascular beds", "ANATOMY", 17, 30], ["gut", "ANATOMY", 39, 42], ["actin fibers", "OBSERVATION", 59, 71], ["BBB", "ANATOMY", 125, 128]]], ["Thus, junctional complexes, in addition to barrier-stabilizing proteins expressed by abluminal pericytes and astrocyte endfeet, maintain the BBB (see Figure 1 ).Pathogen Interactions with Blood and CerebrospinalThe meningeal barrier effectively prevents the CNS entry of a majority of bacterial, fungal, and viral pathogens, while only neutrotropic viruses, molds, and certain parasites are able to readily access the CNS parenchyma (see Table 2 and Figure 1 ).", [["junctional complexes", "ANATOMY", 6, 26], ["abluminal pericytes", "ANATOMY", 85, 104], ["astrocyte endfeet", "ANATOMY", 109, 126], ["BBB", "ANATOMY", 141, 144], ["Blood", "ANATOMY", 188, 193], ["meningeal barrier", "ANATOMY", 215, 232], ["CNS", "ANATOMY", 258, 261], ["CNS parenchyma", "ANATOMY", 418, 432], ["junctional", "CELLULAR_COMPONENT", 6, 16], ["abluminal pericytes", "CELLULAR_COMPONENT", 85, 104], ["astrocyte endfeet", "CELLULAR_COMPONENT", 109, 126], ["BBB", "MULTI-TISSUE_STRUCTURE", 141, 144], ["Blood", "ORGANISM_SUBSTANCE", 188, 193], ["Cerebrospinal", "ORGANISM_SUBSTANCE", 198, 211], ["meningeal barrier", "TISSUE", 215, 232], ["CNS", "ANATOMICAL_SYSTEM", 258, 261], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 418, 432], ["junctional complexes", "PROTEIN", 6, 26], ["barrier-stabilizing proteins", "PROTEIN", 43, 71], ["abluminal pericytes", "CELL_TYPE", 85, 104], ["astrocyte endfeet", "CELL_TYPE", 109, 126], ["junctional complexes", "PROBLEM", 6, 26], ["stabilizing proteins", "PROBLEM", 51, 71], ["Blood", "TEST", 188, 193], ["The meningeal barrier", "TREATMENT", 211, 232], ["bacterial, fungal, and viral pathogens", "PROBLEM", 285, 323], ["neutrotropic viruses", "PROBLEM", 336, 356], ["molds", "PROBLEM", 358, 363], ["certain parasites", "PROBLEM", 369, 386], ["abluminal pericytes", "OBSERVATION", 85, 104], ["Cerebrospinal", "ANATOMY", 198, 211], ["meningeal", "ANATOMY", 215, 224], ["bacterial", "OBSERVATION", 285, 294], ["fungal", "OBSERVATION", 296, 302], ["viral pathogens", "OBSERVATION", 308, 323], ["CNS", "ANATOMY", 418, 421], ["parenchyma", "ANATOMY_MODIFIER", 422, 432]]], ["Viruses enter the CNS via multiple routes including retrograde migration along axons, transendothelial entry within the CSF compartment, or transcytosis across an intact BBB, and via delivery by infected mononuclear cells (Dahm et al., 2016) .", [["CNS", "ANATOMY", 18, 21], ["axons", "ANATOMY", 79, 84], ["transendothelial", "ANATOMY", 86, 102], ["CSF compartment", "ANATOMY", 120, 135], ["BBB", "ANATOMY", 170, 173], ["mononuclear cells", "ANATOMY", 204, 221], ["CNS", "ANATOMICAL_SYSTEM", 18, 21], ["axons", "CELLULAR_COMPONENT", 79, 84], ["transendothelial", "CELL", 86, 102], ["CSF compartment", "CELLULAR_COMPONENT", 120, 135], ["BBB", "MULTI-TISSUE_STRUCTURE", 170, 173], ["mononuclear cells", "CELL", 204, 221], ["infected mononuclear cells", "CELL_TYPE", 195, 221], ["Viruses", "PROBLEM", 0, 7], ["retrograde migration along axons", "TREATMENT", 52, 84], ["transcytosis", "PROBLEM", 140, 152], ["infected mononuclear cells", "PROBLEM", 195, 221], ["CNS", "ANATOMY", 18, 21], ["retrograde", "OBSERVATION_MODIFIER", 52, 62], ["migration", "OBSERVATION", 63, 72], ["transendothelial entry", "OBSERVATION", 86, 108], ["CSF compartment", "OBSERVATION", 120, 135], ["intact", "OBSERVATION", 163, 169], ["BBB", "ANATOMY", 170, 173], ["mononuclear cells", "OBSERVATION", 204, 221]]], ["In the setting of certain viral infections TJ proteins, including ZO-1, VEcadherin, occluding, and claudin 5, might be decreased and so provide a para-cellular route for pathogen or immune cell entry (Bleau et al., 2015; Kim et al., 2015; see Figure 1 ).", [["immune cell", "ANATOMY", 182, 193], ["viral infections", "DISEASE", 26, 42], ["TJ", "GENE_OR_GENE_PRODUCT", 43, 45], ["ZO-1", "GENE_OR_GENE_PRODUCT", 66, 70], ["VEcadherin", "GENE_OR_GENE_PRODUCT", 72, 82], ["claudin 5", "GENE_OR_GENE_PRODUCT", 99, 108], ["immune cell", "CELL", 182, 193], ["TJ proteins", "PROTEIN", 43, 54], ["ZO-1", "PROTEIN", 66, 70], ["VEcadherin", "PROTEIN", 72, 82], ["claudin 5", "PROTEIN", 99, 108], ["certain viral infections TJ proteins", "PROBLEM", 18, 54], ["VEcadherin", "TREATMENT", 72, 82], ["a para-cellular route", "TREATMENT", 144, 165], ["pathogen", "PROBLEM", 170, 178], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["infections", "OBSERVATION", 32, 42], ["decreased", "OBSERVATION_MODIFIER", 119, 128]]], ["This strategy to breach the BBB is relevant to the bacterial organisms L. monocytogenes and N. meningitides, which affect the CNS but use contrasting mechanisms to access this site.", [["CNS", "ANATOMY", 126, 129], ["BBB", "MULTI-TISSUE_STRUCTURE", 28, 31], ["L. monocytogenes", "ORGANISM", 71, 87], ["N. meningitides", "ORGANISM", 92, 107], ["CNS", "ANATOMICAL_SYSTEM", 126, 129], ["L. monocytogenes", "SPECIES", 71, 87], ["N. meningitides", "SPECIES", 92, 107], ["L. monocytogenes", "SPECIES", 71, 87], ["N. meningitides", "SPECIES", 92, 107], ["the bacterial organisms L. monocytogenes", "PROBLEM", 47, 87]]], ["Pathogen Mechanisms for Crossing the Blood Brain Barrier (A) The NVU is composed of astrocyte endfeet, pericytes, and endtothelial cells and the local production of type I IFNs has a major role in controlling opening of the BBB (Daniels et al., 2017; Lazear et al., 2015) .", [["Blood Brain Barrier", "ANATOMY", 37, 56], ["astrocyte endfeet", "ANATOMY", 84, 101], ["pericytes", "ANATOMY", 103, 112], ["endtothelial cells", "ANATOMY", 118, 136], ["NVU", "CANCER", 65, 68], ["astrocyte endfeet", "CELL", 84, 101], ["pericytes", "CELL", 103, 112], ["endtothelial cells", "CELL", 118, 136], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 165, 176], ["BBB", "MULTI-TISSUE_STRUCTURE", 224, 227], ["astrocyte endfeet", "CELL_TYPE", 84, 101], ["pericytes", "CELL_TYPE", 103, 112], ["endtothelial cells", "CELL_TYPE", 118, 136], ["type I IFNs", "PROTEIN", 165, 176], ["endtothelial cells", "PROBLEM", 118, 136], ["astrocyte endfeet", "OBSERVATION", 84, 101], ["pericytes", "ANATOMY", 103, 112], ["endtothelial cells", "OBSERVATION", 118, 136], ["BBB", "ANATOMY", 224, 227]]], ["Micro-organisms utilize three main mechanisms to directly transit the BBB.", [["BBB", "ANATOMY", 70, 73], ["BBB", "MULTI-TISSUE_STRUCTURE", 70, 73], ["Micro-organisms", "PROBLEM", 0, 15]]], ["(B) Trans-cellular route by which viruses or infected cells directly cross through EC (Dahm et al., 2016) .", [["cellular", "ANATOMY", 10, 18], ["cells", "ANATOMY", 54, 59], ["EC", "ANATOMY", 83, 85], ["cells", "CELL", 54, 59], ["EC", "CELL", 83, 85], ["infected cells", "CELL_TYPE", 45, 59], ["EC", "CELL_TYPE", 83, 85], ["Trans-cellular route", "TREATMENT", 4, 24], ["viruses", "PROBLEM", 34, 41], ["infected cells", "PROBLEM", 45, 59], ["infected cells", "OBSERVATION", 45, 59]]], ["(C) Para-cellular route whereby the breakdown of the tight junctions allows access of infected cells or extracellular pathogens to access the peri-vascular unit (Santiago-Tirado et al., 2017; Shi et al., 2010; Vu et al., 2013) .", [["tight junctions", "ANATOMY", 53, 68], ["cells", "ANATOMY", 95, 100], ["extracellular", "ANATOMY", 104, 117], ["peri-vascular unit", "ANATOMY", 142, 160], ["tight junctions", "CELLULAR_COMPONENT", 53, 68], ["cells", "CELL", 95, 100], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 117], ["infected cells", "CELL_TYPE", 86, 100], ["Para-cellular route", "TREATMENT", 4, 23], ["the breakdown", "PROBLEM", 32, 45], ["infected cells", "PROBLEM", 86, 100], ["extracellular pathogens", "PROBLEM", 104, 127], ["infected cells", "OBSERVATION", 86, 100]]], ["(D) Lytic mechanisms in which the ability to infect EC and lyse these cells allows pathogens to access the brain of infected monocytes (the Trojan Horse hypothesis) to transport L. monocytogenes across the BBB (Drevets et al., 2004) provides a template for thinking about how other pathogens might access the CNS.", [["EC", "ANATOMY", 52, 54], ["cells", "ANATOMY", 70, 75], ["brain", "ANATOMY", 107, 112], ["monocytes", "ANATOMY", 125, 134], ["CNS", "ANATOMY", 309, 312], ["EC", "CELL", 52, 54], ["cells", "CELL", 70, 75], ["brain", "ORGAN", 107, 112], ["monocytes", "CELL", 125, 134], ["L. monocytogenes", "ORGANISM", 178, 194], ["BBB", "MULTI-TISSUE_STRUCTURE", 206, 209], ["CNS", "ANATOMICAL_SYSTEM", 309, 312], ["EC", "CELL_TYPE", 52, 54], ["infected monocytes", "CELL_TYPE", 116, 134], ["L. monocytogenes", "SPECIES", 178, 194], ["L. monocytogenes", "SPECIES", 178, 194], ["Lytic mechanisms", "PROBLEM", 4, 20], ["pathogens", "PROBLEM", 83, 92], ["infected monocytes", "PROBLEM", 116, 134], ["brain", "ANATOMY", 107, 112], ["infected monocytes", "OBSERVATION", 116, 134], ["CNS", "ANATOMY", 309, 312]]], ["For N. meningitides, the association of the meningococci with micro-capillaries with the lowest flow rates is a critical factor that allows access to the CNS (Mairey et al., 2006) .", [["micro-capillaries", "ANATOMY", 62, 79], ["CNS", "ANATOMY", 154, 157], ["micro-capillaries", "DISEASE", 62, 79], ["N. meningitides", "ORGANISM", 4, 19], ["meningococci", "ORGANISM", 44, 56], ["CNS", "ANATOMICAL_SYSTEM", 154, 157], ["N. meningitides", "SPECIES", 4, 19], ["N. meningitides", "SPECIES", 4, 19], ["N. meningitides", "PROBLEM", 4, 19], ["the meningococci", "PROBLEM", 40, 56], ["micro-capillaries", "PROBLEM", 62, 79], ["meningitides", "OBSERVATION", 7, 19], ["meningococci", "OBSERVATION", 44, 56], ["CNS", "ANATOMY", 154, 157]]], ["In this setting, pilus-mediated adhesion of the meningococci to endothelial cells initiate a signaling cascade which results in the opening of intercellular junctions, allowing meningeal colonization (Bernard et al., 2014; Coureuil et al., 2009 Coureuil et al., , 2010 .Pathogen Interactions with Blood and CerebrospinalOf the eukaryotic pathogens that affect the brain, C. neoformans and T. gondii, have the highest recognized incidence, with multiple mechanisms proposed for pathogen entry to the CNS.", [["meningococci", "ANATOMY", 48, 60], ["endothelial cells", "ANATOMY", 64, 81], ["intercellular junctions", "ANATOMY", 143, 166], ["meningeal", "ANATOMY", 177, 186], ["Blood", "ANATOMY", 297, 302], ["brain", "ANATOMY", 364, 369], ["CNS", "ANATOMY", 499, 502], ["pilus", "GENE_OR_GENE_PRODUCT", 17, 22], ["meningococci", "CELL", 48, 60], ["endothelial cells", "CELL", 64, 81], ["intercellular junctions", "CELLULAR_COMPONENT", 143, 166], ["meningeal", "PATHOLOGICAL_FORMATION", 177, 186], ["Blood", "ORGANISM_SUBSTANCE", 297, 302], ["CerebrospinalOf", "GENE_OR_GENE_PRODUCT", 307, 322], ["brain", "ORGAN", 364, 369], ["C. neoformans", "ORGANISM", 371, 384], ["T. gondii", "ORGANISM", 389, 398], ["CNS", "ANATOMICAL_SYSTEM", 499, 502], ["endothelial cells", "CELL_TYPE", 64, 81], ["C. neoformans", "SPECIES", 371, 384], ["T. gondii", "SPECIES", 389, 398], ["C. neoformans", "SPECIES", 371, 384], ["T. gondii", "SPECIES", 389, 398], ["pilus", "PROBLEM", 17, 22], ["the meningococci", "PROBLEM", 44, 60], ["endothelial cells", "PROBLEM", 64, 81], ["a signaling cascade", "PROBLEM", 91, 110], ["meningeal colonization", "PROBLEM", 177, 199], ["Blood", "TEST", 297, 302], ["CerebrospinalOf the eukaryotic pathogens", "PROBLEM", 307, 347], ["endothelial", "ANATOMY", 64, 75], ["intercellular junctions", "ANATOMY", 143, 166], ["meningeal", "ANATOMY", 177, 186], ["colonization", "OBSERVATION_MODIFIER", 187, 199], ["eukaryotic pathogens", "OBSERVATION", 327, 347], ["brain", "ANATOMY", 364, 369], ["neoformans", "OBSERVATION", 374, 384], ["CNS", "ANATOMY", 499, 502]]], ["The ability to dissect these events in vivo is challenging and consequently in vitro studies with primary endothelial cells have been used extensively.", [["endothelial cells", "ANATOMY", 106, 123], ["endothelial cells", "CELL", 106, 123], ["primary endothelial cells", "CELL_TYPE", 98, 123], ["vitro studies", "TEST", 79, 92], ["primary endothelial cells", "PROBLEM", 98, 123], ["endothelial cells", "OBSERVATION", 106, 123]]], ["Based on this approach, it has been proposed that both pathogens may enter the CNS via direct infection of brain microvascular endothelial cells (BMECs) and transcytosis from the blood to the brain via mechanisms that damage the BBB, either by disruption of TJs with subsequent edema, or via replication and lysis of BMECs (Huang et al., 2011; Jong et al., 2008; Lachenmaier et al., 2011; Maruvada et al., 2012; Tseng et al., 2012) .", [["CNS", "ANATOMY", 79, 82], ["brain microvascular endothelial cells", "ANATOMY", 107, 144], ["BMECs", "ANATOMY", 146, 151], ["blood", "ANATOMY", 179, 184], ["brain", "ANATOMY", 192, 197], ["BBB", "ANATOMY", 229, 232], ["TJs", "ANATOMY", 258, 261], ["edema", "ANATOMY", 278, 283], ["infection", "DISEASE", 94, 103], ["edema", "DISEASE", 278, 283], ["CNS", "ANATOMICAL_SYSTEM", 79, 82], ["brain microvascular endothelial cells", "CELL", 107, 144], ["BMECs", "CELL", 146, 151], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["brain", "ORGAN", 192, 197], ["BBB", "MULTI-TISSUE_STRUCTURE", 229, 232], ["TJs", "GENE_OR_GENE_PRODUCT", 258, 261], ["edema", "PATHOLOGICAL_FORMATION", 278, 283], ["BMECs", "PATHOLOGICAL_FORMATION", 317, 322], ["brain microvascular endothelial cells", "CELL_TYPE", 107, 144], ["BMECs", "CELL_TYPE", 146, 151], ["TJs", "CELL_TYPE", 258, 261], ["direct infection of brain microvascular endothelial cells", "PROBLEM", 87, 144], ["transcytosis", "PROBLEM", 157, 169], ["the blood to the brain", "PROBLEM", 175, 197], ["damage the BBB", "PROBLEM", 218, 232], ["disruption of TJs", "PROBLEM", 244, 261], ["subsequent edema", "PROBLEM", 267, 283], ["infection", "OBSERVATION", 94, 103], ["brain", "ANATOMY_MODIFIER", 107, 112], ["microvascular endothelial", "ANATOMY", 113, 138], ["brain", "ANATOMY", 192, 197], ["BBB", "ANATOMY", 229, 232], ["edema", "OBSERVATION", 278, 283]]], ["In vitro, C. neoformans leads to alterations in barrier integrity to promote crossing of the BBB via a para-cellular route (Maruvada et al., 2012) or due to transcytosis of infected mononuclear cells (Santiago-Tirado et al., 2017; Shi et al., 2010; Vu et al., 2013) .", [["barrier", "ANATOMY", 48, 55], ["BBB", "ANATOMY", 93, 96], ["mononuclear cells", "ANATOMY", 182, 199], ["C. neoformans", "ORGANISM", 10, 23], ["barrier", "TISSUE", 48, 55], ["BBB", "MULTI-TISSUE_STRUCTURE", 93, 96], ["mononuclear cells", "CELL", 182, 199], ["infected mononuclear cells", "CELL_TYPE", 173, 199], ["C. neoformans", "SPECIES", 10, 23], ["C. neoformans", "SPECIES", 10, 23], ["C. neoformans", "PROBLEM", 10, 23], ["barrier integrity", "TREATMENT", 48, 65], ["a para-cellular route", "TREATMENT", 101, 122], ["transcytosis of infected mononuclear cells", "PROBLEM", 157, 199], ["neoformans", "OBSERVATION", 13, 23], ["infected mononuclear cells", "OBSERVATION", 173, 199]]], ["Monocytes infected with T. gondii are present in the blood and have been implicated as Trojan horses that allow this organism to access the brain (Courret et al., 2006) .", [["Monocytes", "ANATOMY", 0, 9], ["blood", "ANATOMY", 53, 58], ["brain", "ANATOMY", 140, 145], ["Monocytes", "CELL", 0, 9], ["T. gondii", "ORGANISM", 24, 33], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["Trojan horses", "ORGANISM", 87, 100], ["brain", "ORGAN", 140, 145], ["Monocytes", "CELL_TYPE", 0, 9], ["T. gondii", "SPECIES", 24, 33], ["T. gondii", "SPECIES", 24, 33], ["Monocytes infected", "PROBLEM", 0, 18], ["T. gondii", "PROBLEM", 24, 33], ["T. gondii", "OBSERVATION", 24, 33], ["blood", "ANATOMY", 53, 58], ["brain", "ANATOMY", 140, 145]]], ["Infection is also accompanied by the presence of numerous free parasites in the blood and the use of parasite mutants and multiphoton imaging indicate that parasite replication in and lysis of endothelial cells precedes invasion of the CNS .", [["blood", "ANATOMY", 80, 85], ["endothelial cells", "ANATOMY", 193, 210], ["CNS", "ANATOMY", 236, 239], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["endothelial cells", "CELL", 193, 210], ["CNS", "ANATOMICAL_SYSTEM", 236, 239], ["endothelial cells", "CELL_TYPE", 193, 210], ["Infection", "PROBLEM", 0, 9], ["numerous free parasites in the blood", "PROBLEM", 49, 85], ["parasite mutants", "TREATMENT", 101, 117], ["multiphoton imaging", "TEST", 122, 141], ["parasite replication", "TREATMENT", 156, 176], ["lysis of endothelial cells", "TREATMENT", 184, 210], ["invasion of the CNS", "PROBLEM", 220, 239], ["numerous", "OBSERVATION_MODIFIER", 49, 57], ["free", "OBSERVATION_MODIFIER", 58, 62], ["parasites", "OBSERVATION", 63, 72], ["blood", "ANATOMY", 80, 85], ["parasite replication", "OBSERVATION", 156, 176], ["endothelial cells", "OBSERVATION", 193, 210], ["invasion", "OBSERVATION_MODIFIER", 220, 228], ["CNS", "ANATOMY", 236, 239]]], ["One common theme that links several of the more recent studies is the ability to combine genetically modified pathogens with imaging techniques to visualize the BBB in vivo.", [["BBB", "ANATOMY", 161, 164], ["BBB", "MULTI-TISSUE_STRUCTURE", 161, 164], ["imaging techniques", "TEST", 125, 143]]], ["This has provided the opportunity to the dissect the microbial factors that influence interactions with the NVU, and these approaches will be increasingly relevant to understand mechanisms of neurotropism in vivo.Pathogen Interactions with Blood and CerebrospinalInnate Immunity at the BBB The NVU is composed of endothelial cells, pericytes, astrocytes, and neurons and it is now recognized that these cells mediate (Bauer et al., 2014) Herpes simplex viruses (Kramer and Enquist, 2013) West Nile virus (Maximova et al., 2016) Venezuelan equine encephalitis virus (Trabalza et al., 2013) Transendothelial entry within CSF compartment Group B strep (Kim et al., 2015; Schaeffer et al., 2009) M. tuberculosis (Wu et al., 2000) L. monocytogenes (Dinner et al., 2017) N. meningitides (Schwerk et al., 2012) T. pallidum (Castro et al., 2016) Angiostrongylus cantonensis (Barratt et al., 2016) Enteroviruses (Dahm et al., 2016) Measles virus Chikungunya virus Venezuelan/Western equine encephalitis viruses (Phillips et al., 2016) Paracellular entry at the BBB L. monocytogenes (Dinner et al., 2017) Nocardia species (Beaman and Ogata, 1993) (Iovino et al., 2013) T. gondii Taenia solium (Marzal et al., 2014) Influenza A (Dahm et al., 2016) L. monocytogenes (Drevets et al., 2004) C. neoformans (Santiago-Tirado et al., 2017) T. gondii the initial responses to invading micro-organisms and these events are of particular importance to the control of meningeal pathogens (Neal and Gasque, 2013) .", [["Blood", "ANATOMY", 240, 245], ["endothelial cells", "ANATOMY", 313, 330], ["pericytes", "ANATOMY", 332, 341], ["astrocytes", "ANATOMY", 343, 353], ["neurons", "ANATOMY", 359, 366], ["cells", "ANATOMY", 403, 408], ["meningeal", "ANATOMY", 1446, 1455], ["Herpes simplex viruses", "DISEASE", 438, 460], ["Venezuelan equine encephalitis", "DISEASE", 528, 558], ["tuberculosis", "DISEASE", 695, 707], ["Angiostrongylus cantonensis", "DISEASE", 838, 865], ["Measles virus Chikungunya", "DISEASE", 923, 948], ["equine encephalitis", "DISEASE", 974, 993], ["Taenia solium", "DISEASE", 1169, 1182], ["meningeal pathogens", "DISEASE", 1446, 1465], ["Blood", "ORGANISM_SUBSTANCE", 240, 245], ["BBB", "MULTI-TISSUE_STRUCTURE", 286, 289], ["endothelial cells", "CELL", 313, 330], ["pericytes", "CELL", 332, 341], ["astrocytes", "CELL", 343, 353], ["neurons", "CELL", 359, 366], ["cells", "CELL", 403, 408], ["Herpes simplex viruses", "ORGANISM", 438, 460], ["West Nile virus", "ORGANISM", 488, 503], ["Venezuelan equine encephalitis virus", "ORGANISM", 528, 564], ["M. tuberculosis", "ORGANISM", 692, 707], ["L. monocytogenes", "ORGANISM", 726, 742], ["N. meningitides", "ORGANISM", 765, 780], ["T. pallidum", "ORGANISM", 804, 815], ["Angiostrongylus cantonensis", "ORGANISM", 838, 865], ["Measles virus Chikungunya virus Venezuelan", "ORGANISM", 923, 965], ["Western equine encephalitis viruses", "ORGANISM", 966, 1001], ["BBB L. monocytogenes", "ORGANISM", 1052, 1072], ["T. gondii", "ORGANISM", 1159, 1168], ["Taenia solium", "ORGANISM", 1169, 1182], ["L. monocytogenes", "ORGANISM", 1237, 1253], ["C. neoformans", "ORGANISM", 1277, 1290], ["T. gondii", "ORGANISM", 1322, 1331], ["microbial factors", "PROTEIN", 53, 70], ["NVU", "PROTEIN", 294, 297], ["endothelial cells", "CELL_TYPE", 313, 330], ["pericytes", "CELL_TYPE", 332, 341], ["astrocytes", "CELL_TYPE", 343, 353], ["neurons", "CELL_TYPE", 359, 366], ["Herpes simplex viruses", "SPECIES", 438, 460], ["Nile virus", "SPECIES", 493, 503], ["equine encephalitis virus", "SPECIES", 539, 564], ["M. tuberculosis", "SPECIES", 692, 707], ["L. monocytogenes", "SPECIES", 726, 742], ["N. meningitides", "SPECIES", 765, 780], ["T. pallidum", "SPECIES", 804, 815], ["Angiostrongylus cantonensis", "SPECIES", 838, 865], ["Measles virus Chikungunya virus", "SPECIES", 923, 954], ["equine encephalitis viruses", "SPECIES", 974, 1001], ["L. monocytogenes", "SPECIES", 1056, 1072], ["T. gondii", "SPECIES", 1159, 1168], ["Taenia solium", "SPECIES", 1169, 1182], ["L. monocytogenes", "SPECIES", 1237, 1253], ["C. neoformans", "SPECIES", 1277, 1290], ["T. gondii", "SPECIES", 1322, 1331], ["West Nile virus", "SPECIES", 488, 503], ["Venezuelan equine encephalitis virus", "SPECIES", 528, 564], ["L. monocytogenes", "SPECIES", 726, 742], ["N. meningitides", "SPECIES", 765, 780], ["T. pallidum", "SPECIES", 804, 815], ["Angiostrongylus cantonensis", "SPECIES", 838, 865], ["Measles virus Chikungunya virus", "SPECIES", 923, 954], ["Western equine encephalitis viruses", "SPECIES", 966, 1001], ["L. monocytogenes", "SPECIES", 1056, 1072], ["T. gondii", "SPECIES", 1159, 1168], ["Taenia solium", "SPECIES", 1169, 1182], ["L. monocytogenes", "SPECIES", 1237, 1253], ["C. neoformans", "SPECIES", 1277, 1290], ["T. gondii", "SPECIES", 1322, 1331], ["Blood", "TEST", 240, 245], ["endothelial cells", "PROBLEM", 313, 330], ["pericytes, astrocytes, and neurons", "PROBLEM", 332, 366], ["Herpes simplex viruses", "PROBLEM", 438, 460], ["Venezuelan equine encephalitis virus", "TREATMENT", 528, 564], ["Transendothelial entry within CSF compartment Group B strep", "TEST", 589, 648], ["tuberculosis", "PROBLEM", 695, 707], ["Angiostrongylus cantonensis", "PROBLEM", 838, 865], ["Enteroviruses", "PROBLEM", 889, 902], ["Measles virus Chikungunya virus Venezuelan", "PROBLEM", 923, 965], ["equine encephalitis viruses", "PROBLEM", 974, 1001], ["Nocardia species", "TEST", 1095, 1111], ["Influenza", "PROBLEM", 1205, 1214], ["invading micro-organisms", "PROBLEM", 1357, 1381], ["meningeal pathogens", "PROBLEM", 1446, 1465], ["endothelial cells", "OBSERVATION", 313, 330], ["neurons", "ANATOMY", 359, 366], ["meningeal", "ANATOMY", 1446, 1455]]], ["The local expression of diverse pattern-recognition receptors (PRRs) by the BBB allows detection of pathogen associated molecular patterns (PAMPs) via coordination of interactions between infiltrating immune cells within perivascular spaces.", [["infiltrating immune cells", "ANATOMY", 188, 213], ["perivascular spaces", "ANATOMY", 221, 240], ["pattern-recognition receptors", "GENE_OR_GENE_PRODUCT", 32, 61], ["BBB", "MULTI-TISSUE_STRUCTURE", 76, 79], ["pathogen associated molecular patterns", "GENE_OR_GENE_PRODUCT", 100, 138], ["infiltrating immune cells", "CELL", 188, 213], ["perivascular spaces", "TISSUE", 221, 240], ["pattern-recognition receptors", "PROTEIN", 32, 61], ["PRRs", "PROTEIN", 63, 67], ["infiltrating immune cells", "CELL_TYPE", 188, 213], ["the BBB", "TEST", 72, 79], ["pathogen associated molecular patterns (PAMPs", "PROBLEM", 100, 145], ["infiltrating immune cells", "PROBLEM", 188, 213], ["immune cells", "OBSERVATION", 201, 213], ["perivascular", "ANATOMY_MODIFIER", 221, 233]]], ["The scavenger receptor MARCO mediates meningeal recognition of N. meningitides and leads to local production of IL-1 (Braun et al., 2011) .", [["meningeal", "ANATOMY", 38, 47], ["MARCO", "GENE_OR_GENE_PRODUCT", 23, 28], ["N. meningitides", "ORGANISM", 63, 78], ["IL-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["scavenger receptor", "PROTEIN", 4, 22], ["MARCO", "PROTEIN", 23, 28], ["IL", "PROTEIN", 112, 114], ["N. meningitides", "SPECIES", 63, 78], ["N. meningitides", "SPECIES", 63, 78], ["N. meningitides", "PROBLEM", 63, 78], ["meningeal", "ANATOMY", 38, 47], ["N. meningitides", "OBSERVATION", 63, 78], ["local", "OBSERVATION_MODIFIER", 92, 97], ["production", "OBSERVATION_MODIFIER", 98, 108]]], ["For example, activation of Toll-like receptor (TLR)3 leads to barrier opening during WNV infection while TLR7 closes it Wang et al., 2004) .", [["barrier", "ANATOMY", 62, 69], ["infection", "DISEASE", 89, 98], ["Toll-like receptor (TLR)3", "GENE_OR_GENE_PRODUCT", 27, 52], ["barrier", "TISSUE", 62, 69], ["WNV", "ORGANISM", 85, 88], ["TLR7", "GENE_OR_GENE_PRODUCT", 105, 109], ["Toll-like receptor (TLR)3", "PROTEIN", 27, 52], ["TLR7", "PROTEIN", 105, 109], ["WNV", "SPECIES", 85, 88], ["Toll-like receptor (TLR)", "TREATMENT", 27, 51], ["WNV infection", "PROBLEM", 85, 98]]], ["Expression of cytokines downstream of innate immune signaling such as IL-1b and TNF-a also destabilize the barrier.Pathogen Interactions with Blood and CerebrospinalThe type I IFNs are the hallmark of the innate response to viral infections and have potent anti-viral activities.", [["Blood", "ANATOMY", 142, 147], ["viral infections", "DISEASE", 224, 240], ["IL-1b", "GENE_OR_GENE_PRODUCT", 70, 75], ["TNF", "GENE_OR_GENE_PRODUCT", 80, 83], ["barrier", "TISSUE", 107, 114], ["Blood", "ORGANISM_SUBSTANCE", 142, 147], ["Cerebrospinal", "ORGANISM_SUBSTANCE", 152, 165], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 169, 180], ["cytokines", "PROTEIN", 14, 23], ["IL", "PROTEIN", 70, 72], ["TNF", "PROTEIN", 80, 83], ["type I IFNs", "PROTEIN", 169, 180], ["cytokines downstream", "PROBLEM", 14, 34], ["innate immune signaling", "TREATMENT", 38, 61], ["IL", "TEST", 70, 72], ["TNF", "TREATMENT", 80, 83], ["the barrier", "TREATMENT", 103, 114], ["Blood", "TEST", 142, 147], ["viral infections", "PROBLEM", 224, 240], ["cytokines", "OBSERVATION", 14, 23], ["Cerebrospinal", "ANATOMY", 152, 165], ["viral infections", "OBSERVATION", 224, 240]]], ["They also have a context-dependent role in modulating the BBB and signaling via the type I IFN receptor, IFNa/bR (IFNAR) has a prominent role in stabilization of the BBB Lazear et al., 2015) .", [["BBB", "ANATOMY", 58, 61], ["BBB", "MULTI-TISSUE_STRUCTURE", 58, 61], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 84, 103], ["IFNa/bR", "GENE_OR_GENE_PRODUCT", 105, 112], ["IFNAR", "GENE_OR_GENE_PRODUCT", 114, 119], ["type I IFN receptor", "PROTEIN", 84, 103], ["IFNa", "PROTEIN", 105, 109], ["bR", "PROTEIN", 110, 112], ["IFNAR", "PROTEIN", 114, 119], ["prominent", "OBSERVATION_MODIFIER", 127, 136]]], ["Recent studies have highlighted CNS region-specific roles of IFNAR signaling in other cellular members of the NVU, with astrocyte IFNAR signaling important for BBB integrity within the hindbrain during infection with WNV (Daniels et al., 2017) .", [["CNS", "ANATOMY", 32, 35], ["cellular", "ANATOMY", 86, 94], ["NVU", "ANATOMY", 110, 113], ["astrocyte", "ANATOMY", 120, 129], ["BBB", "ANATOMY", 160, 163], ["hindbrain", "ANATOMY", 185, 194], ["infection", "DISEASE", 202, 211], ["CNS", "ANATOMICAL_SYSTEM", 32, 35], ["IFNAR", "GENE_OR_GENE_PRODUCT", 61, 66], ["cellular", "CELL", 86, 94], ["NVU", "GENE_OR_GENE_PRODUCT", 110, 113], ["astrocyte", "CELL", 120, 129], ["IFNAR", "GENE_OR_GENE_PRODUCT", 130, 135], ["BBB", "MULTI-TISSUE_STRUCTURE", 160, 163], ["hindbrain", "ORGAN", 185, 194], ["WNV", "ORGANISM", 217, 220], ["IFNAR", "PROTEIN", 61, 66], ["IFNAR", "PROTEIN", 130, 135], ["WNV", "SPECIES", 217, 220], ["Recent studies", "TEST", 0, 14], ["CNS region", "PROBLEM", 32, 42], ["IFNAR signaling", "PROBLEM", 61, 76], ["astrocyte IFNAR signaling", "PROBLEM", 120, 145], ["BBB integrity", "PROBLEM", 160, 173], ["infection", "PROBLEM", 202, 211], ["CNS", "ANATOMY", 32, 35], ["hindbrain", "ANATOMY", 185, 194], ["infection", "OBSERVATION", 202, 211]]], ["Both BMECs and astrocytes express the TAM receptors Mertk and Axl, which are receptor tyrosine kinases that bind Growth Arrest Specific 6 (Gas6) and Protein S. TAM signaling is enhanced by ligand interactions with phosphatidylserine displayed by apoptotic cells or enveloped viruses (Bhattacharyya et al., 2013) .", [["BMECs", "ANATOMY", 5, 10], ["astrocytes", "ANATOMY", 15, 25], ["cells", "ANATOMY", 256, 261], ["TAM", "CHEMICAL", 38, 41], ["tyrosine", "CHEMICAL", 86, 94], ["TAM", "CHEMICAL", 160, 163], ["phosphatidylserine", "CHEMICAL", 214, 232], ["TAM", "CHEMICAL", 38, 41], ["tyrosine", "CHEMICAL", 86, 94], ["TAM", "CHEMICAL", 160, 163], ["phosphatidylserine", "CHEMICAL", 214, 232], ["BMECs", "CELL", 5, 10], ["astrocytes", "CELL", 15, 25], ["Mertk", "GENE_OR_GENE_PRODUCT", 52, 57], ["Axl", "GENE_OR_GENE_PRODUCT", 62, 65], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 77, 102], ["Growth Arrest Specific 6", "GENE_OR_GENE_PRODUCT", 113, 137], ["Gas6", "GENE_OR_GENE_PRODUCT", 139, 143], ["Protein S. TAM", "GENE_OR_GENE_PRODUCT", 149, 163], ["phosphatidylserine", "SIMPLE_CHEMICAL", 214, 232], ["cells", "CELL", 256, 261], ["BMECs", "CELL_TYPE", 5, 10], ["astrocytes", "CELL_TYPE", 15, 25], ["TAM receptors", "PROTEIN", 38, 51], ["Mertk", "PROTEIN", 52, 57], ["Axl", "PROTEIN", 62, 65], ["receptor tyrosine kinases", "PROTEIN", 77, 102], ["Growth Arrest Specific 6", "PROTEIN", 113, 137], ["Gas6", "PROTEIN", 139, 143], ["apoptotic cells", "CELL_TYPE", 246, 261], ["receptor tyrosine kinases", "TREATMENT", 77, 102], ["bind Growth Arrest", "PROBLEM", 108, 126], ["Gas6) and Protein S. TAM signaling", "TEST", 139, 173], ["phosphatidylserine", "TREATMENT", 214, 232], ["BMECs", "ANATOMY", 5, 10], ["apoptotic cells", "OBSERVATION", 246, 261]]], ["In animal models of WNV encephalitis MertK and IFNR signaling synergize to augment BBB integrity (Miner et al., 2015) .", [["BBB", "ANATOMY", 83, 86], ["WNV encephalitis", "DISEASE", 20, 36], ["WNV encephalitis", "ORGANISM", 20, 36], ["MertK", "GENE_OR_GENE_PRODUCT", 37, 42], ["IFNR", "GENE_OR_GENE_PRODUCT", 47, 51], ["BBB", "MULTI-TISSUE_STRUCTURE", 83, 86], ["IFNR", "PROTEIN", 47, 51], ["WNV encephalitis", "SPECIES", 20, 36], ["WNV encephalitis MertK", "PROBLEM", 20, 42], ["IFNR signaling synergize", "TREATMENT", 47, 71], ["WNV", "OBSERVATION_MODIFIER", 20, 23], ["encephalitis MertK", "OBSERVATION", 24, 42]]], ["In all of these circumstances, IFNAR-mediated tightening of the barrier limited virus and immune cell entry, which prevented immunopathology within the hindbrain (Daniels et al., 2017) .", [["immune cell", "ANATOMY", 90, 101], ["hindbrain", "ANATOMY", 152, 161], ["IFNAR", "GENE_OR_GENE_PRODUCT", 31, 36], ["immune cell", "CELL", 90, 101], ["hindbrain", "ORGAN", 152, 161], ["IFNAR", "PROTEIN", 31, 36], ["the barrier limited virus", "PROBLEM", 60, 85], ["immune cell entry", "TEST", 90, 107], ["immunopathology", "PROBLEM", 125, 140], ["immune cell entry", "OBSERVATION", 90, 107], ["hindbrain", "ANATOMY", 152, 161]]], ["These events might help explain why the majority of patients with WNV encephalitis do not exhibit increased BBB permeability, as assessed via magnetic resonance imaging (MRI) (Chowers et al., 2001; Nash et al., 2001; Olsan et al., 2003) .Pathogen Interactions with Blood and CerebrospinalIn contrast to WNV, certain flaviviruses, such as Japanese encephalitis virus, and other arboviruses that include the alphavirus Venezuelan Equine Encephalitis virus (VEEV), do lead to loss of BBB integrity (Salimi et al., 2016) .", [["BBB", "ANATOMY", 108, 111], ["Blood", "ANATOMY", 265, 270], ["BBB", "ANATOMY", 481, 484], ["WNV encephalitis", "DISEASE", 66, 82], ["WNV", "DISEASE", 303, 306], ["flaviviruses", "DISEASE", 316, 328], ["Japanese encephalitis virus", "DISEASE", 338, 365], ["arboviruses", "DISEASE", 377, 388], ["Equine Encephalitis", "DISEASE", 428, 447], ["VEEV", "DISEASE", 455, 459], ["patients", "ORGANISM", 52, 60], ["WNV encephalitis", "ORGANISM", 66, 82], ["BBB", "MULTI-TISSUE_STRUCTURE", 108, 111], ["Blood", "ORGANISM_SUBSTANCE", 265, 270], ["CerebrospinalIn", "GENE_OR_GENE_PRODUCT", 275, 290], ["WNV", "ORGANISM", 303, 306], ["Japanese encephalitis virus", "ORGANISM", 338, 365], ["alphavirus", "ORGANISM", 406, 416], ["Venezuelan Equine Encephalitis virus", "ORGANISM", 417, 453], ["VEEV", "ORGANISM", 455, 459], ["BBB", "MULTI-TISSUE_STRUCTURE", 481, 484], ["patients", "SPECIES", 52, 60], ["Japanese encephalitis virus", "SPECIES", 338, 365], ["Venezuelan", "SPECIES", 417, 427], ["Equine Encephalitis virus", "SPECIES", 428, 453], ["WNV", "SPECIES", 303, 306], ["Japanese encephalitis virus", "SPECIES", 338, 365], ["Equine Encephalitis virus", "SPECIES", 428, 453], ["VEEV", "SPECIES", 455, 459], ["WNV encephalitis", "PROBLEM", 66, 82], ["increased BBB permeability", "PROBLEM", 98, 124], ["magnetic resonance imaging", "TEST", 142, 168], ["MRI", "TEST", 170, 173], ["Blood and CerebrospinalIn contrast", "TEST", 265, 299], ["WNV", "PROBLEM", 303, 306], ["certain flaviviruses", "PROBLEM", 308, 328], ["Japanese encephalitis virus", "PROBLEM", 338, 365], ["other arboviruses", "PROBLEM", 371, 388], ["the alphavirus Venezuelan Equine Encephalitis virus", "PROBLEM", 402, 453], ["loss of BBB integrity", "PROBLEM", 473, 494]]], ["VEEV, however, does not directly disrupt the barrier, because this occurs late in the course of infection and is associated with the infiltration of monocytes (Cain et al., 2017) .", [["monocytes", "ANATOMY", 149, 158], ["VEEV", "DISEASE", 0, 4], ["infection", "DISEASE", 96, 105], ["VEEV", "ORGANISM", 0, 4], ["monocytes", "CELL", 149, 158], ["monocytes", "CELL_TYPE", 149, 158], ["VEEV", "SPECIES", 0, 4], ["VEEV", "PROBLEM", 0, 4], ["infection", "PROBLEM", 96, 105], ["the infiltration of monocytes", "PROBLEM", 129, 158], ["infection", "OBSERVATION", 96, 105], ["infiltration", "OBSERVATION", 133, 145], ["monocytes", "ANATOMY", 149, 158]]], ["The related flavivirus, dengue can secrete nonstructural protein (NS)1, which disrupts the endothelial glycocalyx and compromise the integrity of peripheral vascular beds (Puerta-Guardo et al., 2016) .", [["endothelial glycocalyx", "ANATOMY", 91, 113], ["peripheral vascular beds", "ANATOMY", 146, 170], ["flavivirus", "DISEASE", 12, 22], ["dengue", "DISEASE", 24, 30], ["nonstructural protein (NS)1", "GENE_OR_GENE_PRODUCT", 43, 70], ["endothelial glycocalyx", "CELLULAR_COMPONENT", 91, 113], ["peripheral vascular beds", "TISSUE", 146, 170], ["nonstructural protein (NS)1", "PROTEIN", 43, 70], ["dengue", "SPECIES", 24, 30], ["The related flavivirus", "PROBLEM", 0, 22], ["dengue", "PROBLEM", 24, 30], ["flavivirus", "OBSERVATION", 12, 22], ["endothelial", "ANATOMY", 91, 102], ["glycocalyx", "ANATOMY_MODIFIER", 103, 113], ["integrity", "OBSERVATION_MODIFIER", 133, 142], ["peripheral", "ANATOMY_MODIFIER", 146, 156], ["vascular beds", "ANATOMY", 157, 170]]], ["This mechanism might contribute to the rare instances when dengue does affect the CNS (Solomon et al., 2000) , but it remains to be determined whether proteins secreted by neurotropic flaviviruses contribute to BBB instability during viremic stages of infection.", [["CNS", "ANATOMY", 82, 85], ["BBB", "ANATOMY", 211, 214], ["dengue", "DISEASE", 59, 65], ["neurotropic flaviviruses", "DISEASE", 172, 196], ["infection", "DISEASE", 252, 261], ["CNS", "ANATOMICAL_SYSTEM", 82, 85], ["neurotropic flaviviruses", "ORGANISM", 172, 196], ["BBB", "MULTI-TISSUE_STRUCTURE", 211, 214], ["proteins secreted", "PROBLEM", 151, 168], ["neurotropic flaviviruses", "PROBLEM", 172, 196], ["BBB instability", "PROBLEM", 211, 226], ["infection", "PROBLEM", 252, 261], ["infection", "OBSERVATION", 252, 261]]], ["Similarly, the HIV-1 protein Tat might induce disruption of the BBB via increased expression of platelet-derived growth factor subunit (PDGF-b) (Niu et al., 2014) .", [["BBB", "ANATOMY", 64, 67], ["HIV-1", "ORGANISM", 15, 20], ["Tat", "GENE_OR_GENE_PRODUCT", 29, 32], ["BBB", "GENE_OR_GENE_PRODUCT", 64, 67], ["platelet-derived growth factor subunit", "GENE_OR_GENE_PRODUCT", 96, 134], ["PDGF-b", "GENE_OR_GENE_PRODUCT", 136, 142], ["HIV-1 protein Tat", "PROTEIN", 15, 32], ["platelet-derived growth factor subunit", "PROTEIN", 96, 134], ["PDGF", "PROTEIN", 136, 140], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 15, 20], ["the HIV", "TEST", 11, 18], ["protein Tat", "TEST", 21, 32], ["disruption of the BBB", "PROBLEM", 46, 67], ["platelet", "TEST", 96, 104]]], ["Thus, the effects of viruses on BBB function might occur at both luminal and abluminal sides of the NVU and thereby promote entry of free virions or virally-infected leukocytes to the CNS (see Figure 2) .Pathogen Interactions with Blood and CerebrospinalPlasmodium falciparum is a mosquito-transmitted parasite that causes cerebral malaria, a complex syndrome characterized by intravascular sequestration of infected erythrocytes and local inflammation within the microcirculation of the CNS.", [["BBB", "ANATOMY", 32, 35], ["luminal", "ANATOMY", 65, 72], ["abluminal sides", "ANATOMY", 77, 92], ["NVU", "ANATOMY", 100, 103], ["virions", "ANATOMY", 138, 145], ["leukocytes", "ANATOMY", 166, 176], ["CNS", "ANATOMY", 184, 187], ["Blood", "ANATOMY", 231, 236], ["cerebral", "ANATOMY", 323, 331], ["intravascular", "ANATOMY", 377, 390], ["erythrocytes", "ANATOMY", 417, 429], ["CNS", "ANATOMY", 488, 491], ["luminal", "CHEMICAL", 65, 72], ["Plasmodium falciparum", "DISEASE", 254, 275], ["mosquito-transmitted parasite", "DISEASE", 281, 310], ["cerebral malaria", "DISEASE", 323, 339], ["inflammation", "DISEASE", 440, 452], ["BBB", "MULTI-TISSUE_STRUCTURE", 32, 35], ["luminal", "TISSUE", 65, 72], ["abluminal sides", "CELLULAR_COMPONENT", 77, 92], ["leukocytes", "CELL", 166, 176], ["CNS", "ANATOMICAL_SYSTEM", 184, 187], ["Blood", "ORGANISM_SUBSTANCE", 231, 236], ["CerebrospinalPlasmodium falciparum", "ORGANISM", 241, 275], ["cerebral", "ORGAN", 323, 331], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 377, 390], ["erythrocytes", "CELL", 417, 429], ["CNS", "ANATOMICAL_SYSTEM", 488, 491], ["virally-infected leukocytes", "CELL_TYPE", 149, 176], ["infected erythrocytes", "CELL_TYPE", 408, 429], ["Plasmodium falciparum", "SPECIES", 254, 275], ["Plasmodium falciparum", "SPECIES", 254, 275], ["viruses", "PROBLEM", 21, 28], ["BBB function", "TEST", 32, 44], ["free virions", "PROBLEM", 133, 145], ["infected leukocytes", "PROBLEM", 157, 176], ["Pathogen Interactions", "PROBLEM", 204, 225], ["Blood", "TEST", 231, 236], ["CerebrospinalPlasmodium falciparum", "PROBLEM", 241, 275], ["transmitted parasite", "PROBLEM", 290, 310], ["cerebral malaria", "PROBLEM", 323, 339], ["a complex syndrome", "PROBLEM", 341, 359], ["intravascular sequestration", "PROBLEM", 377, 404], ["infected erythrocytes", "PROBLEM", 408, 429], ["local inflammation", "PROBLEM", 434, 452], ["viruses", "OBSERVATION", 21, 28], ["free virions", "OBSERVATION", 133, 145], ["infected leukocytes", "OBSERVATION", 157, 176], ["CNS", "ANATOMY", 184, 187], ["CerebrospinalPlasmodium", "ANATOMY", 241, 264], ["cerebral", "ANATOMY", 323, 331], ["malaria", "OBSERVATION", 332, 339], ["complex syndrome", "OBSERVATION", 343, 359], ["intravascular sequestration", "OBSERVATION", 377, 404], ["infected erythrocytes", "OBSERVATION", 408, 429], ["local", "OBSERVATION_MODIFIER", 434, 439], ["inflammation", "OBSERVATION", 440, 452], ["microcirculation", "OBSERVATION_MODIFIER", 464, 480], ["CNS", "ANATOMY", 488, 491]]], ["These events are associated with loss of BBB integrity with subsequent hemorrhage and cerebral edema (reviewed in Hora et al., 2016) .", [["BBB", "ANATOMY", 41, 44], ["cerebral", "ANATOMY", 86, 94], ["hemorrhage", "DISEASE", 71, 81], ["cerebral edema", "DISEASE", 86, 100], ["BBB", "MULTI-TISSUE_STRUCTURE", 41, 44], ["cerebral edema", "PATHOLOGICAL_FORMATION", 86, 100], ["loss of BBB integrity", "PROBLEM", 33, 54], ["subsequent hemorrhage", "PROBLEM", 60, 81], ["cerebral edema", "PROBLEM", 86, 100], ["hemorrhage", "OBSERVATION", 71, 81], ["cerebral", "ANATOMY", 86, 94], ["edema", "OBSERVATION", 95, 100]]], ["While P. falciparum does not directly infect the CNS, studies indicate that the parasite itself, through upregulation of barrier destabilizing inflammatory mediators, or through effects of secreted proteins, might impact on BBB function (Gallego-Delgado et al., 2016; Pal et al., 2016) .", [["CNS", "ANATOMY", 49, 52], ["BBB", "ANATOMY", 224, 227], ["P. falciparum", "DISEASE", 6, 19], ["P. falciparum", "ORGANISM", 6, 19], ["CNS", "ANATOMICAL_SYSTEM", 49, 52], ["BBB", "MULTI-TISSUE_STRUCTURE", 224, 227], ["inflammatory mediators", "PROTEIN", 143, 165], ["secreted proteins", "PROTEIN", 189, 206], ["P. falciparum", "SPECIES", 6, 19], ["P. falciparum", "SPECIES", 6, 19], ["P. falciparum", "PROBLEM", 6, 19], ["the parasite itself", "PROBLEM", 76, 95], ["barrier destabilizing inflammatory mediators", "TREATMENT", 121, 165], ["secreted proteins", "PROBLEM", 189, 206], ["BBB function", "TEST", 224, 236], ["CNS", "ANATOMY", 49, 52], ["parasite", "OBSERVATION", 80, 88]]], ["Thus, P. falciparuminfected erythrocytes induce human brain endothelial cells to express inflammatory molecules including CCL20, CXCL1, CXCL2, IL-6, and IL-8, and intercellular adhesion molecule (ICAM)-1 (Tripathi et al., 2009; Tripathi et al., 2006) .", [["erythrocytes", "ANATOMY", 28, 40], ["brain endothelial cells", "ANATOMY", 54, 77], ["erythrocytes", "CELL", 28, 40], ["human", "ORGANISM", 48, 53], ["brain endothelial cells", "CELL", 54, 77], ["CCL20", "GENE_OR_GENE_PRODUCT", 122, 127], ["CXCL1", "GENE_OR_GENE_PRODUCT", 129, 134], ["CXCL2", "GENE_OR_GENE_PRODUCT", 136, 141], ["IL-6", "GENE_OR_GENE_PRODUCT", 143, 147], ["IL-8", "GENE_OR_GENE_PRODUCT", 153, 157], ["intercellular adhesion molecule (ICAM)-1", "GENE_OR_GENE_PRODUCT", 163, 203], ["P. falciparuminfected erythrocytes", "CELL_TYPE", 6, 40], ["human brain endothelial cells", "CELL_TYPE", 48, 77], ["inflammatory molecules", "PROTEIN", 89, 111], ["CCL20", "PROTEIN", 122, 127], ["CXCL1", "PROTEIN", 129, 134], ["CXCL2", "PROTEIN", 136, 141], ["IL-6", "PROTEIN", 143, 147], ["IL-8", "PROTEIN", 153, 157], ["intercellular adhesion molecule", "PROTEIN", 163, 194], ["ICAM", "PROTEIN", 196, 200], ["human", "SPECIES", 48, 53], ["P. falciparuminfected", "SPECIES", 6, 27], ["human", "SPECIES", 48, 53], ["P. falciparuminfected erythrocytes", "TEST", 6, 40], ["human brain endothelial cells", "PROBLEM", 48, 77], ["inflammatory molecules", "PROBLEM", 89, 111], ["CCL20", "TEST", 122, 127], ["CXCL1", "TEST", 129, 134], ["CXCL2", "TEST", 136, 141], ["IL", "TEST", 143, 145], ["IL", "TEST", 153, 155], ["intercellular adhesion molecule", "TREATMENT", 163, 194], ["brain", "ANATOMY", 54, 59], ["endothelial cells", "OBSERVATION", 60, 77], ["inflammatory", "OBSERVATION_MODIFIER", 89, 101], ["CCL20", "ANATOMY", 122, 127], ["CXCL1", "ANATOMY", 129, 134], ["CXCL2", "ANATOMY", 136, 141], ["intercellular", "ANATOMY_MODIFIER", 163, 176], ["adhesion molecule", "OBSERVATION", 177, 194]]], ["In murine models of cerebral malaria that use the P. berghei ANKA strain, blockade of lymphocyte function-associated antigen (LFA) 1, which binds ICAM-1, and treatment with liposomal corticosteroids, which stabilizes TJ integrity, both reduced BBB disruption.", [["cerebral", "ANATOMY", 20, 28], ["lymphocyte", "ANATOMY", 86, 96], ["TJ", "ANATOMY", 217, 219], ["BBB", "ANATOMY", 244, 247], ["cerebral malaria", "DISEASE", 20, 36], ["liposomal corticosteroids", "CHEMICAL", 173, 198], ["corticosteroids", "CHEMICAL", 183, 198], ["murine", "ORGANISM", 3, 9], ["cerebral", "ORGAN", 20, 28], ["P. berghei", "ORGANISM", 50, 60], ["ANKA", "ORGANISM", 61, 65], ["strain", "ORGANISM", 66, 72], ["lymphocyte function-associated antigen (LFA) 1", "GENE_OR_GENE_PRODUCT", 86, 132], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 146, 152], ["liposomal corticosteroids", "SIMPLE_CHEMICAL", 173, 198], ["TJ", "GENE_OR_GENE_PRODUCT", 217, 219], ["BBB", "MULTI-TISSUE_STRUCTURE", 244, 247], ["lymphocyte function-associated antigen (LFA) 1", "PROTEIN", 86, 132], ["ICAM-1", "PROTEIN", 146, 152], ["TJ", "PROTEIN", 217, 219], ["murine", "SPECIES", 3, 9], ["P. berghei", "SPECIES", 50, 60], ["P. berghei", "SPECIES", 50, 60], ["cerebral malaria", "PROBLEM", 20, 36], ["the P. berghei ANKA strain", "PROBLEM", 46, 72], ["lymphocyte function", "TEST", 86, 105], ["binds ICAM", "TEST", 140, 150], ["treatment", "TREATMENT", 158, 167], ["liposomal corticosteroids", "TREATMENT", 173, 198], ["both reduced BBB disruption", "PROBLEM", 231, 258], ["cerebral", "ANATOMY", 20, 28], ["malaria", "OBSERVATION", 29, 36], ["liposomal corticosteroids", "OBSERVATION", 173, 198], ["reduced", "OBSERVATION_MODIFIER", 236, 243], ["BBB disruption", "OBSERVATION", 244, 258]]], ["Viral Modulation of BBB FunctionViruses might impact on TJ integrity via direct and indirect mechanisms: (1) virus detection by brain endothelial TAM receptors in conjunction with type I IFN signaling enhances TJ integrity (Miner et al., 2015) ; (2) nonstructural protein (NS)1 secretion by flaviviruses might decrease TJ integrity, increasing barrier permeability; (3) PRR signaling during viral infection of astrocytes leads to type I IFN expression which has been shown to improve BBB function via intercellular crosstalk with brain endothelium ; (Pfefferkorn et al., 2015) ; and (4) secretion of transactivator protein (TAT) during CNS infection with HIV-1 induces pericyte expression of PDGFb, which disrupts BBB junctional proteins and promotes pericyte migration away from the vasculature (Niu et al., 2014) , (Winkler et al., 2010) .", [["TJ", "ANATOMY", 56, 58], ["brain endothelial", "ANATOMY", 128, 145], ["TJ", "ANATOMY", 210, 212], ["TJ", "ANATOMY", 319, 321], ["barrier", "ANATOMY", 344, 351], ["astrocytes", "ANATOMY", 410, 420], ["BBB", "ANATOMY", 484, 487], ["intercellular", "ANATOMY", 501, 514], ["brain endothelium", "ANATOMY", 530, 547], ["CNS", "ANATOMY", 636, 639], ["pericyte", "ANATOMY", 669, 677], ["BBB junctional", "ANATOMY", 714, 728], ["pericyte", "ANATOMY", 751, 759], ["vasculature", "ANATOMY", 784, 795], ["TAM", "CHEMICAL", 146, 149], ["infection", "DISEASE", 397, 406], ["infection", "DISEASE", 640, 649], ["TAM", "CHEMICAL", 146, 149], ["BBB FunctionViruses", "GENE_OR_GENE_PRODUCT", 20, 39], ["TJ", "GENE_OR_GENE_PRODUCT", 56, 58], ["brain endothelial TAM receptors", "GENE_OR_GENE_PRODUCT", 128, 159], ["type I IFN", "GENE_OR_GENE_PRODUCT", 180, 190], ["TJ", "TISSUE", 210, 212], ["nonstructural protein (NS)1", "GENE_OR_GENE_PRODUCT", 250, 277], ["TJ", "GENE_OR_GENE_PRODUCT", 319, 321], ["barrier", "TISSUE", 344, 351], ["PRR", "GENE_OR_GENE_PRODUCT", 370, 373], ["astrocytes", "CELL", 410, 420], ["type I IFN", "GENE_OR_GENE_PRODUCT", 430, 440], ["BBB", "MULTI-TISSUE_STRUCTURE", 484, 487], ["brain endothelium", "TISSUE", 530, 547], ["transactivator protein", "GENE_OR_GENE_PRODUCT", 600, 622], ["TAT", "GENE_OR_GENE_PRODUCT", 624, 627], ["CNS", "ANATOMICAL_SYSTEM", 636, 639], ["HIV-1", "ORGANISM", 655, 660], ["pericyte", "CELL", 669, 677], ["PDGFb", "GENE_OR_GENE_PRODUCT", 692, 697], ["BBB junctional", "CELLULAR_COMPONENT", 714, 728], ["pericyte", "CELL", 751, 759], ["vasculature", "MULTI-TISSUE_STRUCTURE", 784, 795], ["brain endothelial TAM receptors", "PROTEIN", 128, 159], ["IFN", "PROTEIN", 187, 190], ["nonstructural protein (NS)1", "PROTEIN", 250, 277], ["PRR", "PROTEIN", 370, 373], ["astrocytes", "CELL_TYPE", 410, 420], ["IFN", "PROTEIN", 437, 440], ["transactivator protein", "PROTEIN", 600, 622], ["TAT", "PROTEIN", 624, 627], ["PDGFb", "PROTEIN", 692, 697], ["BBB junctional proteins", "PROTEIN", 714, 737], ["HIV-1", "SPECIES", 655, 660], ["HIV-1", "SPECIES", 655, 660], ["Viral Modulation of BBB FunctionViruses", "PROBLEM", 0, 39], ["TJ integrity", "TREATMENT", 56, 68], ["virus detection", "TEST", 109, 124], ["brain endothelial TAM receptors", "TREATMENT", 128, 159], ["nonstructural protein (NS)", "TREATMENT", 250, 276], ["flaviviruses", "PROBLEM", 291, 303], ["increasing barrier permeability", "PROBLEM", 333, 364], ["PRR signaling during viral infection of astrocytes", "PROBLEM", 370, 420], ["type I IFN expression", "PROBLEM", 430, 451], ["secretion of transactivator protein (TAT) during CNS infection", "PROBLEM", 587, 649], ["HIV", "PROBLEM", 655, 658], ["pericyte expression of PDGFb", "PROBLEM", 669, 697], ["BBB junctional proteins", "PROBLEM", 714, 737], ["BBB FunctionViruses", "OBSERVATION", 20, 39], ["increasing", "OBSERVATION_MODIFIER", 333, 343], ["barrier permeability", "OBSERVATION_MODIFIER", 344, 364], ["infection", "OBSERVATION", 397, 406], ["brain endothelium", "ANATOMY", 530, 547], ["CNS", "ANATOMY", 636, 639], ["infection", "OBSERVATION", 640, 649], ["pericyte migration", "OBSERVATION", 751, 769], ["vasculature", "ANATOMY", 784, 795]]], ["These latter studies illustrate the principal that targeting the effects of pathogens at the BBB might provide an opportunity for adjuvant therapeutic approaches to prevent or manage local immunopathology..", [["BBB", "ANATOMY", 93, 96], ["BBB", "MULTI-TISSUE_STRUCTURE", 93, 96], ["These latter studies", "TEST", 0, 20], ["pathogens", "PROBLEM", 76, 85], ["adjuvant therapeutic approaches", "TREATMENT", 130, 161], ["local immunopathology", "PROBLEM", 183, 204]]], ["Viral Modulation of BBB FunctionMechanisms of Innate and Adaptive Protective Immunity in the CNS Infections of a host with neurotropic pathogens typically occurs at sites such as the skin, mucosa, gut, or lung, via inoculation, ingestion, or inhalation followed by replication and eventual dissemination to the CNS.", [["CNS", "ANATOMY", 93, 96], ["sites", "ANATOMY", 165, 170], ["skin", "ANATOMY", 183, 187], ["mucosa", "ANATOMY", 189, 195], ["gut", "ANATOMY", 197, 200], ["lung", "ANATOMY", 205, 209], ["CNS", "ANATOMY", 311, 314], ["Infections", "DISEASE", 97, 107], ["neurotropic pathogens", "DISEASE", 123, 144], ["CNS", "ANATOMICAL_SYSTEM", 93, 96], ["skin", "ORGAN", 183, 187], ["mucosa", "MULTI-TISSUE_STRUCTURE", 189, 195], ["gut", "ORGAN", 197, 200], ["lung", "ORGAN", 205, 209], ["CNS", "ANATOMICAL_SYSTEM", 311, 314], ["neurotropic pathogens", "PROBLEM", 123, 144], ["inhalation", "TREATMENT", 242, 252], ["BBB FunctionMechanisms", "OBSERVATION", 20, 42], ["CNS", "ANATOMY", 93, 96], ["Infections", "OBSERVATION", 97, 107], ["skin", "ANATOMY", 183, 187], ["mucosa", "ANATOMY", 189, 195], ["gut", "ANATOMY", 197, 200], ["lung", "ANATOMY", 205, 209]]], ["The temporal nature of these events ensures that the initial activation of innate arms of the immune system occurs in the periphery and influences the generation and expansion of pathogen specific T cells that promote cell intrinsic mechanisms that limit microbial replication.", [["immune system", "ANATOMY", 94, 107], ["T cells", "ANATOMY", 197, 204], ["cell", "ANATOMY", 218, 222], ["immune system", "ANATOMICAL_SYSTEM", 94, 107], ["T cells", "CELL", 197, 204], ["cell", "CELL", 218, 222], ["pathogen specific T cells", "CELL_TYPE", 179, 204], ["pathogen specific T cells", "PROBLEM", 179, 204], ["microbial replication", "TREATMENT", 255, 276], ["temporal", "OBSERVATION_MODIFIER", 4, 12], ["immune system", "OBSERVATION", 94, 107], ["expansion", "OBSERVATION_MODIFIER", 166, 175]]], ["As noted earlier, a wide range of PRRs are expressed by all cells of the NVU and the choroid plexus (CP), and by neuronal and nonneuronal cells within the CNS.", [["cells", "ANATOMY", 60, 65], ["NVU", "ANATOMY", 73, 76], ["choroid plexus", "ANATOMY", 85, 99], ["CP", "ANATOMY", 101, 103], ["neuronal", "ANATOMY", 113, 121], ["nonneuronal cells", "ANATOMY", 126, 143], ["CNS", "ANATOMY", 155, 158], ["PRRs", "GENE_OR_GENE_PRODUCT", 34, 38], ["cells", "CELL", 60, 65], ["NVU", "CANCER", 73, 76], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 85, 99], ["CP", "MULTI-TISSUE_STRUCTURE", 101, 103], ["neuronal", "CELL", 113, 121], ["nonneuronal cells", "CELL", 126, 143], ["CNS", "ANATOMICAL_SYSTEM", 155, 158], ["PRRs", "PROTEIN", 34, 38], ["neuronal and nonneuronal cells", "CELL_TYPE", 113, 143], ["the choroid plexus (CP", "PROBLEM", 81, 103], ["all cells", "OBSERVATION", 56, 65], ["choroid plexus", "ANATOMY", 85, 99], ["nonneuronal cells", "OBSERVATION", 126, 143], ["CNS", "ANATOMY", 155, 158]]], ["These innate sensors direct the local recruitment of leukocytes (most commonly neutrophils, T cells, B cells, monocytes, and dendritic cells), required for microbial control.", [["leukocytes", "ANATOMY", 53, 63], ["neutrophils", "ANATOMY", 79, 90], ["T cells", "ANATOMY", 92, 99], ["B cells", "ANATOMY", 101, 108], ["monocytes", "ANATOMY", 110, 119], ["dendritic cells", "ANATOMY", 125, 140], ["leukocytes", "CELL", 53, 63], ["neutrophils", "CELL", 79, 90], ["T cells", "CELL", 92, 99], ["B cells", "CELL", 101, 108], ["monocytes", "CELL", 110, 119], ["dendritic cells", "CELL", 125, 140], ["leukocytes", "CELL_TYPE", 53, 63], ["neutrophils", "CELL_TYPE", 79, 90], ["T cells", "CELL_TYPE", 92, 99], ["B cells", "CELL_TYPE", 101, 108], ["monocytes", "CELL_TYPE", 110, 119], ["dendritic cells", "CELL_TYPE", 125, 140], ["leukocytes", "TEST", 53, 63], ["neutrophils", "TEST", 79, 90], ["T cells", "TEST", 92, 99], ["B cells", "TEST", 101, 108], ["monocytes", "TEST", 110, 119], ["microbial control", "TREATMENT", 156, 173], ["leukocytes", "ANATOMY", 53, 63], ["monocytes", "ANATOMY", 110, 119], ["dendritic cells", "OBSERVATION", 125, 140]]], ["There are several well-characterized portals of entry for inflammatory cells into the brain, including the fenestrated vasculature within the subarachnoid space and CP, and across epithelial and ependymal cells or astrocyte endfeet of the CP and BBB respectively (Engelhardt et al., 2017) .", [["inflammatory cells", "ANATOMY", 58, 76], ["brain", "ANATOMY", 86, 91], ["vasculature", "ANATOMY", 119, 130], ["subarachnoid space", "ANATOMY", 142, 160], ["epithelial", "ANATOMY", 180, 190], ["ependymal cells", "ANATOMY", 195, 210], ["astrocyte endfeet", "ANATOMY", 214, 231], ["BBB", "ANATOMY", 246, 249], ["inflammatory cells", "CELL", 58, 76], ["brain", "ORGAN", 86, 91], ["fenestrated vasculature", "MULTI-TISSUE_STRUCTURE", 107, 130], ["subarachnoid space", "MULTI-TISSUE_STRUCTURE", 142, 160], ["epithelial", "CELL", 180, 190], ["ependymal cells", "CELL", 195, 210], ["astrocyte endfeet", "CELLULAR_COMPONENT", 214, 231], ["CP", "MULTI-TISSUE_STRUCTURE", 239, 241], ["BBB", "MULTI-TISSUE_STRUCTURE", 246, 249], ["inflammatory cells", "CELL_TYPE", 58, 76], ["epithelial and ependymal cells", "CELL_TYPE", 180, 210], ["inflammatory cells into the brain", "PROBLEM", 58, 91], ["the fenestrated vasculature within the subarachnoid space", "PROBLEM", 103, 160], ["CP", "PROBLEM", 165, 167], ["across epithelial and ependymal cells", "PROBLEM", 173, 210], ["several", "OBSERVATION_MODIFIER", 10, 17], ["well-characterized", "OBSERVATION_MODIFIER", 18, 36], ["portals", "ANATOMY_MODIFIER", 37, 44], ["inflammatory cells", "OBSERVATION", 58, 76], ["brain", "ANATOMY", 86, 91], ["fenestrated", "ANATOMY_MODIFIER", 107, 118], ["vasculature", "ANATOMY", 119, 130], ["subarachnoid space", "ANATOMY", 142, 160], ["CP", "OBSERVATION_MODIFIER", 165, 167], ["epithelial", "ANATOMY_MODIFIER", 180, 190], ["ependymal cells", "OBSERVATION", 195, 210], ["astrocyte endfeet", "OBSERVATION", 214, 231], ["CP", "OBSERVATION_MODIFIER", 239, 241], ["BBB", "ANATOMY", 246, 249]]], ["In this section, we will detail the cellular and molecular mechanisms of innate and adaptive immune responses that control pathogen invasion, replication and persistence within the CNS, citing recent reviews for well-established discoveries.", [["cellular", "ANATOMY", 36, 44], ["CNS", "ANATOMY", 181, 184], ["cellular", "CELL", 36, 44], ["CNS", "ANATOMICAL_SYSTEM", 181, 184], ["pathogen invasion", "PROBLEM", 123, 140], ["CNS", "ANATOMY", 181, 184]]], ["Innate Immunity and Neuro-protection For many pathogens that are restricted to the NVU, access to the CNS parenchyma is generally prevented by robust innate immune responses within the meninges and ventricular system (Neal and Gasque, 2013) .", [["CNS parenchyma", "ANATOMY", 102, 116], ["meninges", "ANATOMY", 185, 193], ["ventricular system", "ANATOMY", 198, 216], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 102, 116], ["meninges", "MULTI-TISSUE_STRUCTURE", 185, 193], ["ventricular system", "MULTI-TISSUE_STRUCTURE", 198, 216], ["Neuro-protection", "TREATMENT", 20, 36], ["many pathogens", "PROBLEM", 41, 55], ["pathogens", "OBSERVATION", 46, 55], ["CNS", "ANATOMY", 102, 105], ["parenchyma", "ANATOMY_MODIFIER", 106, 116], ["meninges", "ANATOMY", 185, 193], ["ventricular system", "ANATOMY", 198, 216]]], ["Interactions of infected myeloid cells or free pathogens with the vasculature at these sites lead to expression of adhesion molecules, including vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1 or -2, and chemoattractants CXCL2, leukotriene B4, and complement component C5a, by epithelial or endothelial barriers that recruit neutrophils and monocytes (Neal and Gasque, 2013) .", [["myeloid cells", "ANATOMY", 25, 38], ["vasculature", "ANATOMY", 66, 77], ["epithelial", "ANATOMY", 315, 325], ["endothelial", "ANATOMY", 329, 340], ["neutrophils", "ANATOMY", 363, 374], ["monocytes", "ANATOMY", 379, 388], ["myeloid cells", "CELL", 25, 38], ["vasculature", "MULTI-TISSUE_STRUCTURE", 66, 77], ["vascular cell adhesion molecule (VCAM)-1", "GENE_OR_GENE_PRODUCT", 145, 185], ["intercellular adhesion molecule (ICAM)-1", "GENE_OR_GENE_PRODUCT", 190, 230], ["-2", "GENE_OR_GENE_PRODUCT", 234, 236], ["CXCL2", "GENE_OR_GENE_PRODUCT", 259, 264], ["leukotriene B4", "GENE_OR_GENE_PRODUCT", 266, 280], ["complement component C5a", "GENE_OR_GENE_PRODUCT", 286, 310], ["epithelial", "CELL", 315, 325], ["endothelial", "CELL", 329, 340], ["neutrophils", "CELL", 363, 374], ["monocytes", "CELL", 379, 388], ["infected myeloid cells", "CELL_TYPE", 16, 38], ["adhesion molecules", "PROTEIN", 115, 133], ["vascular cell adhesion molecule (VCAM)-1", "PROTEIN", 145, 185], ["intercellular adhesion molecule (ICAM)-1 or -2", "PROTEIN", 190, 236], ["chemoattractants", "PROTEIN", 242, 258], ["CXCL2", "PROTEIN", 259, 264], ["leukotriene B4", "PROTEIN", 266, 280], ["complement component C5a", "PROTEIN", 286, 310], ["neutrophils", "CELL_TYPE", 363, 374], ["monocytes", "CELL_TYPE", 379, 388], ["infected myeloid cells", "PROBLEM", 16, 38], ["free pathogens", "PROBLEM", 42, 56], ["the vasculature at these sites", "PROBLEM", 62, 92], ["adhesion molecules", "PROBLEM", 115, 133], ["vascular cell adhesion molecule", "TEST", 145, 176], ["VCAM)", "TEST", 178, 183], ["intercellular adhesion molecule", "TEST", 190, 221], ["ICAM", "TEST", 223, 227], ["chemoattractants CXCL2", "TEST", 242, 264], ["leukotriene B4", "TEST", 266, 280], ["complement component C5a", "PROBLEM", 286, 310], ["epithelial or endothelial barriers", "PROBLEM", 315, 349], ["neutrophils", "TEST", 363, 374], ["monocytes", "TEST", 379, 388], ["infected myeloid cells", "OBSERVATION", 16, 38], ["free", "OBSERVATION_MODIFIER", 42, 46], ["pathogens", "OBSERVATION", 47, 56], ["vasculature", "ANATOMY", 66, 77], ["adhesion molecules", "OBSERVATION", 115, 133], ["vascular cell", "ANATOMY", 145, 158], ["adhesion molecule", "OBSERVATION", 159, 176], ["chemoattractants CXCL2", "ANATOMY", 242, 264], ["epithelial", "ANATOMY_MODIFIER", 315, 325], ["endothelial", "ANATOMY", 329, 340]]], ["There are high constitutive levels of complement proteins present in the CNS, which contribute to normal neuronal function and microglial activity, but less is known about their function during neural infection (Veerhuis et al., 2011) .", [["CNS", "ANATOMY", 73, 76], ["neuronal", "ANATOMY", 105, 113], ["microglial", "ANATOMY", 127, 137], ["neural", "ANATOMY", 194, 200], ["neural infection", "DISEASE", 194, 210], ["complement proteins", "GENE_OR_GENE_PRODUCT", 38, 57], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["neuronal", "CELL", 105, 113], ["microglial", "CELL", 127, 137], ["complement proteins", "PROTEIN", 38, 57], ["complement proteins", "PROBLEM", 38, 57], ["neural infection", "PROBLEM", 194, 210], ["high constitutive", "OBSERVATION_MODIFIER", 10, 27], ["levels", "OBSERVATION_MODIFIER", 28, 34], ["proteins", "OBSERVATION", 49, 57], ["CNS", "ANATOMY", 73, 76], ["normal neuronal function", "OBSERVATION", 98, 122], ["microglial activity", "OBSERVATION", 127, 146], ["infection", "OBSERVATION", 201, 210]]], ["Indirect evidence for their role in the brain is provided by the observation that patients with primary immune deficiencies that affect complement are uniquely susceptible to meningitis caused by N. meningitides (Lewis and Ram, 2014) .", [["brain", "ANATOMY", 40, 45], ["primary immune deficiencies", "DISEASE", 96, 123], ["meningitis", "DISEASE", 175, 185], ["brain", "ORGAN", 40, 45], ["patients", "ORGANISM", 82, 90], ["N. meningitides", "ORGANISM", 196, 211], ["patients", "SPECIES", 82, 90], ["N. meningitides", "SPECIES", 196, 211], ["N. meningitides", "SPECIES", 196, 211], ["their role in the brain", "PROBLEM", 22, 45], ["primary immune deficiencies", "PROBLEM", 96, 123], ["meningitis", "PROBLEM", 175, 185], ["brain", "ANATOMY", 40, 45], ["meningitis", "OBSERVATION", 175, 185]]], ["Further, analysis of human samples of cerebral aspergilosis indicates the highest levels of C3 were associated with fungal control but also that the hyphal forms of this organism were resistant to C3 deposition (Rambach et al., 2008) ..", [["samples", "ANATOMY", 27, 34], ["cerebral", "ANATOMY", 38, 46], ["hyphal", "ANATOMY", 149, 155], ["cerebral aspergilosis", "DISEASE", 38, 59], ["human", "ORGANISM", 21, 26], ["cerebral aspergilosis", "CANCER", 38, 59], ["C3", "GENE_OR_GENE_PRODUCT", 92, 94], ["C3", "SIMPLE_CHEMICAL", 197, 199], ["C3", "PROTEIN", 92, 94], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["human samples", "TEST", 21, 34], ["cerebral aspergilosis", "PROBLEM", 38, 59], ["fungal control", "TREATMENT", 116, 130], ["this organism", "PROBLEM", 165, 178], ["cerebral", "ANATOMY", 38, 46]]], ["Viral Modulation of BBB FunctionThe receptor CCR2 and its ligand CCL2 (aka monocyte chemo-attractant protein 1) plays a major role in the mobilization of monocytes and neutrophils.", [["monocytes", "ANATOMY", 154, 163], ["neutrophils", "ANATOMY", 168, 179], ["BBB", "MULTI-TISSUE_STRUCTURE", 20, 23], ["CCR2", "GENE_OR_GENE_PRODUCT", 45, 49], ["CCL2", "GENE_OR_GENE_PRODUCT", 65, 69], ["aka monocyte chemo-attractant protein 1", "GENE_OR_GENE_PRODUCT", 71, 110], ["monocytes", "CELL", 154, 163], ["neutrophils", "CELL", 168, 179], ["CCR2", "PROTEIN", 45, 49], ["CCL2", "PROTEIN", 65, 69], ["aka monocyte chemo-attractant protein 1", "PROTEIN", 71, 110], ["monocytes", "CELL_TYPE", 154, 163], ["neutrophils", "CELL_TYPE", 168, 179], ["The receptor CCR2", "TEST", 32, 49], ["its ligand CCL2", "TEST", 54, 69], ["aka monocyte chemo-attractant protein", "TREATMENT", 71, 108], ["neutrophils", "TEST", 168, 179]]], ["The infiltration of CCR2-expressing Ly6C hi monocytes has been observed in animal models that study the CNS involvement with T. gondii, WNV, or murine hepatitis virus (MHV).", [["Ly6C hi monocytes", "ANATOMY", 36, 53], ["CNS", "ANATOMY", 104, 107], ["murine hepatitis virus", "DISEASE", 144, 166], ["CCR2", "GENE_OR_GENE_PRODUCT", 20, 24], ["Ly6C hi monocytes", "CELL", 36, 53], ["CNS", "ANATOMICAL_SYSTEM", 104, 107], ["T. gondii", "ORGANISM", 125, 134], ["WNV", "ORGANISM", 136, 139], ["murine hepatitis virus", "ORGANISM", 144, 166], ["MHV", "ORGANISM", 168, 171], ["CCR2", "PROTEIN", 20, 24], ["Ly6C hi monocytes", "CELL_LINE", 36, 53], ["T. gondii", "SPECIES", 125, 134], ["murine", "SPECIES", 144, 150], ["hepatitis virus", "SPECIES", 151, 166], ["T. gondii", "SPECIES", 125, 134], ["WNV", "SPECIES", 136, 139], ["murine hepatitis virus", "SPECIES", 144, 166], ["MHV", "SPECIES", 168, 171], ["The infiltration", "PROBLEM", 0, 16], ["CCR2", "TEST", 20, 24], ["T. gondii", "PROBLEM", 125, 134], ["WNV", "PROBLEM", 136, 139], ["murine hepatitis virus", "PROBLEM", 144, 166], ["infiltration", "OBSERVATION", 4, 16], ["CCR2", "ANATOMY", 20, 24], ["Ly6C", "OBSERVATION_MODIFIER", 36, 40], ["monocytes", "OBSERVATION", 44, 53], ["CNS", "ANATOMY", 104, 107]]], ["In these systems, CCR2 inactivation is associ-ated with decreased leukocyte trafficking and activation of immune cells within the CNS, and a reduced ability to control these pathogens (Benevides et al., 2008; Biswas et al., 2015; Chen et al., 2001) .", [["leukocyte", "ANATOMY", 66, 75], ["immune cells", "ANATOMY", 106, 118], ["CNS", "ANATOMY", 130, 133], ["CCR2", "GENE_OR_GENE_PRODUCT", 18, 22], ["leukocyte", "CELL", 66, 75], ["immune cells", "CELL", 106, 118], ["CNS", "ANATOMICAL_SYSTEM", 130, 133], ["CCR2", "PROTEIN", 18, 22], ["immune cells", "CELL_TYPE", 106, 118], ["CCR2 inactivation", "PROBLEM", 18, 35], ["decreased leukocyte trafficking", "PROBLEM", 56, 87], ["immune cells", "PROBLEM", 106, 118], ["a reduced ability", "PROBLEM", 139, 156], ["CCR2 inactivation", "OBSERVATION", 18, 35], ["decreased leukocyte trafficking", "OBSERVATION", 56, 87], ["immune cells", "OBSERVATION", 106, 118], ["CNS", "ANATOMY", 130, 133]]], ["The presence of anti-inflammatory (M2) macrophages or microglia in the CNS is subject of an ongoing debate, but in a murine model of chronic toxoplasmosis, a subset of infiltrating macrophages express canonical M2 markers: CD206 (the mannose receptor), the chitinase AMCase and arginase (Nance et al., 2012) .", [["macrophages", "ANATOMY", 39, 50], ["microglia", "ANATOMY", 54, 63], ["CNS", "ANATOMY", 71, 74], ["infiltrating macrophages", "ANATOMY", 168, 192], ["chronic toxoplasmosis", "DISEASE", 133, 154], ["mannose", "CHEMICAL", 234, 241], ["macrophages", "CELL", 39, 50], ["microglia", "CELL", 54, 63], ["CNS", "ANATOMICAL_SYSTEM", 71, 74], ["murine", "ORGANISM", 117, 123], ["macrophages", "CELL", 181, 192], ["M2", "GENE_OR_GENE_PRODUCT", 211, 213], ["CD206", "GENE_OR_GENE_PRODUCT", 223, 228], ["mannose receptor", "GENE_OR_GENE_PRODUCT", 234, 250], ["chitinase AMCase", "GENE_OR_GENE_PRODUCT", 257, 273], ["arginase", "GENE_OR_GENE_PRODUCT", 278, 286], ["anti-inflammatory (M2) macrophages", "CELL_TYPE", 16, 50], ["microglia", "CELL_TYPE", 54, 63], ["infiltrating macrophages", "CELL_TYPE", 168, 192], ["M2 markers", "PROTEIN", 211, 221], ["CD206", "PROTEIN", 223, 228], ["mannose receptor", "PROTEIN", 234, 250], ["chitinase AMCase", "PROTEIN", 257, 273], ["arginase", "PROTEIN", 278, 286], ["murine", "SPECIES", 117, 123], ["anti-inflammatory (M2) macrophages", "PROBLEM", 16, 50], ["microglia in the CNS", "PROBLEM", 54, 74], ["chronic toxoplasmosis", "PROBLEM", 133, 154], ["infiltrating macrophages", "PROBLEM", 168, 192], ["the mannose receptor", "TREATMENT", 230, 250], ["the chitinase AMCase", "TEST", 253, 273], ["anti-inflammatory", "OBSERVATION_MODIFIER", 16, 33], ["M2", "OBSERVATION_MODIFIER", 35, 37], ["macrophages", "OBSERVATION", 39, 50], ["CNS", "ANATOMY", 71, 74], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["toxoplasmosis", "OBSERVATION", 141, 154], ["infiltrating macrophages", "OBSERVATION", 168, 192], ["M2", "OBSERVATION_MODIFIER", 211, 213]]], ["While these cells might be expected to have a role in resolution of inflammation, mice that lack AMCase have a higher parasite burden in the CNS.", [["cells", "ANATOMY", 12, 17], ["CNS", "ANATOMY", 141, 144], ["inflammation", "DISEASE", 68, 80], ["cells", "CELL", 12, 17], ["mice", "ORGANISM", 82, 86], ["AMCase", "GENE_OR_GENE_PRODUCT", 97, 103], ["CNS", "ANATOMICAL_SYSTEM", 141, 144], ["AMCase", "PROTEIN", 97, 103], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["inflammation", "PROBLEM", 68, 80], ["a higher parasite burden in the CNS", "PROBLEM", 109, 144], ["inflammation", "OBSERVATION", 68, 80], ["higher", "OBSERVATION_MODIFIER", 111, 117], ["parasite", "OBSERVATION_MODIFIER", 118, 126], ["burden", "OBSERVATION", 127, 133], ["CNS", "ANATOMY", 141, 144]]], ["Based on these results, and those of in vitro studies, it has been proposed that these M2-like populations might be specialized to target the cyst stage of T. gondii (Nance et al., 2012) .", [["cyst", "ANATOMY", 142, 146], ["M2", "GENE_OR_GENE_PRODUCT", 87, 89], ["T. gondii", "ORGANISM", 156, 165], ["M2", "PROTEIN", 87, 89], ["T. gondii", "SPECIES", 156, 165], ["T. gondii", "SPECIES", 156, 165], ["vitro studies", "TEST", 40, 53], ["cyst", "OBSERVATION", 142, 146]]], ["These reports, in diverse experimental models, highlight the context dependent contribution of chemokine-mediated recruitment of myelomonocytic cells for protective immune responses within the CNS.", [["myelomonocytic cells", "ANATOMY", 129, 149], ["CNS", "ANATOMY", 193, 196], ["myelomonocytic cells", "CELL", 129, 149], ["CNS", "ANATOMICAL_SYSTEM", 193, 196], ["chemokine", "PROTEIN", 95, 104], ["myelomonocytic cells", "CELL_TYPE", 129, 149], ["chemokine-mediated recruitment of myelomonocytic cells", "TREATMENT", 95, 149], ["protective immune responses", "TREATMENT", 154, 181], ["myelomonocytic cells", "OBSERVATION", 129, 149], ["CNS", "ANATOMY", 193, 196]]], ["Neural Cell Responses to Infection All neural cell types, including neurons, astrocytes, oligodendrocytes, and microglia, are capable of initiating and responding to inflammatory responses during infection (Nair and Diamond, 2015) .", [["Cell", "ANATOMY", 7, 11], ["neural cell", "ANATOMY", 39, 50], ["neurons", "ANATOMY", 68, 75], ["astrocytes", "ANATOMY", 77, 87], ["oligodendrocytes", "ANATOMY", 89, 105], ["microglia", "ANATOMY", 111, 120], ["Infection", "DISEASE", 25, 34], ["infection", "DISEASE", 196, 205], ["Neural Cell", "CELL", 0, 11], ["neural cell", "CELL", 39, 50], ["neurons", "CELL", 68, 75], ["astrocytes", "CELL", 77, 87], ["oligodendrocytes", "CELL", 89, 105], ["microglia", "CELL", 111, 120], ["neural cell types", "CELL_TYPE", 39, 56], ["neurons", "CELL_TYPE", 68, 75], ["astrocytes", "CELL_TYPE", 77, 87], ["oligodendrocytes", "CELL_TYPE", 89, 105], ["microglia", "CELL_TYPE", 111, 120], ["Infection", "PROBLEM", 25, 34], ["oligodendrocytes", "PROBLEM", 89, 105], ["inflammatory responses during infection", "PROBLEM", 166, 205], ["Infection", "OBSERVATION", 25, 34], ["neural cell types", "OBSERVATION", 39, 56], ["neurons", "ANATOMY", 68, 75], ["astrocytes", "ANATOMY", 77, 87], ["oligodendrocytes", "OBSERVATION", 89, 105], ["microglia", "ANATOMY", 111, 120], ["inflammatory", "OBSERVATION_MODIFIER", 166, 178]]], ["Neurons are electrically excitable cells that process and transmit information via electrical and chemical signals.", [["Neurons", "ANATOMY", 0, 7], ["cells", "ANATOMY", 35, 40], ["Neurons", "CELL", 0, 7], ["cells", "CELL", 35, 40], ["electrically excitable cells", "CELL_TYPE", 12, 40]]], ["Astrocytes and oligodendrocytes are glial cells that maintain CNS homeostasis, improve neurotransmission via chemical or physical insulation, and support and protect neurons (reviewed in J\u20ac akel and Dimou, 2017).", [["Astrocytes", "ANATOMY", 0, 10], ["oligodendrocytes", "ANATOMY", 15, 31], ["glial cells", "ANATOMY", 36, 47], ["CNS", "ANATOMY", 62, 65], ["neurons", "ANATOMY", 166, 173], ["Astrocytes", "CELL", 0, 10], ["oligodendrocytes", "CELL", 15, 31], ["glial cells", "CELL", 36, 47], ["CNS", "ANATOMICAL_SYSTEM", 62, 65], ["neurons", "CELL", 166, 173], ["Astrocytes", "CELL_TYPE", 0, 10], ["oligodendrocytes", "CELL_TYPE", 15, 31], ["glial cells", "CELL_TYPE", 36, 47], ["glial cells", "PROBLEM", 36, 47], ["physical insulation", "TREATMENT", 121, 140], ["glial cells", "OBSERVATION", 36, 47]]], ["Microglia are ontogenetically distinct members of the reticuloendothelial system that function as tissue macrophages within the CNS (reviewed in Colonna and Butovsky, 2017) .", [["Microglia", "ANATOMY", 0, 9], ["reticuloendothelial system", "ANATOMY", 54, 80], ["tissue macrophages", "ANATOMY", 98, 116], ["CNS", "ANATOMY", 128, 131], ["Microglia", "CELL", 0, 9], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 54, 80], ["tissue macrophages", "CELL", 98, 116], ["CNS", "ANATOMICAL_SYSTEM", 128, 131], ["Microglia", "CELL_TYPE", 0, 9], ["tissue macrophages", "CELL_TYPE", 98, 116], ["reticuloendothelial system", "ANATOMY", 54, 80], ["tissue", "OBSERVATION_MODIFIER", 98, 104], ["macrophages", "OBSERVATION", 105, 116], ["CNS", "ANATOMY", 128, 131]]], ["Microglia and resident dendritic cells are among the first responders to pathogen invasion, responding to PAMPs via liberation of pro-inflammatory cytokines and clearance of infected cells and debris (Drokhlyansky et al., 2017; Tufail et al., 2017) .", [["Microglia", "ANATOMY", 0, 9], ["dendritic cells", "ANATOMY", 23, 38], ["cells", "ANATOMY", 183, 188], ["Microglia", "CELL", 0, 9], ["resident dendritic cells", "CELL", 14, 38], ["PAMPs", "GENE_OR_GENE_PRODUCT", 106, 111], ["cells", "CELL", 183, 188], ["Microglia", "CELL_TYPE", 0, 9], ["resident dendritic cells", "CELL_TYPE", 14, 38], ["PAMPs", "PROTEIN", 106, 111], ["pro-inflammatory cytokines", "PROTEIN", 130, 156], ["infected cells", "CELL_TYPE", 174, 188], ["pathogen invasion", "PROBLEM", 73, 90], ["PAMPs", "TREATMENT", 106, 111], ["pro-inflammatory cytokines", "TREATMENT", 130, 156], ["infected cells", "PROBLEM", 174, 188], ["debris", "PROBLEM", 193, 199], ["dendritic cells", "OBSERVATION", 23, 38], ["pathogen", "OBSERVATION_MODIFIER", 73, 81], ["invasion", "OBSERVATION", 82, 90], ["pro-inflammatory cytokines", "OBSERVATION", 130, 156], ["infected cells", "OBSERVATION", 174, 188], ["debris", "OBSERVATION_MODIFIER", 193, 199]]], ["All of these neural cells express TLRs, Nod-like receptors (NLRs), RIG-like receptors (RLRs), mitochondrial anti-viral signaling (MAVS) (Zhao et al., 2016) , AIM2-like receptors (ALRs), C-type lectin receptors, and cytokine receptors (reviewed in Kigerl et al., 2014) .", [["neural cells", "ANATOMY", 13, 25], ["mitochondrial", "ANATOMY", 94, 107], ["neural cells", "CELL", 13, 25], ["TLRs", "GENE_OR_GENE_PRODUCT", 34, 38], ["Nod-like receptors", "GENE_OR_GENE_PRODUCT", 40, 58], ["NLRs", "GENE_OR_GENE_PRODUCT", 60, 64], ["RIG-like receptors", "GENE_OR_GENE_PRODUCT", 67, 85], ["RLRs", "GENE_OR_GENE_PRODUCT", 87, 91], ["mitochondrial", "CELLULAR_COMPONENT", 94, 107], ["MAVS", "GENE_OR_GENE_PRODUCT", 130, 134], ["AIM2-like receptors", "GENE_OR_GENE_PRODUCT", 158, 177], ["ALRs", "GENE_OR_GENE_PRODUCT", 179, 183], ["C-type lectin receptors", "GENE_OR_GENE_PRODUCT", 186, 209], ["neural cells", "CELL_TYPE", 13, 25], ["TLRs", "PROTEIN", 34, 38], ["Nod-like receptors", "PROTEIN", 40, 58], ["NLRs", "PROTEIN", 60, 64], ["RIG-like receptors", "PROTEIN", 67, 85], ["RLRs", "PROTEIN", 87, 91], ["MAVS", "PROTEIN", 130, 134], ["AIM2-like receptors", "PROTEIN", 158, 177], ["ALRs", "PROTEIN", 179, 183], ["C-type lectin receptors", "PROTEIN", 186, 209], ["cytokine receptors", "PROTEIN", 215, 233], ["RIG-like receptors", "PROBLEM", 67, 85], ["mitochondrial anti-viral signaling", "PROBLEM", 94, 128], ["AIM2", "TEST", 158, 162], ["neural cells", "OBSERVATION", 13, 25], ["anti-viral signaling", "OBSERVATION", 108, 128]]], ["Activation of many of these innate immune pathways converge on expression of type I IFNs and mononuclear cell chemoattractants (CCL2, CCL5, and CXCL9-11) and there are many studies that illustrate the relevance to CNS infection.", [["mononuclear cell", "ANATOMY", 93, 109], ["CNS", "ANATOMY", 214, 217], ["CNS infection", "DISEASE", 214, 227], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 77, 88], ["mononuclear cell", "CELL", 93, 109], ["CCL2", "GENE_OR_GENE_PRODUCT", 128, 132], ["CCL5", "GENE_OR_GENE_PRODUCT", 134, 138], ["CXCL9-11", "GENE_OR_GENE_PRODUCT", 144, 152], ["CNS", "ANATOMICAL_SYSTEM", 214, 217], ["type I IFNs", "PROTEIN", 77, 88], ["mononuclear cell chemoattractants", "PROTEIN", 93, 126], ["CCL2", "PROTEIN", 128, 132], ["CCL5", "PROTEIN", 134, 138], ["CXCL9", "PROTEIN", 144, 149], ["type I IFNs", "PROBLEM", 77, 88], ["mononuclear cell chemoattractants", "TEST", 93, 126], ["CCL2", "TEST", 128, 132], ["CCL5", "TEST", 134, 138], ["CXCL9", "TEST", 144, 149], ["many studies", "TEST", 168, 180], ["CNS infection", "PROBLEM", 214, 227], ["mononuclear cell chemoattractants", "OBSERVATION", 93, 126], ["CNS", "ANATOMY", 214, 217], ["infection", "OBSERVATION", 218, 227]]], ["The extended TLR3 signaling pathway is critical in mediating resistance to HSV encephalitis in humans and in mice (Andersen et al., 2015; Casrouge et al., 2006; Dupuis et al., 2003; Herman et al., 2012; Lafaille et al., 2012; Liu et al., 2011; P\u00e9 rez de Diego et al., 2010; Sancho-Shimizu et al., 2011; Zhang et al., 2007) .", [["HSV encephalitis", "DISEASE", 75, 91], ["TLR3", "GENE_OR_GENE_PRODUCT", 13, 17], ["HSV encephalitis", "ORGANISM", 75, 91], ["humans", "ORGANISM", 95, 101], ["mice", "ORGANISM", 109, 113], ["TLR3", "PROTEIN", 13, 17], ["humans", "SPECIES", 95, 101], ["mice", "SPECIES", 109, 113], ["HSV", "SPECIES", 75, 78], ["humans", "SPECIES", 95, 101], ["mice", "SPECIES", 109, 113], ["HSV encephalitis", "PROBLEM", 75, 91], ["HSV", "OBSERVATION_MODIFIER", 75, 78], ["encephalitis", "OBSERVATION", 79, 91]]], ["Other pathways mediate direct anti-pathogen effects, and MAVS sensing of bunyavirus in neurons leads to death of infected cells (Mukherjee et al., 2013) .", [["neurons", "ANATOMY", 87, 94], ["cells", "ANATOMY", 122, 127], ["death", "DISEASE", 104, 109], ["MAVS", "GENE_OR_GENE_PRODUCT", 57, 61], ["bunyavirus", "GENE_OR_GENE_PRODUCT", 73, 83], ["neurons", "CELL", 87, 94], ["cells", "CELL", 122, 127], ["MAVS", "PROTEIN", 57, 61], ["infected cells", "CELL_TYPE", 113, 127], ["direct anti-pathogen effects", "PROBLEM", 23, 51], ["bunyavirus", "PROBLEM", 73, 83], ["infected cells", "PROBLEM", 113, 127], ["bunyavirus", "OBSERVATION", 73, 83], ["infected cells", "OBSERVATION", 113, 127]]], ["In contrast, sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates antiviral defense in the CNS (Reinert et al., 2016) ..", [["microglia", "ANATOMY", 59, 68], ["CNS", "ANATOMY", 107, 110], ["HSV-1", "GENE_OR_GENE_PRODUCT", 24, 29], ["cGAS", "GENE_OR_GENE_PRODUCT", 37, 41], ["STING", "GENE_OR_GENE_PRODUCT", 42, 47], ["microglia", "CELL", 59, 68], ["CNS", "ANATOMICAL_SYSTEM", 107, 110], ["cGAS", "PROTEIN", 37, 41], ["STING", "PROTEIN", 42, 47], ["microglia", "CELL_TYPE", 59, 68], ["HSV-1", "SPECIES", 24, 29], ["HSV", "TEST", 24, 27], ["the cGAS", "TEST", 33, 41], ["antiviral defense", "OBSERVATION", 82, 99], ["CNS", "ANATOMY", 107, 110]]], ["Viral Modulation of BBB FunctionRegional or cellular heterogeneity in innate immune responses of neurons and astrocytes, in particular, might underlie observed differences in pathogen spread, persistence, and immunopathology in different regions of the CNS.", [["cellular", "ANATOMY", 44, 52], ["neurons", "ANATOMY", 97, 104], ["astrocytes", "ANATOMY", 109, 119], ["CNS", "ANATOMY", 253, 256], ["immunopathology", "DISEASE", 209, 224], ["BBB", "GENE_OR_GENE_PRODUCT", 20, 23], ["cellular", "CELL", 44, 52], ["neurons", "CELL", 97, 104], ["astrocytes", "CELL", 109, 119], ["CNS", "ANATOMICAL_SYSTEM", 253, 256], ["neurons", "CELL_TYPE", 97, 104], ["astrocytes", "CELL_TYPE", 109, 119], ["Viral Modulation of BBB", "PROBLEM", 0, 23], ["cellular heterogeneity", "PROBLEM", 44, 66], ["astrocytes", "PROBLEM", 109, 119], ["pathogen spread", "PROBLEM", 175, 190], ["immunopathology", "PROBLEM", 209, 224], ["BBB FunctionRegional", "OBSERVATION", 20, 40], ["cellular heterogeneity", "OBSERVATION", 44, 66], ["innate immune", "OBSERVATION", 70, 83], ["neurons", "ANATOMY", 97, 104], ["astrocytes", "ANATOMY", 109, 119], ["pathogen", "OBSERVATION_MODIFIER", 175, 183], ["spread", "OBSERVATION_MODIFIER", 184, 190], ["CNS", "ANATOMY", 253, 256]]], ["Indeed, cortical neurons have low levels of RIG-I, MDA5, ISG54, and ISG56 and consequently are more permissive to WNV than those in the hindbrain (Daffis et al., 2007) .", [["cortical neurons", "ANATOMY", 8, 24], ["hindbrain", "ANATOMY", 136, 145], ["cortical neurons", "CELL", 8, 24], ["RIG-I", "GENE_OR_GENE_PRODUCT", 44, 49], ["MDA5", "GENE_OR_GENE_PRODUCT", 51, 55], ["ISG54", "GENE_OR_GENE_PRODUCT", 57, 62], ["ISG56", "GENE_OR_GENE_PRODUCT", 68, 73], ["WNV", "ORGANISM", 114, 117], ["hindbrain", "ORGAN", 136, 145], ["cortical neurons", "CELL_TYPE", 8, 24], ["RIG-I", "PROTEIN", 44, 49], ["MDA5", "PROTEIN", 51, 55], ["ISG54", "PROTEIN", 57, 62], ["ISG56", "PROTEIN", 68, 73], ["WNV", "SPECIES", 114, 117], ["MDA5", "TEST", 51, 55], ["ISG54", "TEST", 57, 62], ["cortical", "ANATOMY_MODIFIER", 8, 16], ["neurons", "ANATOMY", 17, 24], ["low levels", "OBSERVATION_MODIFIER", 30, 40], ["MDA5", "ANATOMY", 51, 55], ["WNV", "OBSERVATION", 114, 117], ["hindbrain", "ANATOMY", 136, 145]]], ["Of interest, cerebellar pathology in patients with WNV encephalitis is associated with poorer prognosis (Ali et al., 2005) .", [["cerebellar", "ANATOMY", 13, 23], ["WNV encephalitis", "DISEASE", 51, 67], ["cerebellar pathology", "CANCER", 13, 33], ["patients", "ORGANISM", 37, 45], ["WNV encephalitis", "ORGANISM", 51, 67], ["patients", "SPECIES", 37, 45], ["WNV encephalitis", "SPECIES", 51, 67], ["cerebellar pathology", "PROBLEM", 13, 33], ["WNV encephalitis", "PROBLEM", 51, 67], ["cerebellar", "ANATOMY", 13, 23], ["pathology", "OBSERVATION", 24, 33]]], ["Further studies are needed to determine whether this subset of patients have underlying defects in hindbrain innate immune function that increase their susceptibility to infection.", [["hindbrain", "ANATOMY", 99, 108], ["infection", "DISEASE", 170, 179], ["patients", "ORGANISM", 63, 71], ["hindbrain", "ANATOMICAL_SYSTEM", 99, 108], ["patients", "SPECIES", 63, 71], ["Further studies", "TEST", 0, 15], ["underlying defects in hindbrain innate immune function", "PROBLEM", 77, 131], ["their susceptibility to infection", "PROBLEM", 146, 179], ["defects", "OBSERVATION", 88, 95], ["hindbrain", "ANATOMY", 99, 108], ["infection", "OBSERVATION", 170, 179]]], ["Differences in baseline expression of genes involved in responsiveness to type I IFN and in susceptibility to viral infections might also help to explain the tropism of viruses for different cell types and regions.", [["cell", "ANATOMY", 191, 195], ["viral infections", "DISEASE", 110, 126], ["type I IFN", "GENE_OR_GENE_PRODUCT", 74, 84], ["cell", "CELL", 191, 195], ["type I IFN", "PROTEIN", 74, 84], ["type I IFN", "PROBLEM", 74, 84], ["viral infections", "PROBLEM", 110, 126], ["the tropism of viruses", "PROBLEM", 154, 176], ["different cell types", "PROBLEM", 181, 201], ["viruses", "OBSERVATION", 169, 176], ["cell types", "OBSERVATION", 191, 201]]], ["The expression of the innate genes Ifna, Tlr7, Ifit1, Ifit3, Mda5, Ifi44l, Mx1, Rsad2, Stat1, and Oas1 are elevated in murine cerebellar granule cell neurons and astrocytes, compared with cortical neurons and astrocytes (Cho et al., 2013; Daniels et al., 2017) .", [["cerebellar granule cell neurons", "ANATOMY", 126, 157], ["astrocytes", "ANATOMY", 162, 172], ["cortical neurons", "ANATOMY", 188, 204], ["astrocytes", "ANATOMY", 209, 219], ["Ifna", "GENE_OR_GENE_PRODUCT", 35, 39], ["Tlr7", "GENE_OR_GENE_PRODUCT", 41, 45], ["Ifit1", "GENE_OR_GENE_PRODUCT", 47, 52], ["Ifit3", "GENE_OR_GENE_PRODUCT", 54, 59], ["Mda5", "GENE_OR_GENE_PRODUCT", 61, 65], ["Ifi44l", "GENE_OR_GENE_PRODUCT", 67, 73], ["Mx1", "GENE_OR_GENE_PRODUCT", 75, 78], ["Rsad2", "GENE_OR_GENE_PRODUCT", 80, 85], ["Stat1", "GENE_OR_GENE_PRODUCT", 87, 92], ["Oas1", "GENE_OR_GENE_PRODUCT", 98, 102], ["murine", "ORGANISM", 119, 125], ["cerebellar granule cell neurons", "CELL", 126, 157], ["astrocytes", "CELL", 162, 172], ["cortical neurons", "CELL", 188, 204], ["astrocytes", "CELL", 209, 219], ["innate genes", "DNA", 22, 34], ["Ifna", "DNA", 35, 39], ["Tlr7", "DNA", 41, 45], ["Ifit1", "DNA", 47, 52], ["Ifit3", "DNA", 54, 59], ["Mda5", "DNA", 61, 65], ["Ifi44l", "DNA", 67, 73], ["Mx1", "DNA", 75, 78], ["Rsad2", "DNA", 80, 85], ["Stat1", "DNA", 87, 92], ["Oas1", "DNA", 98, 102], ["murine cerebellar granule cell neurons", "CELL_TYPE", 119, 157], ["astrocytes", "CELL_TYPE", 162, 172], ["cortical neurons", "CELL_TYPE", 188, 204], ["astrocytes", "CELL_TYPE", 209, 219], ["murine", "SPECIES", 119, 125], ["Tlr7", "TEST", 41, 45], ["Ifit3", "TEST", 54, 59], ["Mda5", "TEST", 61, 65], ["Ifi44l", "TEST", 67, 73], ["Mx1", "TEST", 75, 78], ["Rsad2", "TEST", 80, 85], ["Stat1", "TEST", 87, 92], ["Oas1", "TEST", 98, 102], ["cerebellar", "ANATOMY", 126, 136], ["granule cell neurons", "OBSERVATION", 137, 157], ["astrocytes", "ANATOMY", 162, 172]]], ["Despite lower basal expression of many IFN stimulated genes in neurons, basal expression of the type I IFN themselves is elevated in primary hippocampal neurons which is important for early control of measles virus (Cavanaugh et al., 2015) .", [["neurons", "ANATOMY", 63, 70], ["hippocampal neurons", "ANATOMY", 141, 160], ["measles", "DISEASE", 201, 208], ["IFN", "GENE_OR_GENE_PRODUCT", 39, 42], ["neurons", "CELL", 63, 70], ["type I IFN", "GENE_OR_GENE_PRODUCT", 96, 106], ["hippocampal neurons", "CELL", 141, 160], ["measles virus", "ORGANISM", 201, 214], ["IFN stimulated genes", "DNA", 39, 59], ["type I IFN", "PROTEIN", 96, 106], ["primary hippocampal neurons", "CELL_TYPE", 133, 160], ["measles virus", "SPECIES", 201, 214], ["many IFN stimulated genes in neurons", "PROBLEM", 34, 70], ["the type I IFN themselves", "PROBLEM", 92, 117], ["elevated in primary hippocampal neurons", "PROBLEM", 121, 160], ["measles virus", "PROBLEM", 201, 214], ["basal", "ANATOMY_MODIFIER", 14, 19], ["elevated", "OBSERVATION_MODIFIER", 121, 129], ["hippocampal neurons", "ANATOMY", 141, 160]]], ["While infected neural cells might themselves restrict pathogen replication and dissemination, they can also recruit peripheral myeloid and lymphoid cells to localized sites of infection (Miller et al., 2016) .", [["neural cells", "ANATOMY", 15, 27], ["peripheral myeloid", "ANATOMY", 116, 134], ["lymphoid cells", "ANATOMY", 139, 153], ["sites", "ANATOMY", 167, 172], ["infection", "DISEASE", 176, 185], ["neural cells", "CELL", 15, 27], ["peripheral myeloid", "CELL", 116, 134], ["lymphoid cells", "CELL", 139, 153], ["infected neural cells", "CELL_TYPE", 6, 27], ["peripheral myeloid and lymphoid cells", "CELL_TYPE", 116, 153], ["infected neural cells", "PROBLEM", 6, 27], ["peripheral myeloid and lymphoid cells", "PROBLEM", 116, 153], ["infection", "PROBLEM", 176, 185], ["neural cells", "OBSERVATION", 15, 27], ["peripheral myeloid", "OBSERVATION", 116, 134], ["lymphoid cells", "OBSERVATION", 139, 153], ["infection", "OBSERVATION", 176, 185]]], ["Regional or cellular heterogeneity in cytokine or chemokine expression by neurons and astrocytes might also contribute to different local outcomes.", [["cellular", "ANATOMY", 12, 20], ["neurons", "ANATOMY", 74, 81], ["astrocytes", "ANATOMY", 86, 96], ["cellular", "CELL", 12, 20], ["neurons", "CELL", 74, 81], ["astrocytes", "CELL", 86, 96], ["cytokine", "PROTEIN", 38, 46], ["chemokine", "PROTEIN", 50, 59], ["neurons", "CELL_TYPE", 74, 81], ["astrocytes", "CELL_TYPE", 86, 96], ["Regional or cellular heterogeneity in cytokine", "PROBLEM", 0, 46], ["cellular heterogeneity", "OBSERVATION", 12, 34]]], ["Thus, IL-1 is generally regarded as pro-inflammatory, but during WNV encephalitis IL-1 promotes BBB expression of CXCL12, which limits immunopathology via localization and modulation of T cell fates within peri-vascular spaces ..", [["BBB", "ANATOMY", 96, 99], ["T cell", "ANATOMY", 186, 192], ["peri-vascular spaces", "ANATOMY", 206, 226], ["encephalitis", "DISEASE", 69, 81], ["IL-1", "GENE_OR_GENE_PRODUCT", 6, 10], ["WNV encephalitis", "ORGANISM", 65, 81], ["IL-1", "GENE_OR_GENE_PRODUCT", 82, 86], ["BBB", "MULTI-TISSUE_STRUCTURE", 96, 99], ["CXCL12", "GENE_OR_GENE_PRODUCT", 114, 120], ["T cell", "CELL", 186, 192], ["IL-1", "PROTEIN", 6, 10], ["CXCL12", "PROTEIN", 114, 120], ["WNV", "SPECIES", 65, 68], ["WNV encephalitis IL", "PROBLEM", 65, 84], ["CXCL12", "TEST", 114, 120], ["cell fates", "OBSERVATION", 188, 198]]], ["Viral Modulation of BBB FunctionIn order to be able to disseminate, access, and persist in the CNS, neutrotropic organisms need to be able to evade the innate effector mechanisms that are deployed against them.", [["CNS", "ANATOMY", 95, 98], ["CNS", "ANATOMICAL_SYSTEM", 95, 98], ["neutrotropic organisms", "PROBLEM", 100, 122], ["CNS", "ANATOMY", 95, 98]]], ["The principle that the pathways targeted by pathogens are those that matter most is illustrated by the array of mechanisms used by neurotropic organisms that target the type I and II IFNs.", [["type I and II IFNs", "GENE_OR_GENE_PRODUCT", 169, 187], ["type I and II IFNs", "PROTEIN", 169, 187], ["pathogens", "PROBLEM", 44, 53], ["neurotropic organisms", "PROBLEM", 131, 152]]], ["This is relevant to certain arboviruses which have evolved mechanisms to inhibit type I IFN signaling, which allows survival of infected neurons (Samuel and Diamond, 2005) .", [["neurons", "ANATOMY", 137, 144], ["type I IFN", "GENE_OR_GENE_PRODUCT", 81, 91], ["neurons", "CELL", 137, 144], ["IFN", "PROTEIN", 88, 91], ["infected neurons", "CELL_TYPE", 128, 144], ["certain arboviruses", "PROBLEM", 20, 39], ["type I IFN signaling", "PROBLEM", 81, 101]]], ["The type I IFN receptor, IFNAR, activates STAT1/2 via TYK2 and JAK1 signaling and WNV inhibits TYK2 activity, while the related flavivirus, Zika virus degrades human STAT2 (Brasil et al., 2016) .", [["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 4, 23], ["IFNAR", "GENE_OR_GENE_PRODUCT", 25, 30], ["STAT1", "GENE_OR_GENE_PRODUCT", 42, 47], ["2", "GENE_OR_GENE_PRODUCT", 48, 49], ["TYK2", "GENE_OR_GENE_PRODUCT", 54, 58], ["JAK1", "GENE_OR_GENE_PRODUCT", 63, 67], ["WNV", "ORGANISM", 82, 85], ["TYK2", "GENE_OR_GENE_PRODUCT", 95, 99], ["Zika virus", "ORGANISM", 140, 150], ["human", "ORGANISM", 160, 165], ["STAT2", "GENE_OR_GENE_PRODUCT", 166, 171], ["type I IFN receptor", "PROTEIN", 4, 23], ["IFNAR", "PROTEIN", 25, 30], ["STAT1/2", "PROTEIN", 42, 49], ["TYK2", "PROTEIN", 54, 58], ["JAK1", "PROTEIN", 63, 67], ["TYK2", "PROTEIN", 95, 99], ["human STAT2", "PROTEIN", 160, 171], ["human", "SPECIES", 160, 165], ["WNV", "SPECIES", 82, 85], ["Zika virus", "SPECIES", 140, 150], ["human", "SPECIES", 160, 165], ["The type I IFN receptor", "TREATMENT", 0, 23], ["JAK1 signaling", "PROBLEM", 63, 77], ["WNV", "PROBLEM", 82, 85], ["TYK2 activity", "PROBLEM", 95, 108], ["the related flavivirus", "PROBLEM", 116, 138], ["Zika virus", "PROBLEM", 140, 150]]], ["Similarly, VEEV evades activity of the interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) that blocks translation of virion-delivered virus-specific RNAs (Habjan et al., 2013; Hyde et al., 2014) .", [["VEEV", "ORGANISM", 11, 15], ["tetratricopeptide repeats 1", "GENE_OR_GENE_PRODUCT", 71, 98], ["IFIT1", "GENE_OR_GENE_PRODUCT", 100, 105], ["interferon-induced protein", "PROTEIN", 39, 65], ["tetratricopeptide repeats 1", "PROTEIN", 71, 98], ["IFIT1", "PROTEIN", 100, 105], ["VEEV", "SPECIES", 11, 15], ["the interferon-induced protein with tetratricopeptide repeats", "TREATMENT", 35, 96], ["virion", "TREATMENT", 134, 140]]], ["Of relevance to the JAK/STAT pathway, T. gondii secretes an effector molecule into its host cell that recruits a host chromatin repressor complex, which blocks the ability of IFN-g to mediate transcription through STAT1 (Gay et al., 2016; Olias et al., 2016) .", [["cell", "ANATOMY", 92, 96], ["chromatin", "ANATOMY", 118, 127], ["JAK", "GENE_OR_GENE_PRODUCT", 20, 23], ["STAT", "GENE_OR_GENE_PRODUCT", 24, 28], ["T. gondii", "ORGANISM", 38, 47], ["host cell", "CELL", 87, 96], ["chromatin", "CELLULAR_COMPONENT", 118, 127], ["IFN-g", "GENE_OR_GENE_PRODUCT", 175, 180], ["STAT1", "GENE_OR_GENE_PRODUCT", 214, 219], ["JAK", "PROTEIN", 20, 23], ["STAT", "PROTEIN", 24, 28], ["effector molecule", "PROTEIN", 60, 77], ["host chromatin repressor complex", "PROTEIN", 113, 145], ["IFN", "PROTEIN", 175, 178], ["STAT1", "PROTEIN", 214, 219], ["T. gondii", "SPECIES", 38, 47], ["T. gondii", "SPECIES", 38, 47], ["the JAK/STAT pathway", "TEST", 16, 36], ["T. gondii", "TEST", 38, 47], ["host cell", "OBSERVATION", 87, 96]]], ["That diverse organisms have multiple strategies to target JAK/ STAT signaling is consistent with the key role of the IFNs in mediating resistance to these neurotropic pathogens and is relevant to many other innate sensing and effector mechanisms.Astrocytic Responses to InfectionAstrocytes are considered the most numerous cell type in the CNS and, while frequently defined by the expression of the intermediate filament glial fibrillary acidic protein (GFAP), this is a heterogenous cell type with distinct functions in different anatomical regions of the CNS, associated with neuronal health and maintenance.", [["cell type", "ANATOMY", 323, 332], ["CNS", "ANATOMY", 340, 343], ["cell", "ANATOMY", 484, 488], ["CNS", "ANATOMY", 557, 560], ["neuronal", "ANATOMY", 578, 586], ["JAK", "GENE_OR_GENE_PRODUCT", 58, 61], ["STAT", "GENE_OR_GENE_PRODUCT", 63, 67], ["IFNs", "GENE_OR_GENE_PRODUCT", 117, 121], ["cell type", "CELL", 323, 332], ["CNS", "ANATOMICAL_SYSTEM", 340, 343], ["glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 421, 452], ["GFAP", "GENE_OR_GENE_PRODUCT", 454, 458], ["cell type", "CELL", 484, 493], ["CNS", "ANATOMICAL_SYSTEM", 557, 560], ["neuronal", "CELL", 578, 586], ["JAK", "PROTEIN", 58, 61], ["STAT", "PROTEIN", 63, 67], ["IFNs", "PROTEIN", 117, 121], ["intermediate filament glial fibrillary acidic protein", "PROTEIN", 399, 452], ["GFAP", "PROTEIN", 454, 458], ["these neurotropic pathogens", "PROBLEM", 149, 176], ["a heterogenous cell type", "PROBLEM", 469, 493], ["consistent with", "UNCERTAINTY", 81, 96], ["most numerous", "OBSERVATION_MODIFIER", 309, 322], ["cell type", "OBSERVATION", 323, 332], ["CNS", "ANATOMY", 340, 343], ["heterogenous cell type", "OBSERVATION", 471, 493], ["CNS", "ANATOMY", 557, 560]]], ["The use of Aldh1l1-reporter mice in conjunction with screening for differential expression of surface antigens was used to identify five distinct subpopulations of Aldh1l1+ astrocytes within the olfactory bulb, cortex, brainstem, thalamus, and cerebellum that exhibit unique genetic signatures, including a subpopulation that exhibits higher levels of expression of immune molecules (Yang et al., 2011) .", [["surface", "ANATOMY", 94, 101], ["Aldh1l1+ astrocytes", "ANATOMY", 164, 183], ["olfactory bulb", "ANATOMY", 195, 209], ["cortex", "ANATOMY", 211, 217], ["brainstem", "ANATOMY", 219, 228], ["thalamus", "ANATOMY", 230, 238], ["cerebellum", "ANATOMY", 244, 254], ["Aldh1l1", "GENE_OR_GENE_PRODUCT", 11, 18], ["mice", "ORGANISM", 28, 32], ["surface antigens", "GENE_OR_GENE_PRODUCT", 94, 110], ["Aldh1l1", "GENE_OR_GENE_PRODUCT", 164, 171], ["astrocytes", "CELL", 173, 183], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 195, 209], ["cortex", "MULTI-TISSUE_STRUCTURE", 211, 217], ["brainstem", "ANATOMICAL_SYSTEM", 219, 228], ["thalamus", "MULTI-TISSUE_STRUCTURE", 230, 238], ["cerebellum", "ORGAN", 244, 254], ["Aldh1l1", "PROTEIN", 11, 18], ["surface antigens", "PROTEIN", 94, 110], ["Aldh1l1", "PROTEIN", 164, 171], ["astrocytes", "CELL_TYPE", 173, 183], ["immune molecules", "PROTEIN", 366, 382], ["mice", "SPECIES", 28, 32], ["Aldh1l1", "TREATMENT", 11, 18], ["screening", "TEST", 53, 62], ["surface antigens", "TEST", 94, 110], ["Aldh1l1+ astrocytes within the olfactory bulb, cortex, brainstem, thalamus, and cerebellum", "PROBLEM", 164, 254], ["unique genetic signatures", "PROBLEM", 268, 293], ["a subpopulation", "PROBLEM", 305, 320], ["immune molecules", "PROBLEM", 366, 382], ["distinct", "OBSERVATION_MODIFIER", 137, 145], ["subpopulations", "OBSERVATION", 146, 160], ["Aldh1l1+ astrocytes", "OBSERVATION", 164, 183], ["olfactory bulb", "ANATOMY", 195, 209], ["cortex", "ANATOMY_MODIFIER", 211, 217], ["brainstem", "ANATOMY", 219, 228], ["thalamus", "ANATOMY", 230, 238], ["cerebellum", "ANATOMY", 244, 254], ["genetic signatures", "OBSERVATION", 275, 293], ["subpopulation", "OBSERVATION_MODIFIER", 307, 320], ["higher", "OBSERVATION_MODIFIER", 335, 341], ["immune molecules", "OBSERVATION", 366, 382]]], ["Similarly, a comparison of cerebellar with cortical astrocytes revealed that cerebellar cells exhibit higher expression of genes involved in TJ and AJ signaling, supporting their differential effects on BBB stability (Daniels et al., 2017) .", [["cerebellar", "ANATOMY", 27, 37], ["cortical astrocytes", "ANATOMY", 43, 62], ["cerebellar cells", "ANATOMY", 77, 93], ["TJ", "ANATOMY", 141, 143], ["AJ", "ANATOMY", 148, 150], ["BBB", "ANATOMY", 203, 206], ["cerebellar", "MULTI-TISSUE_STRUCTURE", 27, 37], ["cortical astrocytes", "CELL", 43, 62], ["cerebellar cells", "CELL", 77, 93], ["TJ", "GENE_OR_GENE_PRODUCT", 141, 143], ["AJ", "GENE_OR_GENE_PRODUCT", 148, 150], ["BBB", "MULTI-TISSUE_STRUCTURE", 203, 206], ["cortical astrocytes", "CELL_TYPE", 43, 62], ["cerebellar cells", "CELL_TYPE", 77, 93], ["cerebellar cells", "PROBLEM", 77, 93], ["cerebellar", "ANATOMY", 27, 37], ["cortical astrocytes", "OBSERVATION", 43, 62], ["cerebellar cells", "OBSERVATION", 77, 93], ["higher", "OBSERVATION_MODIFIER", 102, 108]]], ["Whether these subpopulations also exhibit differences in susceptibility to infection, inflammatory responses or effects on BBB function remains to be determined.Astrocytic Responses to InfectionThe prominent hypertrophy of astrocytes associated with infections of the CNS and the ability to activate these cells in vitro with IFNs to control pathogen replication led to the idea that these cells would have an important role in the host response to infection.", [["BBB", "ANATOMY", 123, 126], ["astrocytes", "ANATOMY", 223, 233], ["CNS", "ANATOMY", 268, 271], ["cells", "ANATOMY", 306, 311], ["cells", "ANATOMY", 390, 395], ["infection", "DISEASE", 75, 84], ["Infection", "DISEASE", 185, 194], ["infections", "DISEASE", 250, 260], ["infection", "DISEASE", 449, 458], ["BBB", "MULTI-TISSUE_STRUCTURE", 123, 126], ["astrocytes", "CELL", 223, 233], ["CNS", "ANATOMICAL_SYSTEM", 268, 271], ["cells", "CELL", 306, 311], ["IFNs", "GENE_OR_GENE_PRODUCT", 326, 330], ["cells", "CELL", 390, 395], ["astrocytes", "CELL_TYPE", 223, 233], ["IFNs", "PROTEIN", 326, 330], ["infection", "PROBLEM", 75, 84], ["inflammatory responses", "PROBLEM", 86, 108], ["BBB function", "TEST", 123, 135], ["Astrocytic Responses", "PROBLEM", 161, 181], ["Infection", "PROBLEM", 185, 194], ["The prominent hypertrophy of astrocytes", "PROBLEM", 194, 233], ["infections of the CNS", "PROBLEM", 250, 271], ["these cells", "PROBLEM", 300, 311], ["IFNs", "TREATMENT", 326, 330], ["pathogen replication", "TREATMENT", 342, 362], ["these cells", "PROBLEM", 384, 395], ["infection", "PROBLEM", 449, 458], ["infection", "OBSERVATION", 75, 84], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98], ["Infection", "OBSERVATION", 185, 194], ["prominent", "OBSERVATION_MODIFIER", 198, 207], ["hypertrophy", "OBSERVATION", 208, 219], ["astrocytes", "OBSERVATION", 223, 233], ["infections", "OBSERVATION", 250, 260], ["CNS", "ANATOMY", 268, 271], ["infection", "OBSERVATION", 449, 458]]], ["The use of lineage targeting approaches to delete the IFNAR on astrocytes increases WNV infection and immunopathology within the hindbrain (Daniels et al., 2017) , while the removal of STAT1 from these cells results in increased susceptibility to toxoplasmic encephalitis (TE) (Hidano et al., 2016) .", [["astrocytes", "ANATOMY", 63, 73], ["hindbrain", "ANATOMY", 129, 138], ["cells", "ANATOMY", 202, 207], ["WNV infection", "DISEASE", 84, 97], ["immunopathology", "DISEASE", 102, 117], ["toxoplasmic encephalitis", "DISEASE", 247, 271], ["IFNAR", "GENE_OR_GENE_PRODUCT", 54, 59], ["astrocytes", "CELL", 63, 73], ["WNV", "ORGANISM", 84, 87], ["hindbrain", "ORGAN", 129, 138], ["STAT1", "GENE_OR_GENE_PRODUCT", 185, 190], ["cells", "CELL", 202, 207], ["IFNAR", "PROTEIN", 54, 59], ["astrocytes", "CELL_TYPE", 63, 73], ["STAT1", "PROTEIN", 185, 190], ["WNV", "SPECIES", 84, 87], ["lineage targeting approaches", "TREATMENT", 11, 39], ["WNV infection", "PROBLEM", 84, 97], ["immunopathology", "PROBLEM", 102, 117], ["the removal of STAT1", "TREATMENT", 170, 190], ["these cells", "TEST", 196, 207], ["increased susceptibility to toxoplasmic encephalitis", "PROBLEM", 219, 271], ["WNV", "OBSERVATION_MODIFIER", 84, 87], ["infection", "OBSERVATION", 88, 97], ["hindbrain", "ANATOMY", 129, 138], ["increased", "OBSERVATION_MODIFIER", 219, 228], ["toxoplasmic encephalitis", "OBSERVATION", 247, 271]]], ["Interestingly, a genetic screen to identify host factors that enhance the activation of STAT1 revealed that the orphan nuclear hormone receptor TLX, expressed in neural stem cells and astrocytes, is a modifier of STAT1 activity and is required for resistance to T. gondii (Beiting et al., 2015) .", [["nuclear", "ANATOMY", 119, 126], ["neural stem cells", "ANATOMY", 162, 179], ["astrocytes", "ANATOMY", 184, 194], ["STAT1", "GENE_OR_GENE_PRODUCT", 88, 93], ["TLX", "GENE_OR_GENE_PRODUCT", 144, 147], ["neural stem cells", "CELL", 162, 179], ["astrocytes", "CELL", 184, 194], ["STAT1", "GENE_OR_GENE_PRODUCT", 213, 218], ["T. gondii", "ORGANISM", 262, 271], ["STAT1", "PROTEIN", 88, 93], ["orphan nuclear hormone receptor", "PROTEIN", 112, 143], ["TLX", "PROTEIN", 144, 147], ["neural stem cells", "CELL_TYPE", 162, 179], ["astrocytes", "CELL_TYPE", 184, 194], ["STAT1", "PROTEIN", 213, 218], ["T. gondii", "SPECIES", 262, 271], ["T. gondii", "SPECIES", 262, 271], ["a genetic screen", "TEST", 15, 31], ["host factors", "PROBLEM", 44, 56], ["the orphan nuclear hormone receptor TLX", "TEST", 108, 147], ["neural stem cells", "OBSERVATION", 162, 179]]], ["Although astrocytes lack the major known IFN-g-induced pathways that target T. gondii (Halonen and Weiss, 2000; Hunter and Sibley, 2012) , two of the IFN-g-inducible 47 kD Immunity Related GTases (IRGs) are required for murine astrocytes to eliminate T. gondii in vitro (Degrandi et al., 2013; Melzer et al., 2008) .", [["astrocytes", "ANATOMY", 9, 19], ["astrocytes", "ANATOMY", 227, 237], ["astrocytes", "CELL", 9, 19], ["IFN-g", "GENE_OR_GENE_PRODUCT", 41, 46], ["T. gondii", "ORGANISM", 76, 85], ["IFN-g", "GENE_OR_GENE_PRODUCT", 150, 155], ["GTases", "GENE_OR_GENE_PRODUCT", 189, 195], ["IRGs", "GENE_OR_GENE_PRODUCT", 197, 201], ["murine", "ORGANISM", 220, 226], ["astrocytes", "CELL", 227, 237], ["T. gondii", "ORGANISM", 251, 260], ["astrocytes", "CELL_TYPE", 9, 19], ["IFN", "PROTEIN", 41, 44], ["IFN", "PROTEIN", 150, 153], ["47 kD Immunity Related GTases", "PROTEIN", 166, 195], ["IRGs", "PROTEIN", 197, 201], ["murine astrocytes", "CELL_TYPE", 220, 237], ["T. gondii", "SPECIES", 76, 85], ["murine", "SPECIES", 220, 226], ["T. gondii", "SPECIES", 251, 260], ["T. gondii", "SPECIES", 76, 85], ["T. gondii", "SPECIES", 251, 260], ["murine astrocytes", "PROBLEM", 220, 237]]], ["Humans lack IRGs but the p67 guanylate-binding proteins (GBPs) have analogous functions (MacMicking, 2012) and GBP2 is required for parasite killing by murine astrocytes in vitro (Degrandi et al., 2013) .", [["astrocytes", "ANATOMY", 159, 169], ["Humans", "ORGANISM", 0, 6], ["IRGs", "GENE_OR_GENE_PRODUCT", 12, 16], ["p67 guanylate-binding proteins", "GENE_OR_GENE_PRODUCT", 25, 55], ["GBPs", "GENE_OR_GENE_PRODUCT", 57, 61], ["GBP2", "GENE_OR_GENE_PRODUCT", 111, 115], ["murine", "ORGANISM", 152, 158], ["astrocytes", "CELL", 159, 169], ["IRGs", "PROTEIN", 12, 16], ["p67 guanylate-binding proteins", "PROTEIN", 25, 55], ["GBPs", "PROTEIN", 57, 61], ["GBP2", "PROTEIN", 111, 115], ["murine astrocytes", "CELL_TYPE", 152, 169], ["murine", "SPECIES", 152, 158], ["the p67 guanylate", "TEST", 21, 38], ["GBPs", "TEST", 57, 61], ["MacMicking", "TEST", 89, 99], ["GBP2", "TEST", 111, 115], ["parasite killing", "PROBLEM", 132, 148]]], ["These proteins are part of a coordinated response that intersects with autophagic processes that lead to parasite control (Degrandi et al., 2013; Niedelman et al., 2013; Van Grol et al., 2013; Yamamoto et al., 2012) .", [["autophagic processes", "PROBLEM", 71, 91], ["parasite control", "TREATMENT", 105, 121], ["autophagic processes", "OBSERVATION", 71, 91]]], ["From a broader perspective, these findings highlight a major knowledge gap in our understanding of how astrocytes and neurons respond to the IFNs to mediate control of diverse pathogens.", [["astrocytes", "ANATOMY", 103, 113], ["neurons", "ANATOMY", 118, 125], ["astrocytes", "CELL", 103, 113], ["neurons", "CELL", 118, 125], ["IFNs", "GENE_OR_GENE_PRODUCT", 141, 145], ["astrocytes", "CELL_TYPE", 103, 113], ["neurons", "CELL_TYPE", 118, 125], ["IFNs", "PROTEIN", 141, 145], ["how astrocytes and neurons", "PROBLEM", 99, 125], ["the IFNs", "TREATMENT", 137, 145], ["diverse pathogens", "PROBLEM", 168, 185], ["diverse", "OBSERVATION_MODIFIER", 168, 175], ["pathogens", "OBSERVATION", 176, 185]]], ["To date, almost 2,000 IFN stimulated genes (ISG) have been identified in human and mouse cells but few of these genes have been characterized in the context of infection and improved methodologies to dissect the anti-microbial activities in different neural cell types are needed.Astrocytic Responses to InfectionIn the context of sterile or microbial-induced CNS injury, astrocytes start to proliferate, increase expression of GFAP and undergo changes in morphology (termed astrogliosis) that allows them to form dense networks or ''glial scars'' at sites of damage.", [["cells", "ANATOMY", 89, 94], ["neural cell", "ANATOMY", 251, 262], ["CNS", "ANATOMY", 360, 363], ["astrocytes", "ANATOMY", 372, 382], ["networks", "ANATOMY", 520, 528], ["glial scars", "ANATOMY", 534, 545], ["sites", "ANATOMY", 551, 556], ["infection", "DISEASE", 160, 169], ["CNS injury", "DISEASE", 360, 370], ["astrogliosis", "DISEASE", 475, 487], ["ISG", "GENE_OR_GENE_PRODUCT", 44, 47], ["human", "ORGANISM", 73, 78], ["mouse", "ORGANISM", 83, 88], ["cells", "CELL", 89, 94], ["neural cell", "CELL", 251, 262], ["CNS", "ANATOMICAL_SYSTEM", 360, 363], ["astrocytes", "CELL", 372, 382], ["GFAP", "GENE_OR_GENE_PRODUCT", 428, 432], ["glial scars", "TISSUE", 534, 545], ["IFN stimulated genes", "DNA", 22, 42], ["ISG", "DNA", 44, 47], ["human and mouse cells", "CELL_TYPE", 73, 94], ["neural cell types", "CELL_TYPE", 251, 268], ["astrocytes", "CELL_TYPE", 372, 382], ["GFAP", "PROTEIN", 428, 432], ["human", "SPECIES", 73, 78], ["mouse", "SPECIES", 83, 88], ["human", "SPECIES", 73, 78], ["mouse", "SPECIES", 83, 88], ["infection", "PROBLEM", 160, 169], ["Astrocytic Responses", "PROBLEM", 280, 300], ["sterile or microbial-induced CNS injury", "PROBLEM", 331, 370], ["astrocytes", "PROBLEM", 372, 382], ["GFAP", "PROBLEM", 428, 432], ["changes in morphology (termed astrogliosis)", "PROBLEM", 445, 488], ["''glial scars", "PROBLEM", 532, 545], ["damage", "PROBLEM", 560, 566], ["infection", "OBSERVATION", 160, 169], ["neural cell types", "OBSERVATION", 251, 268], ["CNS", "ANATOMY", 360, 363], ["injury", "OBSERVATION", 364, 370], ["astrogliosis", "OBSERVATION", 475, 487], ["dense", "OBSERVATION_MODIFIER", 514, 519], ["damage", "OBSERVATION", 560, 566]]], ["In mice challenged with Staphylococcus aureus or T. gondii, reactive astrocytes are prominent, but the absence of GFAP limits glial scar formation and the ability to restrict inflammation, which leads to pathogen spread (Stenzel et al., 2004) .", [["astrocytes", "ANATOMY", 69, 79], ["glial scar", "ANATOMY", 126, 136], ["Staphylococcus aureus", "DISEASE", 24, 45], ["inflammation", "DISEASE", 175, 187], ["mice", "ORGANISM", 3, 7], ["Staphylococcus aureus", "ORGANISM", 24, 45], ["T. gondii", "ORGANISM", 49, 58], ["astrocytes", "CELL", 69, 79], ["GFAP", "GENE_OR_GENE_PRODUCT", 114, 118], ["glial scar", "TISSUE", 126, 136], ["reactive astrocytes", "CELL_TYPE", 60, 79], ["GFAP", "PROTEIN", 114, 118], ["mice", "SPECIES", 3, 7], ["Staphylococcus aureus", "SPECIES", 24, 45], ["T. gondii", "SPECIES", 49, 58], ["mice", "SPECIES", 3, 7], ["Staphylococcus aureus", "SPECIES", 24, 45], ["T. gondii", "SPECIES", 49, 58], ["Staphylococcus aureus", "PROBLEM", 24, 45], ["T. gondii", "PROBLEM", 49, 58], ["reactive astrocytes", "PROBLEM", 60, 79], ["GFAP", "PROBLEM", 114, 118], ["glial scar formation", "PROBLEM", 126, 146], ["inflammation", "PROBLEM", 175, 187], ["Staphylococcus aureus", "OBSERVATION", 24, 45], ["reactive astrocytes", "OBSERVATION", 60, 79], ["prominent", "OBSERVATION_MODIFIER", 84, 93], ["glial", "OBSERVATION_MODIFIER", 126, 131], ["scar", "OBSERVATION", 132, 136], ["inflammation", "OBSERVATION", 175, 187]]], ["Similarly, when compared to wild-type controls, mice with astrocyte lineage-specific deletion of the cytokine receptor gp130, exhibited increased astrocyte apoptosis and inflammation.", [["astrocyte lineage", "ANATOMY", 58, 75], ["astrocyte", "ANATOMY", 146, 155], ["inflammation", "DISEASE", 170, 182], ["mice", "ORGANISM", 48, 52], ["astrocyte lineage", "CELL", 58, 75], ["gp130", "GENE_OR_GENE_PRODUCT", 119, 124], ["astrocyte", "CELL", 146, 155], ["cytokine receptor gp130", "PROTEIN", 101, 124], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["the cytokine receptor gp130", "TEST", 97, 124], ["increased astrocyte apoptosis", "PROBLEM", 136, 165], ["inflammation", "PROBLEM", 170, 182], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["astrocyte apoptosis", "OBSERVATION", 146, 165], ["inflammation", "OBSERVATION", 170, 182]]], ["Although these mice control parasite numbers, they exhibited a more extensive inflammatory response and increased susceptibility to the chronic phase of infection (Dr\u00f6 gem\u20ac uller et al., 2008) .", [["infection", "DISEASE", 153, 162], ["mice", "ORGANISM", 15, 19], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["a more extensive inflammatory response", "PROBLEM", 61, 99], ["infection", "PROBLEM", 153, 162], ["extensive", "OBSERVATION_MODIFIER", 68, 77], ["inflammatory response", "OBSERVATION", 78, 99], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["chronic", "OBSERVATION_MODIFIER", 136, 143], ["phase", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 153, 162]]], ["This phenotype is recapitulated with the loss of TGF-b signaling in astrocytes, which did not affect parasite burden but resulted in increased inflammation and neuronal damage (Cekanaviciute et al., 2014) .", [["astrocytes", "ANATOMY", 68, 78], ["neuronal", "ANATOMY", 160, 168], ["inflammation", "DISEASE", 143, 155], ["neuronal damage", "DISEASE", 160, 175], ["TGF-b", "GENE_OR_GENE_PRODUCT", 49, 54], ["astrocytes", "CELL", 68, 78], ["neuronal", "CELL", 160, 168], ["TGF-b", "PROTEIN", 49, 54], ["astrocytes", "CELL_TYPE", 68, 78], ["the loss of TGF-b signaling in astrocytes", "PROBLEM", 37, 78], ["parasite burden", "PROBLEM", 101, 116], ["increased inflammation", "PROBLEM", 133, 155], ["neuronal damage", "PROBLEM", 160, 175], ["astrocytes", "ANATOMY", 68, 78], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["inflammation", "OBSERVATION", 143, 155], ["neuronal damage", "OBSERVATION", 160, 175]]], ["These studies indicate that the extensive gliosis associated with many CNS infections is part of a conserved response to local injury (analogous to granuloma function) that provides a physical barrier to limit tissue damage and isolate areas of pathogen replication.Mechanisms of Adaptive Protective ImmunityIn the majority of CNS infections discussed above, the initial priming of T cell responses that contribute to pathogen control are generated in the periphery.", [["CNS", "ANATOMY", 71, 74], ["granuloma", "ANATOMY", 148, 157], ["tissue", "ANATOMY", 210, 216], ["CNS", "ANATOMY", 327, 330], ["T cell", "ANATOMY", 382, 388], ["gliosis", "DISEASE", 42, 49], ["infections", "DISEASE", 75, 85], ["granuloma", "DISEASE", 148, 157], ["infections", "DISEASE", 331, 341], ["CNS", "ANATOMICAL_SYSTEM", 71, 74], ["granuloma", "PATHOLOGICAL_FORMATION", 148, 157], ["tissue", "TISSUE", 210, 216], ["CNS", "ANATOMICAL_SYSTEM", 327, 330], ["T cell", "CELL", 382, 388], ["These studies", "TEST", 0, 13], ["the extensive gliosis", "PROBLEM", 28, 49], ["many CNS infections", "PROBLEM", 66, 85], ["local injury", "PROBLEM", 121, 133], ["granuloma function", "PROBLEM", 148, 166], ["a physical barrier", "TREATMENT", 182, 200], ["tissue damage", "PROBLEM", 210, 223], ["pathogen replication", "TREATMENT", 245, 265], ["CNS infections", "PROBLEM", 327, 341], ["pathogen control", "TREATMENT", 418, 434], ["extensive", "OBSERVATION_MODIFIER", 32, 41], ["gliosis", "OBSERVATION", 42, 49], ["many", "OBSERVATION_MODIFIER", 66, 70], ["CNS", "ANATOMY", 71, 74], ["infections", "OBSERVATION", 75, 85], ["granuloma", "OBSERVATION", 148, 157], ["limit tissue", "OBSERVATION_MODIFIER", 204, 216], ["damage", "OBSERVATION", 217, 223], ["pathogen replication", "OBSERVATION", 245, 265], ["CNS", "ANATOMY", 327, 330], ["infections", "OBSERVATION", 331, 341], ["periphery", "ANATOMY_MODIFIER", 456, 465]]], ["As a consequence of pathogen replication in the brain, pathogen-specific T cells traffic to the CNS and are able to gain parenchymal access.", [["brain", "ANATOMY", 48, 53], ["T cells", "ANATOMY", 73, 80], ["CNS", "ANATOMY", 96, 99], ["parenchymal", "ANATOMY", 121, 132], ["brain", "ORGAN", 48, 53], ["T cells", "CELL", 73, 80], ["CNS", "ANATOMICAL_SYSTEM", 96, 99], ["parenchymal", "TISSUE", 121, 132], ["T cells", "CELL_TYPE", 73, 80], ["pathogen replication in the brain", "PROBLEM", 20, 53], ["pathogen replication", "OBSERVATION", 20, 40], ["brain", "ANATOMY", 48, 53]]], ["While there are a limited number of helminth infections that are associated with T helper 2 (Th2) responses that affect the CNS (neurocystocercosis and aberrant migratory nematodes), most clinically relevant infections of the CNS are viral, bacterial, fungal, or protozoan, and it is not surprising that adaptive resistance to these organisms in the brain is mediated by CD4 + and CD8 + T cells that produce IFN-g.", [["CNS", "ANATOMY", 124, 127], ["CNS", "ANATOMY", 226, 229], ["brain", "ANATOMY", 350, 355], ["CD4 + and CD8 + T cells", "ANATOMY", 371, 394], ["helminth infections", "DISEASE", 36, 55], ["neurocystocercosis", "DISEASE", 129, 147], ["infections", "DISEASE", 208, 218], ["viral, bacterial, fungal, or protozoan", "DISEASE", 234, 272], ["T helper 2", "GENE_OR_GENE_PRODUCT", 81, 91], ["Th2", "GENE_OR_GENE_PRODUCT", 93, 96], ["CNS", "ANATOMICAL_SYSTEM", 124, 127], ["CNS", "ANATOMICAL_SYSTEM", 226, 229], ["brain", "ORGAN", 350, 355], ["CD4", "GENE_OR_GENE_PRODUCT", 371, 374], ["CD8", "GENE_OR_GENE_PRODUCT", 381, 384], ["CD4", "PROTEIN", 371, 374], ["CD8 + T cells", "CELL_TYPE", 381, 394], ["IFN", "PROTEIN", 408, 411], ["helminth infections", "PROBLEM", 36, 55], ["the CNS (neurocystocercosis", "PROBLEM", 120, 147], ["aberrant migratory nematodes", "PROBLEM", 152, 180], ["the CNS", "PROBLEM", 222, 229], ["viral, bacterial, fungal", "PROBLEM", 234, 258], ["protozoan", "PROBLEM", 263, 272], ["these organisms in the brain", "PROBLEM", 327, 355], ["CD4", "TEST", 371, 374], ["CD8 + T cells", "PROBLEM", 381, 394], ["IFN", "TEST", 408, 411], ["helminth", "OBSERVATION_MODIFIER", 36, 44], ["infections", "OBSERVATION", 45, 55], ["CNS", "ANATOMY", 124, 127], ["aberrant", "OBSERVATION_MODIFIER", 152, 160], ["migratory nematodes", "OBSERVATION", 161, 180], ["CNS", "ANATOMY", 226, 229], ["brain", "ANATOMY", 350, 355]]], ["There is a strong dogma that initial entry of pathogen-specific T cells into the CNS is dependent on local antigen presentation which influences their local expansion and retention (Tschen et al., 2006) .", [["T cells", "ANATOMY", 64, 71], ["CNS", "ANATOMY", 81, 84], ["T cells", "CELL", 64, 71], ["CNS", "ANATOMICAL_SYSTEM", 81, 84], ["T cells", "CELL_TYPE", 64, 71], ["CNS", "ANATOMY", 81, 84], ["dependent", "OBSERVATION_MODIFIER", 88, 97], ["local", "OBSERVATION_MODIFIER", 151, 156], ["expansion", "OBSERVATION_MODIFIER", 157, 166], ["retention", "OBSERVATION_MODIFIER", 171, 180]]], ["This is a complex topic, and the reports that activated T cells, regardless of antigen specificity, can traffic to the uninflamed CNS (Wekerle et al., 1986) , suggests the presence of a mechanism that allows surveillance of the CNS that might precede and potentially limit pathogen entry.", [["T cells", "ANATOMY", 56, 63], ["CNS", "ANATOMY", 130, 133], ["CNS", "ANATOMY", 228, 231], ["T cells", "CELL", 56, 63], ["antigen", "GENE_OR_GENE_PRODUCT", 79, 86], ["CNS", "ANATOMICAL_SYSTEM", 130, 133], ["CNS", "ANATOMICAL_SYSTEM", 228, 231], ["activated T cells", "CELL_TYPE", 46, 63], ["activated T cells", "PROBLEM", 46, 63], ["the CNS", "PROBLEM", 224, 231], ["complex", "OBSERVATION_MODIFIER", 10, 17]]], ["In contrast, during TE the activation and expansion of T cells specific for a A C BFigure 3.", [["T cells", "ANATOMY", 55, 62], ["T cells", "CELL", 55, 62], ["T cells", "CELL_TYPE", 55, 62], ["a A C BFigure", "TREATMENT", 76, 89]]], ["Effector Mechanisms Used by T Cells to Control CNS Infection(A) The ability of pathogen-specific CD4 + and CD8 + T cells to exit the circulation, cross the BBB, and access the parenchyma precedes the search for relevant infected CNS-specific targets.", [["T Cells", "ANATOMY", 28, 35], ["CNS", "ANATOMY", 47, 50], ["CD4 + and CD8 + T cells", "ANATOMY", 97, 120], ["BBB", "ANATOMY", 156, 159], ["parenchyma", "ANATOMY", 176, 186], ["CNS", "ANATOMY", 229, 232], ["T Cells", "CELL", 28, 35], ["CD4", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD8", "GENE_OR_GENE_PRODUCT", 107, 110], ["BBB", "MULTI-TISSUE_STRUCTURE", 156, 159], ["parenchyma", "TISSUE", 176, 186], ["CNS", "ANATOMICAL_SYSTEM", 229, 232], ["T Cells", "CELL_TYPE", 28, 35], ["pathogen-specific CD4 + and CD8 + T cells", "CELL_TYPE", 79, 120], ["CNS Infection", "PROBLEM", 47, 60], ["pathogen", "TEST", 79, 87], ["specific CD4", "TEST", 88, 100], ["CD8 + T cells", "PROBLEM", 107, 120], ["CNS", "ANATOMY", 47, 50], ["Infection", "OBSERVATION", 51, 60], ["circulation", "ANATOMY", 133, 144], ["parenchyma", "ANATOMY", 176, 186]]], ["(B) The local production of IFN-g by CD4 + and CD8 + T cells has a prominent role in the activation of STAT1 and the anti-microbial activities of astrocytes and microglia.", [["CD4 + and CD8 + T cells", "ANATOMY", 37, 60], ["astrocytes", "ANATOMY", 146, 156], ["microglia", "ANATOMY", 161, 170], ["IFN-g", "GENE_OR_GENE_PRODUCT", 28, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 47, 50], ["STAT1", "GENE_OR_GENE_PRODUCT", 103, 108], ["astrocytes", "CELL", 146, 156], ["microglia", "CELL", 161, 170], ["IFN", "PROTEIN", 28, 31], ["CD4", "PROTEIN", 37, 40], ["CD8", "PROTEIN", 47, 50], ["T cells", "CELL_TYPE", 53, 60], ["STAT1", "PROTEIN", 103, 108], ["astrocytes", "CELL_TYPE", 146, 156], ["microglia", "CELL_TYPE", 161, 170], ["IFN", "TEST", 28, 31], ["CD4", "TEST", 37, 40], ["CD8 + T cells", "PROBLEM", 47, 60], ["microglia", "PROBLEM", 161, 170], ["prominent", "OBSERVATION_MODIFIER", 67, 76], ["anti-microbial activities", "OBSERVATION", 117, 142], ["microglia", "ANATOMY", 161, 170]]], ["While CD8 + T cells can interact with infected astrocytes and microglia to mediate elimination of infected cells or control of pathogen replication it is unclear whether their interactions with neurons is direct through MHC-TCR interactions or indirect through the activation of microglia.", [["CD8 + T cells", "ANATOMY", 6, 19], ["astrocytes", "ANATOMY", 47, 57], ["microglia", "ANATOMY", 62, 71], ["cells", "ANATOMY", 107, 112], ["neurons", "ANATOMY", 194, 201], ["microglia", "ANATOMY", 279, 288], ["CD8", "GENE_OR_GENE_PRODUCT", 6, 9], ["astrocytes", "CELL", 47, 57], ["microglia", "CELL", 62, 71], ["cells", "CELL", 107, 112], ["neurons", "CELL", 194, 201], ["TCR", "GENE_OR_GENE_PRODUCT", 224, 227], ["microglia", "CELL", 279, 288], ["CD8 + T cells", "CELL_TYPE", 6, 19], ["astrocytes", "CELL_TYPE", 47, 57], ["microglia", "CELL_TYPE", 62, 71], ["infected cells", "CELL_TYPE", 98, 112], ["MHC", "PROTEIN", 220, 223], ["TCR", "PROTEIN", 224, 227], ["microglia", "CELL_TYPE", 279, 288], ["T cells", "PROBLEM", 12, 19], ["infected astrocytes", "PROBLEM", 38, 57], ["infected cells", "PROBLEM", 98, 112], ["pathogen replication", "TREATMENT", 127, 147], ["TCR interactions", "PROBLEM", 224, 240], ["microglia", "PROBLEM", 279, 288], ["infected cells", "OBSERVATION", 98, 112], ["microglia", "ANATOMY", 279, 288]]], ["(C) The development of Th17 responses characterized by the production of IL-17 and/or GM-CSF is correlated with the development of immunopathology and the recruitment of inflammatory monocytes.Figure 3.", [["inflammatory monocytes", "ANATOMY", 170, 192], ["immunopathology", "DISEASE", 131, 146], ["Th17", "CELL", 23, 27], ["IL-17", "GENE_OR_GENE_PRODUCT", 73, 78], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 86, 92], ["monocytes", "CELL", 183, 192], ["IL-17", "PROTEIN", 73, 78], ["CSF", "PROTEIN", 89, 92], ["inflammatory monocytes", "CELL_TYPE", 170, 192], ["IL", "TEST", 73, 75], ["immunopathology", "PROBLEM", 131, 146], ["inflammatory monocytes", "PROBLEM", 170, 192], ["Th17", "OBSERVATION", 23, 27], ["immunopathology", "OBSERVATION", 131, 146], ["inflammatory monocytes", "OBSERVATION", 170, 192]]], ["Effector Mechanisms Used by T Cells to Control CNS Infectionnon-microbial antigen did not result in their entry to the CNS (Wilson et al., 2009) .", [["T Cells", "ANATOMY", 28, 35], ["CNS", "ANATOMY", 119, 122], ["T Cells", "CELL", 28, 35], ["CNS", "ANATOMICAL_SYSTEM", 119, 122], ["T Cells", "CELL_TYPE", 28, 35], ["microbial antigen", "PROTEIN", 64, 81], ["CNS Infectionnon-microbial antigen", "TEST", 47, 81], ["CNS", "ANATOMY", 119, 122]]], ["The observation that activation alone is not sufficient for T cell entry to the inflamed CNS is consistent with the idea that there might be a licensing mechanism that influences T cell entry (Odoardi et al., 2012) .Figure 3.", [["T cell", "ANATOMY", 60, 66], ["CNS", "ANATOMY", 89, 92], ["T cell", "ANATOMY", 179, 185], ["T cell", "CELL", 60, 66], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["T cell", "CELL", 179, 185], ["inflamed CNS", "ANATOMY", 80, 92], ["consistent with", "UNCERTAINTY", 96, 111]]], ["Effector Mechanisms Used by T Cells to Control CNS InfectionRegardless, once access to the CNS has been achieved, these T cell populations need to find their relevant targets and mediate local pathogen control (see Figure 3 ).", [["T Cells", "ANATOMY", 28, 35], ["CNS", "ANATOMY", 91, 94], ["T cell", "ANATOMY", 120, 126], ["T Cells", "CELL", 28, 35], ["CNS", "ANATOMICAL_SYSTEM", 91, 94], ["T cell populations", "CELL", 120, 138], ["T Cells", "CELL_TYPE", 28, 35], ["T cell populations", "CELL_TYPE", 120, 138], ["CNS InfectionRegardless", "PROBLEM", 47, 70], ["these T cell populations", "TREATMENT", 114, 138], ["local pathogen control", "TREATMENT", 187, 209], ["CNS", "ANATOMY", 91, 94]]], ["Mice infected with T. gondii or LCMV have provided tractable models for intra-vital imaging of how T cells in the CNS interact with infected cells and other antigen presenting cells.", [["T cells", "ANATOMY", 99, 106], ["CNS", "ANATOMY", 114, 117], ["cells", "ANATOMY", 141, 146], ["cells", "ANATOMY", 176, 181], ["Mice", "ORGANISM", 0, 4], ["T. gondii", "ORGANISM", 19, 28], ["LCMV", "ORGANISM", 32, 36], ["T cells", "CELL", 99, 106], ["CNS", "ANATOMICAL_SYSTEM", 114, 117], ["cells", "CELL", 141, 146], ["cells", "CELL", 176, 181], ["T cells", "CELL_TYPE", 99, 106], ["infected cells", "CELL_TYPE", 132, 146], ["antigen presenting cells", "CELL_TYPE", 157, 181], ["Mice", "SPECIES", 0, 4], ["T. gondii", "SPECIES", 19, 28], ["T. gondii", "SPECIES", 19, 28], ["LCMV", "SPECIES", 32, 36], ["T. gondii", "PROBLEM", 19, 28], ["LCMV", "TREATMENT", 32, 36], ["tractable models", "TREATMENT", 51, 67], ["intra-vital imaging", "TEST", 72, 91], ["infected cells", "PROBLEM", 132, 146], ["CNS", "ANATOMY", 114, 117], ["infected cells", "OBSERVATION", 132, 146]]], ["Analysis of the movement of parasite specific effector CD8 + T cells in the CNS of mice with TE revealed that these cells did not display a directed migration, rather their behavior was reminiscent of the search strategies utilized in nature to find rare targets (Harris et al., 2012) .", [["effector CD8 + T cells", "ANATOMY", 46, 68], ["CNS", "ANATOMY", 76, 79], ["cells", "ANATOMY", 116, 121], ["CD8", "GENE_OR_GENE_PRODUCT", 55, 58], ["CNS", "ANATOMICAL_SYSTEM", 76, 79], ["mice", "ORGANISM", 83, 87], ["cells", "CELL", 116, 121], ["parasite specific effector CD8 + T cells", "CELL_TYPE", 28, 68], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["T cells", "PROBLEM", 61, 68], ["these cells", "PROBLEM", 110, 121], ["CNS", "ANATOMY", 76, 79], ["migration", "OBSERVATION", 149, 158]]], ["One unexpected outcome of these studies was the idea that locally produced chemokines did not establish gradients to attract effector T cells, but rather provided motogenic signals to promote T cell movement required for the search strategy (Harris et al., 2012) .Figure 3.", [["effector T cells", "ANATOMY", 125, 141], ["T cell", "ANATOMY", 192, 198], ["T cells", "CELL", 134, 141], ["T cell", "CELL", 192, 198], ["chemokines", "PROTEIN", 75, 85], ["effector T cells", "CELL_TYPE", 125, 141], ["these studies", "TEST", 26, 39]]], ["Effector Mechanisms Used by T Cells to Control CNS InfectionBased largely on in vitro and correlative studies, there has been a long held belief that microglia are likely to have a prominent role in the local response to infections either as antigen-presenting cells or as phagocytes capable of killing microorganisms.", [["Cells", "ANATOMY", 30, 35], ["microglia", "ANATOMY", 150, 159], ["cells", "ANATOMY", 261, 266], ["phagocytes", "ANATOMY", 273, 283], ["infections", "DISEASE", 221, 231], ["T Cells", "CELL", 28, 35], ["microglia", "CELL", 150, 159], ["cells", "CELL", 261, 266], ["phagocytes", "CELL", 273, 283], ["T Cells", "CELL_TYPE", 28, 35], ["microglia", "CELL_TYPE", 150, 159], ["antigen-presenting cells", "CELL_TYPE", 242, 266], ["phagocytes", "CELL_TYPE", 273, 283], ["correlative studies", "TEST", 90, 109], ["infections", "PROBLEM", 221, 231], ["killing microorganisms", "PROBLEM", 295, 317], ["prominent", "OBSERVATION_MODIFIER", 181, 190], ["infections", "OBSERVATION", 221, 231]]], ["The interactions of pathogen specific T cells with accessory cells (DC and/or microglia has also been visualized using intravital imaging of CD8 + T cells responding to infection with T. gondii (John et al., 2011; Schaeffer et al., 2009) .", [["T cells", "ANATOMY", 38, 45], ["accessory cells", "ANATOMY", 51, 66], ["DC", "ANATOMY", 68, 70], ["microglia", "ANATOMY", 78, 87], ["CD8 + T cells", "ANATOMY", 141, 154], ["infection", "DISEASE", 169, 178], ["T cells", "CELL", 38, 45], ["accessory cells", "CELL", 51, 66], ["DC", "CELL", 68, 70], ["microglia", "CELL", 78, 87], ["CD8", "GENE_OR_GENE_PRODUCT", 141, 144], ["T. gondii", "ORGANISM", 184, 193], ["pathogen specific T cells", "CELL_TYPE", 20, 45], ["accessory cells", "CELL_TYPE", 51, 66], ["DC", "CELL_TYPE", 68, 70], ["microglia", "CELL_TYPE", 78, 87], ["CD8", "PROTEIN", 141, 144], ["T cells", "CELL_TYPE", 147, 154], ["T. gondii", "SPECIES", 184, 193], ["T. gondii", "SPECIES", 184, 193], ["accessory cells", "PROBLEM", 51, 66], ["microglia", "PROBLEM", 78, 87], ["intravital imaging", "TEST", 119, 137], ["T cells", "PROBLEM", 147, 154], ["infection", "PROBLEM", 169, 178]]], ["During infection with LCMV, microglia are a major reservoir of infection, and antiviral CD8 + T cells can stably engage microglia in an MHC I-dependent manner.", [["microglia", "ANATOMY", 28, 37], ["CD8 + T cells", "ANATOMY", 88, 101], ["microglia", "ANATOMY", 120, 129], ["infection", "DISEASE", 7, 16], ["infection", "DISEASE", 63, 72], ["LCMV", "ORGANISM", 22, 26], ["microglia", "CELL", 28, 37], ["CD8", "GENE_OR_GENE_PRODUCT", 88, 91], ["microglia", "CELL", 120, 129], ["microglia", "CELL_TYPE", 28, 37], ["antiviral CD8 + T cells", "CELL_TYPE", 78, 101], ["microglia", "CELL_TYPE", 120, 129], ["MHC I", "PROTEIN", 136, 141], ["LCMV", "SPECIES", 22, 26], ["infection", "PROBLEM", 7, 16], ["LCMV", "PROBLEM", 22, 26], ["microglia", "PROBLEM", 28, 37], ["infection", "PROBLEM", 63, 72], ["antiviral CD8", "TEST", 78, 91], ["T cells", "PROBLEM", 94, 101], ["infection", "OBSERVATION", 7, 16], ["LCMV", "OBSERVATION", 22, 26], ["infection", "OBSERVATION", 63, 72]]], ["In contrast, CD4 + T cells have less sustained interactions with microglia, likely as consequence of the relative abundance of cognate peptide-MHC I versus MHC II complexes (Herz et al., 2015) .", [["CD4 + T cells", "ANATOMY", 13, 26], ["microglia", "ANATOMY", 65, 74], ["CD4", "GENE_OR_GENE_PRODUCT", 13, 16], ["microglia", "CELL", 65, 74], ["peptide-MHC I", "GENE_OR_GENE_PRODUCT", 135, 148], ["MHC II", "GENE_OR_GENE_PRODUCT", 156, 162], ["CD4", "PROTEIN", 13, 16], ["T cells", "CELL_TYPE", 19, 26], ["microglia", "CELL_TYPE", 65, 74], ["MHC I", "PROTEIN", 143, 148], ["MHC II complexes", "PROTEIN", 156, 172], ["CD4", "TEST", 13, 16], ["T cells", "PROBLEM", 19, 26], ["microglia", "PROBLEM", 65, 74]]], ["A functional role for microglia in modulating CD8 T cell responses was illustrated via pharmacological deletion of microglia during dengue virus infection that resulted in reduced CD8 + T cell responses and increased viral replication (Tsai et al., 2016) .", [["microglia", "ANATOMY", 22, 31], ["CD8 T cell", "ANATOMY", 46, 56], ["microglia", "ANATOMY", 115, 124], ["CD8 + T cell", "ANATOMY", 180, 192], ["dengue virus infection", "DISEASE", 132, 154], ["microglia", "CELL", 22, 31], ["CD8 T cell", "CELL", 46, 56], ["microglia", "CELL", 115, 124], ["dengue virus", "ORGANISM", 132, 144], ["CD8", "GENE_OR_GENE_PRODUCT", 180, 183], ["microglia", "CELL_TYPE", 22, 31], ["CD8", "PROTEIN", 46, 49], ["microglia", "CELL_TYPE", 115, 124], ["CD8", "PROTEIN", 180, 183], ["dengue virus", "SPECIES", 132, 144], ["microglia", "PROBLEM", 22, 31], ["pharmacological deletion of microglia", "PROBLEM", 87, 124], ["dengue virus infection", "PROBLEM", 132, 154], ["reduced CD8 + T cell responses", "PROBLEM", 172, 202], ["increased viral replication", "PROBLEM", 207, 234], ["microglia", "ANATOMY", 115, 124], ["increased", "OBSERVATION_MODIFIER", 207, 216], ["viral replication", "OBSERVATION", 217, 234]]], ["The fundamental advances in understanding microglial development combined with ability to visualize how these cells interact with pathogens and other immune cells and the use of genetic approaches to manipulate microglial immune function will provide the opportunity to better understand the contribution of these cells to resistance to infection or resolution of local inflammation.Figure 3.", [["microglial", "ANATOMY", 42, 52], ["cells", "ANATOMY", 110, 115], ["immune cells", "ANATOMY", 150, 162], ["microglial", "ANATOMY", 211, 221], ["cells", "ANATOMY", 314, 319], ["infection", "DISEASE", 337, 346], ["inflammation", "DISEASE", 370, 382], ["microglial", "CELL", 42, 52], ["cells", "CELL", 110, 115], ["immune cells", "CELL", 150, 162], ["microglial", "CELL", 211, 221], ["cells", "CELL", 314, 319], ["immune cells", "CELL_TYPE", 150, 162], ["pathogens", "PROBLEM", 130, 139], ["genetic approaches", "TREATMENT", 178, 196], ["these cells", "PROBLEM", 308, 319], ["infection", "PROBLEM", 337, 346], ["local inflammation", "PROBLEM", 364, 382], ["infection", "OBSERVATION", 337, 346], ["local", "OBSERVATION_MODIFIER", 364, 369], ["inflammation", "OBSERVATION", 370, 382]]], ["Effector Mechanisms Used by T Cells to Control CNS InfectionT cell production of IFN-g induces a wide range of anti-microbial effector molecules, often in a cell-type-specific fashion (see earlier sections on astrocytes and neurons) and is a key cytokine for neuroinfectious diseases (Griffin, 2003) .", [["T Cells", "ANATOMY", 28, 35], ["CNS InfectionT cell", "ANATOMY", 47, 66], ["cell", "ANATOMY", 157, 161], ["sections", "ANATOMY", 197, 205], ["astrocytes", "ANATOMY", 209, 219], ["neurons", "ANATOMY", 224, 231], ["neuroinfectious diseases", "DISEASE", 259, 283], ["T Cells", "CELL", 28, 35], ["Control CNS InfectionT cell", "CELL", 39, 66], ["IFN-g", "GENE_OR_GENE_PRODUCT", 81, 86], ["cell", "CELL", 157, 161], ["astrocytes", "CELL", 209, 219], ["neurons", "CELL", 224, 231], ["T Cells", "CELL_TYPE", 28, 35], ["IFN", "PROTEIN", 81, 84], ["anti-microbial effector molecules", "PROTEIN", 111, 144], ["astrocytes", "CELL_TYPE", 209, 219], ["neurons", "CELL_TYPE", 224, 231], ["cytokine", "PROTEIN", 246, 254], ["Effector Mechanisms", "PROBLEM", 0, 19], ["T Cells", "TREATMENT", 28, 35], ["IFN", "PROBLEM", 81, 84], ["anti-microbial effector molecules", "PROBLEM", 111, 144], ["neuroinfectious diseases", "PROBLEM", 259, 283]]], ["This principle was established in murine models of toxoplasmosis in which CD4 + and CD8 + T cells in the CNS produce IFN-g that, in combination with other effectors such as TNF-a and CD40L, mediate local parasite control (Denkers et al., 1997; Gazzinelli et al., 1992; Reichmann et al., 2000; Suzuki et al., 1989; Yap and Sher, 1999) .", [["CD4 + and CD8 + T cells", "ANATOMY", 74, 97], ["CNS", "ANATOMY", 105, 108], ["toxoplasmosis", "DISEASE", 51, 64], ["murine", "ORGANISM", 34, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["CD8", "GENE_OR_GENE_PRODUCT", 84, 87], ["CNS", "ANATOMICAL_SYSTEM", 105, 108], ["IFN-g", "GENE_OR_GENE_PRODUCT", 117, 122], ["TNF-a", "GENE_OR_GENE_PRODUCT", 173, 178], ["CD40L", "GENE_OR_GENE_PRODUCT", 183, 188], ["CD4 + and CD8 + T cells", "CELL_TYPE", 74, 97], ["IFN", "PROTEIN", 117, 120], ["TNF", "PROTEIN", 173, 176], ["CD40L", "PROTEIN", 183, 188], ["murine", "SPECIES", 34, 40], ["toxoplasmosis", "PROBLEM", 51, 64], ["CD4", "TEST", 74, 77], ["CD8", "TEST", 84, 87], ["T cells", "PROBLEM", 90, 97], ["other effectors", "PROBLEM", 149, 164], ["TNF", "TEST", 173, 176], ["toxoplasmosis", "OBSERVATION", 51, 64], ["CNS", "ANATOMY", 105, 108]]], ["In this system, in addition to effects on astrocytes, the production of IFN-g drives local macrophage activation, with production of toxic oxygen intermediates such as nitric oxide (NO) required to control intracellular parasites (Deckert-Schl\u20ac uter et al., 1998; Nansen et al., 1998; Scharton-Kersten et al., 1997) .Figure 3.", [["astrocytes", "ANATOMY", 42, 52], ["macrophage", "ANATOMY", 91, 101], ["intracellular", "ANATOMY", 206, 219], ["oxygen", "CHEMICAL", 139, 145], ["nitric oxide", "CHEMICAL", 168, 180], ["NO", "CHEMICAL", 182, 184], ["oxygen", "CHEMICAL", 139, 145], ["nitric oxide", "CHEMICAL", 168, 180], ["NO", "CHEMICAL", 182, 184], ["astrocytes", "CELL", 42, 52], ["IFN-g", "GENE_OR_GENE_PRODUCT", 72, 77], ["macrophage", "CELL", 91, 101], ["oxygen", "SIMPLE_CHEMICAL", 139, 145], ["nitric oxide", "SIMPLE_CHEMICAL", 168, 180], ["NO", "SIMPLE_CHEMICAL", 182, 184], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 206, 219], ["astrocytes", "CELL_TYPE", 42, 52], ["IFN", "PROTEIN", 72, 75], ["astrocytes", "PROBLEM", 42, 52], ["IFN", "TREATMENT", 72, 75], ["local macrophage activation", "TREATMENT", 85, 112], ["toxic oxygen intermediates", "TREATMENT", 133, 159], ["nitric oxide", "TREATMENT", 168, 180], ["toxic", "OBSERVATION_MODIFIER", 133, 138], ["oxygen intermediates", "OBSERVATION", 139, 159]]], ["Effector Mechanisms Used by T Cells to Control CNS InfectionThe neuroimmunology literature has focused on the contribution of T helper 17 (Th17) cells to the development of autoimmune pathology (Korn et al., 2009 ), but less is known about their function during CNS infection.", [["T Cells", "ANATOMY", 28, 35], ["CNS", "ANATOMY", 47, 50], ["T helper 17 (Th17) cells", "ANATOMY", 126, 150], ["CNS", "ANATOMY", 262, 265], ["autoimmune pathology", "DISEASE", 173, 193], ["infection", "DISEASE", 266, 275], ["T Cells", "CELL", 28, 35], ["T helper 17", "CELL", 126, 137], ["CNS", "ANATOMICAL_SYSTEM", 262, 265], ["T Cells", "CELL_TYPE", 28, 35], ["T helper 17 (Th17) cells", "CELL_TYPE", 126, 150], ["CNS Infection", "PROBLEM", 47, 60], ["autoimmune pathology", "PROBLEM", 173, 193], ["CNS infection", "PROBLEM", 262, 275], ["CNS", "ANATOMY", 47, 50], ["Infection", "OBSERVATION", 51, 60], ["autoimmune", "OBSERVATION", 173, 183], ["CNS", "ANATOMY", 262, 265], ["infection", "OBSERVATION", 266, 275]]], ["Perhaps the strongest indication that these cells are protective in the CNS is in the setting of fungal infections where there is a high prevalence of invasive candidiasis of the brain in patients with primary genetic defects in CARD9, an adaptor required for the development of Th17 responses (Alves de Medeiros et al., 2016; Glocker et al., 2009; Herbst et al., 2015) .", [["cells", "ANATOMY", 44, 49], ["CNS", "ANATOMY", 72, 75], ["brain", "ANATOMY", 179, 184], ["fungal infections", "DISEASE", 97, 114], ["candidiasis of the brain", "DISEASE", 160, 184], ["cells", "CELL", 44, 49], ["CNS", "ANATOMICAL_SYSTEM", 72, 75], ["candidiasis", "PATHOLOGICAL_FORMATION", 160, 171], ["brain", "ORGAN", 179, 184], ["patients", "ORGANISM", 188, 196], ["CARD9", "GENE_OR_GENE_PRODUCT", 229, 234], ["Th17", "CELL", 279, 283], ["CARD9", "PROTEIN", 229, 234], ["patients", "SPECIES", 188, 196], ["these cells", "PROBLEM", 38, 49], ["fungal infections", "PROBLEM", 97, 114], ["invasive candidiasis of the brain", "PROBLEM", 151, 184], ["primary genetic defects in CARD9", "PROBLEM", 202, 234], ["an adaptor", "TREATMENT", 236, 246], ["CNS", "ANATOMY", 72, 75], ["fungal", "OBSERVATION_MODIFIER", 97, 103], ["infections", "OBSERVATION", 104, 114], ["high", "OBSERVATION_MODIFIER", 132, 136], ["invasive", "OBSERVATION_MODIFIER", 151, 159], ["candidiasis", "OBSERVATION", 160, 171], ["brain", "ANATOMY", 179, 184], ["defects", "OBSERVATION", 218, 225]]], ["While these patients have reduced Th17 responses, the observation that other genetic deficiencies associated with diminished IL-17 production are not susceptible to Candida suggest that another mechanism might underlie susceptibility.", [["patients", "ORGANISM", 12, 20], ["IL-17", "GENE_OR_GENE_PRODUCT", 125, 130], ["IL", "PROTEIN", 125, 127], ["patients", "SPECIES", 12, 20], ["reduced Th17 responses", "PROBLEM", 26, 48], ["other genetic deficiencies", "PROBLEM", 71, 97], ["diminished IL", "PROBLEM", 114, 127], ["Candida", "PROBLEM", 165, 172], ["diminished", "OBSERVATION_MODIFIER", 114, 124]]], ["Indeed, these patients also have a reduced ability to produce GM-CSF, a cytokine associated with Th17 responses that promotes macrophage and microglial function.", [["macrophage", "ANATOMY", 126, 136], ["microglial", "ANATOMY", 141, 151], ["GM", "CHEMICAL", 62, 64], ["patients", "ORGANISM", 14, 22], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 62, 68], ["Th17", "GENE_OR_GENE_PRODUCT", 97, 101], ["macrophage", "CELL", 126, 136], ["microglial", "CELL", 141, 151], ["GM", "PROTEIN", 62, 64], ["CSF", "PROTEIN", 65, 68], ["cytokine", "PROTEIN", 72, 80], ["patients", "SPECIES", 14, 22], ["a reduced ability", "PROBLEM", 33, 50], ["macrophage", "OBSERVATION_MODIFIER", 126, 136], ["microglial function", "OBSERVATION", 141, 160]]], ["The idea that a reduced ability to make GM-CSF might underlie susceptibility to invasive candidiasis is supported by the success of GM-CSF in these patients as an adjunctive therapy with anti-fungal agents (Gavino et al., 2014) .", [["invasive candidiasis", "ANATOMY", 80, 100], ["GM", "CHEMICAL", 40, 42], ["candidiasis", "DISEASE", 89, 100], ["GM", "CHEMICAL", 132, 134], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 40, 46], ["candidiasis", "CANCER", 89, 100], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 132, 138], ["patients", "ORGANISM", 148, 156], ["CSF", "PROTEIN", 43, 46], ["patients", "SPECIES", 148, 156], ["a reduced ability", "PROBLEM", 14, 31], ["invasive candidiasis", "PROBLEM", 80, 100], ["GM-CSF", "TREATMENT", 132, 138], ["an adjunctive therapy", "TREATMENT", 160, 181], ["anti-fungal agents", "TREATMENT", 187, 205], ["invasive", "OBSERVATION_MODIFIER", 80, 88], ["candidiasis", "OBSERVATION", 89, 100]]], ["Because T-cell-derived GM-CSF is important in the recruitment of CCR2 + inflammatory monocytes to the CNS during experimental allergic encephalomyelitis (EAE) (Croxford et al., 2015) , this pathway might be relevant to models in which monocytes are important for local control of CNS infection (Benevides et al., 2008; Biswas et al., 2015; Chen et al., 2001) .Adaptive Mechanisms to Target NeuronsThe neuron, as a long-lived cell with a unique biology that ensures that a single cell can traverses extensive areas of the CNS, seems an ideal refuge for many pathogens.", [["T-cell", "ANATOMY", 8, 14], ["CCR2 + inflammatory monocytes", "ANATOMY", 65, 94], ["CNS", "ANATOMY", 102, 105], ["monocytes", "ANATOMY", 235, 244], ["CNS", "ANATOMY", 280, 283], ["neuron", "ANATOMY", 401, 407], ["cell", "ANATOMY", 425, 429], ["cell", "ANATOMY", 479, 483], ["CNS", "ANATOMY", 521, 524], ["GM", "CHEMICAL", 23, 25], ["allergic encephalomyelitis", "DISEASE", 126, 152], ["EAE", "DISEASE", 154, 157], ["infection", "DISEASE", 284, 293], ["T-cell", "CELL", 8, 14], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 23, 29], ["CCR2", "GENE_OR_GENE_PRODUCT", 65, 69], ["monocytes", "CELL", 85, 94], ["CNS", "ANATOMICAL_SYSTEM", 102, 105], ["monocytes", "CELL", 235, 244], ["CNS", "ANATOMICAL_SYSTEM", 280, 283], ["Neurons", "CELL", 390, 397], ["neuron", "CELL", 401, 407], ["cell", "CELL", 425, 429], ["cell", "CELL", 479, 483], ["CNS", "ANATOMICAL_SYSTEM", 521, 524], ["GM", "PROTEIN", 23, 25], ["CSF", "PROTEIN", 26, 29], ["CCR2", "PROTEIN", 65, 69], ["inflammatory monocytes", "CELL_TYPE", 72, 94], ["monocytes", "CELL_TYPE", 235, 244], ["T", "TEST", 8, 9], ["inflammatory monocytes", "PROBLEM", 72, 94], ["the CNS", "PROBLEM", 98, 105], ["experimental allergic encephalomyelitis", "PROBLEM", 113, 152], ["CNS infection", "PROBLEM", 280, 293], ["a single cell", "PROBLEM", 470, 483], ["many pathogens", "PROBLEM", 552, 566], ["CCR2", "ANATOMY", 65, 69], ["inflammatory monocytes", "OBSERVATION", 72, 94], ["CNS", "ANATOMY", 102, 105], ["allergic encephalomyelitis", "OBSERVATION", 126, 152], ["CNS", "ANATOMY", 280, 283], ["infection", "OBSERVATION", 284, 293], ["CNS", "ANATOMY", 521, 524]]], ["Indeed, several viruses in the CNS are not cytolytic and have evolved strategies to interfere with anti-microbial pathways and to remain latent in neurons.", [["CNS", "ANATOMY", 31, 34], ["neurons", "ANATOMY", 147, 154], ["CNS", "ANATOMICAL_SYSTEM", 31, 34], ["neurons", "CELL", 147, 154], ["cytolytic", "PROBLEM", 43, 52], ["anti-microbial pathways", "TREATMENT", 99, 122], ["several", "OBSERVATION_MODIFIER", 8, 15], ["viruses", "OBSERVATION", 16, 23], ["CNS", "ANATOMY", 31, 34]]], ["This is illustrated with HSV in which latency associated transcripts generate miRNAs that target immunomodulatory genes that facilitate viral latency (Boss and Renne, 2011) .", [["HSV", "ORGANISM", 25, 28], ["immunomodulatory genes", "DNA", 97, 119], ["HSV", "SPECIES", 25, 28], ["HSV", "PROBLEM", 25, 28], ["viral latency", "PROBLEM", 136, 149], ["HSV", "OBSERVATION", 25, 28]]], ["This ability to target neurons is not exclusive to viruses and a select group of apicomplexan parasites (notably T. gondii) have specialized cyst stages that persist in neurons.", [["neurons", "ANATOMY", 23, 30], ["cyst", "ANATOMY", 141, 145], ["neurons", "ANATOMY", 169, 176], ["neurons", "CELL", 23, 30], ["apicomplexan parasites", "ORGANISM", 81, 103], ["T. gondii", "ORGANISM", 113, 122], ["cyst stages", "MULTI-TISSUE_STRUCTURE", 141, 152], ["neurons", "CELL", 169, 176], ["T. gondii", "SPECIES", 113, 122], ["T. gondii", "SPECIES", 113, 122], ["viruses", "PROBLEM", 51, 58], ["apicomplexan parasites", "PROBLEM", 81, 103], ["T. gondii", "PROBLEM", 113, 122], ["specialized cyst stages", "PROBLEM", 129, 152], ["apicomplexan parasites", "OBSERVATION", 81, 103], ["cyst", "OBSERVATION", 141, 145], ["neurons", "ANATOMY", 169, 176]]], ["It has been proposed that the cellular stress associated with the immune response drives cyst formation and extracellular adenosine (likely released from damaged cells) signaling through CD73 promotes cyst formation (Mahamed et al., 2012) .", [["cellular", "ANATOMY", 30, 38], ["cyst", "ANATOMY", 89, 93], ["extracellular", "ANATOMY", 108, 121], ["cells", "ANATOMY", 162, 167], ["cyst", "ANATOMY", 201, 205], ["adenosine", "CHEMICAL", 122, 131], ["adenosine", "CHEMICAL", 122, 131], ["cellular", "CELL", 30, 38], ["cyst", "CANCER", 89, 93], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["adenosine", "SIMPLE_CHEMICAL", 122, 131], ["cells", "CELL", 162, 167], ["CD73", "GENE_OR_GENE_PRODUCT", 187, 191], ["cyst", "PATHOLOGICAL_FORMATION", 201, 205], ["damaged cells", "CELL_TYPE", 154, 167], ["CD73", "PROTEIN", 187, 191], ["the cellular stress", "PROBLEM", 26, 45], ["cyst formation", "PROBLEM", 89, 103], ["extracellular adenosine", "TREATMENT", 108, 131], ["signaling through CD73 promotes cyst formation", "PROBLEM", 169, 215], ["cellular stress", "OBSERVATION", 30, 45], ["cyst", "OBSERVATION", 201, 205]]], ["It is notable that cysts are typically restricted to neurons, but the loss of STAT1 in astrocytes results in cyst formation in these cells in vivo, a finding that suggests IFN-g can actively prevent cyst formation (Hidano et al., 2016) .", [["cysts", "ANATOMY", 19, 24], ["neurons", "ANATOMY", 53, 60], ["astrocytes", "ANATOMY", 87, 97], ["cyst", "ANATOMY", 109, 113], ["cells", "ANATOMY", 133, 138], ["cyst", "ANATOMY", 199, 203], ["cysts", "PATHOLOGICAL_FORMATION", 19, 24], ["neurons", "CELL", 53, 60], ["STAT1", "GENE_OR_GENE_PRODUCT", 78, 83], ["astrocytes", "CELL", 87, 97], ["cyst", "PATHOLOGICAL_FORMATION", 109, 113], ["cells", "CELL", 133, 138], ["IFN-g", "GENE_OR_GENE_PRODUCT", 172, 177], ["cyst", "PATHOLOGICAL_FORMATION", 199, 203], ["STAT1", "PROTEIN", 78, 83], ["astrocytes", "CELL_TYPE", 87, 97], ["IFN", "PROTEIN", 172, 175], ["cysts", "PROBLEM", 19, 24], ["the loss of STAT1 in astrocytes", "PROBLEM", 66, 97], ["cyst formation", "PROBLEM", 109, 123], ["IFN", "PROBLEM", 172, 175], ["cyst formation", "PROBLEM", 199, 213], ["cysts", "OBSERVATION", 19, 24], ["loss", "OBSERVATION_MODIFIER", 70, 74], ["STAT1", "OBSERVATION", 78, 83], ["cyst", "OBSERVATION", 109, 113], ["cyst", "OBSERVATION", 199, 203]]], ["The ability to study how neurons respond to infection in vivo remains challenging but there are two examples where the ability to genetically modify pathogens to express the Cre recombinase combined with host reporters has provided novel tools that have advanced this topic.", [["neurons", "ANATOMY", 25, 32], ["infection", "DISEASE", 44, 53], ["neurons", "CELL", 25, 32], ["Cre", "GENE_OR_GENE_PRODUCT", 174, 177], ["Cre recombinase", "DNA", 174, 189], ["infection", "PROBLEM", 44, 53], ["the Cre recombinase", "TREATMENT", 170, 189], ["infection", "OBSERVATION", 44, 53]]], ["Thus, the use of rabies that express Cre has shown that the majority of RABV-infected neurons survive infection and clearance and these have been transcriptionally profiled (Gomme et al., 2012) .", [["neurons", "ANATOMY", 86, 93], ["infection", "DISEASE", 102, 111], ["rabies", "ORGANISM", 17, 23], ["Cre", "GENE_OR_GENE_PRODUCT", 37, 40], ["RABV", "ORGANISM", 72, 76], ["neurons", "CELL", 86, 93], ["Cre", "PROTEIN", 37, 40], ["rabies", "SPECIES", 17, 23], ["RABV", "SPECIES", 72, 76], ["Cre", "TEST", 37, 40], ["RABV", "PROBLEM", 72, 76], ["infected neurons survive infection", "PROBLEM", 77, 111]]], ["Similarly, the use of T. gondii strains that secrete Cre into host cells has been used to visualize neurons infected with Toxoplasma (Cabral et al., 2016) .Adaptive Mechanisms to Target NeuronsWhile there is a role of type I IFNs in limiting viral replication in neurons, there are open questions about the mechanisms used by T cells to target these cells.", [["cells", "ANATOMY", 67, 72], ["neurons", "ANATOMY", 100, 107], ["neurons", "ANATOMY", 263, 270], ["T cells", "ANATOMY", 326, 333], ["cells", "ANATOMY", 350, 355], ["T. gondii", "ORGANISM", 22, 31], ["strains", "ORGANISM", 32, 39], ["Cre", "GENE_OR_GENE_PRODUCT", 53, 56], ["host cells", "CELL", 62, 72], ["neurons", "CELL", 100, 107], ["Toxoplasma", "ORGANISM", 122, 132], ["Neurons", "CELL", 186, 193], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 218, 229], ["neurons", "CELL", 263, 270], ["T cells", "CELL", 326, 333], ["cells", "CELL", 350, 355], ["Cre", "PROTEIN", 53, 56], ["host cells", "CELL_TYPE", 62, 72], ["type I IFNs", "PROTEIN", 218, 229], ["neurons", "CELL_TYPE", 263, 270], ["T cells", "CELL_TYPE", 326, 333], ["T. gondii", "SPECIES", 22, 31], ["T. gondii", "SPECIES", 22, 31], ["T. gondii strains", "PROBLEM", 22, 39], ["secrete Cre into host cells", "PROBLEM", 45, 72], ["Toxoplasma", "PROBLEM", 122, 132], ["type I IFNs", "PROBLEM", 218, 229]]], ["For example, the non-cytolytic clearance of Measles (the cause of sub-acute sclerosing panencephalitis) and Sindbis from neurons is IFN-g dependent (Binder and Griffin, 2001; Patterson et al., 2002 ) and there appears to be a bystander role for CD4 + T cells in some of these events (Solomos et al., 2016) .", [["neurons", "ANATOMY", 121, 128], ["CD4 + T cells", "ANATOMY", 245, 258], ["Measles", "DISEASE", 44, 51], ["panencephalitis", "DISEASE", 87, 102], ["Sindbis", "DISEASE", 108, 115], ["Sindbis", "ORGANISM", 108, 115], ["neurons", "CELL", 121, 128], ["IFN-g", "GENE_OR_GENE_PRODUCT", 132, 137], ["CD4", "GENE_OR_GENE_PRODUCT", 245, 248], ["IFN", "PROTEIN", 132, 135], ["CD4", "PROTEIN", 245, 248], ["T cells", "CELL_TYPE", 251, 258], ["Measles", "PROBLEM", 44, 51], ["sub-acute sclerosing panencephalitis", "PROBLEM", 66, 102], ["Sindbis from neurons", "PROBLEM", 108, 128], ["CD4 + T cells", "PROBLEM", 245, 258], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["sclerosing", "OBSERVATION_MODIFIER", 76, 86], ["panencephalitis", "OBSERVATION", 87, 102]]], ["In ''carrier mice'' that have an established LCMV infection in neurons, there is a literature that identifies ''therapeutic'' CD8 + T cells as being important in elimination of this virus pool through the production of IFN-g that licenses microglia to purge virus, present antigen, and amplify the local antiviral T cell response (Herz et al., 2015; Oldstone et al., 1986; Pinschewer et al., 2010) .", [["neurons", "ANATOMY", 63, 70], ["CD8 + T cells", "ANATOMY", 126, 139], ["microglia", "ANATOMY", 239, 248], ["T cell", "ANATOMY", 314, 320], ["LCMV infection", "DISEASE", 45, 59], ["mice", "ORGANISM", 13, 17], ["LCMV", "ORGANISM", 45, 49], ["neurons", "CELL", 63, 70], ["CD8", "GENE_OR_GENE_PRODUCT", 126, 129], ["IFN-g", "GENE_OR_GENE_PRODUCT", 219, 224], ["microglia", "CELL", 239, 248], ["T cell", "CELL", 314, 320], ["CD8 + T cells", "CELL_TYPE", 126, 139], ["IFN", "PROTEIN", 219, 222], ["microglia", "CELL_TYPE", 239, 248], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["LCMV", "SPECIES", 45, 49], ["an established LCMV infection in neurons", "PROBLEM", 30, 70], ["T cells", "PROBLEM", 132, 139], ["this virus pool", "PROBLEM", 177, 192], ["IFN", "TREATMENT", 219, 222], ["purge virus", "PROBLEM", 252, 263], ["LCMV", "OBSERVATION_MODIFIER", 45, 49], ["infection", "OBSERVATION", 50, 59]]], ["How microglia mediate these effects is uncertain, but is associated with a number of STAT1-dependent processes and the presence of a GM-CSF signature (Herz et al., 2015) .Adaptive Mechanisms to Target NeuronsWhile there has been a long-held belief that neurons express no MHC class I (which would make them an ideal cell type to evade CD8 + T cells), the application of more sensitive technologies has led to the recognition that different subsets of these cells can express MHC class I in the developing and adult brain and that these molecules have a role in neurological function (Cullheim and Thams, 2010; Shatz, 2009 ).", [["microglia", "ANATOMY", 4, 13], ["neurons", "ANATOMY", 253, 260], ["cell", "ANATOMY", 316, 320], ["CD8 + T cells", "ANATOMY", 335, 348], ["cells", "ANATOMY", 457, 462], ["brain", "ANATOMY", 515, 520], ["neurological", "ANATOMY", 561, 573], ["GM", "CHEMICAL", 133, 135], ["microglia", "CELL", 4, 13], ["STAT1", "GENE_OR_GENE_PRODUCT", 85, 90], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 133, 139], ["Neurons", "CELL", 201, 208], ["neurons", "CELL", 253, 260], ["MHC class I", "GENE_OR_GENE_PRODUCT", 272, 283], ["cell", "CELL", 316, 320], ["CD8", "GENE_OR_GENE_PRODUCT", 335, 338], ["cells", "CELL", 457, 462], ["MHC class I", "GENE_OR_GENE_PRODUCT", 475, 486], ["brain", "ORGAN", 515, 520], ["microglia", "CELL_TYPE", 4, 13], ["STAT1", "PROTEIN", 85, 90], ["MHC class I", "PROTEIN", 272, 283], ["CD8 + T cells", "CELL_TYPE", 335, 348], ["MHC class I", "PROTEIN", 475, 486], ["STAT1-dependent processes", "PROBLEM", 85, 110], ["a GM-CSF signature", "PROBLEM", 131, 149], ["adult brain", "PROBLEM", 509, 520], ["STAT1", "OBSERVATION", 85, 90], ["dependent", "OBSERVATION_MODIFIER", 91, 100], ["processes", "OBSERVATION", 101, 110], ["brain", "ANATOMY", 515, 520]]], ["There are reports of the induction of neuronal class I during infection (Neumann et al., 1995) , but there remains a major knowledge gap in our understanding of whether neuronal antigen presentation influences resistance or susceptibility to infection in vivo.", [["neuronal", "ANATOMY", 38, 46], ["neuronal", "ANATOMY", 169, 177], ["infection", "DISEASE", 62, 71], ["infection", "DISEASE", 242, 251], ["neuronal class I", "GENE_OR_GENE_PRODUCT", 38, 54], ["neuronal", "CELL", 169, 177], ["neuronal class I", "PROTEIN", 38, 54], ["neuronal antigen presentation", "PROBLEM", 169, 198], ["susceptibility to infection in vivo", "PROBLEM", 224, 259], ["infection", "OBSERVATION", 242, 251]]], ["There is in vitro and in vivo evidence for CD8 + T cells interacting directly with infected neurons during Theiler's virus, LCMV, Borna and picornavirus infection (Chevalier et al., 2011; Huseby Kelcher et al., 2017; McDole et al., 2010; Rall et al., 1995) and there is evidence that the ability of HSV to inhibit class I expression in neurons in basal ganglia is key to avoid CD8 + T cell responses (Orr et al., 2007) .", [["CD8 + T cells", "ANATOMY", 43, 56], ["neurons", "ANATOMY", 92, 99], ["neurons", "ANATOMY", 336, 343], ["basal ganglia", "ANATOMY", 347, 360], ["CD8 + T cell", "ANATOMY", 377, 389], ["Borna and picornavirus infection", "DISEASE", 130, 162], ["CD8", "GENE_OR_GENE_PRODUCT", 43, 46], ["neurons", "CELL", 92, 99], ["Theiler's virus", "ORGANISM", 107, 122], ["LCMV", "ORGANISM", 124, 128], ["Borna", "ORGANISM", 130, 135], ["picornavirus", "ORGANISM", 140, 152], ["HSV", "ORGANISM", 299, 302], ["class I", "GENE_OR_GENE_PRODUCT", 314, 321], ["neurons", "CELL", 336, 343], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 347, 360], ["CD8", "GENE_OR_GENE_PRODUCT", 377, 380], ["CD8", "PROTEIN", 43, 46], ["T cells", "CELL_TYPE", 49, 56], ["CD8", "PROTEIN", 377, 380], ["Theiler", "SPECIES", 107, 114], ["Theiler's virus", "SPECIES", 107, 122], ["LCMV", "SPECIES", 124, 128], ["HSV", "SPECIES", 299, 302], ["CD8", "PROBLEM", 43, 46], ["T cells", "PROBLEM", 49, 56], ["infected neurons", "PROBLEM", 83, 99], ["Theiler's virus", "PROBLEM", 107, 122], ["LCMV", "PROBLEM", 124, 128], ["Borna", "PROBLEM", 130, 135], ["picornavirus infection", "PROBLEM", 140, 162], ["HSV", "PROBLEM", 299, 302], ["LCMV", "OBSERVATION", 124, 128], ["Borna", "ANATOMY", 130, 135], ["picornavirus infection", "OBSERVATION", 140, 162], ["neurons", "ANATOMY", 336, 343], ["basal ganglia", "ANATOMY", 347, 360]]], ["Unexpectedly, imaging studies indicate that CD11c + cells (likely microglia or DC), but not parasitespecific CD8 + T cells, frequently interact with cysts of T. gondii (John et al., 2011; Schaeffer et al., 2009) .", [["CD11c + cells", "ANATOMY", 44, 57], ["microglia", "ANATOMY", 66, 75], ["DC", "ANATOMY", 79, 81], ["parasitespecific CD8 + T cells", "ANATOMY", 92, 122], ["cysts", "ANATOMY", 149, 154], ["CD11c", "GENE_OR_GENE_PRODUCT", 44, 49], ["microglia", "CELL", 66, 75], ["DC", "CELL", 79, 81], ["CD8", "GENE_OR_GENE_PRODUCT", 109, 112], ["T. gondii", "ORGANISM", 158, 167], ["CD11c", "PROTEIN", 44, 49], ["microglia", "CELL_TYPE", 66, 75], ["DC", "CELL_TYPE", 79, 81], ["parasitespecific CD8 + T cells", "CELL_TYPE", 92, 122], ["T. gondii", "SPECIES", 158, 167], ["T. gondii", "SPECIES", 158, 167], ["imaging studies", "TEST", 14, 29], ["CD11c + cells", "PROBLEM", 44, 57], ["microglia", "PROBLEM", 66, 75], ["CD11c", "OBSERVATION", 44, 49], ["likely", "UNCERTAINTY", 59, 65]]], ["The ability to generate parasites with altered expression of stage-specific antigens (cyst versus non-cyst), has demonstrated that antigens associated with latency do not trigger the same immune responses as those produced during active infection (Kim and Boothroyd, 2005) .", [["cyst", "ANATOMY", 86, 90], ["non-cyst", "ANATOMY", 98, 106], ["infection", "DISEASE", 237, 246], ["cyst", "CANCER", 86, 90], ["non-cyst", "CANCER", 98, 106], ["antigens", "PROTEIN", 131, 139], ["parasites", "PROBLEM", 24, 33], ["stage-specific antigens (cyst versus non-cyst)", "PROBLEM", 61, 107], ["active infection", "PROBLEM", 230, 246], ["cyst", "OBSERVATION", 86, 90], ["active", "OBSERVATION_MODIFIER", 230, 236], ["infection", "OBSERVATION", 237, 246]]], ["These results highlight an immune evasion strategy to promote parasite persistence that would likely be relevant to many pathogens that have latent stages.", [["an immune evasion strategy", "TREATMENT", 24, 50], ["parasite persistence", "PROBLEM", 62, 82], ["many pathogens", "PROBLEM", 116, 130]]], ["Tissue-Resident Memory Populations in the CNS For many of the pathogens discussed here, the control of the acute phase of the disease is mediated by T cells and as antigen load is reduced the number of pathogen-specific T cells contract.", [["Tissue", "ANATOMY", 0, 6], ["CNS", "ANATOMY", 42, 45], ["T cells", "ANATOMY", 149, 156], ["T cells", "ANATOMY", 220, 227], ["Tissue", "TISSUE", 0, 6], ["CNS", "ANATOMICAL_SYSTEM", 42, 45], ["T cells", "CELL", 149, 156], ["T cells", "CELL", 220, 227], ["T cells", "CELL_TYPE", 149, 156], ["T cells", "CELL_TYPE", 220, 227], ["the pathogens", "PROBLEM", 58, 71], ["the disease", "PROBLEM", 122, 133], ["antigen load", "TEST", 164, 176], ["CNS", "ANATOMY", 42, 45], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["disease", "OBSERVATION", 126, 133]]], ["One consequence of these events is the generation of a long-lived pool of tissue-resident memory T (Trm) cells, which reside in barrier tissues like the lung, skin reproductive tract, and gut where they maintain post-infection homeostatic surveillance (Ariotti et al., 2012; Schenkel et al., 2014; Steinert et al., 2015) .", [["tissue-resident memory T (Trm) cells", "ANATOMY", 74, 110], ["barrier tissues", "ANATOMY", 128, 143], ["lung", "ANATOMY", 153, 157], ["skin reproductive tract", "ANATOMY", 159, 182], ["gut", "ANATOMY", 188, 191], ["infection", "DISEASE", 217, 226], ["tissue-resident memory T (Trm) cells", "CELL", 74, 110], ["barrier tissues", "TISSUE", 128, 143], ["lung", "ORGAN", 153, 157], ["skin", "ORGAN", 159, 163], ["reproductive tract", "MULTI-TISSUE_STRUCTURE", 164, 182], ["gut", "ORGAN", 188, 191], ["tissue-resident memory T (Trm) cells", "CELL_TYPE", 74, 110], ["these events", "PROBLEM", 19, 31], ["barrier tissues", "ANATOMY", 128, 143], ["lung", "ANATOMY", 153, 157], ["skin", "ANATOMY", 159, 163], ["reproductive tract", "OBSERVATION", 164, 182], ["infection", "OBSERVATION", 217, 226]]], ["Identification of these populations has been based on the expression of CD103 (the aE integrin) and CD69 (a proximal marker of TCR activation and tissue retention).", [["tissue", "ANATOMY", 146, 152], ["CD103", "GENE_OR_GENE_PRODUCT", 72, 77], ["aE integrin", "GENE_OR_GENE_PRODUCT", 83, 94], ["CD69", "GENE_OR_GENE_PRODUCT", 100, 104], ["TCR", "GENE_OR_GENE_PRODUCT", 127, 130], ["tissue", "TISSUE", 146, 152], ["CD103", "PROTEIN", 72, 77], ["aE integrin", "PROTEIN", 83, 94], ["CD69", "PROTEIN", 100, 104], ["TCR", "PROTEIN", 127, 130], ["these populations", "PROBLEM", 18, 35], ["CD69", "TEST", 100, 104], ["TCR activation", "PROBLEM", 127, 141], ["tissue retention", "PROBLEM", 146, 162], ["proximal", "OBSERVATION_MODIFIER", 108, 116], ["TCR activation", "OBSERVATION", 127, 141], ["tissue retention", "OBSERVATION", 146, 162]]], ["In several models, viral-specific CD8 + Trm are maintained in the CNS in the absence of detectable virus.", [["CD8 + Trm", "ANATOMY", 34, 43], ["CNS", "ANATOMY", 66, 69], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["Trm", "GENE_OR_GENE_PRODUCT", 40, 43], ["CNS", "ANATOMICAL_SYSTEM", 66, 69], ["CD8", "PROTEIN", 34, 37], ["Trm", "PROTEIN", 40, 43], ["viral", "TEST", 19, 24], ["Trm", "PROBLEM", 40, 43], ["detectable virus", "PROBLEM", 88, 104], ["CNS", "ANATOMY", 66, 69], ["detectable", "OBSERVATION_MODIFIER", 88, 98], ["virus", "OBSERVATION", 99, 104]]], ["Thus, in mice challenged with neurotopic influenza virus, CD8 + T cells were present at this site 320 days after infection (Hawke et al., 1998) .", [["CD8 + T cells", "ANATOMY", 58, 71], ["infection", "DISEASE", 113, 122], ["mice", "ORGANISM", 9, 13], ["neurotopic influenza virus", "ORGANISM", 30, 56], ["CD8", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD8 + T cells", "CELL_TYPE", 58, 71], ["mice", "SPECIES", 9, 13], ["mice", "SPECIES", 9, 13], ["neurotopic influenza virus", "SPECIES", 30, 56], ["neurotopic influenza virus", "PROBLEM", 30, 56], ["CD8 + T cells", "PROBLEM", 58, 71], ["infection", "PROBLEM", 113, 122]]], ["Similarly, following clearance of VSV from the brains of mice, clusters of CD103 + CD8 + T cells persist at likely sites of previous infection (Wakim et al., 2010) .", [["brains", "ANATOMY", 47, 53], ["CD103 + CD8 + T cells", "ANATOMY", 75, 96], ["sites", "ANATOMY", 115, 120], ["infection", "DISEASE", 133, 142], ["VSV", "ORGANISM", 34, 37], ["brains", "ORGAN", 47, 53], ["mice", "ORGANISM", 57, 61], ["CD103", "GENE_OR_GENE_PRODUCT", 75, 80], ["CD8", "GENE_OR_GENE_PRODUCT", 83, 86], ["CD103", "PROTEIN", 75, 80], ["CD8 + T cells", "CELL_TYPE", 83, 96], ["mice", "SPECIES", 57, 61], ["VSV", "SPECIES", 34, 37], ["mice", "SPECIES", 57, 61], ["CD103", "TEST", 75, 80], ["T cells", "PROBLEM", 89, 96], ["previous infection", "PROBLEM", 124, 142], ["infection", "OBSERVATION", 133, 142]]], ["LCMV-specific brain Trm are also found close to epithelial cells of the ventricular lining, within the choroid plexus, and in the meninges (Steinbach et al., 2016) .", [["brain", "ANATOMY", 14, 19], ["epithelial cells", "ANATOMY", 48, 64], ["ventricular lining", "ANATOMY", 72, 90], ["choroid plexus", "ANATOMY", 103, 117], ["meninges", "ANATOMY", 130, 138], ["LCMV", "ORGANISM", 0, 4], ["brain Trm", "CANCER", 14, 23], ["epithelial cells", "CELL", 48, 64], ["ventricular lining", "TISSUE", 72, 90], ["choroid plexus", "MULTI-TISSUE_STRUCTURE", 103, 117], ["meninges", "ORGAN", 130, 138], ["epithelial cells", "CELL_TYPE", 48, 64], ["LCMV", "SPECIES", 0, 4], ["LCMV", "TEST", 0, 4], ["brain Trm", "OBSERVATION", 14, 23], ["epithelial cells", "OBSERVATION", 48, 64], ["ventricular", "ANATOMY", 72, 83], ["lining", "ANATOMY_MODIFIER", 84, 90], ["choroid plexus", "ANATOMY", 103, 117], ["meninges", "ANATOMY", 130, 138]]], ["The ability to generate CNS-specific Trm is not specific to viral infection or dependent on antigen clearance and increasing chronicity of toxoplasma infection is associated with an enrichment of cells that co-express CD103 and CD69 and which are transcriptionally similar to VSV-specific Trm (Landrith et al., 2017) .Adaptive Mechanisms to Target NeuronsWith the recognition that pathogen-specific Trm populations are present in the CNS there has been interest in understanding the processes that influence their formation.", [["CNS", "ANATOMY", 24, 27], ["cells", "ANATOMY", 196, 201], ["CNS", "ANATOMY", 434, 437], ["infection", "DISEASE", 66, 75], ["toxoplasma infection", "DISEASE", 139, 159], ["CNS", "ANATOMICAL_SYSTEM", 24, 27], ["Trm", "GENE_OR_GENE_PRODUCT", 37, 40], ["antigen", "GENE_OR_GENE_PRODUCT", 92, 99], ["toxoplasma", "ORGANISM", 139, 149], ["cells", "CELL", 196, 201], ["CD103", "GENE_OR_GENE_PRODUCT", 218, 223], ["CD69", "GENE_OR_GENE_PRODUCT", 228, 232], ["VSV", "ORGANISM", 276, 279], ["Trm", "GENE_OR_GENE_PRODUCT", 289, 292], ["Trm populations", "CELL", 399, 414], ["CNS", "ANATOMICAL_SYSTEM", 434, 437], ["Trm", "PROTEIN", 37, 40], ["CD103", "PROTEIN", 218, 223], ["CD69", "PROTEIN", 228, 232], ["Trm populations", "CELL_TYPE", 399, 414], ["viral infection", "PROBLEM", 60, 75], ["antigen clearance", "TEST", 92, 109], ["toxoplasma infection", "PROBLEM", 139, 159], ["an enrichment of cells", "PROBLEM", 179, 201], ["CD69", "TEST", 228, 232], ["Adaptive Mechanisms", "TREATMENT", 318, 337], ["pathogen", "PROBLEM", 381, 389], ["infection", "OBSERVATION", 66, 75], ["toxoplasma infection", "OBSERVATION", 139, 159], ["CNS", "ANATOMY", 434, 437]]], ["Following WNV infection, the production of TGF-b results in increased expression of CD103 by CD8 + T cells, which allows a large pool of resident memory T cells to be maintained (Graham et al., 2014) .", [["CD8 + T cells", "ANATOMY", 93, 106], ["memory T cells", "ANATOMY", 146, 160], ["WNV infection", "DISEASE", 10, 23], ["WNV", "ORGANISM", 10, 13], ["TGF-b", "GENE_OR_GENE_PRODUCT", 43, 48], ["CD103", "GENE_OR_GENE_PRODUCT", 84, 89], ["CD8", "GENE_OR_GENE_PRODUCT", 93, 96], ["memory T cells", "CELL", 146, 160], ["TGF-b", "PROTEIN", 43, 48], ["CD103", "PROTEIN", 84, 89], ["CD8", "PROTEIN", 93, 96], ["T cells", "CELL_TYPE", 99, 106], ["resident memory T cells", "CELL_TYPE", 137, 160], ["WNV", "SPECIES", 10, 13], ["WNV infection", "PROBLEM", 10, 23], ["TGF", "TEST", 43, 46], ["WNV", "OBSERVATION_MODIFIER", 10, 13], ["infection", "OBSERVATION", 14, 23], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["CD103", "ANATOMY", 84, 89], ["large", "OBSERVATION_MODIFIER", 123, 128]]], ["During acute infection with the mouse polyoma virus the high-affinity effector cells give rise to high-affinity Trm.", [["cells", "ANATOMY", 79, 84], ["infection", "DISEASE", 13, 22], ["mouse", "ORGANISM", 32, 37], ["polyoma virus", "ORGANISM", 38, 51], ["cells", "CELL", 79, 84], ["Trm", "GENE_OR_GENE_PRODUCT", 112, 115], ["high-affinity effector cells", "CELL_TYPE", 56, 84], ["high-affinity Trm", "PROTEIN", 98, 115], ["mouse", "SPECIES", 32, 37], ["polyoma virus", "SPECIES", 38, 51], ["mouse polyoma virus", "SPECIES", 32, 51], ["acute infection", "PROBLEM", 7, 22], ["the mouse polyoma virus", "PROBLEM", 28, 51], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22], ["polyoma virus", "OBSERVATION", 38, 51]]], ["Functional studies have shown that virus-specific Trm have a TCR affinity that is approximately 20-fold higher in CD8 + T cells derived from the brain versus those of the spleen (Frost et al., 2015) .", [["CD8 + T cells", "ANATOMY", 114, 127], ["brain", "ANATOMY", 145, 150], ["spleen", "ANATOMY", 171, 177], ["Trm", "GENE_OR_GENE_PRODUCT", 50, 53], ["TCR", "GENE_OR_GENE_PRODUCT", 61, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 114, 117], ["brain", "ORGAN", 145, 150], ["spleen", "ORGAN", 171, 177], ["Trm", "PROTEIN", 50, 53], ["TCR", "PROTEIN", 61, 64], ["CD8 + T cells", "CELL_TYPE", 114, 127], ["Functional studies", "TEST", 0, 18], ["virus", "PROBLEM", 35, 40], ["a TCR affinity", "PROBLEM", 59, 73], ["brain", "ANATOMY", 145, 150], ["spleen", "ANATOMY", 171, 177]]], ["This selection for high TCR affinity could improve the ability of Trm to detect infected cells that express low levels of pathogen derived MHC-peptide complexes.", [["cells", "ANATOMY", 89, 94], ["TCR", "CHEMICAL", 24, 27], ["TCR", "GENE_OR_GENE_PRODUCT", 24, 27], ["Trm", "GENE_OR_GENE_PRODUCT", 66, 69], ["cells", "CELL", 89, 94], ["TCR", "PROTEIN", 24, 27], ["Trm", "PROTEIN", 66, 69], ["infected cells", "CELL_TYPE", 80, 94], ["MHC", "PROTEIN", 139, 142], ["This selection", "TREATMENT", 0, 14], ["high TCR affinity", "PROBLEM", 19, 36], ["infected cells", "PROBLEM", 80, 94], ["low levels of pathogen", "PROBLEM", 108, 130]]], ["Concrete evidence that Trm are of functional significance in the CNS is provided by the use of mice that had cleared LCMV.", [["CNS", "ANATOMY", 65, 68], ["Trm", "GENE_OR_GENE_PRODUCT", 23, 26], ["CNS", "ANATOMICAL_SYSTEM", 65, 68], ["mice", "ORGANISM", 95, 99], ["LCMV", "ORGANISM", 117, 121], ["Trm", "PROTEIN", 23, 26], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["CNS", "ANATOMY", 65, 68]]], ["In this setting, intracerebral inoculation of virus resulted in LCMV specific CD8 + Trm entering cell cycle and mediating viral control independently of peripheral CD8 + T cells via production of IFN-g and perforin (Steinbach et al., 2016) .", [["intracerebral", "ANATOMY", 17, 30], ["CD8 + Trm", "ANATOMY", 78, 87], ["cell", "ANATOMY", 97, 101], ["peripheral CD8 + T cells", "ANATOMY", 153, 177], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 30], ["LCMV", "ORGANISM", 64, 68], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["cell", "CELL", 97, 101], ["CD8", "GENE_OR_GENE_PRODUCT", 164, 167], ["IFN-g", "GENE_OR_GENE_PRODUCT", 196, 201], ["perforin", "GENE_OR_GENE_PRODUCT", 206, 214], ["CD8", "PROTEIN", 78, 81], ["peripheral CD8 + T cells", "CELL_TYPE", 153, 177], ["IFN", "PROTEIN", 196, 199], ["perforin", "PROTEIN", 206, 214], ["LCMV", "SPECIES", 64, 68], ["intracerebral inoculation of virus", "PROBLEM", 17, 51], ["LCMV", "PROBLEM", 64, 68], ["mediating viral control", "TREATMENT", 112, 135], ["IFN", "TEST", 196, 199], ["intracerebral", "ANATOMY", 17, 30], ["virus", "OBSERVATION", 46, 51], ["peripheral", "ANATOMY_MODIFIER", 153, 163], ["CD8", "ANATOMY", 164, 167]]], ["These types of experimental systems will help understand the rules that govern these populations and aid with the development of strategies to promote the generation of Trm that could limit pathogen reactivation within the CNS.Adaptive Mechanisms to Target NeuronsLimiting Inflammation in the CNS: Immunomodulatory Cytokines, Inhibitory Receptors, and Treg Cells While the presence of inflammatory cells in the CNS is critical for local control of infection, this immune response is often patho-logical and regardless of the initiating factor, will frequently converge on pathways that induce neurotoxicity.", [["CNS", "ANATOMY", 223, 226], ["CNS", "ANATOMY", 293, 296], ["Treg Cells", "ANATOMY", 352, 362], ["inflammatory cells", "ANATOMY", 385, 403], ["CNS", "ANATOMY", 411, 414], ["Inflammation", "DISEASE", 273, 285], ["infection", "DISEASE", 448, 457], ["neurotoxicity", "DISEASE", 593, 606], ["Trm", "GENE_OR_GENE_PRODUCT", 169, 172], ["CNS", "ANATOMICAL_SYSTEM", 223, 226], ["CNS", "ANATOMICAL_SYSTEM", 293, 296], ["Treg Cells", "CELL", 352, 362], ["inflammatory cells", "CELL", 385, 403], ["CNS", "ANATOMICAL_SYSTEM", 411, 414], ["Trm", "PROTEIN", 169, 172], ["Immunomodulatory Cytokines", "PROTEIN", 298, 324], ["Inhibitory Receptors", "PROTEIN", 326, 346], ["Treg Cells", "CELL_TYPE", 352, 362], ["inflammatory cells", "CELL_TYPE", 385, 403], ["experimental systems", "PROBLEM", 15, 35], ["strategies", "TREATMENT", 129, 139], ["pathogen reactivation", "PROBLEM", 190, 211], ["Adaptive Mechanisms", "TREATMENT", 227, 246], ["Target NeuronsLimiting Inflammation", "PROBLEM", 250, 285], ["Immunomodulatory Cytokines", "TREATMENT", 298, 324], ["Inhibitory Receptors", "TREATMENT", 326, 346], ["Treg Cells", "TREATMENT", 352, 362], ["inflammatory cells", "PROBLEM", 385, 403], ["infection", "PROBLEM", 448, 457], ["neurotoxicity", "PROBLEM", 593, 606], ["Inflammation", "OBSERVATION", 273, 285], ["CNS", "ANATOMY", 293, 296], ["Treg Cells", "OBSERVATION", 352, 362], ["inflammatory cells", "OBSERVATION", 385, 403], ["CNS", "ANATOMY", 411, 414], ["infection", "OBSERVATION", 448, 457]]], ["A variety of models can be used to distinguish the immune processes required for resistance to infections from those that induce bystander damage or post-infectious sequelae.", [["infections", "DISEASE", 95, 105], ["the immune processes", "PROBLEM", 47, 67], ["infections", "PROBLEM", 95, 105], ["bystander damage", "PROBLEM", 129, 145], ["post-infectious sequelae", "PROBLEM", 149, 173], ["post-infectious", "OBSERVATION_MODIFIER", 149, 164]]], ["Indeed, there are numerous examples in which altered chemokine signaling or reduction of T cell numbers in the setting of CNS infection results in unexpected but improved outcome (Campanella et al., 2008; Christensen et al., 2006; Reichmann et al., 1999) .Adaptive Mechanisms to Target NeuronsDuring murine infections with WNV, CCL-dependent accumulation of monocytes is associated with development of pathology (Bardina et al., 2015; Getts et al., 2008; Lim et al., 2011) , whereas in mice infected with HSV, innate cell infiltration is associated with fatal disease (Lundberg et al., 2008) .", [["T cell", "ANATOMY", 89, 95], ["CNS", "ANATOMY", 122, 125], ["monocytes", "ANATOMY", 358, 367], ["cell", "ANATOMY", 517, 521], ["infection", "DISEASE", 126, 135], ["infections", "DISEASE", 307, 317], ["T cell", "CELL", 89, 95], ["CNS", "ANATOMICAL_SYSTEM", 122, 125], ["murine", "ORGANISM", 300, 306], ["WNV", "ORGANISM", 323, 326], ["CCL", "GENE_OR_GENE_PRODUCT", 328, 331], ["monocytes", "CELL", 358, 367], ["mice", "ORGANISM", 486, 490], ["HSV", "ORGANISM", 505, 508], ["innate cell", "CELL", 510, 521], ["chemokine", "PROTEIN", 53, 62], ["monocytes", "CELL_TYPE", 358, 367], ["murine", "SPECIES", 300, 306], ["mice", "SPECIES", 486, 490], ["WNV", "SPECIES", 323, 326], ["mice", "SPECIES", 486, 490], ["HSV", "SPECIES", 505, 508], ["altered chemokine signaling", "PROBLEM", 45, 72], ["T cell numbers", "PROBLEM", 89, 103], ["CNS infection", "PROBLEM", 122, 135], ["Adaptive Mechanisms", "TREATMENT", 256, 275], ["Target NeuronsDuring murine infections", "PROBLEM", 279, 317], ["WNV", "PROBLEM", 323, 326], ["dependent accumulation of monocytes", "PROBLEM", 332, 367], ["pathology", "PROBLEM", 402, 411], ["HSV", "PROBLEM", 505, 508], ["innate cell infiltration", "PROBLEM", 510, 534], ["fatal disease", "PROBLEM", 554, 567], ["altered", "OBSERVATION_MODIFIER", 45, 52], ["chemokine signaling", "OBSERVATION", 53, 72], ["reduction", "OBSERVATION_MODIFIER", 76, 85], ["cell numbers", "OBSERVATION", 91, 103], ["CNS", "ANATOMY", 122, 125], ["infection", "OBSERVATION", 126, 135], ["improved", "OBSERVATION_MODIFIER", 162, 170], ["infections", "OBSERVATION", 307, 317], ["dependent", "OBSERVATION_MODIFIER", 332, 341], ["accumulation of monocytes", "OBSERVATION", 342, 367], ["pathology", "OBSERVATION", 402, 411], ["HSV", "OBSERVATION", 505, 508], ["innate cell infiltration", "OBSERVATION", 510, 534], ["associated with", "UNCERTAINTY", 538, 553], ["fatal", "OBSERVATION_MODIFIER", 554, 559]]], ["Similarly, the CCCR2-dependent monocytes associated with Theiler's murine encephalitis virus (TMEV) mediate the demyelination that characterizes this infection (Bennett et al., 2007) .", [["monocytes", "ANATOMY", 31, 40], ["Theiler's murine encephalitis", "DISEASE", 57, 86], ["demyelination", "DISEASE", 112, 125], ["infection", "DISEASE", 150, 159], ["CCCR2", "GENE_OR_GENE_PRODUCT", 15, 20], ["monocytes", "CELL", 31, 40], ["Theiler's murine encephalitis virus", "ORGANISM", 57, 92], ["TMEV", "ORGANISM", 94, 98], ["CCCR2", "PROTEIN", 15, 20], ["monocytes", "CELL_TYPE", 31, 40], ["Theiler", "SPECIES", 57, 64], ["murine encephalitis virus", "SPECIES", 67, 92], ["TMEV", "SPECIES", 94, 98], ["Theiler's murine encephalitis virus", "SPECIES", 57, 92], ["TMEV", "SPECIES", 94, 98], ["the CCCR2-dependent monocytes", "PROBLEM", 11, 40], ["Theiler's murine encephalitis virus", "PROBLEM", 57, 92], ["the demyelination", "PROBLEM", 108, 125], ["this infection", "PROBLEM", 145, 159], ["dependent", "OBSERVATION_MODIFIER", 21, 30], ["monocytes", "OBSERVATION", 31, 40], ["demyelination", "OBSERVATION", 112, 125], ["infection", "OBSERVATION", 150, 159]]], ["The intra-cerebral challenge with LCMV results in immunopathologic CD8 + T cell responses in the meningeal compartment that is characterized by the recruitment of neutrophils and monocytes that mediate the vascular injury and the onset of seizures (Kim et al., 2009) .", [["intra-cerebral", "ANATOMY", 4, 18], ["CD8 + T cell", "ANATOMY", 67, 79], ["meningeal compartment", "ANATOMY", 97, 118], ["neutrophils", "ANATOMY", 163, 174], ["monocytes", "ANATOMY", 179, 188], ["vascular", "ANATOMY", 206, 214], ["vascular injury", "DISEASE", 206, 221], ["seizures", "DISEASE", 239, 247], ["LCMV", "ORGANISM", 34, 38], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["meningeal compartment", "MULTI-TISSUE_STRUCTURE", 97, 118], ["neutrophils", "CELL", 163, 174], ["monocytes", "CELL", 179, 188], ["vascular", "MULTI-TISSUE_STRUCTURE", 206, 214], ["CD8", "PROTEIN", 67, 70], ["neutrophils", "CELL_TYPE", 163, 174], ["monocytes", "CELL_TYPE", 179, 188], ["LCMV", "SPECIES", 34, 38], ["The intra-cerebral challenge", "TEST", 0, 28], ["immunopathologic CD8", "TEST", 50, 70], ["T cell responses in the meningeal compartment", "PROBLEM", 73, 118], ["monocytes", "TEST", 179, 188], ["the vascular injury", "PROBLEM", 202, 221], ["seizures", "PROBLEM", 239, 247], ["LCMV", "OBSERVATION", 34, 38], ["cell responses", "OBSERVATION", 75, 89], ["meningeal compartment", "ANATOMY", 97, 118], ["recruitment", "OBSERVATION_MODIFIER", 148, 159], ["vascular", "ANATOMY", 206, 214], ["injury", "OBSERVATION", 215, 221]]], ["In the latter model, the type I IFN have a key role in priming the pathological monocyte response (Nayak et al., 2013) and can lead to edema, neuronal death, and herniation (Matullo et al., 2011; Matullo et al., 2010) .", [["monocyte", "ANATOMY", 80, 88], ["edema", "ANATOMY", 135, 140], ["neuronal", "ANATOMY", 142, 150], ["edema", "DISEASE", 135, 140], ["neuronal death", "DISEASE", 142, 156], ["herniation", "DISEASE", 162, 172], ["type I IFN", "GENE_OR_GENE_PRODUCT", 25, 35], ["monocyte", "CELL", 80, 88], ["edema", "PATHOLOGICAL_FORMATION", 135, 140], ["neuronal", "CELL", 142, 150], ["type I IFN", "PROTEIN", 25, 35], ["edema", "PROBLEM", 135, 140], ["neuronal death", "PROBLEM", 142, 156], ["herniation", "PROBLEM", 162, 172], ["edema", "OBSERVATION", 135, 140], ["neuronal death", "OBSERVATION", 142, 156], ["herniation", "OBSERVATION", 162, 172]]], ["A similar phenotype is apparent in mice infected with picornovirus (Huseby Kelcher et al., 2017) and in murine models of cerebral malaria.", [["cerebral", "ANATOMY", 121, 129], ["cerebral malaria", "DISEASE", 121, 137], ["mice", "ORGANISM", 35, 39], ["murine", "ORGANISM", 104, 110], ["cerebral", "ORGAN", 121, 129], ["mice", "SPECIES", 35, 39], ["murine", "SPECIES", 104, 110], ["mice", "SPECIES", 35, 39], ["A similar phenotype", "PROBLEM", 0, 19], ["cerebral malaria", "PROBLEM", 121, 137], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["phenotype", "OBSERVATION", 10, 19], ["infected", "OBSERVATION_MODIFIER", 40, 48], ["cerebral", "ANATOMY", 121, 129], ["malaria", "OBSERVATION", 130, 137]]], ["In the latter system, CD8 + T cell responses are associated with alterations in TJs and vascular breakdown in the meninges and parenchyma, resulting in edema, neuronal cell death within the brainstem, and cerebral herniation (Huggins et al., 2017; Swanson et al., 2016) , reminiscent of the disease process observed in humans (Seydel et al., 2015) .", [["CD8 + T cell", "ANATOMY", 22, 34], ["TJs", "ANATOMY", 80, 83], ["vascular", "ANATOMY", 88, 96], ["meninges", "ANATOMY", 114, 122], ["parenchyma", "ANATOMY", 127, 137], ["edema", "ANATOMY", 152, 157], ["neuronal cell", "ANATOMY", 159, 172], ["brainstem", "ANATOMY", 190, 199], ["cerebral", "ANATOMY", 205, 213], ["edema", "DISEASE", 152, 157], ["neuronal cell death", "DISEASE", 159, 178], ["cerebral herniation", "DISEASE", 205, 224], ["CD8", "GENE_OR_GENE_PRODUCT", 22, 25], ["TJs", "CELL", 80, 83], ["vascular", "MULTI-TISSUE_STRUCTURE", 88, 96], ["meninges", "TISSUE", 114, 122], ["parenchyma", "TISSUE", 127, 137], ["edema", "PATHOLOGICAL_FORMATION", 152, 157], ["neuronal cell", "CELL", 159, 172], ["brainstem", "ORGAN", 190, 199], ["cerebral", "ORGAN", 205, 213], ["humans", "ORGANISM", 319, 325], ["CD8", "PROTEIN", 22, 25], ["humans", "SPECIES", 319, 325], ["humans", "SPECIES", 319, 325], ["CD8", "TEST", 22, 25], ["alterations in TJs", "PROBLEM", 65, 83], ["vascular breakdown in the meninges and parenchyma", "PROBLEM", 88, 137], ["edema", "PROBLEM", 152, 157], ["neuronal cell death within the brainstem", "PROBLEM", 159, 199], ["cerebral herniation", "PROBLEM", 205, 224], ["the disease process", "PROBLEM", 287, 306], ["T cell responses", "OBSERVATION", 28, 44], ["TJs", "OBSERVATION", 80, 83], ["vascular", "ANATOMY", 88, 96], ["breakdown", "OBSERVATION", 97, 106], ["meninges", "ANATOMY", 114, 122], ["parenchyma", "ANATOMY", 127, 137], ["edema", "OBSERVATION", 152, 157], ["neuronal cell death", "OBSERVATION", 159, 178], ["brainstem", "ANATOMY", 190, 199], ["cerebral", "ANATOMY", 205, 213], ["herniation", "OBSERVATION", 214, 224], ["disease", "OBSERVATION", 291, 298]]], ["Thus, inflammation that results in bystander neuronal death or damage to regions of the brain that control autonomic functions can significantly impact host survival.Adaptive Mechanisms to Target NeuronsAnother possible consequence of local inflammation is the release of autoantigens and breakdown of tolerance that might lead to a bona fide autoimmune process mediated by T or B cells.", [["neuronal", "ANATOMY", 45, 53], ["brain", "ANATOMY", 88, 93], ["T", "ANATOMY", 374, 375], ["B cells", "ANATOMY", 379, 386], ["inflammation", "DISEASE", 6, 18], ["neuronal death", "DISEASE", 45, 59], ["inflammation", "DISEASE", 241, 253], ["neuronal", "CELL", 45, 53], ["brain", "ORGAN", 88, 93], ["Neurons", "CELL", 196, 203], ["T", "CELL", 374, 375], ["B cells", "CELL", 379, 386], ["autoantigens", "PROTEIN", 272, 284], ["T or B cells", "CELL_TYPE", 374, 386], ["inflammation", "PROBLEM", 6, 18], ["bystander neuronal death", "PROBLEM", 35, 59], ["damage to regions of the brain", "PROBLEM", 63, 93], ["Adaptive Mechanisms", "TREATMENT", 166, 185], ["local inflammation", "PROBLEM", 235, 253], ["autoantigens", "PROBLEM", 272, 284], ["breakdown of tolerance", "PROBLEM", 289, 311], ["a bona fide autoimmune process", "PROBLEM", 331, 361], ["inflammation", "OBSERVATION", 6, 18], ["brain", "ANATOMY", 88, 93], ["local", "OBSERVATION_MODIFIER", 235, 240], ["inflammation", "OBSERVATION", 241, 253], ["autoimmune", "OBSERVATION", 343, 353]]], ["For example, after HSV encephalitis the development of auto-antibodies specific for N-methyl-D-aspartate receptor (NMDAR) can lead to a post-viral encephalitic syndrome characterized by seizures and psychosis (H\u00f6 ftberger et al., 2013; Westman et al., 2016) .", [["HSV encephalitis", "DISEASE", 19, 35], ["auto-antibodies", "DISEASE", 55, 70], ["N-methyl-D-aspartate", "CHEMICAL", 84, 104], ["post-viral encephalitic syndrome", "DISEASE", 136, 168], ["seizures", "DISEASE", 186, 194], ["psychosis", "DISEASE", 199, 208], ["N-methyl-D-aspartate", "CHEMICAL", 84, 104], ["HSV encephalitis", "ORGANISM", 19, 35], ["N-methyl-D-aspartate receptor", "GENE_OR_GENE_PRODUCT", 84, 113], ["NMDAR", "GENE_OR_GENE_PRODUCT", 115, 120], ["auto-antibodies", "PROTEIN", 55, 70], ["N-methyl-D-aspartate receptor", "PROTEIN", 84, 113], ["NMDAR", "PROTEIN", 115, 120], ["HSV", "SPECIES", 19, 22], ["HSV encephalitis", "PROBLEM", 19, 35], ["auto-antibodies specific", "PROBLEM", 55, 79], ["D-aspartate receptor (NMDAR)", "TREATMENT", 93, 121], ["a post-viral encephalitic syndrome", "PROBLEM", 134, 168], ["seizures", "PROBLEM", 186, 194], ["psychosis", "PROBLEM", 199, 208], ["encephalitic syndrome", "OBSERVATION", 147, 168]]], ["Similarly, damaged oligodendrocytes during MHV infection promote the recognition of Myelin Basic Protein by auto-reactive CD4 + T cells, leading to epitope spreading and the development of demyelinating disease that is reminiscent of MS (McMahon et al., 2005) .", [["oligodendrocytes", "ANATOMY", 19, 35], ["auto-reactive CD4 + T cells", "ANATOMY", 108, 135], ["MHV infection", "DISEASE", 43, 56], ["demyelinating disease", "DISEASE", 189, 210], ["MS", "DISEASE", 234, 236], ["oligodendrocytes", "CELL", 19, 35], ["MHV", "ORGANISM", 43, 46], ["Myelin Basic Protein", "GENE_OR_GENE_PRODUCT", 84, 104], ["CD4", "GENE_OR_GENE_PRODUCT", 122, 125], ["damaged oligodendrocytes", "CELL_TYPE", 11, 35], ["Myelin Basic Protein", "PROTEIN", 84, 104], ["auto-reactive CD4 + T cells", "CELL_TYPE", 108, 135], ["MHV", "SPECIES", 43, 46], ["damaged oligodendrocytes", "PROBLEM", 11, 35], ["MHV infection", "PROBLEM", 43, 56], ["Myelin Basic Protein", "TEST", 84, 104], ["auto-reactive CD4 + T cells", "PROBLEM", 108, 135], ["epitope spreading", "PROBLEM", 148, 165], ["demyelinating disease", "PROBLEM", 189, 210], ["damaged oligodendrocytes", "OBSERVATION", 11, 35], ["MHV", "OBSERVATION_MODIFIER", 43, 46], ["infection", "OBSERVATION", 47, 56], ["demyelinating disease", "OBSERVATION", 189, 210]]], ["It seems likely that the true prevalence and consequences of these types of post-infectious sequlae in patients is not fully appreciated .Adaptive Mechanisms to Target NeuronsWhile the development of neuroinflammation is important to respond to local infections, there are also conserved regulatory processes that help with the resolution of CNS inflammation or which exist to limit the development of overwhelming immune pathology (Galea et al., 2007) .", [["CNS", "ANATOMY", 342, 345], ["neuroinflammation", "DISEASE", 200, 217], ["infections", "DISEASE", 251, 261], ["inflammation", "DISEASE", 346, 358], ["patients", "ORGANISM", 103, 111], ["CNS", "ANATOMICAL_SYSTEM", 342, 345], ["patients", "SPECIES", 103, 111], ["post-infectious sequlae", "PROBLEM", 76, 99], ["Adaptive Mechanisms", "TREATMENT", 138, 157], ["neuroinflammation", "PROBLEM", 200, 217], ["local infections", "PROBLEM", 245, 261], ["CNS inflammation", "PROBLEM", 342, 358], ["overwhelming immune pathology", "PROBLEM", 402, 431], ["seems likely", "UNCERTAINTY", 3, 15], ["post-infectious sequlae", "OBSERVATION", 76, 99], ["neuroinflammation", "OBSERVATION", 200, 217], ["infections", "OBSERVATION", 251, 261], ["CNS", "ANATOMY", 342, 345], ["inflammation", "OBSERVATION", 346, 358]]], ["The cytokine IL-10 is important negative regulator of inflammation, which acts directly on DCs, microglia, and macrophages to downregulate expression of costimulatory molecules and the ability to present antigen and produce inflammatory cytokines.", [["DCs", "ANATOMY", 91, 94], ["microglia", "ANATOMY", 96, 105], ["macrophages", "ANATOMY", 111, 122], ["inflammation", "DISEASE", 54, 66], ["IL-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["DCs", "CELL", 91, 94], ["microglia", "CELL", 96, 105], ["macrophages", "CELL", 111, 122], ["cytokine", "PROTEIN", 4, 12], ["IL-10", "PROTEIN", 13, 18], ["DCs", "CELL_TYPE", 91, 94], ["microglia", "CELL_TYPE", 96, 105], ["macrophages", "CELL_TYPE", 111, 122], ["costimulatory molecules", "PROTEIN", 153, 176], ["inflammatory cytokines", "PROTEIN", 224, 246], ["The cytokine IL", "TEST", 0, 15], ["inflammation", "PROBLEM", 54, 66], ["macrophages", "TREATMENT", 111, 122], ["costimulatory molecules", "PROBLEM", 153, 176], ["inflammatory cytokines", "PROBLEM", 224, 246], ["negative regulator", "OBSERVATION_MODIFIER", 32, 50], ["inflammation", "OBSERVATION", 54, 66], ["inflammatory cytokines", "OBSERVATION", 224, 246]]], ["While there are multiple sources of IL-10, in the setting of many infections, the ability of T cells to produce IL-10 provides a critical negative regulatory loop that prevents T cell hyper-activity (Couper et al., 2008) .", [["T cells", "ANATOMY", 93, 100], ["T cell", "ANATOMY", 177, 183], ["infections", "DISEASE", 66, 76], ["IL-10", "GENE_OR_GENE_PRODUCT", 36, 41], ["T cells", "CELL", 93, 100], ["IL-10", "GENE_OR_GENE_PRODUCT", 112, 117], ["T cell", "CELL", 177, 183], ["IL", "PROTEIN", 36, 38], ["T cells", "CELL_TYPE", 93, 100], ["IL-10", "PROTEIN", 112, 117], ["IL", "TEST", 36, 38], ["many infections", "PROBLEM", 61, 76], ["IL", "TEST", 112, 114], ["T cell hyper-activity", "PROBLEM", 177, 198], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["many", "OBSERVATION_MODIFIER", 61, 65], ["infections", "OBSERVATION", 66, 76], ["negative regulatory loop", "OBSERVATION", 138, 162], ["cell hyper-activity", "OBSERVATION", 179, 198]]], ["In mice chronically infected with T. gondii the absence of IL-10, leads to lethal CNS inflammation mediated by CD4 + T cells and characterized by elevated IL-17 production (Wilson et al., 2005) .", [["CNS", "ANATOMY", 82, 85], ["CD4 + T cells", "ANATOMY", 111, 124], ["inflammation", "DISEASE", 86, 98], ["mice", "ORGANISM", 3, 7], ["T. gondii", "ORGANISM", 34, 43], ["IL-10", "GENE_OR_GENE_PRODUCT", 59, 64], ["CNS", "ANATOMICAL_SYSTEM", 82, 85], ["CD4", "GENE_OR_GENE_PRODUCT", 111, 114], ["IL-17", "GENE_OR_GENE_PRODUCT", 155, 160], ["IL-10", "PROTEIN", 59, 64], ["CD4", "PROTEIN", 111, 114], ["T cells", "CELL_TYPE", 117, 124], ["IL", "PROTEIN", 155, 157], ["mice", "SPECIES", 3, 7], ["T. gondii", "SPECIES", 34, 43], ["mice", "SPECIES", 3, 7], ["T. gondii", "SPECIES", 34, 43], ["T. gondii", "TEST", 34, 43], ["IL", "TEST", 59, 61], ["lethal CNS inflammation", "PROBLEM", 75, 98], ["CD4 + T cells", "PROBLEM", 111, 124], ["elevated IL", "PROBLEM", 146, 157], ["chronically", "OBSERVATION_MODIFIER", 8, 19], ["infected", "OBSERVATION", 20, 28], ["lethal CNS", "ANATOMY", 75, 85], ["inflammation", "OBSERVATION", 86, 98], ["elevated", "OBSERVATION_MODIFIER", 146, 154]]], ["For LCMV, the presence of IL-10 promotes viral persistence in the CNS (Brooks et al., 2006) , while IL-10 deficient mice infected with Sindbis develop an aberrant Th17 response associated with neuronal cell death (Kulcsar et al., 2014) and IL-10 derived from CD8 + T cells protect from pathology during coronavirus infection (Trandem et al., 2011) .Adaptive Mechanisms to Target NeuronsIL-27 is a cytokine produced by microglia and other macrophage populations in the inflamed CNS that has emerged as having an important role in limiting neuroinflammation.", [["CNS", "ANATOMY", 66, 69], ["neuronal cell", "ANATOMY", 193, 206], ["CD8 + T cells", "ANATOMY", 259, 272], ["microglia", "ANATOMY", 418, 427], ["macrophage populations", "ANATOMY", 438, 460], ["CNS", "ANATOMY", 477, 480], ["neuronal cell death", "DISEASE", 193, 212], ["coronavirus infection", "DISEASE", 303, 324], ["neuroinflammation", "DISEASE", 538, 555], ["LCMV", "ORGANISM", 4, 8], ["IL-10", "GENE_OR_GENE_PRODUCT", 26, 31], ["CNS", "ANATOMICAL_SYSTEM", 66, 69], ["IL-10", "GENE_OR_GENE_PRODUCT", 100, 105], ["mice", "ORGANISM", 116, 120], ["Sindbis", "ORGANISM", 135, 142], ["Th17", "CELL", 163, 167], ["neuronal cell", "CELL", 193, 206], ["IL-10", "GENE_OR_GENE_PRODUCT", 240, 245], ["CD8", "GENE_OR_GENE_PRODUCT", 259, 262], ["coronavirus", "ORGANISM", 303, 314], ["NeuronsIL-27", "GENE_OR_GENE_PRODUCT", 379, 391], ["microglia", "CELL", 418, 427], ["macrophage populations", "CELL", 438, 460], ["CNS", "ANATOMICAL_SYSTEM", 477, 480], ["IL-10", "PROTEIN", 26, 31], ["IL-10", "PROTEIN", 100, 105], ["IL-10", "PROTEIN", 240, 245], ["CD8 + T cells", "CELL_TYPE", 259, 272], ["Target NeuronsIL-27", "PROTEIN", 372, 391], ["cytokine", "PROTEIN", 397, 405], ["microglia", "CELL_TYPE", 418, 427], ["macrophage populations", "CELL_TYPE", 438, 460], ["mice", "SPECIES", 116, 120], ["LCMV", "SPECIES", 4, 8], ["mice", "SPECIES", 116, 120], ["Sindbis", "SPECIES", 135, 142], ["LCMV", "PROBLEM", 4, 8], ["IL", "TREATMENT", 26, 28], ["Sindbis", "PROBLEM", 135, 142], ["an aberrant Th17 response", "PROBLEM", 151, 176], ["neuronal cell death", "PROBLEM", 193, 212], ["IL", "TEST", 240, 242], ["coronavirus infection", "PROBLEM", 303, 324], ["Target NeuronsIL", "TEST", 372, 388], ["other macrophage populations", "PROBLEM", 432, 460], ["the inflamed CNS", "PROBLEM", 464, 480], ["neuroinflammation", "PROBLEM", 538, 555], ["LCMV", "OBSERVATION", 4, 8], ["viral persistence", "OBSERVATION", 41, 58], ["CNS", "ANATOMY", 66, 69], ["aberrant Th17", "OBSERVATION", 154, 167], ["neuronal cell death", "OBSERVATION", 193, 212], ["macrophage populations", "OBSERVATION", 438, 460], ["inflamed CNS", "ANATOMY", 468, 480], ["neuroinflammation", "OBSERVATION", 538, 555]]], ["Thus, in the absence of IL-27 signaling, mice infected with T. gondii, Coronaviruses, or Sindbis are characterized by elevated production of IL-17 and GM-CSF in the CNS, which correlate with the development of T cell-mediated immune pathology (de Aquino et al., 2014; Kulcsar et al., 2014; Stumhofer et al., 2006; Tirotta et al., 2012; Young et al., 2012) .", [["CNS", "ANATOMY", 165, 168], ["T cell", "ANATOMY", 210, 216], ["IL-27", "GENE_OR_GENE_PRODUCT", 24, 29], ["mice", "ORGANISM", 41, 45], ["T. gondii", "ORGANISM", 60, 69], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 71, 84], ["Sindbis", "ORGANISM", 89, 96], ["IL-17", "GENE_OR_GENE_PRODUCT", 141, 146], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 151, 157], ["CNS", "ANATOMICAL_SYSTEM", 165, 168], ["T cell", "CELL", 210, 216], ["IL", "PROTEIN", 24, 26], ["IL-17", "PROTEIN", 141, 146], ["GM", "PROTEIN", 151, 153], ["CSF", "PROTEIN", 154, 157], ["mice", "SPECIES", 41, 45], ["T. gondii", "SPECIES", 60, 69], ["mice", "SPECIES", 41, 45], ["T. gondii", "SPECIES", 60, 69], ["Sindbis", "SPECIES", 89, 96], ["IL", "TEST", 24, 26], ["T. gondii", "PROBLEM", 60, 69], ["Coronaviruses", "PROBLEM", 71, 84], ["Sindbis", "PROBLEM", 89, 96], ["elevated production of IL", "PROBLEM", 118, 143], ["GM-CSF in the CNS", "TEST", 151, 168], ["T cell-mediated immune pathology", "PROBLEM", 210, 242], ["elevated", "OBSERVATION_MODIFIER", 118, 126], ["production", "OBSERVATION_MODIFIER", 127, 137], ["CNS", "ANATOMY", 165, 168]]], ["While there is good evidence that IL-27 can directly limit T cell production of IL-17 and GM-CSF, it can also promote T cell production of IL-10, Treg cell responses, and T cell expression of inhibitory receptors (Do et al., 2016; Hall et al., 2012; Hirahara et al., 2012) .", [["T cell", "ANATOMY", 59, 65], ["T cell", "ANATOMY", 118, 124], ["Treg cell", "ANATOMY", 146, 155], ["T cell", "ANATOMY", 171, 177], ["IL-27", "GENE_OR_GENE_PRODUCT", 34, 39], ["T cell", "CELL", 59, 65], ["IL-17", "GENE_OR_GENE_PRODUCT", 80, 85], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 90, 96], ["T cell", "CELL", 118, 124], ["IL-10", "GENE_OR_GENE_PRODUCT", 139, 144], ["Treg cell", "CELL", 146, 155], ["T cell", "CELL", 171, 177], ["IL-27", "PROTEIN", 34, 39], ["IL-17", "PROTEIN", 80, 85], ["inhibitory receptors", "PROTEIN", 192, 212], ["IL", "TEST", 34, 36], ["IL", "TEST", 80, 82], ["GM-CSF", "TEST", 90, 96], ["IL", "TEST", 139, 141], ["good", "OBSERVATION_MODIFIER", 15, 19]]], ["The enhanced CNS pathology observed in the absence of IL-10 or IL-27 suggests that while they might target different cell populations and have fundamentally different mechanisms of action, these cytokines are shared components of an immunoregulatory cassette that acts to temper T cell mediated CNS inflammation.Adaptive Mechanisms to Target NeuronsMany of the overarching principles that have guided the study of ''inhibitory receptors'' (PD-1, PD-L1, CTLA-4, TIGIT, Tim-3, LAG-3) that provide cell-intrinsic signals that limit T cell responses emerged from studies of peripheral responses to LCMV (Jin et al., 2010; Wherry, 2011) .", [["CNS", "ANATOMY", 13, 16], ["cell", "ANATOMY", 117, 121], ["T cell", "ANATOMY", 279, 285], ["CNS", "ANATOMY", 295, 298], ["cell", "ANATOMY", 495, 499], ["T cell", "ANATOMY", 529, 535], ["inflammation", "DISEASE", 299, 311], ["CNS", "ANATOMICAL_SYSTEM", 13, 16], ["IL-10", "GENE_OR_GENE_PRODUCT", 54, 59], ["IL-27", "GENE_OR_GENE_PRODUCT", 63, 68], ["cell populations", "CELL", 117, 133], ["T cell", "CELL", 279, 285], ["CNS inflammation", "PATHOLOGICAL_FORMATION", 295, 311], ["PD-1", "GENE_OR_GENE_PRODUCT", 440, 444], ["PD-L1", "GENE_OR_GENE_PRODUCT", 446, 451], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 453, 459], ["TIGIT", "GENE_OR_GENE_PRODUCT", 461, 466], ["Tim-3", "GENE_OR_GENE_PRODUCT", 468, 473], ["LAG-3", "GENE_OR_GENE_PRODUCT", 475, 480], ["cell", "CELL", 495, 499], ["T cell", "CELL", 529, 535], ["LCMV", "ORGANISM", 594, 598], ["IL", "PROTEIN", 54, 56], ["IL-27", "PROTEIN", 63, 68], ["cytokines", "PROTEIN", 195, 204], ["immunoregulatory cassette", "DNA", 233, 258], ["inhibitory receptors", "PROTEIN", 416, 436], ["PD", "PROTEIN", 446, 448], ["L1", "PROTEIN", 449, 451], ["CTLA", "PROTEIN", 453, 457], ["TIGIT", "PROTEIN", 461, 466], ["Tim-3", "DNA", 468, 473], ["LAG-3", "DNA", 475, 480], ["The enhanced CNS pathology", "TEST", 0, 26], ["different cell populations", "PROBLEM", 107, 133], ["an immunoregulatory cassette", "TREATMENT", 230, 258], ["temper T cell mediated CNS inflammation", "PROBLEM", 272, 311], ["the study", "TEST", 401, 410], ["''inhibitory receptors", "TEST", 414, 436], ["PD", "TEST", 440, 442], ["PD", "TEST", 446, 448], ["CTLA", "TEST", 453, 457], ["TIGIT", "TEST", 461, 466], ["Tim", "TEST", 468, 471], ["LAG", "TEST", 475, 478], ["enhanced", "OBSERVATION_MODIFIER", 4, 12], ["CNS", "ANATOMY", 13, 16], ["pathology", "OBSERVATION", 17, 26], ["different cell populations", "OBSERVATION", 107, 133], ["CNS", "ANATOMY", 295, 298], ["inflammation", "OBSERVATION", 299, 311], ["L1", "ANATOMY", 449, 451]]], ["One model suggests that serial engagement of T cells in the context of persistent antigen results in a hierarchical acquisition of inhibitory receptors that results in ''exhaustion'' but allows d\u00e9 tente between viral persistence and the pathological consequences of T cell responses (Wherry, 2011) .", [["T cells", "ANATOMY", 45, 52], ["T cell", "ANATOMY", 266, 272], ["T cells", "CELL", 45, 52], ["T cell", "CELL", 266, 272], ["T cells", "CELL_TYPE", 45, 52], ["inhibitory receptors", "PROTEIN", 131, 151], ["T cells", "PROBLEM", 45, 52], ["persistent antigen", "PROBLEM", 71, 89], ["''exhaustion''", "PROBLEM", 168, 182], ["viral persistence", "PROBLEM", 211, 228], ["persistent", "OBSERVATION_MODIFIER", 71, 81]]], ["During neural involvement of LCMV there is increased T cell expression of PD-1 in the CNS (Blackburn et al., 2010) , but there is a paucity of studies that have dissected the impact of inhibitory receptors on local responses in the brain.", [["neural", "ANATOMY", 7, 13], ["T cell", "ANATOMY", 53, 59], ["CNS", "ANATOMY", 86, 89], ["brain", "ANATOMY", 232, 237], ["LCMV", "ORGANISM", 29, 33], ["T cell", "CELL", 53, 59], ["PD-1", "GENE_OR_GENE_PRODUCT", 74, 78], ["CNS", "ANATOMICAL_SYSTEM", 86, 89], ["brain", "ORGAN", 232, 237], ["PD-1", "PROTEIN", 74, 78], ["inhibitory receptors", "PROTEIN", 185, 205], ["LCMV", "SPECIES", 29, 33], ["LCMV", "PROBLEM", 29, 33], ["increased T cell expression of PD", "PROBLEM", 43, 76], ["a paucity of studies", "PROBLEM", 130, 150], ["LCMV", "OBSERVATION", 29, 33], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["T cell expression", "OBSERVATION", 53, 70], ["CNS", "ANATOMY", 86, 89], ["brain", "ANATOMY", 232, 237]]], ["Similarly, during HSV infection in mice, viral-specific CD8 + T cells express increased levels of LAG3, TIM3, and PD-1, which is associated with an inability to control viral replication in the CNS (Menendez et al., 2016) .", [["CD8 + T cells", "ANATOMY", 56, 69], ["CNS", "ANATOMY", 194, 197], ["HSV infection", "DISEASE", 18, 31], ["HSV", "ORGANISM", 18, 21], ["mice", "ORGANISM", 35, 39], ["CD8", "GENE_OR_GENE_PRODUCT", 56, 59], ["LAG3", "GENE_OR_GENE_PRODUCT", 98, 102], ["TIM3", "GENE_OR_GENE_PRODUCT", 104, 108], ["PD-1", "GENE_OR_GENE_PRODUCT", 114, 118], ["CNS", "ANATOMICAL_SYSTEM", 194, 197], ["CD8 + T cells", "CELL_TYPE", 56, 69], ["LAG3", "PROTEIN", 98, 102], ["TIM3", "PROTEIN", 104, 108], ["mice", "SPECIES", 35, 39], ["HSV", "SPECIES", 18, 21], ["mice", "SPECIES", 35, 39], ["HSV infection", "PROBLEM", 18, 31], ["viral", "TEST", 41, 46], ["T cells", "PROBLEM", 62, 69], ["increased levels", "PROBLEM", 78, 94], ["LAG3", "TEST", 98, 102], ["TIM3", "TEST", 104, 108], ["PD", "TEST", 114, 116], ["an inability to control viral replication", "PROBLEM", 145, 186], ["infection", "OBSERVATION", 22, 31], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["CNS", "ANATOMY", 194, 197]]], ["During toxoplasmosis, parasite-specific CD8 + T cells recruited to the brain downregulate their ability to produce IFN-g and granzyme over time, which correlates with increased expression of PD-1, LAG3, and TIGIT (Hidano et al., 2016; Wilson et al., 2009) .", [["CD8 + T cells", "ANATOMY", 40, 53], ["brain", "ANATOMY", 71, 76], ["toxoplasmosis", "DISEASE", 7, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 40, 43], ["brain", "ORGAN", 71, 76], ["IFN-g", "GENE_OR_GENE_PRODUCT", 115, 120], ["granzyme", "GENE_OR_GENE_PRODUCT", 125, 133], ["PD-1", "GENE_OR_GENE_PRODUCT", 191, 195], ["LAG3", "GENE_OR_GENE_PRODUCT", 197, 201], ["TIGIT", "GENE_OR_GENE_PRODUCT", 207, 212], ["CD8 + T cells", "CELL_TYPE", 40, 53], ["IFN", "PROTEIN", 115, 118], ["granzyme", "PROTEIN", 125, 133], ["toxoplasmosis", "PROBLEM", 7, 20], ["parasite", "TEST", 22, 30], ["T cells", "PROBLEM", 46, 53], ["IFN", "TEST", 115, 118], ["PD", "TEST", 191, 193], ["LAG3", "TEST", 197, 201], ["toxoplasmosis", "OBSERVATION", 7, 20], ["brain", "ANATOMY", 71, 76], ["increased", "OBSERVATION_MODIFIER", 167, 176]]], ["The potential significance of these observations is emphasized by the report that the blockade of PD-1 during the chronic phase of this infection results in enhanced parasite clearance (Bhadra et al., 2011) .", [["infection", "DISEASE", 136, 145], ["PD-1", "GENE_OR_GENE_PRODUCT", 98, 102], ["PD-1", "PROTEIN", 98, 102], ["the blockade of PD", "TREATMENT", 82, 100], ["this infection", "PROBLEM", 131, 145], ["infection", "OBSERVATION", 136, 145]]], ["This is clearly a topic where additional studies are required to determine the relative impact of diverse inhibitory receptors on antimicrobial effector activities and whether they promote microbial persistence.Adaptive Mechanisms to Target NeuronsTreg cells are defined by the expression of the transcription factor Foxp3 and maintain homeostasis within the T cell compartment through direct antagonism of T cell function, as well as effects on DC populations (Josefowicz et al., 2012) .", [["NeuronsTreg cells", "ANATOMY", 241, 258], ["T cell compartment", "ANATOMY", 359, 377], ["T cell", "ANATOMY", 407, 413], ["DC", "ANATOMY", 446, 448], ["NeuronsTreg cells", "CELL", 241, 258], ["Foxp3", "GENE_OR_GENE_PRODUCT", 317, 322], ["T cell", "CELL", 359, 365], ["T cell", "CELL", 407, 413], ["inhibitory receptors", "PROTEIN", 106, 126], ["Treg cells", "CELL_TYPE", 248, 258], ["transcription factor", "PROTEIN", 296, 316], ["Foxp3", "PROTEIN", 317, 322], ["DC populations", "CELL_TYPE", 446, 460], ["additional studies", "TEST", 30, 48], ["antimicrobial effector activities", "TREATMENT", 130, 163], ["Adaptive Mechanisms", "TREATMENT", 211, 230], ["Target NeuronsTreg cells", "TREATMENT", 234, 258], ["microbial persistence", "OBSERVATION", 189, 210], ["NeuronsTreg cells", "OBSERVATION", 241, 258]]], ["These suppressive activities are attributed to multiple mechanisms that include the production of IL-10 as well as expression of inhibitory receptors.", [["IL-10", "GENE_OR_GENE_PRODUCT", 98, 103], ["IL-10", "PROTEIN", 98, 103], ["inhibitory receptors", "PROTEIN", 129, 149]]], ["Treg cells are absent from the uninflamed CNS, but during infection are co-recruited with effector T cells.", [["Treg cells", "ANATOMY", 0, 10], ["CNS", "ANATOMY", 42, 45], ["effector T cells", "ANATOMY", 90, 106], ["infection", "DISEASE", 58, 67], ["Treg cells", "CELL", 0, 10], ["CNS", "ANATOMICAL_SYSTEM", 42, 45], ["effector T cells", "CELL", 90, 106], ["Treg cells", "CELL_TYPE", 0, 10], ["effector T cells", "CELL_TYPE", 90, 106], ["Treg cells", "TREATMENT", 0, 10], ["the uninflamed CNS", "PROBLEM", 27, 45], ["infection", "PROBLEM", 58, 67], ["effector T cells", "PROBLEM", 90, 106], ["CNS", "ANATOMY", 42, 45], ["infection", "OBSERVATION", 58, 67]]], ["Given their prominent role in other inflammatory diseases settings, there have been questions about whether these regulatory populations contribute to the outcome of CNS infection.", [["CNS", "ANATOMY", 166, 169], ["infection", "DISEASE", 170, 179], ["CNS", "ANATOMICAL_SYSTEM", 166, 169], ["other inflammatory diseases settings", "PROBLEM", 30, 66], ["these regulatory populations", "PROBLEM", 108, 136], ["CNS infection", "PROBLEM", 166, 179], ["prominent", "OBSERVATION_MODIFIER", 12, 21], ["inflammatory", "OBSERVATION_MODIFIER", 36, 48], ["diseases", "OBSERVATION", 49, 57], ["CNS", "ANATOMY", 166, 169], ["infection", "OBSERVATION", 170, 179]]], ["In mice infected with measles virus, expansion of Treg cells resulted in enhanced viral levels in neurons while the transient depletion of Foxp3 + Treg cells led to expanded populations of virus-specific CD8 + T cells and improved viral control (Reuter et al., 2012) .", [["Treg cells", "ANATOMY", 50, 60], ["neurons", "ANATOMY", 98, 105], ["Foxp3 + Treg cells", "ANATOMY", 139, 157], ["CD8 + T cells", "ANATOMY", 204, 217], ["measles virus", "DISEASE", 22, 35], ["mice", "ORGANISM", 3, 7], ["measles virus", "ORGANISM", 22, 35], ["Treg cells", "CELL", 50, 60], ["neurons", "CELL", 98, 105], ["Foxp3", "GENE_OR_GENE_PRODUCT", 139, 144], ["CD8", "GENE_OR_GENE_PRODUCT", 204, 207], ["Treg cells", "CELL_TYPE", 50, 60], ["Foxp3", "PROTEIN", 139, 144], ["Treg cells", "CELL_TYPE", 147, 157], ["CD8 + T cells", "CELL_TYPE", 204, 217], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["measles virus", "SPECIES", 22, 35], ["measles virus", "PROBLEM", 22, 35], ["expansion of Treg cells", "PROBLEM", 37, 60], ["enhanced viral levels in neurons", "PROBLEM", 73, 105], ["Foxp3 + Treg cells", "PROBLEM", 139, 157], ["expanded populations of virus", "PROBLEM", 165, 194], ["T cells", "PROBLEM", 210, 217], ["infected", "OBSERVATION_MODIFIER", 8, 16], ["measles virus", "OBSERVATION", 22, 35], ["Treg cells", "OBSERVATION", 50, 60], ["viral levels", "OBSERVATION", 82, 94], ["neurons", "ANATOMY", 98, 105], ["Foxp3 + Treg cells", "OBSERVATION", 139, 157]]], ["Following challenge with MHV, virus-specific Treg cells are present in the CNS and have a role in limiting immune-pathology (Anghelina et al., 2009 ).", [["Treg cells", "ANATOMY", 45, 55], ["CNS", "ANATOMY", 75, 78], ["MHV", "ORGANISM", 25, 28], ["Treg cells", "CELL", 45, 55], ["CNS", "ANATOMICAL_SYSTEM", 75, 78], ["Treg cells", "CELL_TYPE", 45, 55], ["MHV", "SPECIES", 25, 28], ["MHV", "TREATMENT", 25, 28], ["Treg cells", "TREATMENT", 45, 55], ["CNS", "ANATOMY", 75, 78]]], ["These MHV-specific Treg cells inhibit the expansion of viral specific CD4 + T cell effector responses, which is associated with reduced microglial activation and decreased mortality, without affecting virus clearance (Zhao et al., 2014) .", [["Treg cells", "ANATOMY", 19, 29], ["CD4 + T cell", "ANATOMY", 70, 82], ["microglial", "ANATOMY", 136, 146], ["Treg cells", "CELL", 19, 29], ["CD4", "GENE_OR_GENE_PRODUCT", 70, 73], ["microglial", "CELL", 136, 146], ["Treg cells", "CELL_TYPE", 19, 29], ["CD4", "PROTEIN", 70, 73], ["MHV", "SPECIES", 6, 9], ["Treg cells", "TREATMENT", 19, 29], ["reduced microglial activation", "PROBLEM", 128, 157], ["decreased mortality", "PROBLEM", 162, 181], ["affecting virus clearance", "PROBLEM", 191, 216], ["expansion", "OBSERVATION_MODIFIER", 42, 51], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["cell", "OBSERVATION", 78, 82], ["associated with", "UNCERTAINTY", 112, 127], ["reduced", "OBSERVATION_MODIFIER", 128, 135], ["microglial activation", "OBSERVATION", 136, 157], ["decreased", "OBSERVATION_MODIFIER", 162, 171], ["without", "UNCERTAINTY", 183, 190]]], ["Intravital imaging of Treg cells has shown that they are highly migratory in secondary lymphoid tissues but during TE they appear restricted to perivascular regions where they form sustained interactions with DC (O'Brien et al., 2017) .", [["Treg cells", "ANATOMY", 22, 32], ["lymphoid tissues", "ANATOMY", 87, 103], ["perivascular regions", "ANATOMY", 144, 164], ["DC", "ANATOMY", 209, 211], ["Treg cells", "CELL", 22, 32], ["lymphoid tissues", "TISSUE", 87, 103], ["Treg cells", "CELL_TYPE", 22, 32], ["DC", "CELL_TYPE", 209, 211], ["Intravital imaging of Treg cells", "TEST", 0, 32], ["secondary lymphoid tissues", "PROBLEM", 77, 103], ["Treg cells", "OBSERVATION", 22, 32], ["highly", "OBSERVATION_MODIFIER", 57, 63], ["migratory", "OBSERVATION_MODIFIER", 64, 73], ["secondary lymphoid tissues", "OBSERVATION", 77, 103], ["perivascular", "ANATOMY_MODIFIER", 144, 156]]], ["While it is possible that Treg cells might lose expression of Foxp3 as they migrate into the CNS, this exclusion from the parenchyma might allow enhanced effector cell function within the brain.", [["Treg cells", "ANATOMY", 26, 36], ["CNS", "ANATOMY", 93, 96], ["parenchyma", "ANATOMY", 122, 132], ["effector cell", "ANATOMY", 154, 167], ["brain", "ANATOMY", 188, 193], ["Treg cells", "CELL", 26, 36], ["Foxp3", "GENE_OR_GENE_PRODUCT", 62, 67], ["CNS", "ANATOMICAL_SYSTEM", 93, 96], ["parenchyma", "TISSUE", 122, 132], ["cell", "CELL", 163, 167], ["brain", "ORGAN", 188, 193], ["Treg cells", "CELL_TYPE", 26, 36], ["Foxp3", "PROTEIN", 62, 67], ["Treg cells", "PROBLEM", 26, 36], ["Foxp3", "TREATMENT", 62, 67], ["Treg cells", "OBSERVATION", 26, 36], ["CNS", "ANATOMY", 93, 96], ["parenchyma", "ANATOMY", 122, 132], ["effector cell function", "OBSERVATION", 154, 176], ["brain", "ANATOMY", 188, 193]]], ["This observation also supports the idea that perivascular compartments represent a site where regulation of T and B cell effector functions occurs Durrant et al., 2013; Phares et al., 2013) .Future DirectionsCan CNS Infection Be Beneficial through Innate Immune Activation?", [["perivascular compartments", "ANATOMY", 45, 70], ["B cell", "ANATOMY", 114, 120], ["perivascular compartments", "MULTI-TISSUE_STRUCTURE", 45, 70], ["T", "CELL", 108, 109], ["B cell", "CELL", 114, 120], ["a site", "PROBLEM", 81, 87], ["CNS Infection", "PROBLEM", 212, 225], ["perivascular", "ANATOMY_MODIFIER", 45, 57]]], ["While persistent immune activation in the brain is associated with a number of infectious, autoimmune, and neurodegenerative conditions, it is unclear whether all inflammatory pathways are detrimental for brain function.", [["brain", "ANATOMY", 42, 47], ["brain", "ANATOMY", 205, 210], ["infectious, autoimmune, and neurodegenerative conditions", "DISEASE", 79, 135], ["brain", "ORGAN", 42, 47], ["brain", "ORGAN", 205, 210], ["persistent immune activation in the brain", "PROBLEM", 6, 47], ["infectious", "PROBLEM", 79, 89], ["autoimmune", "PROBLEM", 91, 101], ["neurodegenerative conditions", "PROBLEM", 107, 135], ["all inflammatory pathways", "PROBLEM", 159, 184], ["persistent", "OBSERVATION_MODIFIER", 6, 16], ["immune activation", "OBSERVATION", 17, 34], ["brain", "ANATOMY", 42, 47], ["associated with", "UNCERTAINTY", 51, 66], ["infectious", "OBSERVATION", 79, 89], ["autoimmune", "OBSERVATION", 91, 101], ["neurodegenerative conditions", "OBSERVATION", 107, 135], ["inflammatory", "OBSERVATION", 163, 175]]], ["There is evidence that many of the innate immune molecules discussed above in the context of infection, are required for normal CNS development, function, and repair.", [["CNS", "ANATOMY", 128, 131], ["infection", "DISEASE", 93, 102], ["CNS", "ANATOMICAL_SYSTEM", 128, 131], ["innate immune molecules", "PROTEIN", 35, 58], ["the innate immune molecules", "TREATMENT", 31, 58], ["infection", "PROBLEM", 93, 102], ["repair", "TREATMENT", 159, 165], ["many", "OBSERVATION_MODIFIER", 23, 27], ["infection", "OBSERVATION", 93, 102], ["repair", "OBSERVATION", 159, 165]]], ["Ontology studies have shown that microglia are derived from erythromyeloid precursors in the yolk sac, migrating, and proliferating within the CNS early during embryonic development, via processes that requires CSF-1R, its ligand IL-34 and TGF-b.", [["microglia", "ANATOMY", 33, 42], ["erythromyeloid precursors", "ANATOMY", 60, 85], ["yolk sac", "ANATOMY", 93, 101], ["CNS", "ANATOMY", 143, 146], ["embryonic", "ANATOMY", 160, 169], ["microglia", "CELL", 33, 42], ["erythromyeloid precursors", "CELL", 60, 85], ["yolk sac", "ORGAN", 93, 101], ["CNS", "ANATOMICAL_SYSTEM", 143, 146], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 160, 169], ["CSF-1R", "GENE_OR_GENE_PRODUCT", 211, 217], ["IL-34", "GENE_OR_GENE_PRODUCT", 230, 235], ["TGF", "GENE_OR_GENE_PRODUCT", 240, 243], ["microglia", "CELL_TYPE", 33, 42], ["erythromyeloid precursors", "CELL_TYPE", 60, 85], ["CSF-1R", "PROTEIN", 211, 217], ["TGF", "PROTEIN", 240, 243], ["Ontology studies", "TEST", 0, 16], ["microglia", "PROBLEM", 33, 42], ["erythromyeloid precursors in the yolk sac", "PROBLEM", 60, 101], ["CSF", "TEST", 211, 214], ["its ligand IL", "TEST", 219, 232], ["TGF", "TEST", 240, 243], ["microglia", "OBSERVATION", 33, 42], ["yolk sac", "ANATOMY", 93, 101], ["migrating", "OBSERVATION_MODIFIER", 103, 112], ["CNS", "ANATOMY", 143, 146]]], ["Mice deficient in these molecules exhibit severely decreased numbers of microglia in many brain regions (Colonna and Butovsky, 2017) .", [["microglia", "ANATOMY", 72, 81], ["brain", "ANATOMY", 90, 95], ["Mice", "ORGANISM", 0, 4], ["microglia", "CELL", 72, 81], ["brain", "ORGAN", 90, 95], ["microglia", "CELL_TYPE", 72, 81], ["Mice", "SPECIES", 0, 4], ["Mice deficient in these molecules", "PROBLEM", 0, 33], ["severely decreased numbers of microglia", "PROBLEM", 42, 81], ["severely", "OBSERVATION_MODIFIER", 42, 50], ["decreased", "OBSERVATION_MODIFIER", 51, 60], ["numbers", "OBSERVATION_MODIFIER", 61, 68], ["microglia", "OBSERVATION", 72, 81], ["many", "ANATOMY_MODIFIER", 85, 89], ["brain", "ANATOMY", 90, 95], ["regions", "ANATOMY_MODIFIER", 96, 103]]], ["Activated, CD68 + microglia are normally present in the developing forebrain subventricular zone, where neural precursors reside.", [["CD68 + microglia", "ANATOMY", 11, 27], ["forebrain subventricular zone", "ANATOMY", 67, 96], ["neural precursors", "ANATOMY", 104, 121], ["CD68", "GENE_OR_GENE_PRODUCT", 11, 15], ["forebrain subventricular zone", "IMMATERIAL_ANATOMICAL_ENTITY", 67, 96], ["neural precursors", "MULTI-TISSUE_STRUCTURE", 104, 121], ["CD68", "PROTEIN", 11, 15], ["microglia", "CELL_TYPE", 18, 27], ["neural precursors", "CELL_TYPE", 104, 121], ["CD68", "OBSERVATION", 11, 15], ["microglia", "OBSERVATION", 18, 27], ["forebrain", "ANATOMY_MODIFIER", 67, 76], ["subventricular", "ANATOMY_MODIFIER", 77, 91], ["zone", "ANATOMY_MODIFIER", 92, 96], ["neural precursors", "OBSERVATION", 104, 121]]], ["Treatment of mice with minocycline, a broad-spectrum antibiotic that decreases microglia activation, or genetic deficiency in CSF-1R, is associated with disruption of periventricular cellular architecture, decreased neurogenesis, and oligogenesis, the latter of which produces myelinating cells of the CNS (Erblich et al., 2011; Farmer et al., 2013) .", [["microglia", "ANATOMY", 79, 88], ["periventricular cellular", "ANATOMY", 167, 191], ["myelinating cells", "ANATOMY", 277, 294], ["CNS", "ANATOMY", 302, 305], ["minocycline", "CHEMICAL", 23, 34], ["minocycline", "CHEMICAL", 23, 34], ["mice", "ORGANISM", 13, 17], ["minocycline", "SIMPLE_CHEMICAL", 23, 34], ["microglia", "CELL", 79, 88], ["CSF-1R", "GENE_OR_GENE_PRODUCT", 126, 132], ["periventricular cellular", "TISSUE", 167, 191], ["myelinating cells", "CELL", 277, 294], ["CNS", "ANATOMICAL_SYSTEM", 302, 305], ["CSF-1R", "PROTEIN", 126, 132], ["myelinating cells", "CELL_TYPE", 277, 294], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["minocycline", "TREATMENT", 23, 34], ["a broad-spectrum antibiotic", "TREATMENT", 36, 63], ["microglia activation", "PROBLEM", 79, 99], ["genetic deficiency in CSF-1R", "PROBLEM", 104, 132], ["disruption of periventricular cellular architecture", "PROBLEM", 153, 204], ["decreased neurogenesis", "PROBLEM", 206, 228], ["oligogenesis", "PROBLEM", 234, 246], ["microglia activation", "OBSERVATION", 79, 99], ["associated with", "UNCERTAINTY", 137, 152], ["periventricular", "ANATOMY_MODIFIER", 167, 182], ["cellular architecture", "OBSERVATION", 183, 204], ["decreased", "OBSERVATION_MODIFIER", 206, 215], ["neurogenesis", "OBSERVATION_MODIFIER", 216, 228], ["myelinating cells", "OBSERVATION", 277, 294], ["CNS", "ANATOMY", 302, 305]]], ["Similarly, TLRs and TAM receptor signaling is critical for adult neurogenesis within the dentate gyrus, a process that is essential for learning and memory (Ji et al., 2013; Matsuda et al., 2015; Moraga et al., 2014) .", [["dentate gyrus", "ANATOMY", 89, 102], ["TAM", "CHEMICAL", 20, 23], ["TAM", "CHEMICAL", 20, 23], ["TLRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["TAM receptor", "GENE_OR_GENE_PRODUCT", 20, 32], ["dentate gyrus", "MULTI-TISSUE_STRUCTURE", 89, 102], ["TLRs", "PROTEIN", 11, 15], ["TAM receptor", "PROTEIN", 20, 32], ["adult neurogenesis", "PROBLEM", 59, 77], ["dentate gyrus", "ANATOMY", 89, 102]]], ["There are also numerous reports that link the microbiota with neural development that is covered in depth in this issue by Yoo and Mazmanian (2017) but is exemplified by the link between microbiome-driven TLR4 signaling in EC that leads to cerebral cavernous malformations (Tang et al., 2017) .", [["neural", "ANATOMY", 62, 68], ["EC", "ANATOMY", 223, 225], ["cerebral cavernous", "ANATOMY", 240, 258], ["cerebral cavernous malformations", "DISEASE", 240, 272], ["TLR4", "GENE_OR_GENE_PRODUCT", 205, 209], ["EC", "CELL", 223, 225], ["cerebral cavernous malformations", "PATHOLOGICAL_FORMATION", 240, 272], ["TLR4", "PROTEIN", 205, 209], ["EC", "CELL_TYPE", 223, 225], ["cerebral cavernous malformations", "PROBLEM", 240, 272], ["numerous", "OBSERVATION_MODIFIER", 15, 23], ["cerebral cavernous", "ANATOMY", 240, 258], ["malformations", "OBSERVATION", 259, 272]]], ["Neuronal differentiation is further associated with expression of IRF9, IFNAR, and STAT1 (Farmer et al., 2013) .", [["Neuronal", "ANATOMY", 0, 8], ["Neuronal", "CELL", 0, 8], ["IRF9", "GENE_OR_GENE_PRODUCT", 66, 70], ["IFNAR", "GENE_OR_GENE_PRODUCT", 72, 77], ["STAT1", "GENE_OR_GENE_PRODUCT", 83, 88], ["IRF9", "PROTEIN", 66, 70], ["IFNAR", "PROTEIN", 72, 77], ["STAT1", "PROTEIN", 83, 88]]], ["Moreover, mice deficient in IFNAR signaling develop defects in neuronal autophagy, suggesting a critical role for this molecule in CNS homeostasis (Ejlerskov et al., 2015) .", [["neuronal", "ANATOMY", 63, 71], ["CNS", "ANATOMY", 131, 134], ["mice", "ORGANISM", 10, 14], ["IFNAR", "GENE_OR_GENE_PRODUCT", 28, 33], ["neuronal", "CELL", 63, 71], ["CNS", "ANATOMICAL_SYSTEM", 131, 134], ["IFNAR", "PROTEIN", 28, 33], ["mice", "SPECIES", 10, 14], ["mice", "SPECIES", 10, 14], ["mice deficient in IFNAR signaling", "PROBLEM", 10, 43], ["defects in neuronal autophagy", "PROBLEM", 52, 81], ["defects", "OBSERVATION", 52, 59], ["neuronal autophagy", "OBSERVATION", 63, 81], ["CNS", "ANATOMY", 131, 134]]], ["TAM signaling within neural cells might also exhibit synergistic effects on type I IFNmediated cellular processes (Miner et al., 2015) , supporting the notion that baseline activation of IFNAR supports normal brain function.Future DirectionsPrevious sections have emphasized the development of protective inflammatory response and the mechanisms that limit pathology but there are also regenerative processes that serve to restore neural function.", [["neural cells", "ANATOMY", 21, 33], ["cellular", "ANATOMY", 95, 103], ["brain", "ANATOMY", 209, 214], ["sections", "ANATOMY", 250, 258], ["neural", "ANATOMY", 431, 437], ["TAM", "CHEMICAL", 0, 3], ["TAM", "CHEMICAL", 0, 3], ["TAM", "SIMPLE_CHEMICAL", 0, 3], ["neural cells", "CELL", 21, 33], ["cellular", "CELL", 95, 103], ["IFNAR", "GENE_OR_GENE_PRODUCT", 187, 192], ["brain", "ORGAN", 209, 214], ["neural cells", "CELL_TYPE", 21, 33], ["IFNAR", "PROTEIN", 187, 192], ["TAM signaling within neural cells", "PROBLEM", 0, 33], ["synergistic effects", "PROBLEM", 53, 72], ["Previous sections", "TEST", 241, 258], ["protective inflammatory response", "PROBLEM", 294, 326], ["regenerative processes", "PROBLEM", 386, 408], ["neural cells", "OBSERVATION", 21, 33], ["protective", "OBSERVATION_MODIFIER", 294, 304], ["inflammatory", "OBSERVATION", 305, 317], ["regenerative processes", "OBSERVATION", 386, 408], ["neural function", "OBSERVATION", 431, 446]]], ["Given the role of immune pathways in normal neuronal development, it is not surprising that innate responses triggered during infection are also involved in CNS homeostasis, repair, and recovery.", [["neuronal", "ANATOMY", 44, 52], ["CNS", "ANATOMY", 157, 160], ["infection", "DISEASE", 126, 135], ["neuronal", "CELL", 44, 52], ["CNS", "ANATOMICAL_SYSTEM", 157, 160], ["immune pathways", "PROBLEM", 18, 33], ["infection", "PROBLEM", 126, 135], ["repair", "TREATMENT", 174, 180], ["normal neuronal development", "OBSERVATION", 37, 64]]], ["Chemokines can also promote expression of anti-inflammatory molecules and growth factors, such as transforming growth factor (TGF)-b, insulin growth factor (IGF)-1, fibroblast growth factor (FGF)2, and platelet derived growth factor (PDGF)-A (Church et al., 2016; Wattananit et al., 2016) .", [["transforming growth factor (TGF)-b", "GENE_OR_GENE_PRODUCT", 98, 132], ["insulin growth factor (IGF)-1", "GENE_OR_GENE_PRODUCT", 134, 163], ["fibroblast growth factor (FGF)2", "GENE_OR_GENE_PRODUCT", 165, 196], ["platelet derived growth factor (PDGF)-A", "GENE_OR_GENE_PRODUCT", 202, 241], ["Chemokines", "PROTEIN", 0, 10], ["anti-inflammatory molecules", "PROTEIN", 42, 69], ["growth factors", "PROTEIN", 74, 88], ["transforming growth factor (TGF)-b", "PROTEIN", 98, 132], ["insulin growth factor (IGF)-1", "PROTEIN", 134, 163], ["fibroblast growth factor (FGF)2", "PROTEIN", 165, 196], ["platelet derived growth factor", "PROTEIN", 202, 232], ["PDGF", "PROTEIN", 234, 238], ["anti-inflammatory molecules", "PROBLEM", 42, 69], ["growth factors", "PROBLEM", 74, 88], ["transforming growth factor", "TEST", 98, 124], ["TGF", "TEST", 126, 129], ["insulin growth factor (IGF)", "TEST", 134, 161], ["fibroblast growth factor (FGF)", "TEST", 165, 195], ["anti-inflammatory molecules", "OBSERVATION", 42, 69]]], ["Myeloid cells are instrumental in CNS repair by virtue of their phagocytic and cytokine expression functions (London et al., 2013) (Herz et al., 2017) .", [["Myeloid cells", "ANATOMY", 0, 13], ["CNS", "ANATOMY", 34, 37], ["Myeloid cells", "CELL", 0, 13], ["CNS", "ANATOMICAL_SYSTEM", 34, 37], ["Myeloid cells", "CELL_TYPE", 0, 13], ["cytokine", "PROTEIN", 79, 87], ["Myeloid cells", "PROBLEM", 0, 13], ["CNS repair", "TREATMENT", 34, 44], ["CNS repair", "OBSERVATION", 34, 44]]], ["Activation of PRRs on myeloid cells, including TLRs 1 and 2, CR3, Dectin-1 and 2, promotes phagocytosis, oxidative burst, and cytokine production.", [["myeloid cells", "ANATOMY", 22, 35], ["PRRs", "GENE_OR_GENE_PRODUCT", 14, 18], ["myeloid cells", "CELL", 22, 35], ["TLRs 1", "GENE_OR_GENE_PRODUCT", 47, 53], ["2", "GENE_OR_GENE_PRODUCT", 58, 59], ["CR3", "GENE_OR_GENE_PRODUCT", 61, 64], ["Dectin-1", "GENE_OR_GENE_PRODUCT", 66, 74], ["2", "GENE_OR_GENE_PRODUCT", 79, 80], ["PRRs", "PROTEIN", 14, 18], ["myeloid cells", "CELL_TYPE", 22, 35], ["TLRs 1 and 2", "PROTEIN", 47, 59], ["CR3", "PROTEIN", 61, 64], ["Dectin-1 and 2", "PROTEIN", 66, 80], ["cytokine", "PROTEIN", 126, 134], ["myeloid cells", "TEST", 22, 35], ["TLRs", "TEST", 47, 51], ["CR3", "TEST", 61, 64], ["Dectin", "TEST", 66, 72], ["oxidative burst", "PROBLEM", 105, 120], ["cytokine production", "TREATMENT", 126, 145], ["myeloid cells", "OBSERVATION", 22, 35], ["oxidative burst", "OBSERVATION", 105, 120], ["cytokine production", "OBSERVATION", 126, 145]]], ["Phagocytic receptors CD14, CD36, TREM2, and TLR4 are critical for pathogen clearance while complement opsonins C1q, C3 and iC3b and PRRs, TAMs, and TREM2 facilitate removal of apoptotic cells (reviewed in Colonna and Butovsky, 2017) .", [["cells", "ANATOMY", 186, 191], ["CD14", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD36", "GENE_OR_GENE_PRODUCT", 27, 31], ["TREM2", "GENE_OR_GENE_PRODUCT", 33, 38], ["TLR4", "GENE_OR_GENE_PRODUCT", 44, 48], ["complement opsonins C1q", "GENE_OR_GENE_PRODUCT", 91, 114], ["C3", "GENE_OR_GENE_PRODUCT", 116, 118], ["iC3b", "GENE_OR_GENE_PRODUCT", 123, 127], ["PRRs", "GENE_OR_GENE_PRODUCT", 132, 136], ["TAMs", "GENE_OR_GENE_PRODUCT", 138, 142], ["TREM2", "GENE_OR_GENE_PRODUCT", 148, 153], ["cells", "CELL", 186, 191], ["Phagocytic receptors", "PROTEIN", 0, 20], ["CD14", "PROTEIN", 21, 25], ["CD36", "PROTEIN", 27, 31], ["TREM2", "PROTEIN", 33, 38], ["TLR4", "PROTEIN", 44, 48], ["complement opsonins", "PROTEIN", 91, 110], ["C1q", "PROTEIN", 111, 114], ["C3", "PROTEIN", 116, 118], ["iC3b", "PROTEIN", 123, 127], ["PRRs", "PROTEIN", 132, 136], ["TAMs", "PROTEIN", 138, 142], ["TREM2", "PROTEIN", 148, 153], ["apoptotic cells", "CELL_TYPE", 176, 191], ["Phagocytic receptors CD14", "TEST", 0, 25], ["CD36", "TEST", 27, 31], ["TREM2", "TEST", 33, 38], ["TLR4", "PROBLEM", 44, 48], ["pathogen clearance", "TEST", 66, 84], ["complement opsonins C1q", "TEST", 91, 114], ["C3", "TEST", 116, 118], ["iC3b", "TEST", 123, 127], ["TAMs", "TEST", 138, 142], ["removal", "TREATMENT", 165, 172], ["apoptotic cells", "PROBLEM", 176, 191], ["apoptotic cells", "OBSERVATION", 176, 191]]], ["Studies using mice deficient in TREM2 or TLR4 demonstrate that lack of debris elimination results in defects in repair of demyelination and axonal regeneration, respectively (Cantoni et al., 2015; Rajbhandari et al., 2014) .", [["axonal", "ANATOMY", 140, 146], ["demyelination", "DISEASE", 122, 135], ["mice", "ORGANISM", 14, 18], ["TREM2", "GENE_OR_GENE_PRODUCT", 32, 37], ["TLR4", "GENE_OR_GENE_PRODUCT", 41, 45], ["axonal", "MULTI-TISSUE_STRUCTURE", 140, 146], ["TREM2", "PROTEIN", 32, 37], ["TLR4", "PROTEIN", 41, 45], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["Studies", "TEST", 0, 7], ["mice deficient in TREM2", "PROBLEM", 14, 37], ["debris elimination", "PROBLEM", 71, 89], ["defects", "PROBLEM", 101, 108], ["repair", "TREATMENT", 112, 118], ["demyelination", "PROBLEM", 122, 135], ["axonal regeneration", "PROBLEM", 140, 159], ["debris", "OBSERVATION", 71, 77], ["defects", "OBSERVATION", 101, 108], ["repair", "OBSERVATION", 112, 118], ["demyelination", "OBSERVATION", 122, 135], ["axonal regeneration", "OBSERVATION", 140, 159]]], ["CNS region-specific effects of macrophage-specific PRRs have also been observed; activation of dectin-1, a C-type lectin receptor, promotes optic nerve, but not spinal cord, axon regeneration via Erk1/2 MAP-kinase signaling and cAMP response element-binding protein (CREB) activation, while TLR2 activation has the reverse effects during injury of these two CNS regions (Baldwin et al., 2015; Gensel et al., 2015) .", [["CNS", "ANATOMY", 0, 3], ["macrophage", "ANATOMY", 31, 41], ["optic nerve", "ANATOMY", 140, 151], ["spinal cord", "ANATOMY", 161, 172], ["axon", "ANATOMY", 174, 178], ["CNS regions", "ANATOMY", 358, 369], ["cAMP", "CHEMICAL", 228, 232], ["cAMP", "CHEMICAL", 228, 232], ["CNS", "ANATOMICAL_SYSTEM", 0, 3], ["macrophage", "CELL", 31, 41], ["PRRs", "GENE_OR_GENE_PRODUCT", 51, 55], ["dectin-1", "GENE_OR_GENE_PRODUCT", 95, 103], ["C-type lectin receptor", "GENE_OR_GENE_PRODUCT", 107, 129], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 140, 151], ["spinal cord", "ORGAN", 161, 172], ["axon", "MULTI-TISSUE_STRUCTURE", 174, 178], ["Erk1/2", "GENE_OR_GENE_PRODUCT", 196, 202], ["MAP-kinase", "GENE_OR_GENE_PRODUCT", 203, 213], ["cAMP response element-binding protein", "GENE_OR_GENE_PRODUCT", 228, 265], ["CREB", "GENE_OR_GENE_PRODUCT", 267, 271], ["TLR2", "GENE_OR_GENE_PRODUCT", 291, 295], ["PRRs", "PROTEIN", 51, 55], ["dectin-1", "PROTEIN", 95, 103], ["C-type lectin receptor", "PROTEIN", 107, 129], ["cAMP response element-binding protein", "PROTEIN", 228, 265], ["CREB", "PROTEIN", 267, 271], ["TLR2", "PROTEIN", 291, 295], ["CNS region", "PROBLEM", 0, 10], ["macrophage", "PROBLEM", 31, 41], ["dectin", "TEST", 95, 101], ["axon regeneration", "TEST", 174, 191], ["Erk1/2 MAP", "TEST", 196, 206], ["kinase signaling", "TEST", 207, 223], ["cAMP response element", "TEST", 228, 249], ["optic nerve", "ANATOMY", 140, 151], ["spinal cord", "ANATOMY", 161, 172], ["CNS", "ANATOMY", 358, 361]]], ["Cooperative signaling between CD14, TLRs, and dectin-1 in activated myeloid cells also leads to expression of type I IFN, which can limit glial scar formation, remove degenerating axons and promote their regrowth (Hosmane et al., 2012; Nishimura et al., 2013; Zanon et al., 2010) .", [["myeloid cells", "ANATOMY", 68, 81], ["glial scar", "ANATOMY", 138, 148], ["axons", "ANATOMY", 180, 185], ["CD14", "GENE_OR_GENE_PRODUCT", 30, 34], ["TLRs", "GENE_OR_GENE_PRODUCT", 36, 40], ["dectin-1", "GENE_OR_GENE_PRODUCT", 46, 54], ["myeloid cells", "CELL", 68, 81], ["type I IFN", "GENE_OR_GENE_PRODUCT", 110, 120], ["glial scar", "TISSUE", 138, 148], ["axons", "MULTI-TISSUE_STRUCTURE", 180, 185], ["CD14", "PROTEIN", 30, 34], ["TLRs", "PROTEIN", 36, 40], ["dectin-1", "PROTEIN", 46, 54], ["activated myeloid cells", "CELL_TYPE", 58, 81], ["type I IFN", "PROTEIN", 110, 120], ["CD14", "TEST", 30, 34], ["TLRs", "TEST", 36, 40], ["dectin", "TEST", 46, 52], ["activated myeloid cells", "PROBLEM", 58, 81], ["type I IFN", "PROBLEM", 110, 120], ["glial scar formation", "PROBLEM", 138, 158], ["degenerating axons", "PROBLEM", 167, 185], ["myeloid cells", "OBSERVATION", 68, 81], ["scar", "OBSERVATION", 144, 148]]], ["The identification of innate immune pathways that promote recovery from pathogen-mediated brain injury could provide new targets for the development of therapies to treat non-infectious CNS disorders.", [["brain", "ANATOMY", 90, 95], ["CNS", "ANATOMY", 186, 189], ["brain injury", "DISEASE", 90, 102], ["non-infectious CNS disorders", "DISEASE", 171, 199], ["brain", "ORGAN", 90, 95], ["CNS", "ANATOMICAL_SYSTEM", 186, 189], ["innate immune pathways", "TREATMENT", 22, 44], ["pathogen-mediated brain injury", "PROBLEM", 72, 102], ["therapies", "TREATMENT", 152, 161], ["non-infectious CNS disorders", "PROBLEM", 171, 199], ["brain", "ANATOMY", 90, 95], ["injury", "OBSERVATION", 96, 102]]], ["Can Immune-Mediated Strategies Be Developed to Better Manage CNS Infections?", [["Infections", "DISEASE", 65, 75], ["CNS Infections", "PROBLEM", 61, 75], ["Infections", "OBSERVATION", 65, 75]]], ["From a clinical perspective, the management of patients with neuroinfectious disease is complicated by the lack of treatment options available to suppress inflammation without compromising protective responses.", [["neuroinfectious disease", "DISEASE", 61, 84], ["inflammation", "DISEASE", 155, 167], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["neuroinfectious disease", "PROBLEM", 61, 84], ["treatment options", "TREATMENT", 115, 132], ["inflammation", "PROBLEM", 155, 167]]], ["Moreover, the concept that boosting anti-pathogen responses in the CNS is a clinically viable strategy runs counter to the perception that inflammation of the CNS should be avoided.", [["CNS", "ANATOMY", 67, 70], ["CNS", "ANATOMY", 159, 162], ["inflammation", "DISEASE", 139, 151], ["CNS", "ANATOMICAL_SYSTEM", 67, 70], ["CNS", "ANATOMICAL_SYSTEM", 159, 162], ["inflammation of the CNS", "PROBLEM", 139, 162], ["CNS", "ANATOMY", 67, 70], ["CNS", "ANATOMY", 159, 162]]], ["The use of clinically relevant models described throughout this review have already provided insights into the balance between stringent regulation of immune cell access to the CNS and the need for anti-pathogen immunity.", [["immune cell", "ANATOMY", 151, 162], ["CNS", "ANATOMY", 177, 180], ["immune cell", "CELL", 151, 162], ["CNS", "ANATOMICAL_SYSTEM", 177, 180], ["immune cell access", "TREATMENT", 151, 169], ["anti-pathogen immunity", "TREATMENT", 198, 220], ["immune cell", "OBSERVATION", 151, 162], ["CNS", "ANATOMY", 177, 180]]], ["The natural history of human infections and the use of antibody-based therapies to treat inflammatory diseases illustrates the importance of surveillance and effector mechanism that are relevant to immunity in the CNS but also the ability to balance therapeutic dose to allow clinical benefit versus compromise of CNS surveillance (Ali et al., 2013; Berger and Koralnik, 2005) .", [["CNS", "ANATOMY", 214, 217], ["CNS", "ANATOMY", 314, 317], ["infections", "DISEASE", 29, 39], ["inflammatory diseases", "DISEASE", 89, 110], ["human", "ORGANISM", 23, 28], ["CNS", "ANATOMICAL_SYSTEM", 214, 217], ["CNS", "ANATOMICAL_SYSTEM", 314, 317], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["human infections", "PROBLEM", 23, 39], ["antibody-based therapies", "TREATMENT", 55, 79], ["inflammatory diseases", "PROBLEM", 89, 110], ["CNS surveillance", "TEST", 314, 330], ["infections", "OBSERVATION", 29, 39], ["inflammatory", "OBSERVATION", 89, 101], ["CNS", "ANATOMY", 314, 317]]], ["One area where there might be an opportunity to augment anti-pathogen responses in the CNS relates to the function of inhibitory receptors.", [["CNS", "ANATOMY", 87, 90], ["CNS", "ANATOMICAL_SYSTEM", 87, 90], ["inhibitory receptors", "PROTEIN", 118, 138], ["CNS", "ANATOMY", 87, 90]]], ["The clinical success of targeting PD-1, PD-L1, and CTLA-4 to reinvigorate pre-existing anti-tumor T cell responses has the potential to determine whether these pathways operate constitutively in the CNS.", [["anti-tumor T cell", "ANATOMY", 87, 104], ["CNS", "ANATOMY", 199, 202], ["PD-1", "GENE_OR_GENE_PRODUCT", 34, 38], ["PD-L1", "GENE_OR_GENE_PRODUCT", 40, 45], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 51, 57], ["anti-tumor T cell", "CELL", 87, 104], ["CNS", "ANATOMICAL_SYSTEM", 199, 202], ["CTLA-4", "DNA", 51, 57], ["targeting PD", "TREATMENT", 24, 36], ["PD-L1", "TREATMENT", 40, 45], ["CTLA", "TEST", 51, 55], ["L1", "ANATOMY", 43, 45], ["CNS", "ANATOMY", 199, 202]]], ["There is an expanding cancer patient base that are treated with these therapies, but it is not yet clear whether these treatments will impact the immune response to latent infections of the CNS.", [["cancer", "ANATOMY", 22, 28], ["CNS", "ANATOMY", 190, 193], ["cancer", "DISEASE", 22, 28], ["infections", "DISEASE", 172, 182], ["cancer", "CANCER", 22, 28], ["patient", "ORGANISM", 29, 36], ["CNS", "ANATOMICAL_SYSTEM", 190, 193], ["patient", "SPECIES", 29, 36], ["an expanding cancer patient base", "PROBLEM", 9, 41], ["these therapies", "TREATMENT", 64, 79], ["these treatments", "TREATMENT", 113, 129], ["latent infections of the CNS", "PROBLEM", 165, 193], ["expanding", "OBSERVATION_MODIFIER", 12, 21], ["cancer", "OBSERVATION", 22, 28], ["base", "ANATOMY_MODIFIER", 37, 41], ["latent", "OBSERVATION_MODIFIER", 165, 171], ["infections", "OBSERVATION", 172, 182], ["CNS", "ANATOMY", 190, 193]]], ["In one scenario, treatments that target inhibitory pathways might lead to silent clearance of pre-existing chronic infections of the CNS and/or result in overt or transient immune pathology, perhaps associated with pathogen clearance.", [["CNS", "ANATOMY", 133, 136], ["infections", "DISEASE", 115, 125], ["CNS", "ANATOMICAL_SYSTEM", 133, 136], ["treatments", "TREATMENT", 17, 27], ["target inhibitory pathways", "PROBLEM", 33, 59], ["pre-existing chronic infections", "PROBLEM", 94, 125], ["the CNS", "PROBLEM", 129, 136], ["overt or transient immune pathology", "PROBLEM", 154, 189], ["pathogen clearance", "PROBLEM", 215, 233], ["chronic", "OBSERVATION_MODIFIER", 107, 114], ["infections", "OBSERVATION", 115, 125], ["CNS", "ANATOMY", 133, 136], ["transient", "OBSERVATION_MODIFIER", 163, 172], ["immune pathology", "OBSERVATION", 173, 189], ["perhaps associated with", "UNCERTAINTY", 191, 214]]], ["The latter findings would argue that immunotherapy is a viable approach to target latent of persistent infections of the CNS.", [["CNS", "ANATOMY", 121, 124], ["infections", "DISEASE", 103, 113], ["CNS", "ANATOMICAL_SYSTEM", 121, 124], ["immunotherapy", "TREATMENT", 37, 50], ["a viable approach", "TREATMENT", 54, 71], ["persistent infections of the CNS", "PROBLEM", 92, 124], ["persistent", "OBSERVATION_MODIFIER", 92, 102], ["infections", "OBSERVATION", 103, 113], ["CNS", "ANATOMY", 121, 124]]], ["The utility of this type of approach is illustrated by the success of CAR T cell therapies to target cancer and which might be applicable to infectious diseases (Parida et al., 2015) .", [["T cell", "ANATOMY", 74, 80], ["cancer", "ANATOMY", 101, 107], ["cancer", "DISEASE", 101, 107], ["infectious diseases", "DISEASE", 141, 160], ["CAR T cell", "CELL", 70, 80], ["cancer", "CANCER", 101, 107], ["CAR T cell therapies", "TREATMENT", 70, 90], ["target cancer", "PROBLEM", 94, 107], ["cancer", "OBSERVATION", 101, 107]]], ["The willingness to target CNS infections would need to be based on the belief that T cells are part of the normal surveillance in the brain, and that these populations could be engineered to traffic into the CNS and function there with specificity and minimal bystander damage.", [["CNS", "ANATOMY", 26, 29], ["T cells", "ANATOMY", 83, 90], ["brain", "ANATOMY", 134, 139], ["CNS", "ANATOMY", 208, 211], ["infections", "DISEASE", 30, 40], ["CNS", "ANATOMICAL_SYSTEM", 26, 29], ["T cells", "CELL", 83, 90], ["brain", "ORGAN", 134, 139], ["CNS", "ANATOMICAL_SYSTEM", 208, 211], ["T cells", "CELL_TYPE", 83, 90], ["CNS infections", "PROBLEM", 26, 40], ["T cells", "PROBLEM", 83, 90], ["minimal bystander damage", "PROBLEM", 252, 276], ["normal", "OBSERVATION", 107, 113], ["brain", "ANATOMY", 134, 139], ["CNS", "ANATOMY", 208, 211], ["minimal", "OBSERVATION_MODIFIER", 252, 259]]]], "PMC7474514": [["IntroductionDiagnosis of COVID-19 is typically associated with both the symptoms of pneumonia and Chest X-ray tests [25].", [["pneumonia", "DISEASE", 84, 93], ["COVID", "TEST", 25, 30], ["the symptoms", "PROBLEM", 68, 80], ["pneumonia", "PROBLEM", 84, 93], ["Chest X-ray tests", "TEST", 98, 115], ["pneumonia", "OBSERVATION", 84, 93], ["Chest", "ANATOMY", 98, 103]]], ["Chest X-ray is the first imaging technique that plays an important role in the diagnosis of COVID-19 disease.", [["COVID-19 disease", "CANCER", 92, 108], ["Chest X-ray", "TEST", 0, 11], ["the first imaging technique", "TEST", 15, 42], ["COVID-19 disease", "PROBLEM", 92, 108]]], ["Figure 1 shows a negative example of a normal chest X-ray, a positive one with COVID-19, and a positive one with the severe acute respiratory syndrome (SARS).", [["chest", "ANATOMY", 46, 51], ["acute respiratory syndrome", "DISEASE", 124, 150], ["SARS", "DISEASE", 152, 156], ["COVID", "TEST", 79, 84], ["the severe acute respiratory syndrome", "PROBLEM", 113, 150], ["chest", "ANATOMY", 46, 51], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory syndrome", "OBSERVATION", 130, 150]]]], "70a25d53d1e5423b4e72d5fec9831ada8781a579": [["1 They suggest that older patients taking inhibitors of the renin-angiotensin-aldosterone system (RAAS) could be at greater risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as well as of a worse outcome of COVID-19.", [["angiotensin", "CHEMICAL", 66, 77], ["aldosterone", "CHEMICAL", 78, 89], ["acute respiratory syndrome coronavirus", "DISEASE", 139, 177], ["infection", "DISEASE", 193, 202], ["aldosterone", "CHEMICAL", 78, 89], ["patients", "ORGANISM", 26, 34], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 60, 89], ["SARS-CoV-2", "ORGANISM", 181, 191], ["renin", "PROTEIN", 60, 65], ["patients", "SPECIES", 26, 34], ["severe acute respiratory syndrome coronavirus", "SPECIES", 132, 177], ["SARS-CoV-2", "SPECIES", 181, 191], ["inhibitors", "TREATMENT", 42, 52], ["the renin-angiotensin-aldosterone system", "TREATMENT", 56, 96], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 132, 177], ["SARS-CoV", "PROBLEM", 181, 189], ["infection", "PROBLEM", 193, 202], ["COVID", "TEST", 236, 241], ["severe", "OBSERVATION_MODIFIER", 132, 138], ["acute", "OBSERVATION_MODIFIER", 139, 144], ["respiratory syndrome", "OBSERVATION", 145, 165]]]], "6b01680b9cafe2939d8a8c6c6392f3475b78e299": [["INTRODUCTIONWorldwide, traffic accidents represent the leading cause of unnatural deaths.", [["traffic accidents", "DISEASE", 23, 40], ["deaths", "DISEASE", 82, 88], ["unnatural deaths", "PROBLEM", 72, 88], ["unnatural deaths", "OBSERVATION", 72, 88]]], ["1 A total of 10%-20% of bereaved people who experience natural deaths (eg, illness) develop severe and persistent grief-related distress, including persistent complex bereavement disorder (PCBD), post-traumatic stress disorder (PTSD) and depression.", [["deaths", "DISEASE", 63, 69], ["illness", "DISEASE", 75, 82], ["grief", "DISEASE", 114, 119], ["distress", "DISEASE", 128, 136], ["bereavement disorder", "DISEASE", 167, 187], ["PCBD", "DISEASE", 189, 193], ["traumatic stress disorder", "DISEASE", 201, 226], ["PTSD", "DISEASE", 228, 232], ["depression", "DISEASE", 238, 248], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["severe and persistent grief-related distress", "PROBLEM", 92, 136], ["persistent complex bereavement disorder", "PROBLEM", 148, 187], ["post-traumatic stress disorder", "PROBLEM", 196, 226], ["PTSD", "PROBLEM", 228, 232], ["depression", "PROBLEM", 238, 248], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["persistent", "OBSERVATION_MODIFIER", 103, 113], ["grief", "OBSERVATION", 114, 119], ["persistent", "OBSERVATION_MODIFIER", 148, 158], ["complex", "OBSERVATION_MODIFIER", 159, 166], ["bereavement", "OBSERVATION", 167, 178], ["traumatic stress disorder", "OBSERVATION", 201, 226]]], ["2 3 Notably, PCBD has been introduced as other specified trauma-related and stressor-related disorder, in the latest version of the Diagnostic and Statistical manual of Mental Diseases (DSM-5).", [["PCBD", "CHEMICAL", 13, 17], ["trauma", "DISEASE", 57, 63], ["disorder", "DISEASE", 93, 101], ["Mental Diseases", "DISEASE", 169, 184], ["PCBD", "CANCER", 13, 17], ["PCBD", "TREATMENT", 13, 17], ["stressor-related disorder", "PROBLEM", 76, 101], ["Mental Diseases", "PROBLEM", 169, 184], ["DSM", "TEST", 186, 189], ["Mental Diseases", "OBSERVATION", 169, 184]]], ["4 PCBD can be diagnosed if, after the death of a significant other at least 12 months earlier, a person experiences persistent yearning for the deceased and symptoms of reactive distress (eg, emotional numbness) and social/identity disruption (eg, feeling alone) causing impairment in daily life.", [["death", "DISEASE", 38, 43], ["reactive distress", "DISEASE", 169, 186], ["numbness", "DISEASE", 202, 210], ["person", "SPECIES", 97, 103], ["symptoms", "PROBLEM", 157, 165], ["reactive distress", "PROBLEM", 169, 186], ["emotional numbness", "PROBLEM", 192, 210], ["social/identity disruption", "PROBLEM", 216, 242], ["reactive", "OBSERVATION_MODIFIER", 169, 177], ["distress", "OBSERVATION", 178, 186]]], ["While some PCBD symptoms overlap with PTSD (eg, anger) and depression symptoms (eg, diminished interest in activities), several studies have shown that these three syndromes are distinct.", [["PTSD", "DISEASE", 38, 42], ["depression", "DISEASE", 59, 69], ["some PCBD symptoms", "PROBLEM", 6, 24], ["PTSD", "PROBLEM", 38, 42], ["depression symptoms", "PROBLEM", 59, 78], ["diminished interest in activities", "PROBLEM", 84, 117], ["several studies", "TEST", 120, 135], ["these three syndromes", "PROBLEM", 152, 173], ["distinct", "OBSERVATION_MODIFIER", 178, 186]]], ["[5] [6] [7] Unexpected/violent losses of a significant other, also referred to as a traumatic losses, including deaths caused by Strengths and limitations of this study \u25ba This study is the first to examine the effectiveness of online cognitive-behavioural therapy (CBT) (vs waitlist controls) in reducing psychopathology after traumatic loss in a randomised controlled trial. \u25ba This study is one of the first to examine potential correlates of change in symptom levels following online treatment after traumatic loss. \u25ba We are not able to formally test mediators or moderators of treatment effects. \u25ba We are not able to examine if online CBT has equal effects as face-to-face CBT. \u25ba We are not able to establish formal diagnoses, as we use self-report questionnaires, instead of diagnostic interviews, to assess symptom levels.INTRODUCTIONOpen access traffic accidents, increase risks for the development of PCBD, PTSD and depression.", [["traumatic losses", "DISEASE", 84, 100], ["deaths", "DISEASE", 112, 118], ["psychopathology", "DISEASE", 305, 320], ["traumatic loss", "DISEASE", 327, 341], ["traumatic loss", "DISEASE", 502, 516], ["traffic accidents", "DISEASE", 851, 868], ["PCBD", "DISEASE", 908, 912], ["PTSD", "DISEASE", 914, 918], ["depression", "DISEASE", 923, 933], ["[5] [6] [7]", "SIMPLE_CHEMICAL", 0, 11], ["a traumatic losses", "PROBLEM", 82, 100], ["this study", "TEST", 158, 168], ["This study", "TEST", 171, 181], ["online cognitive", "TREATMENT", 227, 243], ["behavioural therapy", "TREATMENT", 244, 263], ["CBT", "TEST", 265, 268], ["reducing psychopathology", "PROBLEM", 296, 320], ["traumatic loss", "PROBLEM", 327, 341], ["a randomised controlled trial", "TREATMENT", 345, 374], ["This study", "TEST", 378, 388], ["change in symptom levels", "PROBLEM", 444, 468], ["online treatment", "TREATMENT", 479, 495], ["traumatic loss", "PROBLEM", 502, 516], ["treatment effects", "TREATMENT", 580, 597], ["CBT", "TEST", 638, 641], ["face", "TEST", 663, 667], ["CBT", "TEST", 676, 679], ["symptom levels", "TEST", 812, 826], ["PCBD", "PROBLEM", 908, 912], ["PTSD", "PROBLEM", 914, 918], ["depression", "PROBLEM", 923, 933]]], ["8 9 HEIGHTENED RISK FOR DEVELOPING PSYCHOPATHOLOGY AFTER DEATHS DUE TO TRAFFIC ACCIDENT Specific circumstances of losses caused by accidents may account for the elevated risk of grief-related distress.", [["accidents", "DISEASE", 131, 140], ["grief", "DISEASE", 178, 183], ["DEVELOPING PSYCHOPATHOLOGY", "PROBLEM", 24, 50], ["grief", "PROBLEM", 178, 183], ["related distress", "PROBLEM", 184, 200]]], ["For instance, experiencing multiple losses simultaneously, being a witness to the accident, and juridical and financial consequences are proposed to exacerbate grief-related distress.", [["grief", "DISEASE", 160, 165], ["multiple losses simultaneously", "PROBLEM", 27, 57], ["grief-related distress", "PROBLEM", 160, 182], ["multiple", "OBSERVATION_MODIFIER", 27, 35], ["losses", "OBSERVATION", 36, 42]]], ["10 Furthermore, negative cognitions and avoidance behaviours may mediate the influence of sudden/ violent loss on grief, PTSD and depression levels.", [["sudden/ violent loss", "DISEASE", 90, 110], ["grief", "DISEASE", 114, 119], ["PTSD", "DISEASE", 121, 125], ["depression", "DISEASE", 130, 140], ["sudden/ violent loss on grief", "PROBLEM", 90, 119], ["PTSD", "PROBLEM", 121, 125], ["depression levels", "PROBLEM", 130, 147]]], ["11 According to a cognitive-behavioural model, three interacting malleable processes underlie disturbed grief reactions: (1) negative cognitions, (2) avoidance behaviour and (3) difficulties integrating the loss into the autobiographical knowledge base.", [["grief", "DISEASE", 104, 109], ["disturbed grief reactions", "PROBLEM", 94, 119], ["avoidance behaviour and (3) difficulties integrating the loss into the autobiographical knowledge base", "PROBLEM", 150, 252]]], ["12 Experiencing a loss due to a traffic accident may violate basic assumptions about the world being a safe place.", [["traffic accident", "DISEASE", 32, 48], ["a loss", "PROBLEM", 16, 22]]], ["13 This may fuel negative cognitions (eg, 'I'm less worthy, since s/he died' and 'The death of him/her has taught me that the world is unjust') that may exacerbate and maintain acute grief responses.", [["death", "DISEASE", 86, 91], ["grief", "DISEASE", 183, 188], ["acute grief responses", "PROBLEM", 177, 198]]], ["14 Avoidance behaviours include depressive avoidance and anxious avoidance strategies.", [["depressive avoidance", "DISEASE", 32, 52], ["depressive avoidance", "PROBLEM", 32, 52], ["anxious avoidance strategies", "TREATMENT", 57, 85]]], ["Depressive avoidance refers to withdrawal from social and occupational activities that were perceived as fulfilling before the death, out of the conviction that these activities are no longer meaningful.", [["Depressive avoidance", "DISEASE", 0, 20], ["death", "DISEASE", 127, 132], ["Depressive avoidance", "PROBLEM", 0, 20], ["withdrawal", "PROBLEM", 31, 41]]], ["Anxious avoidance strategies serve to prevent confrontation with the reality of the death, out of fear that confrontation is too painful.", [["death", "DISEASE", 84, 89], ["Anxious avoidance strategies", "TREATMENT", 0, 28], ["the death", "PROBLEM", 80, 89], ["too painful", "PROBLEM", 125, 136]]], ["15 This seems to be a frequently used avoidant coping strategy in bereaved people after traffic accidents and is strongly related to PTSD.", [["traffic accidents", "DISEASE", 88, 105], ["PTSD", "DISEASE", 133, 137], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["PTSD", "PROBLEM", 133, 137]]], ["16 Difficulty with integration of the loss into the autobiographical knowledge base refers to the difficulties connecting factual knowledge that the loss is irreversible with existing information about the self and the relationship with the lost person, stored in autobiographical memory.", [["person", "SPECIES", 246, 252], ["the loss", "PROBLEM", 34, 42], ["the loss", "PROBLEM", 145, 153], ["irreversible", "OBSERVATION_MODIFIER", 157, 169]]], ["Memories related to the loss may lack context in terms of time and place, causing the loss to be experienced as unreal.", [["the loss", "PROBLEM", 20, 28], ["the loss", "PROBLEM", 82, 90]]], ["17 It has been argued that this 'sense of unrealness' may trigger intrusive memories and increase feelings of numbness or shock once the bereaved person is confronted with reminders of the loss.", [["unrealness", "DISEASE", 42, 52], ["numbness", "DISEASE", 110, 118], ["shock", "DISEASE", 122, 127], ["person", "SPECIES", 146, 152], ["intrusive memories", "PROBLEM", 66, 84], ["numbness", "PROBLEM", 110, 118], ["shock", "PROBLEM", 122, 127], ["the loss", "PROBLEM", 185, 193]]], ["17 18 The extent to which a person believes that one is capable of managing stressor-related thoughts, emotions and behaviours, also referred to as self-efficacy (eg, 'I can usually handle whatever comes my way'), has also been determined as an important factor facilitating coping with traumatic stressors.", [["person", "SPECIES", 28, 34], ["traumatic stressors", "PROBLEM", 287, 306]]], ["19 Decreased self-efficacy, negative cognitions and insufficient integration of the loss may contribute to increased sensitivity to loss reminders or secondary stressors following traumatic loss.", [["traumatic loss", "DISEASE", 180, 194], ["the loss", "PROBLEM", 80, 88], ["increased sensitivity", "PROBLEM", 107, 128], ["loss reminders", "TREATMENT", 132, 146], ["secondary stressors", "PROBLEM", 150, 169], ["traumatic loss", "PROBLEM", 180, 194], ["traumatic loss", "OBSERVATION", 180, 194]]], ["20 CBT FOR GRIEF-RELATED DISTRESS Grief-specific CBT has been demonstrated to be the most effective treatment for bereaved people with elevated grief levels.", [["elevated grief", "DISEASE", 135, 149], ["people", "ORGANISM", 123, 129], ["people", "SPECIES", 123, 129], ["GRIEF", "PROBLEM", 11, 16], ["DISTRESS", "PROBLEM", 25, 33], ["Grief", "PROBLEM", 34, 39], ["specific CBT", "TEST", 40, 52], ["elevated grief levels", "PROBLEM", 135, 156]]], ["[21] [22] [23] [24] CBT targets the abovementioned cognitivebehavioural variables with cognitive restructuring, lossrelated exposure and behavioural activation.", [["[21] [22] [23] [24] CBT", "CHEMICAL", 0, 23], ["[21] [22] [23] [24] CBT", "SIMPLE_CHEMICAL", 0, 23], ["CBT targets", "TEST", 20, 31], ["the abovementioned cognitivebehavioural variables", "PROBLEM", 32, 81], ["cognitive restructuring", "PROBLEM", 87, 110], ["lossrelated exposure", "PROBLEM", 112, 132], ["behavioural activation", "PROBLEM", 137, 159]]], ["Notably, research on putative mechanisms of change of griefspecific CBT is sparse 23 (but see refs 25 26) .", [["griefspecific CBT", "TEST", 54, 71]]], ["Examining the effectiveness of grief-specific CBT and its potential mechanisms of change in traumatically bereaved people with traumatic grief is clinically relevant because it would enable tailoring of interventions to the specific needs of this group, which could improve treatment outcomes.", [["traumatic grief", "DISEASE", 127, 142], ["people", "ORGANISM", 115, 121], ["people", "SPECIES", 115, 121], ["grief", "PROBLEM", 31, 36], ["specific CBT", "TEST", 37, 49], ["traumatic grief", "PROBLEM", 127, 142], ["interventions", "TREATMENT", 203, 216]]], ["27 While the majority of trials assess the efficacy of faceto-face CBT, 24 so far, to the best of our knowledge, three online CBT-based interventions have been developed for distressed bereaved people.", [["people", "ORGANISM", 194, 200], ["people", "SPECIES", 194, 200], ["faceto-face CBT", "TREATMENT", 55, 70], ["based interventions", "TREATMENT", 130, 149]]], ["[28] [29] [30] These prior studies provided preliminary data on the potential effectiveness of online grief-specific CBT, but had some limitations.", [["These prior studies", "TEST", 15, 34], ["preliminary data", "TEST", 44, 60], ["online grief", "TEST", 95, 107], ["specific CBT", "TEST", 108, 120]]], ["For instance, treatment was solely provided to people who experienced perinatal loss 29 or included relatively small samples.", [["samples", "ANATOMY", 117, 124], ["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["treatment", "TREATMENT", 14, 23], ["perinatal loss", "PROBLEM", 70, 84], ["relatively small samples", "PROBLEM", 100, 124]]], ["28 Comparability between these three studies is also limited, because interventions differed in treatment content; different elements of CBT were offered, for instance, behavioural activation, exposure 28 or writing assignments.", [["these three studies", "TEST", 25, 44], ["interventions", "TREATMENT", 70, 83], ["CBT", "TREATMENT", 137, 140]]], ["It may lower the threshold for seeking treatment, because it can be delivered independent of geographical location.", [["seeking treatment", "TREATMENT", 31, 48]]], ["31 This may counter barriers to mental health service use, such as difficulties with finding help, transportation concerns or difficulties scheduling treatment sessions.", [["treatment sessions", "TREATMENT", 150, 168]]], ["32 In addition, online CBT could reduce treatment costs, improving accessibility and dissemination of care for people in need of support.", [["people", "ORGANISM", 111, 117], ["people", "SPECIES", 111, 117], ["online CBT", "TREATMENT", 16, 26], ["treatment costs", "TREATMENT", 40, 55], ["dissemination of care", "TREATMENT", 85, 106], ["support", "TREATMENT", 129, 136]]], ["33 Moreover, during times of a crisis, such as the COVID-19 pandemic, it seems more relevant than ever to further examine the effectiveness of online CBT for distressed bereaved people, as it will allow them to retain access to evidence-based care.", [["people", "ORGANISM", 178, 184], ["people", "SPECIES", 178, 184], ["a crisis", "PROBLEM", 29, 37], ["the COVID", "TEST", 47, 56], ["online CBT", "TREATMENT", 143, 153]]], ["34 A potential downside to online CBT is the high dropout rate found in earlier studies.", [["online CBT", "TEST", 27, 37], ["the high dropout rate", "PROBLEM", 41, 62], ["earlier studies", "TEST", 72, 87]]], ["33 35 It has been argued that a strong therapeutic alliance might support adherence to online treatment and mediates treatment effects.", [["online treatment", "TREATMENT", 87, 103], ["mediates treatment effects", "TREATMENT", 108, 134]]], ["36 Therapeutic alliance is defined as a positive emotional bond between client and therapist, whereby both parties agree on the tasks and goals of the treatment.", [["the treatment", "TREATMENT", 147, 160]]], ["37 The clienttherapist relationship might also explain why online treatments are more effective with therapist guidance than without.", [["online treatments", "TREATMENT", 59, 76], ["therapist guidance", "TREATMENT", 101, 119]]], ["38 However, studies in non-bereaved samples indicate that developing Open access a strong therapeutic alliance is possible during online treatment 33 and that therapeutic alliance is often related to online treatment outcomes, 39 but not always.", [["studies in non-bereaved samples", "TEST", 12, 43], ["online treatment", "TREATMENT", 130, 146], ["online treatment outcomes", "TREATMENT", 200, 225]]], ["33 More research is needed to further examine the interrelations of the quality of client-therapist relationship, drop-out and treatment outcomes in online CBT.STUDY OBJECTIVESOur first aim is to examine the effectiveness of online CBT (vs a waiting list control condition) in reducing symptom levels of PCBD, PTSD, and depression in people bereaved by a traffic accident.", [["PCBD", "DISEASE", 304, 308], ["PTSD", "DISEASE", 310, 314], ["depression", "DISEASE", 320, 330], ["traffic accident", "DISEASE", 355, 371], ["people", "ORGANISM", 334, 340], ["people", "SPECIES", 334, 340], ["treatment outcomes", "TREATMENT", 127, 145], ["online CBT", "TREATMENT", 149, 159], ["online CBT", "TREATMENT", 225, 235], ["a waiting list control condition", "TREATMENT", 240, 272], ["PTSD", "PROBLEM", 310, 314], ["depression", "PROBLEM", 320, 330]]], ["We expect that participants assigned to the online CBT condition will show larger reductions in symptom levels of PCBD, PTSD and depression compared with waitlist controls at post-treatment assessments (hypothesis 1).STUDY OBJECTIVESOur second aim is to explore correlates of change.", [["PCBD", "DISEASE", 114, 118], ["PTSD", "DISEASE", 120, 124], ["depression", "DISEASE", 129, 139], ["participants", "SPECIES", 15, 27], ["larger reductions in symptom levels of PCBD", "PROBLEM", 75, 118], ["PTSD", "PROBLEM", 120, 124], ["depression", "PROBLEM", 129, 139], ["post-treatment assessments", "TEST", 175, 201], ["larger", "OBSERVATION_MODIFIER", 75, 81], ["reductions", "OBSERVATION_MODIFIER", 82, 92]]], ["Based on prior research and theories, 12 16 19 we expect that reductions in negative cognitions, avoidance behaviours, state anger, a sense of unrealness and improvement in self-efficacy are related to reductions in PCBD, PTSD and depression levels in online CBT (hypothesis 2a).", [["unrealness", "DISEASE", 143, 153], ["PTSD", "DISEASE", 222, 226], ["depression", "DISEASE", 231, 241], ["unrealness", "PROBLEM", 143, 153], ["PCBD", "TREATMENT", 216, 220], ["PTSD", "PROBLEM", 222, 226], ["depression levels", "PROBLEM", 231, 248]]], ["Additionally, we aim to explore whether background characteristics (ie, gender, age and educational level, kinship to the deceased and time since loss) and accident-related stressors (ie, single vs multiple loss, witnessing the accident and status of legal trial) are related to treatment effects (hypothesis 2b).", [["accident", "DISEASE", 156, 164], ["multiple loss", "PROBLEM", 198, 211]]], ["We have no specific expectations regarding these associations because prior treatment studies in bereaved people showed inconsistent results.", [["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["prior treatment studies", "TEST", 70, 93]]], ["24 25 40 However, based on clinical experience, we expect that accident-related stressors are associated with treatment effects, such that multiple loss, witnessing the accident and ongoing legal trial negatively impact treatment effects.STUDY OBJECTIVESOur third aim is to explore the associations between quality of the therapeutic alliance and drop-out rates and treatment outcomes.", [["treatment effects", "TREATMENT", 110, 127], ["multiple loss", "PROBLEM", 139, 152], ["treatment outcomes", "TREATMENT", 366, 384]]], ["We expect that a stronger therapeutic alliance is related to lower drop-out rates and better treatment outcomes.METHODS AND ANALYSIS DesignA two-arm (online CBT vs waiting list) multicentre open label parallel randomised controlled trial (RCT) will be conducted.", [["lower drop-out rates", "PROBLEM", 61, 81], ["DesignA", "TEST", 133, 140], ["multicentre open label parallel randomised controlled trial (RCT)", "TREATMENT", 178, 243], ["arm", "ANATOMY", 145, 148]]], ["Randomisation will take place after the participant is screened for eligibility-based inclusion criteria (described below).", [["participant", "SPECIES", 40, 51], ["Randomisation", "TREATMENT", 0, 13]]], ["A random number generator ( www. random. org) will be used by a blinded independent researcher, to perform the blocking randomisation procedure.", [["the blocking randomisation procedure", "TREATMENT", 107, 143]]], ["An allocation ratio of 1:1 will be applied.METHODS AND ANALYSIS DesignParticipants allocated to the online CBT condition receive treatment within 1 week after allocation.", [["An allocation ratio", "TEST", 0, 19], ["the online CBT condition", "TREATMENT", 96, 120], ["treatment", "TREATMENT", 129, 138]]], ["All participants will be asked to fill in questionnaires (described below) at baseline (T1), 12 weeks postallocation (T2 for the intervention condition and T1a for waitlist controls) and 20 weeks postallocation (T3 for the intervention condition and T1b for waitlist controls).", [["participants", "SPECIES", 4, 16], ["the intervention condition", "TREATMENT", 125, 151], ["T1a", "TREATMENT", 156, 159], ["the intervention condition", "TREATMENT", 219, 245], ["T1b", "TREATMENT", 250, 253]]], ["For participants in the waiting list control group, at the end of the 20-week waiting period after which they will receive online CBT, they will be asked to fill in T2 and T3 12 and 20 weeks after starting treatment, respectively (see figure 1 ).", [["participants", "SPECIES", 4, 16], ["online CBT", "TREATMENT", 123, 133], ["treatment", "TREATMENT", 206, 215]]], ["A link to online questionnaires will be sent to the participants by a non-blinded member of the research team at each time point.", [["participants", "SPECIES", 52, 64]]], ["A waitlist control group (instead of a no treatment control group) is chosen to increase the likelihood of continued study participation by guaranteeing that all participants receive treatment.", [["participants", "SPECIES", 162, 174], ["A waitlist control group", "TREATMENT", 0, 24], ["a no treatment control group", "TREATMENT", 37, 65], ["treatment", "TREATMENT", 183, 192]]], ["Furthermore, the inclusion of a waiting list control group allows a treatment versus no treatment comparison that will provide knowledge about the effects of treatment relative to natural recovery from loss.METHODS AND ANALYSIS DesignIn line with prior treatment studies from our research group, 40 41 the online treatment is guided by governmentally licensed psychologists, connected with a Dutch informal 'traumatic loss network' of therapists specialised in treating emotional distress following traumatic loss.", [["traumatic loss", "DISEASE", 408, 422], ["emotional distress", "DISEASE", 470, 488], ["traumatic loss", "DISEASE", 499, 513], ["a treatment", "TREATMENT", 66, 77], ["treatment comparison", "TREATMENT", 88, 108], ["treatment", "TREATMENT", 158, 167], ["loss", "PROBLEM", 202, 206], ["prior treatment studies", "TEST", 247, 270], ["emotional distress", "PROBLEM", 470, 488], ["traumatic loss", "PROBLEM", 499, 513], ["traumatic loss", "OBSERVATION", 499, 513]]], ["In total six therapists (including authors PB and JdK who are registered clinical psychologists) will guide the participants online; participants will receive feedback from the same therapist each time.", [["participants", "SPECIES", 112, 124], ["participants", "SPECIES", 133, 145]]], ["The therapists will receive a training, provided by LL, PB and JdK, on Open access the use of the treatment protocol of this intervention study.", [["a training", "TREATMENT", 28, 38], ["the treatment protocol", "TREATMENT", 94, 116], ["this intervention study", "TEST", 120, 143]]], ["In preparation for the training, therapists read all treatment materials and a selection of grief treatment literature.", [["the training", "TREATMENT", 19, 31], ["therapists", "TREATMENT", 33, 43], ["all treatment materials", "TREATMENT", 49, 72], ["grief treatment literature", "TREATMENT", 92, 118]]], ["Instructions about the use of the online treatment interface will be given by its developers.", [["the online treatment interface", "TREATMENT", 30, 60]]], ["During a 5-hour face-to-face group meeting the rationale of the online treatment will be explained and research procedures will be discussed.", [["the online treatment", "TREATMENT", 60, 80], ["research procedures", "TREATMENT", 103, 122]]], ["In a 2-hour online video meeting outstanding questions regarding the treatment and the research project will be answered.", [["the treatment", "TREATMENT", 65, 78]]], ["Supervision (by telephone or email) by PB and JdK is possible on request, for instance, when therapists encounter difficulties in treatment.", [["treatment", "TREATMENT", 130, 139]]], ["Therapists will be contacted by a member of the research team by phone or email biweekly to monitor treatment progress and protocol adherence.", [["treatment progress", "TREATMENT", 100, 118]]], ["Treatment costs will be reimbursed.ParticipantsThis RCT is part of a larger ongoing research project (the 'TrafVic-project') examining the psychological impact of, and care after, the death of a loved one due to a traffic accident.", [["death", "DISEASE", 184, 189], ["Participants", "SPECIES", 35, 47], ["Treatment costs", "TREATMENT", 0, 15]]], ["We expect to recruit the majority of the participants via a survey that started in December 2018 and included the following question: 'In this study we would like to offer psychological help to persons who experience emotional problems.", [["persons", "ORGANISM", 194, 201], ["participants", "SPECIES", 41, 53], ["persons", "SPECIES", 194, 201], ["emotional problems", "PROBLEM", 217, 235]]], ["May we approach you with more information about this offer, if your answers to this questionnaire show that you experience emotional problems?'", [["emotional problems", "PROBLEM", 123, 141]]], ["Those who answered 'yes' will be sent a letter with information about the intervention, the treatment study and an informed consent form (see online supplementary file).", [["the intervention", "TREATMENT", 70, 86], ["the treatment study", "TEST", 88, 107]]], ["A Dutch website ( www. rouw nave rkee rson geval. nl) has been developed so that potential participants can read information about the research and treatment.", [["participants", "SPECIES", 91, 103], ["treatment", "TREATMENT", 148, 157]]], ["People who are interested can also sign up for the study via this website.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["the study", "TEST", 47, 56]]], ["Recruitment for this RCT had not started at the time of submission of this manuscript.ParticipantsTo be eligible for study participation, the person must (1) be a family member, spouse or friend of a person who died due to a traffic accident at least 1 year earlier, (2) be \u226518 years of age and (3) meet DSM-5 criteria for PCBD and/or PTSD and/or experience clinically relevant depression, based on questionnaire scores (see below for more details).", [["traffic accident", "DISEASE", 225, 241], ["PCBD", "DISEASE", 323, 327], ["PTSD", "DISEASE", 335, 339], ["depression", "DISEASE", 378, 388], ["Participants", "SPECIES", 86, 98], ["person", "SPECIES", 142, 148], ["person", "SPECIES", 200, 206], ["this RCT", "TEST", 16, 24], ["PCBD", "PROBLEM", 323, 327], ["PTSD", "PROBLEM", 335, 339], ["clinically relevant depression", "PROBLEM", 358, 388], ["questionnaire scores", "TEST", 399, 419]]], ["People are excluded when they do not master the Dutch language or have no internet access.Sample sizeTo test our primary hypothesis (hypothesis 1), a test for each outcome separately (PCBD, PTSD and depression) will be conducted to assess the effects of online CBT versus waitlist controls.", [["PTSD", "DISEASE", 190, 194], ["depression", "DISEASE", 199, 209], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["Sample sizeTo test", "TEST", 90, 108], ["a test", "TEST", 148, 154], ["PTSD", "PROBLEM", 190, 194], ["depression", "PROBLEM", 199, 209], ["online CBT", "TREATMENT", 254, 264], ["waitlist controls", "TREATMENT", 272, 289]]], ["To find a difference between two groups (online CBT vs waitlist controls) of at least a medium effect size (f=0.25; based on prior research 22 28 40 ) with a power of 80%, an \u03b1 of 0.017 (corrected for multiple testing, that is, 0.05/3, as there are three primary outcome measures (PCBD, PTSD and depression), and a strong association (r=0.50) between the preassessment and postassessment, a sample size of 23 per condition is sufficient.", [["PTSD", "DISEASE", 287, 291], ["depression", "DISEASE", 296, 306], ["online CBT vs waitlist controls", "TREATMENT", 41, 72], ["multiple testing", "TEST", 201, 217], ["PTSD", "PROBLEM", 287, 291], ["depression", "PROBLEM", 296, 306], ["a sample size", "TEST", 389, 402], ["medium effect", "OBSERVATION_MODIFIER", 88, 101], ["size", "OBSERVATION_MODIFIER", 102, 106], ["size", "OBSERVATION_MODIFIER", 398, 402]]], ["Taking into account an average dropout rate of 19%, 22 a total sample size of 55 (46+9) is required to test hypothesis 1.Sample sizeBecause our data are nested (repeated measures) (level 1) within individuals (level 2), and possibly within families sharing the same household (level 3), multi-evel modelling will be performed to test hypothesis 1.", [["a total sample size", "TEST", 55, 74]]], ["Conducting a power analysis within a multilevel framework is not feasible for various reasons.", [["a power analysis", "TEST", 11, 27]]], ["42 Our power analysis is therefore based on a repeated measures analysis of variance.InterventionOnline CBT will consist of eight one-on-one sessions, called lessons, offered within a timeframe of 12 weeks.", [["Our power analysis", "TEST", 3, 21], ["a repeated measures analysis", "TEST", 44, 72], ["InterventionOnline CBT", "TREATMENT", 85, 107]]], ["40 Following Dutch guidelines for grief-specific CBT, 42 central components of the treatment are exposure, cognitive restructuring and behavioural activation.", [["grief", "DISEASE", 34, 39], ["grief", "PROBLEM", 34, 39], ["specific CBT", "TEST", 40, 52], ["the treatment", "TREATMENT", 79, 92], ["cognitive restructuring", "PROBLEM", 107, 130], ["behavioural activation", "PROBLEM", 135, 157], ["central components", "OBSERVATION_MODIFIER", 57, 75], ["behavioural activation", "OBSERVATION", 135, 157]]], ["In the first session, psychoeducation is offered, including information about possible emotional reactions to the death of a loved one in a traffic accident and processes that might foster or hamper recovery.", [["death", "DISEASE", 114, 119], ["emotional reactions", "PROBLEM", 87, 106]]], ["A rationale for the CBT interventions is provided.InterventionThen, sessions 2-4 are focused on exposure; the circumstances and story of the loss are presented in detail, and the participant is encouraged to confront stimuli that s/ he tends to avoid.", [["participant", "SPECIES", 179, 190], ["the CBT interventions", "TREATMENT", 16, 37], ["the loss", "PROBLEM", 137, 145]]], ["30 These writing assignments are focused on writing a detailed narrative of the loss and its circumstances.InterventionThe next sessions (5 and 6) focus on identifying and changing negative cognitions that hamper adjustment (ie, cognitive restructuring); specific attention is paid to cognitions connected with responsibility/guilt and anger that may be experienced following the accidental death.", [["death", "DISEASE", 391, 396], ["Intervention", "TREATMENT", 107, 119], ["the accidental death", "PROBLEM", 376, 396]]], ["Participants are instructed to undertake these three steps by providing a daily description of (1) an emotional moment/event, (2) their thoughts during this event, (3) their feelings (and intensity of these feelings on a scale of 1-10), (4) their behaviour, (5) evaluation of their thoughts) and (6) alternative helpful thoughts.InterventionIn sessions 7 and 8, participants are encouraged to re-engage in previously valued social, recreational and occupational activities in order to facilitate the process of adjustment.", [["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 362, 374]]], ["Session 8 is also focused on what the participant has learnt and how to deal with difficulties in the future.InterventionAll information and assignments are presented in an online framework, offered via a secure website.", [["Intervention", "TREATMENT", 109, 121]]], ["Participants receive online written information that consists ofOpen accesspsychoeducation, information about treatment content and structure, and homework assignments.", [["Participants", "SPECIES", 0, 12]]], ["As part of the online treatment, participants also listen to a video therapist verbally sharing parts of information that are also presented in text.", [["participants", "SPECIES", 33, 45], ["the online treatment", "TREATMENT", 11, 31]]], ["The video therapists are two members from the traumatic loss network; one male and one female psychotherapist who are middle aged and specialised in treating bereaved people.", [["traumatic loss", "DISEASE", 46, 60], ["people", "ORGANISM", 167, 173], ["people", "SPECIES", 167, 173]]], ["At the start of the treatment the video therapists introduce themselves and the participant is asked to select one of the video-therapists.", [["participant", "SPECIES", 80, 91]]], ["Each participant, therefore, receives the same information from a video therapist.", [["participant", "SPECIES", 5, 16]]], ["Direct contact with the video therapist is not possible.Open accessParticipants receive weekly asynchronous written feedback from one online therapist on each assignment that they complete online.", [["not possible", "UNCERTAINTY", 43, 55]]], ["As mentioned earlier, six online therapists are trained to guide the participants.", [["participants", "SPECIES", 69, 81]]], ["The online therapists are instructed to contact the participant twice a week; once to encourage participants to log in and complete assignments and once to provide feedback on assignments.", [["participant", "SPECIES", 52, 63], ["participants", "SPECIES", 96, 108]]], ["Moreover, participants are encouraged to ask a family member or friend to support them during treatment.", [["participants", "SPECIES", 10, 22], ["treatment", "TREATMENT", 94, 103]]], ["This support figure is then informed about the treatment through written information in an online framework.MeasuresPrimary outcome measures PCBD will be assessed with the Traumatic Grief Inventory-Self Report (TGI-SR).", [["the treatment", "TREATMENT", 43, 56], ["TGI", "TEST", 211, 214]]], ["43 The TGI-SR consists of 18 items on a 5-point Likert scale ranging from 1=never to 5=always.", [["The TGI", "TEST", 3, 10], ["Likert scale", "TEST", 48, 60]]], ["Four items tapping disturbed grief criteria according to the 11th edition of the International Classification of Diseases were added.", [["Diseases", "PROBLEM", 113, 121], ["Diseases", "OBSERVATION", 113, 121]]], ["The instruction of the original questionnaire was altered from referring to 'the death of your loved one' to 'the death of your loved one(s) due to a traffic accident'.", [["death", "DISEASE", 81, 86], ["death", "DISEASE", 114, 119]]], ["Psychometric properties of the TGI-SR are adequate.", [["the TGI", "TEST", 27, 34], ["adequate", "OBSERVATION", 42, 50]]], ["43 45 Participants are considered to meet criteria for DSM-5 PCBD 4 when they score at least 3 ('sometimes') on at least 1 criterion B symptom (Item 1, item 2, item 3 and item 14), at least six criteria C symptoms (item 4 up to 11, and item 15 up to 18) and the criterion D symptom (item 13).MeasuresPTSD will be assessed with the PTSD checklist for DSM-5 (PCL-5) 46 (Dutch version 47 ).", [["PTSD", "DISEASE", 331, 335], ["Participants", "SPECIES", 6, 18], ["DSM", "TEST", 55, 58], ["C symptoms", "PROBLEM", 203, 213], ["the criterion D symptom", "PROBLEM", 258, 281], ["DSM", "TEST", 350, 353], ["PCL", "TEST", 357, 360]]], ["Participants rate how often they were bothered by each symptom (eg, 'In the past month, how much were you bothered by trouble remembering important parts of the accident?') on 5-point Likert scales (0=not at all and 4=extremely).", [["Participants", "SPECIES", 0, 12], ["Likert scales", "TEST", 184, 197]]], ["The instruction and the items of the original questionnaire are altered from referring to the 'stressful event' to the 'the death of your loved one(s) due to a traffic accident'.", [["death", "DISEASE", 124, 129]]], ["The PCL-5 has shown to be reliable and valid.", [["PCL-5", "CHEMICAL", 4, 9]]], ["46 Participants meet the criteria for DSM-5 PTSD 4 when they score at least 2 ('Moderately') on 1 criterion B item (items 1-5), 1 criterion C item (items 6-7), 2 criterion D items (items [8] [9] [10] [11] [12] [13] [14] , and 2 criterion E items (items [15] [16] [17] [18] [19] [20] .MeasuresDepression symptom levels are assessed with the depression subscale of the HADS-D.", [["PTSD", "DISEASE", 44, 48], ["Depression", "DISEASE", 292, 302], ["depression", "DISEASE", 340, 350], ["8] [9] [10] [11] [12] [13", "SIMPLE_CHEMICAL", 188, 213], ["Participants", "SPECIES", 3, 15], ["criterion E items", "TEST", 228, 245], ["Depression symptom levels", "PROBLEM", 292, 317]]], ["The Dutch HADS-D is a reliable and valid screening tool for depression.", [["depression", "DISEASE", 60, 70], ["valid screening tool", "TEST", 35, 55], ["depression", "PROBLEM", 60, 70]]], ["49 A cut-off score of \u22658 is used as indicator for clinically relevant depression.", [["depression", "DISEASE", 70, 80], ["A cut", "TEST", 3, 8], ["clinically relevant depression", "PROBLEM", 50, 80]]], ["48 Secondary outcome measures Negative grief-related cognitions are assessed with 18 items from the Grief Cognitions Questionnaire.", [["grief", "PROBLEM", 39, 44]]], ["14 Participants are asked to rate their agreement with each item (eg, 'Since [-] is dead, I feel less worthy') on 6-point scales varying from 0=disagree strongly through 5=agree strongly.", [["Participants", "SPECIES", 3, 15]]], ["14 Avoidance is measured with the Depressive and Anxious Avoidance in Prolonged Grief Questionnaire (DAAPGQ).", [["Depressive", "DISEASE", 34, 44], ["the Depressive and Anxious Avoidance", "PROBLEM", 30, 66]]], ["50 The depressive avoidance subscale consists of 5 items (eg, 'Since [-] is dead, I do much less of the things that I used to enjoy.') and the anxious avoidance subscale consists of 4 items (eg, 'I avoid to dwell on painful thoughts and memories connected to his/her death.').", [["depressive avoidance", "DISEASE", 7, 27], ["death", "DISEASE", 267, 272], ["The depressive avoidance subscale", "PROBLEM", 3, 36]]], ["Participants answer each item on an 8-point scale with 0=not at all true for me, and 7=completely true for me.", [["Participants", "SPECIES", 0, 12]]], ["The DAAPGQ has adequate psychometric properties.", [["DAAPGQ", "PROTEIN", 4, 10], ["adequate", "OBSERVATION_MODIFIER", 15, 23], ["psychometric properties", "OBSERVATION", 24, 47]]], ["50 State anger is assessed with the 15-item state anger subscale of the State-Trait Anger Expression Inventory-2 (STAXI-2) 51 (Dutch version: 52 ).", [["Expression Inventory", "TEST", 90, 110]]], ["Participants are asked to rate on 4-point Likert scales (1=not at all and 4=extremely) how angry they feel right now (eg, 'I feel annoyed').", [["Participants", "SPECIES", 0, 12]]], ["The STAXI-2 is a valid and reliable measure to assess state anger.", [["STAXI", "DNA", 4, 9]]], ["52 A sense of unrealness is measured with the 5-item Experienced Unrealness Scale.", [["unrealness", "DISEASE", 14, 24], ["A sense of unrealness", "PROBLEM", 3, 24]]], ["17 Participants are asked to rate their agreement with each item (eg, 'I still can hardly imagine that [-] will never be here again') on 8-point scales (0=not at all true for me 7=completely true for me).", [["Participants", "SPECIES", 3, 15]]], ["This instrument demonstrated adequate psychometric properties.", [["adequate", "OBSERVATION_MODIFIER", 29, 37], ["psychometric properties", "OBSERVATION", 38, 61]]], ["53 The GSES is a 10-item measure.", [["GSES", "DNA", 7, 11]]], ["Participants are asked to rate their agreement with each item (eg, 'I can solve most problems if I invest the necessary effort.') on a 4-point scale (1=completely not true, 4=completely true).", [["Participants", "SPECIES", 0, 12]]], ["The GSES has shown excellent reliability and validity.", [["The GSES", "TEST", 0, 8], ["excellent", "OBSERVATION_MODIFIER", 19, 28], ["reliability", "OBSERVATION_MODIFIER", 29, 40]]], ["53 Quality of the therapeutic alliance is measured with the 12-item Work Alliance Inventory-Short Form, Client Version and Therapist Version after session 4 (WAI-SF) 54 (Dutch version 55 ) The WAI-SF consists of 12 items (eg, Client version: ' We agree on what is important for me to work on', Therapist Version: 'We are working towards mutually agreed on goals.') that are rated on 5-point Open access scales (1=never and 5=always).", [["Open access scales", "TREATMENT", 391, 409]]], ["Higher total scores indicate a higher quality of the therapeutic alliance as perceived by the participant and therapist.", [["participant", "SPECIES", 94, 105], ["Higher total scores", "PROBLEM", 0, 19]]], ["The WAI-SF is a reliable and valid assessment tool.", [["The WAI", "TEST", 0, 7], ["valid assessment tool", "TEST", 29, 50]]], ["56 Other measures Background characteristics (ie, gender, age and educational level, kinship to the deceased and time since loss) and accident-related stressors (ie, single vs multiple loss, witnessed the accident and status of legal trial) will be assessed with single items.MeasuresParticipants are allowed to receive other forms of psychosocial, instrumental or legal support during participation in the trial.", [["accident", "DISEASE", 134, 142], ["multiple loss", "PROBLEM", 176, 189], ["legal support", "TREATMENT", 365, 378]]], ["Using a single question, we will assess whether the participants received other forms of psychosocial professional support.", [["participants", "SPECIES", 52, 64], ["psychosocial professional support", "TREATMENT", 89, 122]]], ["We will also include two dichotomous items (yes/no) at T1 to assess psychological support received prior to participation in the study, namely: 'Did you ever receive support from a psychologist, therapist or psychiatrist, for your own emotional/mental problems, prior to the loss of your loved one due to a traffic accident?' and 'Did you ever receive support from a psychologist, therapist or psychiatrist, for your own emotional/ mental problems, related to the loss of your loved one due to a traffic accident?'Statistical analysesTo examine the differences in reductions of symptom levels of PCBD, PTSD and depression from pretreatment to post-treatment/waiting period between the conditions (online CBT vs waitlist), three independent multilevel models will be built (hypothesis 1).", [["PCBD", "DISEASE", 596, 600], ["PTSD", "DISEASE", 602, 606], ["depression", "DISEASE", 611, 621], ["psychological support", "TREATMENT", 68, 89], ["the study", "TEST", 125, 134], ["your own emotional/mental problems", "PROBLEM", 226, 260], ["your own emotional/ mental problems", "PROBLEM", 412, 447], ["Statistical analyses", "TEST", 514, 534], ["symptom levels", "TEST", 578, 592], ["PCBD", "TREATMENT", 596, 600], ["PTSD", "PROBLEM", 602, 606], ["depression", "PROBLEM", 611, 621], ["pretreatment", "TREATMENT", 627, 639], ["treatment", "TREATMENT", 648, 657]]], ["Symptom levels of PCBD, PTSD, and depression will consecutively be included as dependent variables and condition (online CBT vs waitlist controls), time and time \u00d7 condition (interaction term) as predictor variables, taking into account that repeated observations (level 1) are nested within individuals (level 2), and within households (level 3; if applicable).", [["PTSD", "DISEASE", 24, 28], ["depression", "DISEASE", 34, 44], ["Symptom levels", "TEST", 0, 14], ["PCBD", "PROBLEM", 18, 22], ["PTSD", "PROBLEM", 24, 28], ["depression", "PROBLEM", 34, 44]]], ["Additionally, relevant background, lossrelated variables and use of cointerventions (yes/no) during participation in our study will be included in the analysis as covariates.", [["cointerventions", "TREATMENT", 68, 83], ["our study", "TEST", 117, 126], ["the analysis", "TEST", 147, 159]]], ["Deviance tests will be used to examine whether inclusion of these covariates improves model fit.", [["Deviance tests", "TEST", 0, 14]]], ["57 Data of all participants entering the study will be included in all analyses (ie, intention-to-treat analysis).", [["participants", "SPECIES", 15, 27], ["the study", "TEST", 37, 46]]], ["Furthermore, percentages of people meeting diagnostic criteria for PCBD, PTSD and clinically relevant depression will be calculated for each measurement occasion and percentages of people reporting reliable change scores for each outcome measure, using a formula from Jacobson and Truax, 58 p 14 will be reported.Statistical analysesTo examine to what extent symptom improvement after treatment is related to improvement in possible correlates of change, residual gain scores will be calculated for all outcome measures (ie, PCBD, PTSD and depression) and possible correlates of change (ie, negative cognitions, avoidance behaviours, state anger, a sense of unrealness and self-efficacy).", [["PCBD", "DISEASE", 67, 71], ["PTSD", "DISEASE", 73, 77], ["depression", "DISEASE", 102, 112], ["PTSD", "DISEASE", 531, 535], ["depression", "DISEASE", 540, 550], ["people", "ORGANISM", 28, 34], ["people", "ORGANISM", 181, 187], ["people", "SPECIES", 28, 34], ["people", "SPECIES", 181, 187], ["diagnostic criteria", "TEST", 43, 62], ["PCBD", "TREATMENT", 67, 71], ["PTSD", "PROBLEM", 73, 77], ["clinically relevant depression", "PROBLEM", 82, 112], ["Statistical analyses", "TEST", 313, 333], ["treatment", "TREATMENT", 385, 394], ["residual gain scores", "PROBLEM", 455, 475], ["all outcome measures", "TREATMENT", 499, 519], ["PTSD", "PROBLEM", 531, 535], ["depression", "PROBLEM", 540, 550]]], ["Following previous research 59 , residual gain scores will be calculated by subtracting the standardised combined pretreatment scores of both conditions (T1 data from immediate treatment condition and T1b data from waitlist condition) multiplied by the correlation coefficient between standardised combined pretreatment scores and standardised post-treatment (or follow-up) scores from standardised post-treatment (or follow-up) scores.", [["residual gain scores", "PROBLEM", 33, 53], ["immediate treatment condition", "TREATMENT", 167, 196], ["T1b data", "TEST", 201, 209]]], ["To test hypothesis 2a, multiple regression analyses will be conducted to examine the associations between residual gain scores of PCBD, PTSD or depression and residual gain scores of negative cognitions, avoidance behaviours, state anger, a sense of unrealness and self-efficacy.Statistical analysesTo achieve research aim 2b, multiple regression analyses will be used to examine to what extent residual gain scores of PCBD, PTSD and depression varies as function of a) background characteristics, including gender (male/female), age (in years) and educational level (low/ high), kinship to the deceased (child/spouse vs other) and time since loss (in years) and b) accident-related stressors, including number of losses (single vs multiple), witnessing the accident (yes/no) and status of legal trial (not applicable/ongoing/completed).", [["PCBD", "DISEASE", 130, 134], ["PTSD", "DISEASE", 136, 140], ["depression", "DISEASE", 144, 154], ["PCBD", "DISEASE", 419, 423], ["PTSD", "DISEASE", 425, 429], ["depression", "DISEASE", 434, 444], ["accident", "DISEASE", 666, 674], ["multiple regression analyses", "TEST", 23, 51], ["residual gain scores of PCBD", "PROBLEM", 106, 134], ["PTSD", "PROBLEM", 136, 140], ["depression", "PROBLEM", 144, 154], ["residual gain scores of negative cognitions", "PROBLEM", 159, 202], ["Statistical analyses", "TEST", 279, 299], ["multiple regression analyses", "TEST", 327, 355], ["residual gain scores of PCBD", "PROBLEM", 395, 423], ["PTSD", "PROBLEM", 425, 429], ["depression", "PROBLEM", 434, 444]]], ["Condition (intervention vs waitlist controls) will be added as a covariate to fulfil research aims 2a and 2b.Statistical analysesTo achieve the third research aim: (1) differences in therapeutic alliance scores will be assessed between people who completed and dropped out of treatment and (2) multiple regression analyses will be used to examine to what extent symptom improvement in PCBD, PTSD and depression is related to therapeutic alliance (from both participant and therapist perspectives).Ethics and disseminationThe initial plan for this study was to conduct a three-arm (face-to-face CBT, online CBT and waiting list) RCT to examine the effectiveness of face-to-face CBT (vs waitlist controls) and online CBT (vs waitlist controls).", [["PCBD", "DISEASE", 385, 389], ["PTSD", "DISEASE", 391, 395], ["depression", "DISEASE", 400, 410], ["people", "ORGANISM", 236, 242], ["people", "SPECIES", 236, 242], ["waitlist controls)", "TREATMENT", 27, 45], ["Statistical analyses", "TEST", 109, 129], ["treatment", "TREATMENT", 276, 285], ["multiple regression analyses", "TEST", 294, 322], ["PTSD", "PROBLEM", 391, 395], ["depression", "PROBLEM", 400, 410], ["this study", "TEST", 542, 552], ["online CBT", "TEST", 599, 609], ["RCT", "TEST", 628, 631], ["face", "TEST", 664, 668], ["CBT", "TEST", 677, 680], ["online CBT", "TEST", 708, 718]]], ["This study has been approved by the Medical Ethics Review Board of the University Medical Center Groningen (METc UMCG: ID number: M20.252121).", [["This study", "TEST", 0, 10]]], ["Due to the COVID-19 outbreak, we had to change our study protocol, because face-to-face contact with a therapist was not possible because of social distancing measures.", [["the COVID", "TEST", 7, 16], ["our study protocol", "TEST", 47, 65], ["social distancing measures", "TREATMENT", 141, 167]]], ["Instead of comparing the effects of online and face-to-face CBT with waitlist controls, we changed the design of the study by comparing the effects of online CBT versus waitlist controls before enrolment of participants took place.", [["participants", "SPECIES", 207, 219], ["waitlist controls", "TREATMENT", 69, 86], ["the study", "TEST", 113, 122], ["online CBT", "TREATMENT", 151, 161], ["waitlist controls", "TREATMENT", 169, 186]]], ["This amendment to our study has been approved by the same ethics committee.Ethics and disseminationThe study will be conducted according to the principles of the Declaration of Helsinki (eighth version, 2013) and in accordance with the Medical Research Involving Human Subjects Act.", [["Human", "ORGANISM", 263, 268], ["Human", "SPECIES", 263, 268], ["our study", "TEST", 18, 27], ["The study", "TEST", 99, 108]]], ["Unidentifiable data from this trial will be stored in data repositories from the University of Groningen and Utrecht University.Ethics and disseminationFindings of this RCT will be disseminated among participants by means of a newsletter.", [["participants", "SPECIES", 200, 212], ["this RCT", "PROBLEM", 164, 172]]], ["If shown to be effective, the online framework will be made publicly accessible, so that it can benefit other bereaved people.", [["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125]]], ["Findings will also be disseminated among lay people by uploading the newsletters on our website ( www. rouw nave rkee rson geval. nl) and through media performances.", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["Our findings will be presented to our collaborators, including nongovernmental organisations and (peer-)support organisations for bereaved people.", [["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145]]], ["Treatment materials will also be made available on request.", [["Treatment materials", "TREATMENT", 0, 19]]], ["Lastly, colleagues will be informed about our findings during presentations at (inter)national conferences and publications in scientific journals.Patient and public involvementAt the start of this project an advisory committee was established.", [["Patient", "SPECIES", 147, 154]]], ["This committee includes someone who lost a significant other after a traffic accident, a lawyer with expertise in supporting bereaved people after traffic accidents, and representatives of Victim Support the Netherlands and Fund Victim Support.", [["traffic accidents", "DISEASE", 147, 164], ["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140]]], ["This committee was involved in the development of the research questions, outcomes measures and design of the study by reading and commenting on drafts of our research proposal and study protocol.", [["the study", "TEST", 106, 115], ["study protocol", "TEST", 181, 195]]], ["This committee pilot tested the questionnaires and was involved in the development of recruitment materials, recruitment strategies, and information materials for participants by reading, revising and approving the drafts.", [["participants", "SPECIES", 163, 175], ["recruitment materials", "TREATMENT", 86, 107], ["recruitment strategies", "TREATMENT", 109, 131], ["recruitment materials", "OBSERVATION", 86, 107]]], ["This committee helps the research team in recruiting participants by sharing information about this study in their own professional network.", [["professional network", "MULTI-TISSUE_STRUCTURE", 119, 139], ["participants", "SPECIES", 53, 65], ["this study", "TEST", 95, 105]]], ["The advisory committee is not involved in conducting the study or development of treatment materials.", [["the study", "TEST", 53, 62], ["treatment materials", "TREATMENT", 81, 100]]], ["The committee will support the research team when disseminating the study findings among relevant audiences by help writing and reviewing newsletters and press releases.DISCUSSIONThe relatively few RCTs among general bereaved people with elevated grief levels indicate that grief-specific CBTbased interventions yield the largest effects on postloss mental health compared with a waiting list.", [["elevated grief", "DISEASE", 238, 252], ["grief", "DISEASE", 274, 279], ["people", "ORGANISM", 226, 232], ["people", "SPECIES", 226, 232], ["the study", "TEST", 64, 73], ["elevated grief levels", "PROBLEM", 238, 259], ["grief", "PROBLEM", 274, 279], ["specific CBTbased interventions", "TREATMENT", 280, 311], ["few", "OBSERVATION_MODIFIER", 194, 197], ["largest", "OBSERVATION_MODIFIER", 322, 329]]], ["[21] [22] [23] [24] RCTs evaluating face-to-face or online treatment effects for people with elevated mental health complaints after confrontation with sudden/violent losses are lacking, with the exception of two studies that compared face-to-face EMDR plus CBT against waitlist controls.", [["elevated mental health complaints", "DISEASE", 93, 126], ["[21] [22] [23] [24]", "SIMPLE_CHEMICAL", 0, 19], ["people", "ORGANISM", 81, 87], ["people", "SPECIES", 81, 87], ["RCTs evaluating face", "TEST", 20, 40], ["online treatment effects", "TREATMENT", 52, 76], ["elevated mental health complaints", "PROBLEM", 93, 126], ["sudden/violent losses", "PROBLEM", 152, 173], ["two studies", "TEST", 209, 220], ["CBT", "TREATMENT", 258, 261], ["face", "ANATOMY", 44, 48]]], ["40 59 Given that traumatically bereaved people are at risk for PCBD and comorbid PTSD and depression, 8 it seems particularly relevant to develop evidence-based interventions for this population.DISCUSSIONThis will be the first RCT to examine the effectiveness of online CBT in a sample exclusively comprised of people who experienced a traumatic death.", [["PCBD", "DISEASE", 63, 67], ["PTSD", "DISEASE", 81, 85], ["depression", "DISEASE", 90, 100], ["traumatic death", "DISEASE", 337, 352], ["people", "ORGANISM", 40, 46], ["people", "ORGANISM", 312, 318], ["people", "SPECIES", 40, 46], ["people", "SPECIES", 312, 318], ["PCBD", "PROBLEM", 63, 67], ["comorbid PTSD", "PROBLEM", 72, 85], ["depression", "PROBLEM", 90, 100], ["based interventions", "TREATMENT", 155, 174], ["this population", "PROBLEM", 179, 194], ["online CBT", "TREATMENT", 264, 274], ["a traumatic death", "PROBLEM", 335, 352]]], ["We are not able to test whether the online CBT has equal effects as face-toface CBT.", [["the online CBT", "TEST", 32, 46], ["face", "TEST", 68, 72], ["CBT", "TEST", 80, 83]]], ["Nonetheless, the findings are expected to yield important insights in the effects of online CBT.", [["online CBT", "TREATMENT", 85, 95]]], ["In this RCT, the online treatment is designed to be as similar as possible to face-face CBT in terms of treatment content, treatment duration, and experience and training of therapists.", [["the online treatment", "TREATMENT", 13, 33], ["treatment content", "TREATMENT", 104, 121]]], ["When we find effect sizes for online CBT that are similar to effect sizes found in earlier studies for face-toface CBT, delivering CBT online can be considered as supplement to face-to-face treatment, in particular when barriers to face-to-face treatments, such as waiting lists and travel expenses, are experienced.DISCUSSIONWe will also examine potential correlates of change.", [["online CBT", "TEST", 30, 40], ["earlier studies", "TEST", 83, 98], ["face-toface CBT", "TREATMENT", 103, 118], ["CBT online", "TREATMENT", 131, 141], ["face treatment", "TREATMENT", 185, 199], ["face treatments", "TREATMENT", 240, 255]]], ["These analyses, examining the associations between reductions in symptoms levels and among others negative cognitions and avoidance behaviours, will provide insights in potential underlying therapeutic processes to foster recovery from traumatic loss.", [["traumatic loss", "DISEASE", 236, 250], ["These analyses", "TEST", 0, 14], ["symptoms levels", "PROBLEM", 65, 80], ["traumatic loss", "PROBLEM", 236, 250], ["traumatic loss", "OBSERVATION", 236, 250]]], ["These insights are deemed important to design treatments that more effectively target these correlates of change.", [["design treatments", "TREATMENT", 39, 56]]], ["We also expect to improve our knowledge on for whom (eg, women or people who are more remotely bereaved) grief-specific CBT works best.", [["women", "ORGANISM", 57, 62], ["people", "ORGANISM", 66, 72], ["women", "SPECIES", 57, 62], ["people", "SPECIES", 66, 72]]], ["Findings on these potential correlates of change are necessary to improve treatments given that a maximum of 42% of bereaved people report clinically relevant reductions in grief levels after treatment.", [["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["treatments", "TREATMENT", 74, 84], ["grief levels", "TEST", 173, 185], ["treatment", "TREATMENT", 192, 201], ["reductions", "OBSERVATION_MODIFIER", 159, 169]]], ["21 Lastly, the role of therapeutic alliance on therapy outcomes will be explored.", [["therapy outcomes", "TREATMENT", 47, 63]]], ["Prior research in bereaved people has shown that greater therapeutic alliance, from the perspective of the client, at week 4 of a face-to-face grief-specific treatment, was related to greater reductions in grief levels.", [["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["specific treatment", "TREATMENT", 149, 167], ["greater reductions in grief levels", "PROBLEM", 184, 218], ["greater", "OBSERVATION_MODIFIER", 49, 56]]], ["This therapeutic alliance-grief relationship was not significant for a non-grief-specific treatment.", [["specific treatment", "TREATMENT", 81, 99]]], ["60 Our exploration of this association, from the perspective of client and therapist, may for the first time shed light on therapeutic processes in online CBT for traumatic grief.DISCUSSIONAn anticipated limitation of our RCT is the selfselected sample.", [["traumatic grief", "DISEASE", 163, 178], ["Our exploration", "TEST", 3, 18], ["online CBT", "TREATMENT", 148, 158], ["traumatic grief", "PROBLEM", 163, 178]]], ["It is possible that people who are more open towards innovative technology in general 61 and who received support prior to the loss 32 are more likely to sign up for this study, limiting the generalisability of findings emerging from this study.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["support", "TREATMENT", 106, 113], ["this study", "TEST", 166, 176], ["this study", "TEST", 234, 244]]], ["Due to the absence of an active control group (eg, face-to-face CBT), we are not able to test the effects of online CBT compared with an alternative treatment.", [["face", "TEST", 51, 55], ["online CBT", "TREATMENT", 109, 119], ["an alternative treatment", "TREATMENT", 134, 158], ["active", "OBSERVATION_MODIFIER", 25, 31]]], ["Furthermore, we will use selfreport measures instead of diagnostic interviews, which may increase the risk of overestimating symptom levels.", [["selfreport measures", "TREATMENT", 25, 44], ["overestimating symptom levels", "PROBLEM", 110, 139]]], ["62 In addition, participants might experience difficulties with completing the mid-treatment assessment of the therapeutic relationship because the video therapist that provides information through recorded video messages (interaction between video therapist and participant is not possible) might be a different person than the online Open access therapist who provides personal written feedback twice a week.", [["participants", "SPECIES", 16, 28], ["person", "SPECIES", 313, 319], ["the mid-treatment assessment", "TEST", 75, 103]]], ["Although the instructions of the therapeutic alliance measure explicitly refer to the interaction with the online therapist (not the video therapist), this might still be confusing for some participants.", [["participants", "SPECIES", 190, 202]]], ["Another potential limitation of this trial relates to the fact that the operationalisation and assessment of grief as a disorder is still under debate.", [["grief", "DISEASE", 109, 114], ["disorder", "DISEASE", 120, 128], ["the operationalisation", "TEST", 68, 90], ["assessment", "TEST", 95, 105], ["grief", "PROBLEM", 109, 114], ["a disorder", "PROBLEM", 118, 128]]], ["[63] [64] [65] For instance, PCBD, included as 'condition for further study' in the DSM-5, is likely to be changed in a revision of the DSM.", [["PCBD", "CHEMICAL", 29, 33], ["PCBD", "SIMPLE_CHEMICAL", 29, 33], ["further study", "TEST", 62, 75], ["a revision", "TREATMENT", 118, 128], ["the DSM", "PROBLEM", 132, 139], ["revision", "OBSERVATION", 120, 128]]], ["To maximise diagnostic compatibility, we added four items to the TGI-SR, corresponding to Prolonged Grief Disorder (PGD) criteria according to the 11th edition of the International Classification of Diseases (ICD-11), enabling operationalision of our primary outcome measure in terms of diagnoses of pathological grief according to both the DSM-5 and the ICD-11.DISCUSSIONTo conclude, this RCT will provide new insights in effectiveness of online CBT for people who experience clinically relevant distress after bereavement due to a traffic accident, as well as in potential correlates of therapeutic change.", [["Grief Disorder", "DISEASE", 100, 114], ["grief", "DISEASE", 313, 318], ["people", "ORGANISM", 455, 461], ["people", "SPECIES", 455, 461], ["the TGI", "TEST", 61, 68], ["Prolonged Grief Disorder", "PROBLEM", 90, 114], ["Diseases (ICD", "TREATMENT", 199, 212], ["pathological grief", "PROBLEM", 300, 318], ["the DSM", "TEST", 337, 344], ["the ICD", "TREATMENT", 351, 358], ["online CBT", "TREATMENT", 440, 450], ["clinically relevant distress", "PROBLEM", 477, 505], ["therapeutic change", "PROBLEM", 589, 607], ["therapeutic", "OBSERVATION", 589, 600]]], ["As trials to date have primarily focused on effects of face-to-face treatment for non-traumatically bereaved people, our findings are expected to provide a valuable addition to the knowledge base on treating severely distressed bereaved people.DISCUSSIONContributors JdK is principal investigator.", [["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115], ["severely distressed", "PROBLEM", 208, 227]]], ["LL is executive researcher.", [["executive", "OBSERVATION", 6, 15]]], ["JdK, PB, ME and GS are grant holders.", [["JdK", "TEST", 0, 3], ["PB", "ANATOMY", 5, 7]]], ["LL developed the study design and wrote the ethics proposal and drafts of the manuscript.", [["the study", "TEST", 13, 22]]], ["JdK, ME, GS and PB read, revised, and approved the drafts of the study design, ethics proposal and the manuscript.DISCUSSIONFunding Fund Victim Support subsidized this work (grant number: not applicable).DISCUSSIONCompeting interests None declared.DISCUSSIONPatient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research.", [["Patients", "ORGANISM", 289, 297], ["Patients", "SPECIES", 289, 297], ["the study", "TEST", 61, 70]]], ["See: https:// creativecommons. org/ licenses/ by/ 4.", [["https", "GENE_OR_GENE_PRODUCT", 5, 10]]], ["0/.ORCID iDLonneke Lenferink http:// orcid. org/ 0000-0003-1329-6413", [["org/ 0000-0003-1329-6413", "CHEMICAL", 44, 68], ["org/ 0000-0003-1329-6413", "SPECIES", 44, 68]]]], "f2151c1879dea6a717c035408fdc94f433aba545": [["I t is inspiring to see how quickly the scientific community has mobilized to address a new threat to human health.", [["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107]]], ["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the COVID-19 virus) contains a spike protein that mediates entry into the host's cells by binding a cell surface receptor there called angiotensin converting enzyme 2 (ACE2).", [["cells", "ANATOMY", 142, 147], ["cell surface", "ANATOMY", 161, 173], ["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["angiotensin", "CHEMICAL", 196, 207], ["SARS-CoV-2", "ORGANISM", 49, 59], ["COVID-19 virus", "ORGANISM", 65, 79], ["cells", "CELL", 142, 147], ["cell", "CELL", 161, 165], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 196, 227], ["ACE2", "GENE_OR_GENE_PRODUCT", 229, 233], ["spike protein", "PROTEIN", 92, 105], ["host's cells", "CELL_TYPE", 135, 147], ["cell surface receptor", "PROTEIN", 161, 182], ["angiotensin converting enzyme 2", "PROTEIN", 196, 227], ["ACE2", "PROTEIN", 229, 233], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV-2", "SPECIES", 49, 59], ["COVID-19 virus", "SPECIES", 65, 79], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["the COVID", "TEST", 61, 70], ["a spike protein", "PROBLEM", 90, 105], ["a cell surface receptor", "TREATMENT", 159, 182], ["angiotensin converting enzyme", "TREATMENT", 196, 225], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33]]], ["1 This Viewpoint focuses on factors that influence the SARS-CoV-2spike protein\u00b7ACE2 protein\u2212protein interaction and how it may be targeted for therapeutic gain.", [["SARS", "DISEASE", 55, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["SARS-CoV-2spike protein", "PROTEIN", 55, 78], ["ACE2", "PROTEIN", 79, 83], ["the SARS", "TEST", 51, 59], ["CoV", "TEST", 60, 63], ["ACE2 protein\u2212protein interaction", "PROBLEM", 79, 111]]]], "409d48061931f0551fb8890d6a0553202c3e309b": [["IntroductionOne need look no farther than a recent paper in the journal Molecular and Cellular Proteomics to understand the importance of mass spectrometry in everyday life.", [["mass spectrometry", "PROBLEM", 138, 155]]], ["A multidisciplinary group of scientists from Manitoba used the combination of matrix-assisted laser desorption ionization (MALDI) and a quadrupole/time-of-flight mass spectrometer to identify two novel proteins associated with the virus believed to be responsible for severe acute respiratory syndrome (SARS) [1] .", [["acute respiratory syndrome", "DISEASE", 275, 301], ["SARS", "DISEASE", 303, 307], ["matrix-assisted laser desorption ionization", "TREATMENT", 78, 121], ["two novel proteins", "PROBLEM", 192, 210], ["the virus", "PROBLEM", 227, 236], ["severe acute respiratory syndrome", "PROBLEM", 268, 301], ["responsible for", "UNCERTAINTY", 252, 267], ["severe", "OBSERVATION_MODIFIER", 268, 274], ["acute", "OBSERVATION_MODIFIER", 275, 280], ["respiratory syndrome", "OBSERVATION", 281, 301]]], ["At that time the SARS outbreak had spread from China to Hong Kong, Vietnam, Canada, the USA, and several other countries leading to increasing worldwide concern of a pandemic.", [["SARS", "DISEASE", 17, 21], ["the SARS outbreak", "PROBLEM", 13, 30], ["a pandemic", "PROBLEM", 164, 174], ["pandemic", "OBSERVATION", 166, 174]]], ["The unique attributes of mass spectrometry, especially using hybrid instrumentation, allowed rapid identification and characterization of possible immunogens that may be useful for early diagnosis or prophylaxis of SARS.IntroductionThe Manitoba group made use of a hybrid tandem mass spectrometer in which the final quadrupole of a triple quadrupole (QqQ) instrument was replaced with a time-offlight (ToF) mass spectrometer [1] .", [["SARS", "DISEASE", 215, 219], ["mass spectrometry", "PROBLEM", 25, 42], ["hybrid instrumentation", "TREATMENT", 61, 83], ["rapid identification", "TEST", 93, 113], ["immunogens", "TREATMENT", 147, 157], ["prophylaxis", "TREATMENT", 200, 211], ["SARS", "PROBLEM", 215, 219], ["a hybrid tandem mass spectrometer", "TREATMENT", 263, 296], ["a triple quadrupole (QqQ) instrument", "TREATMENT", 330, 366], ["a time-offlight (ToF) mass spectrometer", "TREATMENT", 385, 424], ["mass spectrometry", "OBSERVATION", 25, 42]]], ["Although these QqToF instruments have been commercially available for less than 10 years, they are widespread because of their full scan sensitivity, good mass spectral resolution and mass accu-racy, and their capability to perform MS and product ion MS/MS analyses.", [["their full scan sensitivity", "TEST", 121, 148], ["mass accu-racy", "PROBLEM", 184, 198], ["MS", "TEST", 232, 234], ["MS/MS analyses", "TEST", 251, 265], ["mass", "OBSERVATION", 184, 188]]], ["This kind of \"hybridization\" in mass spectrometry is now driving new instrument development because it allows the addition (or replacement) of sections of conventional tandem mass spectrometers with devices that provide different or superior performance characteristics.", [["sections", "ANATOMY", 143, 151], ["\"hybridization\"", "PROBLEM", 13, 28], ["mass spectrometry", "PROBLEM", 32, 49], ["replacement", "TREATMENT", 127, 138], ["conventional tandem mass spectrometers", "TREATMENT", 155, 193], ["devices", "TREATMENT", 199, 206], ["mass", "OBSERVATION", 32, 36]]], ["Novel mass spectrometers have been reported recently, but this is relatively rare.", [["Novel mass spectrometers", "PROBLEM", 0, 24], ["mass", "OBSERVATION", 6, 10]]], ["Much of the commercial instrument development of \"new\" instrumentation takes the form of this hybridization approach.IntroductionThis review will examine the published developments in mass analyzers over the past three years with an emphasis on hybrid instrumentation and some of the novel analyzer developments.", [["\"new\" instrumentation", "TREATMENT", 49, 70], ["this hybridization approach", "TREATMENT", 89, 116], ["mass analyzers", "PROBLEM", 184, 198], ["hybrid instrumentation", "TREATMENT", 245, 267], ["new", "OBSERVATION_MODIFIER", 50, 53], ["instrumentation", "OBSERVATION", 55, 70], ["mass", "OBSERVATION", 184, 188]]], ["Of particular interest is the motivation for combining certain mass analyzers, or mass-filtering devices, in tandem and the performance advantages of these combinations.", [["combining certain mass analyzers", "PROBLEM", 45, 77], ["mass", "PROBLEM", 82, 86], ["filtering devices", "TREATMENT", 87, 104], ["these combinations", "TREATMENT", 150, 168], ["mass", "OBSERVATION", 82, 86], ["filtering devices", "OBSERVATION", 87, 104]]], ["Quadrupoles, ion traps, and ToF sections all provide unique capabilities for mass analysis and ion processing that is proving to be useful for answering specific analytical challenges.", [["Quadrupoles", "SIMPLE_CHEMICAL", 0, 11], ["ion traps", "TREATMENT", 13, 22], ["ToF sections", "TEST", 28, 40], ["mass analysis", "TEST", 77, 90]]], ["Several of the more common mass analyzers are illustrated in Fig. 1 .", [["the more common mass analyzers", "PROBLEM", 11, 41], ["more", "OBSERVATION_MODIFIER", 15, 19], ["common", "OBSERVATION_MODIFIER", 20, 26], ["mass", "OBSERVATION", 27, 31], ["Fig", "OBSERVATION_MODIFIER", 61, 64]]], ["The context of the review is tandem, or multiple stage, mass analysis since this approach is of the greatest importance for analyses of complex samples.IntroductionArguably the most important characteristic of a tandem instrument is the nature of the final mass spectrometer, since it usually provides the analytical mass spectrum.", [["samples", "ANATOMY", 144, 151], ["samples", "CANCER", 144, 151], ["multiple stage, mass analysis", "PROBLEM", 40, 69], ["this approach", "TREATMENT", 76, 89], ["complex samples", "TEST", 136, 151], ["a tandem instrument", "TREATMENT", 210, 229], ["the final mass spectrometer", "PROBLEM", 247, 274], ["mass", "OBSERVATION", 56, 60], ["final", "OBSERVATION_MODIFIER", 251, 256], ["mass", "OBSERVATION", 257, 261], ["mass", "OBSERVATION", 317, 321]]], ["Figures of merit such as mass spectral resolution, mass assignment accuracy, and speed of data acquisition all play key roles in the quality of the final mass spectrum.", [["mass spectral resolution", "PROBLEM", 25, 49], ["accuracy", "TEST", 67, 75], ["data acquisition", "TEST", 90, 106], ["resolution", "OBSERVATION_MODIFIER", 39, 49], ["mass", "OBSERVATION", 51, 55], ["mass", "OBSERVATION", 154, 158]]], ["Some mass spectrometers are well suited for recording high-quality mass spectra but are not as useful for precursor ion isolation and fragmentation.", [["Some mass spectrometers", "PROBLEM", 0, 23], ["recording high-quality mass spectra", "PROBLEM", 44, 79], ["precursor ion isolation", "PROBLEM", 106, 129], ["fragmentation", "PROBLEM", 134, 147], ["mass", "OBSERVATION", 5, 9]]], ["The trend in many modern mass spectrometer research programs is toward moving some of these \"ion processing\" steps away from the final mass analyzer, often with significant performance enhancements.Tandem mass spectrometryTandem mass spectrometry or MS/MS involves two stages of mass analysis separated by a reaction, or fragmenta-James W. Hager tion, step [2] .", [["many modern mass spectrometer research programs", "TREATMENT", 13, 60], ["the final mass analyzer", "TEST", 125, 148], ["Tandem mass spectrometry", "PROBLEM", 198, 222], ["Tandem mass spectrometry", "PROBLEM", 222, 246], ["MS", "PROBLEM", 250, 252], ["MS", "PROBLEM", 253, 255], ["mass analysis", "PROBLEM", 279, 292], ["a reaction", "PROBLEM", 306, 316], ["trend", "OBSERVATION_MODIFIER", 4, 9], ["mass", "OBSERVATION", 25, 29], ["mass", "OBSERVATION", 135, 139], ["mass", "OBSERVATION", 205, 209], ["mass", "OBSERVATION", 279, 283]]], ["The most important advantage of MS/MS is the reduction of \"chemical noise\" due to the high specificity of the instrument [2] .", [["MS/MS", "PROBLEM", 32, 37], ["\"chemical noise", "PROBLEM", 58, 73]]], ["For an ion to be detected the precursor ion must be stable in the first stage of mass analysis and a fragment ion must be stable in the second stage.", [["mass analysis", "PROBLEM", 81, 94], ["a fragment ion", "PROBLEM", 99, 113], ["stable", "OBSERVATION_MODIFIER", 52, 58], ["mass", "OBSERVATION", 81, 85], ["stable", "OBSERVATION_MODIFIER", 122, 128]]], ["High specificity can be achieved since most of the ions in even complex mixtures do not satisfy this criterion.Tandem mass spectrometryThere are two fundamentally different approaches to MS/MS [2] : tandem-in-space and tandem-in-time.", [["Tandem mass spectrometry", "PROBLEM", 111, 135], ["MS/MS", "TEST", 187, 192], ["tandem", "TEST", 199, 205], ["mass", "OBSERVATION", 118, 122]]], ["Tandemin-space instruments have two independent mass spectrometers in physically different locations in the instrument.", [["Tandemin-space instruments", "TREATMENT", 0, 26], ["two independent mass spectrometers", "PROBLEM", 32, 66], ["space instruments", "OBSERVATION", 9, 26], ["two", "OBSERVATION_MODIFIER", 32, 35], ["independent", "OBSERVATION_MODIFIER", 36, 47], ["mass spectrometers", "OBSERVATION", 48, 66], ["physically", "OBSERVATION_MODIFIER", 70, 80], ["different", "OBSERVATION_MODIFIER", 81, 90], ["locations", "OBSERVATION_MODIFIER", 91, 100], ["instrument", "OBSERVATION", 108, 118]]], ["Examples of these instruments include, but are not limited to, triple quadrupole (QqQ) and quadrupole/ timeof-flight (QqToF) instruments.", [["quadrupole/ timeof-flight (QqToF) instruments", "TREATMENT", 91, 136]]], ["The most common MS/MS mode of operation is the product ion scan in which the first quadrupole selects a precursor ion.", [["operation", "TREATMENT", 30, 39], ["the product ion scan", "TEST", 43, 63]]], ["The precursor ion is then subjected to collision-activated dissociation in a collision cell, and a mass spectrum of the resulting fragment ions is captured with the final mass spectrometer.", [["cell", "ANATOMY", 87, 91], ["cell", "CELL", 87, 91], ["activated dissociation", "PROBLEM", 49, 71], ["a collision cell", "PROBLEM", 75, 91], ["a mass spectrum", "PROBLEM", 97, 112], ["the resulting fragment ions", "PROBLEM", 116, 143], ["dissociation", "OBSERVATION_MODIFIER", 59, 71], ["collision cell", "OBSERVATION", 77, 91], ["mass", "OBSERVATION", 99, 103], ["resulting", "OBSERVATION_MODIFIER", 120, 129], ["fragment ions", "OBSERVATION", 130, 143], ["final", "OBSERVATION_MODIFIER", 165, 170], ["mass", "OBSERVATION", 171, 175]]], ["Although the collision cell can be an RF-only quadrupole, hexapole, octapole, or ring guide, these instruments will be referred to as QqQ devices.", [["cell", "ANATOMY", 23, 27], ["hexapole", "CHEMICAL", 58, 66], ["cell", "CELL", 23, 27], ["hexapole", "SIMPLE_CHEMICAL", 58, 66], ["octapole", "SIMPLE_CHEMICAL", 68, 76], ["collision cell", "OBSERVATION", 13, 27]]], ["A very common mode of operation is multiple reaction monitoring (MRM) in which the two resolving quadrupoles monitor specific precursorto-fragment ion transitions by \"hopping\" between the appropriate m/z values.", [["operation", "TREATMENT", 22, 31], ["multiple reaction monitoring", "TEST", 35, 63], ["MRM", "TEST", 65, 68], ["operation", "OBSERVATION", 22, 31], ["multiple", "OBSERVATION_MODIFIER", 35, 43]]], ["MRM operation maximizes the instrument duty cycle and is often used for quantitation applications.", [["MRM operation", "TREATMENT", 0, 13], ["the instrument duty cycle", "TREATMENT", 24, 49], ["quantitation applications", "TREATMENT", 72, 97]]], ["Other less frequently used, but very selective, MS/MS scans for identification of targeted analytes in complicated matrices are the precursor ion and constant neutral loss scans.", [["MS/MS scans", "TEST", 48, 59], ["targeted analytes", "PROBLEM", 82, 99], ["complicated matrices", "PROBLEM", 103, 123], ["constant neutral loss scans", "PROBLEM", 150, 177]]], ["Here, the first mass analyzer is scanned while the second analyzer is fixed (precursor ion scan) or scanned at a set mass difference from the first (constant neutral loss scan) [3] .", [["the first mass analyzer", "TEST", 6, 29], ["the second analyzer", "TEST", 47, 66], ["precursor ion scan", "TEST", 77, 95], ["a set mass difference", "PROBLEM", 111, 132], ["mass", "OBSERVATION", 117, 121]]], ["These tandem-in-space mass spectrometers have the advantage of independent optimization of each stage of mass analysis.Tandem mass spectrometryTandem-in-time instruments are, in general, ion-trapping mass spectrometers such as two-dimensional or three-dimensional quadrupole ion traps and Fourier transform ion cyclotron (FTICR), more commonly known as Fourier transform mass spectrometers (FTMS).", [["These tandem-in-space mass spectrometers", "TREATMENT", 0, 40], ["mass analysis", "PROBLEM", 105, 118], ["Tandem mass spectrometry", "PROBLEM", 119, 143], ["ion-trapping mass spectrometers", "TREATMENT", 187, 218], ["three-dimensional quadrupole ion traps", "TREATMENT", 246, 284], ["Fourier transform ion cyclotron (FTICR", "TREATMENT", 289, 327], ["tandem", "OBSERVATION_MODIFIER", 6, 12], ["mass", "OBSERVATION", 105, 109], ["mass", "OBSERVATION", 126, 130]]], ["The various stages of mass spectrometry are conducted within the same physical trapping volume but at different times during the experiment.", [["mass spectrometry", "PROBLEM", 22, 39], ["various", "OBSERVATION_MODIFIER", 4, 11], ["stages", "OBSERVATION_MODIFIER", 12, 18], ["mass spectrometry", "OBSERVATION", 22, 39], ["trapping volume", "OBSERVATION", 79, 94]]], ["The approach here allows the ions from the ion source into the trapping volume, isolating the precursor ions of interest by ejecting the unwanted ions, fragmenting the precursor ions, and performing a final mass analysis step.", [["the ions", "TREATMENT", 25, 33], ["the trapping volume", "PROBLEM", 59, 78], ["a final mass analysis", "TEST", 199, 220], ["trapping volume", "OBSERVATION", 63, 78], ["precursor ions", "OBSERVATION", 168, 182], ["mass", "OBSERVATION", 207, 211]]], ["In principle these devices are capable of many, or \"n\", stages of mass spectrometry, leading to the term \"MS n \".", [["mass spectrometry", "PROBLEM", 66, 83], ["devices", "OBSERVATION", 19, 26], ["mass", "OBSERVATION", 66, 70]]], ["Ion trapping instruments are inherently scanning instruments and are, in general, capable of survey MS and product ion MS/MS operation only.", [["Ion trapping instruments", "TREATMENT", 0, 24], ["inherently scanning instruments", "TEST", 29, 60], ["MS operation", "TREATMENT", 122, 134]]], ["However, since they can record a complete mass spectrum of each pulse of ions introduced into the trapping volume, they are very sensitive instruments.QqQ instrumentationUntil recently there have been very few new developments in triple quadrupole instrumentation.", [["each pulse of ions", "TREATMENT", 59, 77], ["QqQ instrumentation", "TREATMENT", 151, 170], ["triple quadrupole instrumentation", "TREATMENT", 230, 263], ["mass", "OBSERVATION", 42, 46], ["trapping volume", "OBSERVATION", 98, 113], ["very", "OBSERVATION_MODIFIER", 201, 205], ["few", "OBSERVATION_MODIFIER", 206, 209], ["new", "OBSERVATION_MODIFIER", 210, 213], ["triple quadrupole instrumentation", "OBSERVATION", 230, 263]]], ["Commercial manufacturers have enhanced instrument sensitivity by opening the atmosphere-to-vacuum apertures with associated in- Fig. 1 Common mass spectrometers creases in the vacuum pumping capacity [4] .", [["Common mass spectrometers creases", "PROBLEM", 135, 168], ["the vacuum pumping capacity", "TREATMENT", 172, 199], ["vacuum apertures", "OBSERVATION", 91, 107], ["Common", "OBSERVATION_MODIFIER", 135, 141], ["mass", "OBSERVATION", 142, 146], ["spectrometers creases", "OBSERVATION", 147, 168], ["vacuum pumping", "OBSERVATION", 176, 190]]], ["The quadrupoles themselves have, however, remained relatively unchanged, although some recent instruments have been equipped with ring guide collision cells.QqQ instrumentationAn exception to this is a higher-resolution QqQ instrument that is capable of peak widths of the order of 0.1 amu (FWHM) and mass assignment accuracies of <10 milliamu [5, 6] .", [["cells", "ANATOMY", 151, 156], ["cells", "CELL", 151, 156], ["ring guide collision cells", "CELL_LINE", 130, 156], ["some recent instruments", "PROBLEM", 82, 105], ["mass assignment accuracies", "TEST", 301, 327], ["relatively", "OBSERVATION_MODIFIER", 51, 61], ["unchanged", "OBSERVATION_MODIFIER", 62, 71], ["collision cells", "OBSERVATION", 141, 156], ["peak widths", "OBSERVATION_MODIFIER", 254, 265]]], ["The enhanced resolution compared to a standard quadrupole, which operates with peak widths of approximately 0.5-0.7 amu (FWHM), has been shown to be yield additional selectivity in precursor ion selection for product ion spectra as well as distinguishing isobaric interferences [5, 6] .", [["peak widths", "TEST", 79, 90], ["product ion spectra", "TREATMENT", 209, 228], ["isobaric interferences", "PROBLEM", 255, 277], ["enhanced", "OBSERVATION_MODIFIER", 4, 12], ["resolution", "OBSERVATION_MODIFIER", 13, 23], ["peak", "OBSERVATION_MODIFIER", 79, 83], ["widths", "OBSERVATION_MODIFIER", 84, 90]]], ["Although good mass accuracy has been reported previously for LC/MS/MS [7] analyses using a conventional triple quadrupole and moderate mass resolution, it is the advent of the narrower peak widths that has spurred interest in the use of triple quadrupole platform for accurate mass measurements.", [["LC/MS/MS", "TEST", 61, 69], ["a conventional triple quadrupole", "TREATMENT", 89, 121], ["moderate mass resolution", "PROBLEM", 126, 150], ["triple quadrupole platform", "TREATMENT", 237, 263], ["accurate mass measurements", "TEST", 268, 294], ["good", "OBSERVATION_MODIFIER", 9, 13], ["mass", "OBSERVATION", 14, 18], ["moderate", "OBSERVATION_MODIFIER", 126, 134], ["mass", "OBSERVATION", 135, 139], ["resolution", "OBSERVATION_MODIFIER", 140, 150], ["narrower", "OBSERVATION_MODIFIER", 176, 184], ["peak widths", "OBSERVATION", 185, 196], ["mass", "OBSERVATION", 277, 281]]], ["The published capabilities [5, 6] suggest that some combination of internal and external mass calibration should allow reasonable mass assignment accuracy with the enhanced resolution triple quadrupole.QqQ instrumentationThe enhanced resolution quadrupole instruments pose some challenges for manufacturers and analysts, since mass stability becomes more crucial with narrow peaks.", [["internal and external mass calibration", "TREATMENT", 67, 105], ["the enhanced resolution triple quadrupole", "TREATMENT", 160, 201], ["QqQ instrumentation", "TREATMENT", 202, 221], ["The enhanced resolution quadrupole instruments", "TREATMENT", 221, 267], ["mass stability", "PROBLEM", 327, 341], ["narrow peaks", "PROBLEM", 368, 380], ["mass", "OBSERVATION", 89, 93], ["enhanced", "OBSERVATION_MODIFIER", 225, 233], ["resolution", "OBSERVATION_MODIFIER", 234, 244], ["quadrupole", "OBSERVATION_MODIFIER", 245, 255], ["narrow", "OBSERVATION_MODIFIER", 368, 374], ["peaks", "OBSERVATION_MODIFIER", 375, 380]]], ["Procedures for maximizing data quality and instrument ruggedness have been published [5] .QqToFThe QqToF instrument can be thought of as replacement of the final resolving mass filter of a triple quadrupole platform with a time-of-flight mass spectrometer.", [["instrument ruggedness", "TEST", 43, 64], ["replacement", "TREATMENT", 137, 148], ["a triple quadrupole platform", "TEST", 187, 215], ["resolving", "OBSERVATION_MODIFIER", 162, 171], ["mass", "OBSERVATION", 172, 176]]], ["By using a ToF for the final stage of mass analysis in a tandem instrument this provides the benefits of high resolution (ca.", [["ToF", "PROTEIN", 11, 14], ["mass analysis", "PROBLEM", 38, 51], ["a tandem instrument", "TREATMENT", 55, 74], ["mass", "OBSERVATION", 38, 42]]], ["5,000-20,000 FWHM), good mass assignment accuracy (<5 ppm), high sensitivity, and the ability to record a complete mass spectrum for each pulse of ions injected into the device [8] .", [["accuracy", "TEST", 41, 49], ["high sensitivity", "PROBLEM", 60, 76], ["each pulse of ions", "TREATMENT", 133, 151], ["the device", "TREATMENT", 166, 176], ["mass", "OBSERVATION", 25, 29], ["mass", "OBSERVATION", 115, 119]]], ["Most commercial QqToF instruments employ an orthogonal geometry for injection of the ions into the ToF section, which decouples the ion velocity in the ion beam from the TOF axis [9] .", [["injection of the ions into the ToF section", "TREATMENT", 68, 110], ["ion velocity", "OBSERVATION", 132, 144]]], ["This gives rise to a low initial velocity along the ToF axis and results in excellent resolution and a nearly linear mass calibration scale.", [["a low initial velocity", "PROBLEM", 19, 41], ["a nearly linear mass calibration scale", "PROBLEM", 101, 139], ["low", "OBSERVATION_MODIFIER", 21, 24], ["velocity", "OBSERVATION_MODIFIER", 33, 41], ["excellent", "OBSERVATION_MODIFIER", 76, 85], ["resolution", "OBSERVATION_MODIFIER", 86, 96], ["linear", "OBSERVATION_MODIFIER", 110, 116], ["mass", "OBSERVATION", 117, 121]]], ["Both of these attributes have contributed to the very good reported mass assignment accuracy (<5 ppm) [10] .QqToFResearchers have gradually increased the FWHM mass resolution of ToF analyzers to m/\u2206m\u224818,000 by using techniques such as multiple passes over the same 0.4-m flight path [11] .", [["QqToFResearchers", "TREATMENT", 108, 124], ["ToF analyzers", "TEST", 178, 191], ["mass", "OBSERVATION", 68, 72]]], ["Lewin et al. have described the use of near-parallel wire grids in accelerators and ion mirrors to improve ion transmission by 2-4 times while maintaining excellent resolution [12] .", [["near-parallel wire grids in accelerators", "TREATMENT", 39, 79]]], ["The instrument described utilizes an additional ion mirror located between the pusher and deflector to send the ions back into the analyzer.", [["an additional ion mirror", "TREATMENT", 34, 58]]], ["This \"W-mode\" of operation (so named for the W-shaped ion flight path in the ToF) results in FWHM resolution of m/\u2206m of >23,000 [12] .QqToFRobinson and coworkers [13] have described the operation of a QqToF instrument with a mass range of m/z 90,000-150,000 for the ToF section and the ability to isolate precursor ions with the resolving quadrupole to approximately m/z 22,000.", [["ToF", "PROTEIN", 77, 80], ["operation", "TREATMENT", 17, 26], ["the W-shaped ion flight path", "TREATMENT", 41, 69], ["m/\u2206m", "TEST", 112, 116], ["the ToF section", "TREATMENT", 262, 277], ["mass", "OBSERVATION", 225, 229]]], ["The achievement of such a large mass range was accomplished largely by reduction of the frequency of the main drive frequency for the Qq section.", [["Qq section", "PROTEIN", 134, 144], ["a large mass range", "PROBLEM", 24, 42], ["the Qq section", "TREATMENT", 130, 144], ["large", "OBSERVATION_MODIFIER", 26, 31], ["mass", "OBSERVATION", 32, 36], ["reduction", "OBSERVATION_MODIFIER", 71, 80], ["main drive", "ANATOMY_MODIFIER", 105, 115]]], ["The instrument was designed with the goal of studying high molecular weight macromolecular complexes [13] .QqToFOne of the disadvantages of the QqToF-type instruments is the inefficient precursor ion operation mode, relative to a triple quadrupole, since this mode does not benefit from simultaneous ToF detection.", [["ToF", "SIMPLE_CHEMICAL", 300, 303], ["ToF", "PROTEIN", 300, 303], ["the QqToF-type instruments", "TREATMENT", 140, 166], ["the inefficient precursor ion operation mode", "TREATMENT", 170, 214], ["a triple quadrupole", "TREATMENT", 228, 247], ["simultaneous ToF detection", "TEST", 287, 313]]], ["To overcome this limitation, trapping and releasing techniques using the collision cell as an accumulation linear ion trap have been used to enhance sensitivity in selected regions of the mass spectrum [14] .", [["cell", "ANATOMY", 83, 87], ["cell", "CELL", 83, 87], ["releasing techniques", "TREATMENT", 42, 62], ["the collision cell", "TREATMENT", 69, 87], ["an accumulation linear ion trap", "TREATMENT", 91, 122], ["mass", "OBSERVATION", 188, 192]]], ["The result is sensitivity gains of 5-15 times in precursor ion scan mode over a limited m/z range [14] .QqToFThe ability to trap ions in the collision cell has also led to a novel type of charge state separation capability in QqToF instruments [15] .", [["collision cell", "ANATOMY", 141, 155], ["cell", "CELL", 151, 155], ["precursor ion scan mode", "TEST", 49, 72], ["a limited m/z range", "TEST", 78, 97]]], ["The idea here is that a population of ions characterized by different charge states can be collisionally cooled to thermal energies via trapping and storing in the collision cell.", [["cell", "ANATOMY", 174, 178], ["cell", "CELL", 174, 178], ["collision cell", "OBSERVATION", 164, 178]]], ["The trapped ions experience different axial DC barriers to exit the collision cell that are proportional to their charge states.", [["DC", "ANATOMY", 44, 46], ["cell", "ANATOMY", 78, 82], ["cell", "CELL", 78, 82], ["different axial DC barriers", "TREATMENT", 28, 55], ["collision cell", "OBSERVATION", 68, 82]]], ["As the magnitude of the repulsive exit DC barrier is reduced, singly charged ions are released toward the ToF section first, followed by doubly charged ions, and so on.", [["DC", "ANATOMY", 39, 41], ["the repulsive exit DC barrier", "TREATMENT", 20, 49], ["the ToF section", "TREATMENT", 102, 117], ["repulsive", "OBSERVATION_MODIFIER", 24, 33]]], ["The result is the ability to identify multiply charged ions from the ion source that previously were completely obscured by singly charged chemical noise ions [15] .Ion trap-ToFA variation of the QqToF instrument [16] is obtained by substituting the Qq section with a quadrupole ion trap (QIT).", [["Ion trap", "TEST", 165, 173], ["a quadrupole ion trap", "TREATMENT", 266, 287]]], ["Ions from the source are accumulated in the QIT and are subjected to further processing, such as precursor ion isolation and fragmentation via resonant excitation.", [["precursor ion isolation", "TREATMENT", 97, 120], ["fragmentation via resonant excitation", "TREATMENT", 125, 162], ["ion isolation", "OBSERVATION", 107, 120], ["resonant excitation", "OBSERVATION", 143, 162]]], ["This introduces the capability to perform precursor ion isolation and multiple stages of mass spectrometry within the QIT prior to ToF mass measurement [16] .", [["precursor ion isolation", "TREATMENT", 42, 65], ["mass spectrometry", "PROBLEM", 89, 106], ["ToF mass measurement", "TEST", 131, 151], ["mass", "OBSERVATION", 89, 93], ["mass", "OBSERVATION", 135, 139]]], ["Early instruments, which were largely based on linear ToF instrumentation, were characterized by relatively low sensitivity and resolution [16] .", [["Early instruments", "PROBLEM", 0, 17], ["linear ToF instrumentation", "TREATMENT", 47, 73], ["relatively low sensitivity", "PROBLEM", 97, 123], ["instruments", "OBSERVATION", 6, 17], ["low sensitivity", "OBSERVATION_MODIFIER", 108, 123]]], ["Modern instruments using improved ion extraction from the QIT and reflectron ToFs provide much better resolution and sensitivity [17, 18, 19] .", [["QIT", "DNA", 58, 61], ["Modern instruments", "TREATMENT", 0, 18], ["improved ion extraction", "TREATMENT", 25, 48], ["the QIT and reflectron ToFs", "TREATMENT", 54, 81], ["sensitivity", "TEST", 117, 128]]], ["Mass resolution (FWHM) of up to 16,000 and sub-femtomole sensitivity levels for peptides have been reported [18, 19] .Ion trap-ToFDouglas [20] first proposed use of a linear ion trap in front of a conventional three-dimensional ion trap as a way to enhance the duty cycle of the combined instrument.", [["Mass resolution", "PROBLEM", 0, 15], ["FWHM", "TEST", 17, 21], ["sub-femtomole sensitivity levels", "TEST", 43, 75], ["peptides", "TEST", 80, 88], ["a linear ion trap", "TREATMENT", 165, 182], ["a conventional three-dimensional ion trap", "TREATMENT", 195, 236], ["resolution", "OBSERVATION_MODIFIER", 5, 15]]], ["His group has gone on to extend this to instruments in which linear ion traps are placed in front of ToF mass spectrometers [21, 22] .", [["linear ion traps", "TREATMENT", 61, 77]]], ["In both cases the linear ion trap adds additional functionality by offering a method to select precursor ions, induce fragmentation, and enhance duty cycle when using continuous ion sources, such as electrospray.", [["a method", "TREATMENT", 76, 84], ["precursor ions", "PROBLEM", 95, 109], ["fragmentation", "PROBLEM", 118, 131], ["continuous ion sources", "TREATMENT", 167, 189], ["fragmentation", "OBSERVATION", 118, 131]]], ["They have also published fundamental investigations on resonance excitation processes in linear ion traps that precede ToF mass analyzers [23] .ToF/ToF instrumentationToF/ToF instrumentation has been described [24, 25, 26] in the literature for about 15 years, although it is only recently that a commercial product has been available [27] .", [["resonance excitation processes", "TREATMENT", 55, 85], ["linear ion traps", "TREATMENT", 89, 105], ["ToF", "TEST", 144, 147], ["ToF instrumentationToF/ToF instrumentation", "TREATMENT", 148, 190], ["instrumentation", "OBSERVATION", 175, 190]]], ["In one of the most recently published incarnations a 26-cm Wiley McLaren ToF followed by a timed ion selector is used for precursor ion selection [27] .", [["a 26-cm Wiley McLaren ToF", "TREATMENT", 51, 76], ["a timed ion selector", "TREATMENT", 89, 109], ["precursor ion selection", "TREATMENT", 122, 145]]], ["Precursor ion fragmentation can be induced in a short, low-pressure collision cell.", [["cell", "ANATOMY", 78, 82], ["cell", "CELL", 78, 82], ["Precursor ion fragmentation", "PROBLEM", 0, 27], ["a short, low-pressure collision cell", "PROBLEM", 46, 82], ["ion fragmentation", "OBSERVATION", 10, 27], ["collision cell", "OBSERVATION", 68, 82]]], ["Final mass analysis is accomplished with a reflectron ToF section.", [["Final mass analysis", "TEST", 0, 19], ["a reflectron ToF section", "TREATMENT", 41, 65], ["mass", "OBSERVATION", 6, 10]]], ["The instrument was designed to be used with a MALDI ion source and thus for singly charged ions.", [["The instrument", "TREATMENT", 0, 14], ["a MALDI ion source", "TREATMENT", 44, 62], ["singly charged ions", "TREATMENT", 76, 95]]], ["The high-energy CID process for high m/z ions may be advantageous compared to conventional low-energy dissociation techniques [27] .ToF/ToF instrumentationPrecursor ion isolation is achieved with a timed ion selector made from two tandem deflector gates.", [["The high-energy CID process", "PROBLEM", 0, 27], ["high m/z ions", "PROBLEM", 32, 45], ["ToF/ToF instrumentation", "TREATMENT", 132, 155], ["Precursor ion isolation", "TREATMENT", 155, 178], ["a timed ion selector", "TREATMENT", 196, 216], ["high", "OBSERVATION_MODIFIER", 4, 8], ["energy CID", "OBSERVATION", 9, 19]]], ["Typical isolation widths were not published, but are likely worse than for a conventional resolving quadrupole mass filter.", [["Typical isolation widths", "PROBLEM", 0, 24], ["a conventional resolving quadrupole mass filter", "TREATMENT", 75, 122], ["isolation widths", "OBSERVATION", 8, 24], ["quadrupole mass", "OBSERVATION", 100, 115], ["filter", "OBSERVATION", 116, 122]]], ["Mass resolution values of 2-3,000 for fragment ions and approximately 5,000 for single MS scans have been reported [27] .Fourier transform mass spectrometer (FTMS)The FTMS instrument is an ion-trapping mass spectrometer that relies on magnetic and electric fields for ion confinement [28] .", [["Mass resolution values", "TEST", 0, 22], ["fragment ions", "PROBLEM", 38, 51], ["single MS scans", "TEST", 80, 95], ["Fourier transform mass spectrometer", "PROBLEM", 121, 156], ["The FTMS instrument", "TREATMENT", 163, 182], ["an ion-trapping mass spectrometer", "PROBLEM", 186, 219], ["resolution", "OBSERVATION_MODIFIER", 5, 15], ["mass", "OBSERVATION", 139, 143], ["mass", "OBSERVATION", 202, 206]]], ["These instruments are characterized by high resolution, very good mass assignment accuracy, and high sensitivity.", [["high sensitivity", "PROBLEM", 96, 112], ["high resolution", "OBSERVATION_MODIFIER", 39, 54], ["mass", "OBSERVATION", 66, 70]]], ["There is, however, a basic incompatibility between FTMS instruments, which operate best at very low pressures, and the neutral gas densities required to attain rapid CID for fragment ion generation.", [["a basic incompatibility between FTMS instruments", "PROBLEM", 19, 67], ["the neutral gas densities", "PROBLEM", 115, 140], ["fragment ion generation", "PROBLEM", 174, 197], ["basic", "OBSERVATION_MODIFIER", 21, 26], ["incompatibility", "OBSERVATION", 27, 42], ["low", "OBSERVATION_MODIFIER", 96, 99], ["pressures", "OBSERVATION_MODIFIER", 100, 109], ["neutral", "OBSERVATION_MODIFIER", 119, 126], ["gas densities", "OBSERVATION", 127, 140]]], ["Consequently, alternative fragmentation techniques have been developed such as infrared laser multiphoton-induced dissociation (IRMPD) [29] and electron capture dissociation (ECD) [30] .", [["alternative fragmentation techniques", "TREATMENT", 14, 50], ["infrared laser multiphoton-induced dissociation", "PROBLEM", 79, 126], ["electron capture dissociation", "TEST", 144, 173]]], ["\"Top-down\" protein characterization [31] , in which the entire protein, rather than proteolytic fragments, is sequenced makes use of the high resolution and mass accuracy of FTMS instrumentation.", [["fragments", "ANATOMY", 96, 105], ["proteolytic fragments", "PROTEIN", 84, 105], ["protein characterization", "TEST", 11, 35], ["proteolytic fragments", "PROBLEM", 84, 105], ["FTMS instrumentation", "TREATMENT", 174, 194], ["fragments", "OBSERVATION", 96, 105]]], ["In an elegant example of this approach McLafferty and coworkers [31] have demonstrated ECD cleavage of 250 out of 258 total peptide bonds in a 29-kDa protein.Fourier transform mass spectrometer (FTMS)Placement of a linear ion trap in front of the ICR cell can yield important performance enhancements in much the same way described above for ToF mass spectrometers [32, 33, 34] .", [["ICR cell", "ANATOMY", 247, 255], ["ICR cell", "CELL", 247, 255], ["29-kDa protein", "PROTEIN", 143, 157], ["ICR cell", "CELL_LINE", 247, 255], ["ECD cleavage", "TEST", 87, 99], ["total peptide bonds", "TEST", 118, 137], ["Fourier transform mass spectrometer", "PROBLEM", 158, 193], ["a linear ion trap", "TREATMENT", 213, 230], ["ToF mass spectrometers", "PROBLEM", 342, 364], ["mass", "OBSERVATION", 176, 180], ["ICR", "ANATOMY", 247, 250]]], ["Trapped ions gradually approach thermal kinetic energies allowing more efficient injection into the very low pressure ICR.", [["thermal kinetic energies", "TREATMENT", 32, 56], ["the very low pressure ICR", "PROBLEM", 96, 121], ["kinetic energies", "OBSERVATION", 40, 56]]], ["Other ion population conditioning steps, such as analyte pre-concentration and precursor ion isolation can be conducted in linear ion traps [35, 36, 37] .", [["analyte pre-concentration", "TREATMENT", 49, 74], ["precursor ion isolation", "TREATMENT", 79, 102]]], ["Some research groups have taken the approach of affecting precursor ion fragmentation outside of the ICR cell by using linear multipole ion traps and then admitting all or a portion of these ions into the FTMS for the final stage of mass analysis [38] .Fourier transform mass spectrometer (FTMS)Removal of ions that are not of analytical interest prior to the FTMS, which enhances dynamic range, has also been reported [34, 35, 36, 37] .", [["ICR cell", "ANATOMY", 101, 109], ["ICR cell", "CELL", 101, 109], ["ICR cell", "CELL_LINE", 101, 109], ["precursor ion fragmentation", "PROBLEM", 58, 85], ["linear multipole ion traps", "TREATMENT", 119, 145], ["mass analysis", "TEST", 233, 246], ["Fourier transform mass spectrometer (FTMS", "TREATMENT", 253, 294], ["Removal of ions", "TREATMENT", 295, 310], ["the FTMS", "TEST", 356, 364], ["ion fragmentation", "OBSERVATION", 68, 85], ["mass", "OBSERVATION", 233, 237], ["mass", "OBSERVATION", 271, 275], ["ions", "OBSERVATION", 306, 310]]], ["Smith and coworkers have been very active in the field of external ion accumulation prior to injection into the FTMS.", [["ion", "SIMPLE_CHEMICAL", 67, 70], ["external ion accumulation", "PROBLEM", 58, 83], ["very", "OBSERVATION_MODIFIER", 30, 34], ["active", "OBSERVATION_MODIFIER", 35, 41]]], ["They have been particularly concerned with protein identification and characterization in very complicated mixtures.", [["protein identification", "TEST", 43, 65]]], ["Their goal has been to expand the dynamic range of the FTMS by utilizing as much of the ICR trap capacity as possible to store and mass analyze the less abundant ions.", [["the ICR trap capacity", "TEST", 84, 105], ["mass", "PROBLEM", 131, 135], ["mass", "OBSERVATION", 131, 135], ["less", "OBSERVATION_MODIFIER", 148, 152], ["abundant", "OBSERVATION_MODIFIER", 153, 161], ["ions", "OBSERVATION", 162, 166]]], ["FTMS instruments are ion trapping devices and can suffer from mass spectral distortions from space charge.", [["FTMS instruments", "TREATMENT", 0, 16], ["ion trapping devices", "TREATMENT", 21, 41], ["mass spectral distortions from space charge", "PROBLEM", 62, 105], ["ion trapping", "OBSERVATION", 21, 33], ["mass", "OBSERVATION", 62, 66], ["space charge", "OBSERVATION", 93, 105]]], ["Smith's group has devised an instrument that, under software control, sequentially resonantly ejects and eliminates abundant species in an external linear quadrupole ion trap [34, 35, 36, 37, 39, 40] .", [["an instrument", "TREATMENT", 26, 39], ["sequentially resonantly ejects", "PROBLEM", 70, 100], ["abundant species", "PROBLEM", 116, 132]]], ["This allows preferential filling of the ICR cell with the increasingly less abundant ions in a stepwise manner.", [["ICR cell", "ANATOMY", 40, 48], ["ICR cell", "CELL", 40, 48], ["ICR cell", "CELL_TYPE", 40, 48], ["the ICR cell", "TREATMENT", 36, 48], ["preferential", "OBSERVATION_MODIFIER", 12, 24], ["filling", "OBSERVATION_MODIFIER", 25, 32], ["ICR cell", "OBSERVATION", 40, 48], ["increasingly", "OBSERVATION_MODIFIER", 58, 70], ["less", "OBSERVATION_MODIFIER", 71, 75], ["abundant", "OBSERVATION_MODIFIER", 76, 84], ["ions", "OBSERVATION", 85, 89]]], ["The practical result is an enhancement in the number of detected peptides by about 40% in an LC/MS/MS run [36] .Linear ion trap mass spectrometersAs described above in the context of ToF and FTMS instrumentation, linear ion traps can be used as ion processing units prior to final analysis by another mass spectrometer.", [["an enhancement", "PROBLEM", 24, 38], ["Linear ion trap mass spectrometers", "PROBLEM", 112, 146], ["ToF and FTMS instrumentation", "TREATMENT", 183, 211], ["linear ion traps", "TREATMENT", 213, 229], ["final analysis", "TEST", 275, 289], ["another mass spectrometer", "PROBLEM", 293, 318], ["enhancement", "OBSERVATION", 27, 38], ["ion trap", "OBSERVATION", 119, 127], ["mass spectrometers", "OBSERVATION", 128, 146]]], ["This type of linear ion trap can resonantly eject unwanted ion species and concentrate desired analytes by making use of their high ion capacities [41] .", [["linear ion trap", "PROBLEM", 13, 28], ["ion species", "PROBLEM", 59, 70]]], ["They can also provide a degree of time compression by accumulating ions from an ion source for many tens or hundreds of milliseconds and delivering a very short pulse of ions for subsequent analysis [33] .", [["time compression", "PROBLEM", 34, 50], ["accumulating ions", "PROBLEM", 54, 71], ["a very short pulse of ions", "TREATMENT", 148, 174], ["subsequent analysis", "TEST", 179, 198]]], ["Linear ion traps can also affect precursor ion isolation and fragmentation via resonance excitation processes [21, 22, 42] .Linear ion trap mass spectrometersThere have been two notable developments in the use of linear ion traps as true mass spectrometers using either mass-selective radial [43] or axial ion ejection [44] .", [["Linear ion traps", "TREATMENT", 0, 16], ["Linear ion trap mass spectrometers", "PROBLEM", 124, 158], ["linear ion traps", "TREATMENT", 213, 229], ["true mass spectrometers", "PROBLEM", 233, 256], ["either mass", "PROBLEM", 263, 274], ["axial ion ejection", "TEST", 300, 318], ["ion traps", "OBSERVATION", 7, 16], ["ion isolation", "OBSERVATION", 43, 56], ["ion trap", "OBSERVATION", 131, 139], ["mass spectrometers", "OBSERVATION", 140, 158], ["two", "OBSERVATION_MODIFIER", 174, 177], ["notable", "OBSERVATION_MODIFIER", 178, 185], ["mass", "OBSERVATION", 270, 274], ["radial", "ANATOMY_MODIFIER", 285, 291]]], ["Massselective radial ion ejection involves trapping the ions in a four-rod quadrupole structure and resonantly ejecting the ions radially through a slot cut in one of the quadrupole rods.", [["Massselective radial ion ejection", "TREATMENT", 0, 33], ["a slot cut", "TREATMENT", 146, 156], ["radial", "ANATOMY_MODIFIER", 14, 20], ["ion ejection", "OBSERVATION", 21, 33], ["ions", "OBSERVATION_MODIFIER", 56, 60], ["rod", "OBSERVATION_MODIFIER", 71, 74], ["quadrupole structure", "OBSERVATION", 75, 95], ["resonantly ejecting", "OBSERVATION", 100, 119], ["ions", "OBSERVATION_MODIFIER", 124, 128], ["radially", "OBSERVATION_MODIFIER", 129, 137], ["slot", "OBSERVATION_MODIFIER", 148, 152], ["quadrupole rods", "OBSERVATION", 171, 186]]], ["Schwartz et al. have demonstrated that replacement of a conventional three-dimensional ion trap with a radial ejection linear ion trap yields detection limit improvements of about 5 times as well as the ability to conduct all of the standard ion trap scan modes [43] .", [["a conventional three-dimensional ion trap", "TREATMENT", 54, 95], ["a radial ejection linear ion trap", "TREATMENT", 101, 134], ["the standard ion trap scan modes", "TEST", 229, 261], ["replacement", "OBSERVATION_MODIFIER", 39, 50]]], ["The sensitivity enhancement is due to the considerably larger ion capacity of linear ion traps, which has been estimated to be more than an order of magnitude larger than that of a conventional ion trap.", [["The sensitivity enhancement", "TEST", 0, 27], ["linear ion traps", "TREATMENT", 78, 94], ["a conventional ion trap", "TREATMENT", 179, 202], ["considerably", "OBSERVATION_MODIFIER", 42, 54], ["larger", "OBSERVATION_MODIFIER", 55, 61], ["ion", "OBSERVATION_MODIFIER", 62, 65], ["capacity", "OBSERVATION_MODIFIER", 66, 74], ["linear", "OBSERVATION_MODIFIER", 78, 84], ["ion traps", "OBSERVATION", 85, 94], ["magnitude", "OBSERVATION_MODIFIER", 149, 158], ["larger", "OBSERVATION_MODIFIER", 159, 165]]], ["High ejection efficiencies were reported, despite the fact that the ions being ejected from this radial ejection linear ion trap emerge from a slot cut in one of the quadrupole rods [43] .Linear ion trap mass spectrometersMass-selective axial ejection from a linear ion trap is a less obvious technique for ion extraction.", [["ion", "SIMPLE_CHEMICAL", 307, 310], ["High ejection efficiencies", "PROBLEM", 0, 26], ["the ions", "PROBLEM", 64, 72], ["this radial ejection linear ion trap", "TREATMENT", 92, 128], ["a slot cut", "TREATMENT", 141, 151], ["Linear ion trap mass spectrometers", "PROBLEM", 188, 222], ["Mass", "PROBLEM", 222, 226], ["selective axial ejection", "TREATMENT", 227, 251], ["a linear ion trap", "TREATMENT", 257, 274], ["ion extraction", "TREATMENT", 307, 321], ["ejection efficiencies", "OBSERVATION", 5, 26], ["quadrupole rods", "OBSERVATION", 166, 181], ["ion trap", "OBSERVATION", 195, 203], ["mass spectrometers", "OBSERVATION", 204, 222], ["selective", "OBSERVATION_MODIFIER", 227, 236], ["axial ejection", "OBSERVATION", 237, 251]]], ["Axial ejection is affected in the exit fringe field region of a linear ion trap due to the coupling of the radial and axial degrees of freedom of the trapped ions [44] .", [["Axial ejection", "TEST", 0, 14], ["a linear ion trap", "TREATMENT", 62, 79], ["ejection", "OBSERVATION", 6, 14], ["radial", "ANATOMY_MODIFIER", 107, 113], ["axial degrees", "OBSERVATION_MODIFIER", 118, 131], ["freedom", "OBSERVATION_MODIFIER", 135, 142], ["trapped ions", "OBSERVATION", 150, 162]]], ["This is the ion trap analog to the RF-only transmission quadrupole mass spectrometer [45, 46] .Linear ion trap mass spectrometersSince the axial ejection linear ion trap operates in the low 10 -5 torr regime and ions emerge from the end of the device it has proven to be a good match with the ion path of a QqQ instrument [47] .", [["ions", "SIMPLE_CHEMICAL", 212, 216], ["Linear ion trap mass spectrometers", "PROBLEM", 95, 129], ["the axial ejection linear ion trap", "TREATMENT", 135, 169], ["the low 10 -5 torr regime", "TREATMENT", 182, 207], ["the device", "TREATMENT", 240, 250], ["ion trap", "OBSERVATION", 102, 110], ["mass spectrometers", "OBSERVATION", 111, 129], ["low", "OBSERVATION_MODIFIER", 186, 189]]], ["A commercial product with a QqQ linear ion trap geometry combines all of the features of a conventional triple quadrupole mass spectrometer and a linear ion trap [47, 48] .", [["A commercial product", "TREATMENT", 0, 20], ["a QqQ linear ion trap geometry", "TREATMENT", 26, 56], ["a conventional triple quadrupole mass spectrometer", "TREATMENT", 89, 139], ["a linear ion trap", "TEST", 144, 161], ["mass", "OBSERVATION", 122, 126]]], ["One product ion scan mode uses the first quadrupole for precursor ion selection and the collision cell for fragmentation prior to ion introduction into the linear ion trap [47] .", [["cell", "ANATOMY", 98, 102], ["cell", "CELL", 98, 102], ["precursor ion selection", "TREATMENT", 56, 79], ["the collision cell", "TREATMENT", 84, 102], ["fragmentation", "PROBLEM", 107, 120], ["collision cell", "OBSERVATION", 88, 102]]], ["The analytical mass scan is conducted with the linear ion trap.", [["The analytical mass scan", "TEST", 0, 24], ["the linear ion trap", "TREATMENT", 43, 62], ["mass", "OBSERVATION", 15, 19]]], ["During the analytical scan the instrument can accumulate ions from the ion source enhancing duty cycle, and ultimately, sensitivity [47] .", [["the analytical scan", "TEST", 7, 26], ["sensitivity", "TEST", 120, 131]]], ["The advantages to this tandem-in-space approach are that only the fragment and residual precursor ions are admitted into the ion trap thereby preserving dynamic range.", [["fragment", "CELLULAR_COMPONENT", 66, 74], ["this tandem-in-space approach", "TREATMENT", 18, 47], ["the fragment", "PROBLEM", 62, 74], ["residual precursor ions", "PROBLEM", 79, 102], ["fragment", "OBSERVATION", 66, 74], ["residual", "OBSERVATION_MODIFIER", 79, 87], ["precursor ions", "OBSERVATION", 88, 102]]], ["Also, since the fragmentation step and the final mass analysis steps are spatially separated there is no inherent low mass cutoff in the product ion spectra.", [["the fragmentation step", "PROBLEM", 12, 34], ["the final mass analysis steps", "TEST", 39, 68], ["inherent low mass cutoff", "PROBLEM", 105, 129], ["fragmentation", "OBSERVATION", 16, 29], ["final", "OBSERVATION_MODIFIER", 43, 48], ["mass", "OBSERVATION", 49, 53], ["no", "UNCERTAINTY", 102, 104], ["inherent", "OBSERVATION_MODIFIER", 105, 113], ["low", "OBSERVATION_MODIFIER", 114, 117], ["mass", "OBSERVATION", 118, 122], ["ion spectra", "OBSERVATION", 145, 156]]], ["Sensitivity gains of factors greater than 500 times that of standard triple quadrupole product ion scan mode have been reported [47] .Linear ion trap mass spectrometersThe advantage of having triple quadrupole and ion trap functionality on the same instrument has been illustrated for the analysis of complicated mixtures [48, 49] .", [["Sensitivity gains of factors", "PROBLEM", 0, 28], ["scan mode", "TEST", 99, 108], ["Linear ion trap mass spectrometers", "PROBLEM", 134, 168], ["triple quadrupole", "TREATMENT", 192, 209], ["ion trap functionality", "TREATMENT", 214, 236], ["ion trap", "OBSERVATION", 141, 149], ["mass spectrometers", "OBSERVATION", 150, 168]]], ["The very selective, although relatively insensitive, triple quadrupole precursor ion and constant neutral loss scans were used to locate specific analyte types that could then be characterized by using the high sensitivity ion trap functionality [48, 49] .", [["relatively insensitive, triple quadrupole precursor ion", "PROBLEM", 29, 84], ["constant neutral loss scans", "PROBLEM", 89, 116], ["very", "OBSERVATION_MODIFIER", 4, 8], ["selective", "OBSERVATION", 9, 18]]], ["The triple quadrupole multiple reaction monitoring using specific precursor-to-fragment transitions could then be used to generate quantitation calibration curves over 5 orders of magnitude [48] .Linear ion trap mass spectrometersIn-trap fragmentation similar to that accomplished in other ion trap instruments can also be accomplished in low-pressure linear ion traps.", [["The triple quadrupole multiple reaction monitoring", "TREATMENT", 0, 50], ["specific precursor-to-fragment transitions", "TREATMENT", 57, 99], ["quantitation calibration curves", "TEST", 131, 162], ["Linear ion trap mass spectrometers", "PROBLEM", 196, 230], ["trap fragmentation", "PROBLEM", 233, 251], ["other ion trap instruments", "TREATMENT", 284, 310], ["low-pressure linear ion traps", "TREATMENT", 339, 368], ["ion trap", "OBSERVATION", 203, 211], ["mass spectrometers", "OBSERVATION", 212, 230], ["trap fragmentation", "OBSERVATION", 233, 251]]], ["Collings et al. [42] have shown that even at linear ion trap pressures in the low 10 -5 torr range, efficient fragmentation can be affected even for precursor ions at approximately m/z 2,700.Conclusions and future directionsModern tandem mass spectrometers combine both tandem-in-space and tandem-in-time approaches within single instrument packages in order to extract as much analytical information as possible.", [["trap pressures", "TEST", 56, 70], ["efficient fragmentation", "PROBLEM", 100, 123], ["precursor ions", "PROBLEM", 149, 163], ["Modern tandem mass spectrometers", "TREATMENT", 224, 256], ["single instrument packages", "TREATMENT", 323, 349], ["fragmentation", "OBSERVATION", 110, 123], ["mass", "OBSERVATION", 238, 242]]], ["Most notable perhaps is the proliferation of linear ion traps of all types.", [["linear ion traps", "TREATMENT", 45, 61], ["proliferation", "OBSERVATION_MODIFIER", 28, 41], ["linear", "OBSERVATION_MODIFIER", 45, 51], ["ion traps", "OBSERVATION", 52, 61], ["all types", "OBSERVATION_MODIFIER", 65, 74]]], ["This is driven by the necessity to perform a variety of high-efficiency ion-processing steps prior to, or concurrent with, the final stage of mass analysis.", [["mass analysis", "PROBLEM", 142, 155], ["mass", "OBSERVATION", 142, 146]]], ["The combination of what on the surface appears to be dissimilar mass analyzers, or mass filters, has allowed mass measurement instrumentation to develop beyond the conventional tandem-in-space and tandem-in-time platforms.", [["surface", "ANATOMY", 31, 38], ["surface", "CELLULAR_COMPONENT", 31, 38], ["dissimilar mass analyzers", "PROBLEM", 53, 78], ["mass filters", "TREATMENT", 83, 95], ["mass measurement instrumentation", "TREATMENT", 109, 141], ["the conventional tandem", "TEST", 160, 183], ["appears to be", "UNCERTAINTY", 39, 52], ["dissimilar", "OBSERVATION_MODIFIER", 53, 63], ["mass", "OBSERVATION", 64, 68], ["mass filters", "OBSERVATION", 83, 95], ["mass", "OBSERVATION", 109, 113]]], ["Most common in this arena of continued hybridization is the linear ion trap.", [["continued hybridization", "TREATMENT", 29, 52], ["the linear ion trap", "TREATMENT", 56, 75]]], ["These ion traps are easy to build, tolerate high pressures, and can add significant functionality to other more traditional mass analyzers.Conclusions and future directionsThere are other novel mass analyzers on the horizon that have not yet been fully developed.", [["high pressures", "TREATMENT", 44, 58], ["other novel mass analyzers", "PROBLEM", 182, 208], ["the horizon", "TREATMENT", 212, 223], ["mass", "OBSERVATION", 124, 128], ["novel", "OBSERVATION_MODIFIER", 188, 193], ["mass", "OBSERVATION", 194, 198]]], ["The orbitrap [50, 51] mass spectrometer makes use of a quadro-logarithmic field and has been reported to yield FWHM mass resolution of in excess of 150,000 with good mass range and mass assignment accuracies of a few ppm.", [["The orbitrap", "TEST", 0, 12], ["a few ppm", "TREATMENT", 211, 220], ["mass", "OBSERVATION", 166, 170], ["mass", "OBSERVATION", 181, 185]]], ["A linear ion trap has been used for external ion accumulation and injection into the 10 -10 torr pressure orbitrap with good success [51] .", [["A linear ion trap", "TREATMENT", 0, 17], ["external ion accumulation", "TREATMENT", 36, 61], ["torr pressure orbitrap", "TREATMENT", 92, 114], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["ion trap", "OBSERVATION", 9, 17]]], ["Such a mass analyzer may, in the future, provide a smaller and less costly alternative to FTMS systems.Conclusions and future directionsAt the other end of the spectrum are the miniature cylindrical ion traps that have been designed for fieldportable applications [52, 53] .", [["a mass analyzer", "TEST", 5, 20], ["a smaller and less costly alternative to FTMS systems", "PROBLEM", 49, 102], ["the miniature cylindrical ion traps", "TREATMENT", 173, 208], ["mass", "OBSERVATION", 7, 11]]], ["In one incarnation [52] a small battery-powered instrument has been described with a mass range of about m/z 250, unit-resolution-resolving capability, and MS, MS 2 , and MS 3 capabilities.", [["a small battery-powered instrument", "TREATMENT", 24, 58], ["MS", "TEST", 160, 162], ["small", "OBSERVATION_MODIFIER", 26, 31], ["mass", "OBSERVATION", 85, 89]]], ["Analysis of several analyte classes, such as environmentally significant compounds and chemical warfare agents, have shown FWHM mass resolution of about 100 and detection limits as low as 1 pg.Conclusions and future directionsThe mass spectrometers of the future will undoubtedly be more sensitive, more selective, and allow higher throughput than those of today.", [["several analyte classes", "PROBLEM", 12, 35], ["chemical warfare agents", "TREATMENT", 87, 110], ["FWHM mass resolution", "PROBLEM", 123, 143], ["The mass spectrometers", "PROBLEM", 226, 248], ["mass", "OBSERVATION", 230, 234], ["selective", "OBSERVATION_MODIFIER", 304, 313], ["higher", "OBSERVATION_MODIFIER", 325, 331]]], ["The analysis of complex mixtures from the drug design and discovery processes, as well as proteomics, demands improvements in these areas.", [["The analysis", "TEST", 0, 12], ["complex mixtures", "PROBLEM", 16, 32], ["the drug design and discovery processes", "PROBLEM", 38, 77]]]], "c41c1db843dbab2748de47a291e222508529815e": [["Furthermore, the patient's mouth and nose are often exposed74We hope that these suggestions provide the best possible protection for dermatologic efficiency particle air, RT-PCR, reverse transcription-polymerase chain reaction, SARS-CoV-2, 81 severe acute respiratory syndrome coronavirus 2", [["mouth", "ANATOMY", 27, 32], ["nose", "ANATOMY", 37, 41], ["acute respiratory syndrome coronavirus", "DISEASE", 250, 288], ["patient", "ORGANISM", 17, 24], ["mouth", "ORGANISM_SUBDIVISION", 27, 32], ["nose", "ORGAN", 37, 41], ["SARS-CoV-2", "ORGANISM", 228, 238], ["patient", "SPECIES", 17, 24], ["SARS-CoV", "SPECIES", 228, 236], ["severe acute respiratory syndrome coronavirus", "SPECIES", 243, 288], ["dermatologic efficiency particle air", "PROBLEM", 133, 169], ["RT-PCR", "TEST", 171, 177], ["polymerase chain reaction", "PROBLEM", 201, 226], ["SARS", "TEST", 228, 232], ["CoV", "TEST", 233, 236], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 243, 288], ["mouth", "ANATOMY", 27, 32], ["nose", "ANATOMY", 37, 41], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["respiratory syndrome", "OBSERVATION", 256, 276]]]], "d3d29e7ae22aaff4cdc9769cbe97e57c438d5ef2": [["A s obligate intracellular parasites, viruses have to penetrate living cells in order to replicate.", [["intracellular", "ANATOMY", 13, 26], ["cells", "ANATOMY", 71, 76], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 26], ["cells", "CELL", 71, 76], ["living cells", "CELL_TYPE", 64, 76], ["A s obligate intracellular parasites", "PROBLEM", 0, 36], ["viruses", "PROBLEM", 38, 45], ["intracellular parasites", "OBSERVATION", 13, 36]]], ["While viruses generally have one or more cell surface receptors or attachment factors, only a few virus types can enter the cells through direct fusion with the plasma membrane.", [["cell surface", "ANATOMY", 41, 53], ["cells", "ANATOMY", 124, 129], ["plasma membrane", "ANATOMY", 161, 176], ["cell", "CELL", 41, 45], ["cells", "CELL", 124, 129], ["plasma membrane", "CELLULAR_COMPONENT", 161, 176], ["cell surface receptors", "PROTEIN", 41, 63], ["attachment factors", "PROTEIN", 67, 85], ["attachment factors", "PROBLEM", 67, 85], ["a few virus types", "PROBLEM", 92, 109], ["direct fusion", "TREATMENT", 138, 151], ["the plasma membrane", "TREATMENT", 157, 176], ["plasma membrane", "OBSERVATION", 161, 176]]], ["Throughout evolution, most viruses have developed elegant strategies to hijack the endosomal network, a maze of tubular and vesicular structures in eukaryotic cells tasked with cellular trafficking, to penetrate the cell and deliver their genome.", [["endosomal network", "ANATOMY", 83, 100], ["tubular", "ANATOMY", 112, 119], ["vesicular structures", "ANATOMY", 124, 144], ["cells", "ANATOMY", 159, 164], ["cellular", "ANATOMY", 177, 185], ["cell", "ANATOMY", 216, 220], ["endosomal network", "MULTI-TISSUE_STRUCTURE", 83, 100], ["tubular", "TISSUE", 112, 119], ["vesicular structures", "CELLULAR_COMPONENT", 124, 144], ["cells", "CELL", 159, 164], ["cellular", "CELL", 177, 185], ["cell", "CELL", 216, 220], ["eukaryotic cells", "CELL_TYPE", 148, 164], ["most viruses", "PROBLEM", 22, 34], ["tubular and vesicular structures in eukaryotic cells", "PROBLEM", 112, 164], ["cellular trafficking", "TREATMENT", 177, 197], ["endosomal network", "OBSERVATION", 83, 100], ["tubular", "ANATOMY_MODIFIER", 112, 119], ["vesicular structures", "ANATOMY", 124, 144], ["eukaryotic cells", "OBSERVATION", 148, 164], ["cellular trafficking", "OBSERVATION", 177, 197]]], ["Endosomes pick up cargo at the plasma membrane and transport it through the cell with the goal of delivering it to the cytoplasm or to other organelles, routing it to the lysosomal graveyard, or recycling back to the plasma membrane.", [["plasma membrane", "ANATOMY", 31, 46], ["cell", "ANATOMY", 76, 80], ["cytoplasm", "ANATOMY", 119, 128], ["organelles", "ANATOMY", 141, 151], ["lysosomal", "ANATOMY", 171, 180], ["plasma membrane", "ANATOMY", 217, 232], ["Endosomes", "GENE_OR_GENE_PRODUCT", 0, 9], ["plasma membrane", "CELLULAR_COMPONENT", 31, 46], ["cell", "CELL", 76, 80], ["cytoplasm", "ORGANISM_SUBSTANCE", 119, 128], ["organelles", "CELLULAR_COMPONENT", 141, 151], ["lysosomal", "CELLULAR_COMPONENT", 171, 180], ["plasma membrane", "CELLULAR_COMPONENT", 217, 232], ["Endosomes", "PROTEIN", 0, 9], ["lysosomal graveyard", "PROTEIN", 171, 190], ["plasma membrane", "ANATOMY", 217, 232]]], ["To do this, endosomes undergo a maturation process that is accompanied by morphological and physiochemical transformations, including acidification and acquisition of various functional molecules.", [["endosomes", "ANATOMY", 12, 21], ["endosomes", "CELLULAR_COMPONENT", 12, 21], ["functional molecules", "PROTEIN", 175, 195], ["a maturation process", "PROBLEM", 30, 50], ["morphological and physiochemical transformations", "PROBLEM", 74, 122], ["acidification", "PROBLEM", 134, 147], ["various functional molecules", "PROBLEM", 167, 195], ["physiochemical transformations", "OBSERVATION", 92, 122]]], ["Ebola virus (EBOV) utilizes this dynamic endosomal environment to regulate a complex set of transformations of its own envelope glycoprotein that are necessary for fusion of viral and endosomal membranes and delivery of the viral genome into host cells.", [["endosomal", "ANATOMY", 41, 50], ["endosomal membranes", "ANATOMY", 184, 203], ["cells", "ANATOMY", 247, 252], ["Ebola", "DISEASE", 0, 5], ["Ebola virus", "ORGANISM", 0, 11], ["EBOV", "ORGANISM", 13, 17], ["endosomal", "CELLULAR_COMPONENT", 41, 50], ["endosomal membranes", "CELLULAR_COMPONENT", 184, 203], ["host cells", "CELL", 242, 252], ["envelope glycoprotein", "PROTEIN", 119, 140], ["viral genome", "DNA", 224, 236], ["host cells", "CELL_TYPE", 242, 252], ["Ebola virus", "SPECIES", 0, 11], ["Ebola virus", "SPECIES", 0, 11], ["EBOV", "SPECIES", 13, 17], ["Ebola virus", "PROBLEM", 0, 11], ["this dynamic endosomal environment", "TREATMENT", 28, 62], ["envelope glycoprotein", "TREATMENT", 119, 140], ["fusion", "TREATMENT", 164, 170], ["viral and endosomal membranes", "TREATMENT", 174, 203], ["delivery", "TREATMENT", 208, 216], ["the viral genome into host cells", "PROBLEM", 220, 252], ["viral", "OBSERVATION", 174, 179], ["endosomal membranes", "OBSERVATION", 184, 203], ["viral genome", "OBSERVATION", 224, 236], ["host cells", "OBSERVATION", 242, 252]]]], "086fd0dfca81adc2e10768d1f54ea28be146c393": [["INTRODUCTION BackgroundViral severe acute respiratory infections are infectious transmittable diseases that have pandemic potential.", [["respiratory", "ANATOMY", 42, 53], ["acute respiratory infections", "DISEASE", 36, 64], ["BackgroundViral severe acute respiratory infections", "PROBLEM", 13, 64], ["infectious transmittable diseases", "PROBLEM", 69, 102], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["respiratory", "ANATOMY", 42, 53], ["infections", "OBSERVATION", 54, 64], ["infectious", "OBSERVATION_MODIFIER", 69, 79]]], ["1 The World Health Organization declared the coronavirus disease 2019 (COVID-19) outbreak a public health emergency of international concern on February 11, 2020, and a pandemic on March 11, 2020.", [["coronavirus disease", "DISEASE", 45, 64], ["COVID-19", "CHEMICAL", 71, 79], ["coronavirus", "ORGANISM", 45, 56], ["the coronavirus disease", "PROBLEM", 41, 64], ["COVID", "TEST", 71, 76], ["coronavirus disease", "OBSERVATION", 45, 64]]], ["2 As of June 7, 2020, COVID-19 had been diagnosed in approximately 7 million patients worldwide, with the number of new cases continually increasing.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["COVID", "TEST", 22, 27], ["new", "OBSERVATION_MODIFIER", 116, 119], ["cases", "OBSERVATION", 120, 125]]], ["3 Severe acute respiratory infections often present with acute respiratory distress.", [["respiratory", "ANATOMY", 15, 26], ["respiratory", "ANATOMY", 63, 74], ["acute respiratory infections", "DISEASE", 9, 37], ["acute respiratory distress", "DISEASE", 57, 83], ["Severe acute respiratory infections", "PROBLEM", 2, 37], ["acute respiratory distress", "PROBLEM", 57, 83], ["acute", "OBSERVATION_MODIFIER", 9, 14], ["respiratory", "ANATOMY", 15, 26], ["infections", "OBSERVATION", 27, 37], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory distress", "OBSERVATION", 63, 83]]], ["4, 5 Consequently, the initial treatment most often provided is oxygen therapy.", [["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["the initial treatment", "TREATMENT", 19, 40], ["oxygen therapy", "TREATMENT", 64, 78], ["oxygen therapy", "OBSERVATION", 64, 78]]], ["4, 5 Although some cases require early mechanical ventilation, others can be managed with supplemental oxygen alone or noninvasive ventilation.", [["oxygen", "CHEMICAL", 103, 109], ["oxygen", "CHEMICAL", 103, 109], ["oxygen", "SIMPLE_CHEMICAL", 103, 109], ["early mechanical ventilation", "TREATMENT", 33, 61], ["supplemental oxygen", "TREATMENT", 90, 109], ["noninvasive ventilation", "TREATMENT", 119, 142], ["early", "OBSERVATION_MODIFIER", 33, 38], ["mechanical ventilation", "OBSERVATION", 39, 61]]], ["4, 6 Also, before intubation for mechanical ventilation, patients often need supplemental oxygen or noninvasive ventilation, and these may be the only treatments available for some patients in the midst of aEditor's Capsule SummaryWhat is already known on this topic The delivery of oxygen may create fomites and aerosols that can spread pathogens to health care workers.Editor's Capsule SummaryWhat question this study addressed Which oxygen delivery methods elevate the risk of respiratory pathogen transmission to bedside health care workers?Editor's Capsule SummaryWhat this study adds to our knowledge From a meta-analysis of 50 trials, most with bias threats, intubation carried the highest risk of potential transmission, but other methods also likely elevated risk compared with nonuse.Editor's Capsule SummaryHow this is relevant to clinical practice Carefully weigh the need for oxygen and the delivery method, especially when a potentially transmissible severe viral respiratory infection is suspected.Editor's Capsule Summarypandemic, given the surge of patients in respiratory distress.", [["respiratory", "ANATOMY", 978, 989], ["respiratory", "ANATOMY", 1078, 1089], ["oxygen", "CHEMICAL", 90, 96], ["oxygen", "CHEMICAL", 283, 289], ["oxygen", "CHEMICAL", 436, 442], ["oxygen", "CHEMICAL", 889, 895], ["viral respiratory infection", "DISEASE", 972, 999], ["respiratory distress", "DISEASE", 1078, 1098], ["oxygen", "CHEMICAL", 90, 96], ["oxygen", "CHEMICAL", 283, 289], ["oxygen", "CHEMICAL", 436, 442], ["oxygen", "CHEMICAL", 889, 895], ["patients", "ORGANISM", 57, 65], ["oxygen", "SIMPLE_CHEMICAL", 90, 96], ["patients", "ORGANISM", 181, 189], ["oxygen", "SIMPLE_CHEMICAL", 283, 289], ["oxygen", "SIMPLE_CHEMICAL", 436, 442], ["oxygen", "SIMPLE_CHEMICAL", 889, 895], ["patients", "ORGANISM", 1066, 1074], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 1066, 1074], ["intubation", "TREATMENT", 18, 28], ["mechanical ventilation", "TREATMENT", 33, 55], ["supplemental oxygen", "TREATMENT", 77, 96], ["noninvasive ventilation", "TREATMENT", 100, 123], ["The delivery of oxygen", "TREATMENT", 267, 289], ["this study", "TEST", 409, 419], ["oxygen delivery methods", "TREATMENT", 436, 459], ["intubation", "TREATMENT", 666, 676], ["elevated risk", "PROBLEM", 759, 772], ["oxygen", "TREATMENT", 889, 895], ["the delivery method", "TREATMENT", 900, 919], ["a potentially transmissible severe viral respiratory infection", "PROBLEM", 937, 999], ["Capsule Summarypandemic", "TREATMENT", 1022, 1045], ["respiratory distress", "PROBLEM", 1078, 1098], ["mechanical ventilation", "OBSERVATION", 33, 55], ["severe", "OBSERVATION_MODIFIER", 965, 971], ["viral", "OBSERVATION_MODIFIER", 972, 977], ["respiratory infection", "OBSERVATION", 978, 999], ["respiratory distress", "OBSERVATION", 1078, 1098]]], ["6, 7 Some modalities of oxygen therapy have been shown to generate aerosols, which can increase severe acute respiratory infection transmission.", [["respiratory", "ANATOMY", 109, 120], ["oxygen", "CHEMICAL", 24, 30], ["acute respiratory infection", "DISEASE", 103, 130], ["oxygen", "CHEMICAL", 24, 30], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["oxygen therapy", "TREATMENT", 24, 38], ["severe acute respiratory infection transmission", "PROBLEM", 96, 143], ["oxygen therapy", "OBSERVATION", 24, 38], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory infection", "OBSERVATION", 109, 130]]], ["8ImportanceAlthough all health care workers face a significant risk of infection when treating patients with severe acute respiratory infection, the modality of oxygen therapy used might modify that risk.", [["respiratory", "ANATOMY", 122, 133], ["infection", "DISEASE", 71, 80], ["acute respiratory infection", "DISEASE", 116, 143], ["oxygen", "CHEMICAL", 161, 167], ["oxygen", "CHEMICAL", 161, 167], ["patients", "ORGANISM", 95, 103], ["oxygen", "SIMPLE_CHEMICAL", 161, 167], ["patients", "SPECIES", 95, 103], ["infection", "PROBLEM", 71, 80], ["severe acute respiratory infection", "PROBLEM", 109, 143], ["oxygen therapy", "TREATMENT", 161, 175], ["infection", "OBSERVATION", 71, 80], ["severe", "OBSERVATION_MODIFIER", 109, 115], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["respiratory", "ANATOMY", 122, 133], ["infection", "OBSERVATION", 134, 143], ["oxygen therapy", "OBSERVATION", 161, 175]]], ["[8] [9] [10] [11] Ideally, respiratory protection should be maximized for all health care workers in contact with patients, but this might not be possible during a pandemic.", [["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 17], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["respiratory protection", "TREATMENT", 27, 49], ["a pandemic", "PROBLEM", 162, 172]]], ["12 A better understanding of the risk involved in providing different modalities of oxygen therapy to patients with severe acute respiratory infection would assist clinicians in selecting the most suitable approach for patients, improve the allocation of respiratory protective equipment, improve health care workers' confidence when caring for these patients, and decrease the overall burden of these diseases.Goals of This InvestigationTo maximize health care worker safety and limit nosocomial transmission of severe acute respiratory infections, it is crucial to synthesize the evidence regarding the health care workers' risk of infection when caring for patients with severe acute respiratory infection requiring oxygen therapy.", [["respiratory", "ANATOMY", 129, 140], ["respiratory", "ANATOMY", 526, 537], ["respiratory", "ANATOMY", 687, 698], ["oxygen", "CHEMICAL", 84, 90], ["acute respiratory infection", "DISEASE", 123, 150], ["acute respiratory infections", "DISEASE", 520, 548], ["infection", "DISEASE", 634, 643], ["acute respiratory infection", "DISEASE", 681, 708], ["oxygen", "CHEMICAL", 719, 725], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "CHEMICAL", 719, 725], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 351, 359], ["patients", "ORGANISM", 660, 668], ["oxygen", "SIMPLE_CHEMICAL", 719, 725], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 351, 359], ["patients", "SPECIES", 660, 668], ["oxygen therapy", "TREATMENT", 84, 98], ["severe acute respiratory infection", "PROBLEM", 116, 150], ["respiratory protective equipment", "TREATMENT", 255, 287], ["these diseases", "PROBLEM", 396, 410], ["severe acute respiratory infections", "PROBLEM", 513, 548], ["infection", "PROBLEM", 634, 643], ["severe acute respiratory infection", "PROBLEM", 674, 708], ["oxygen therapy", "TREATMENT", 719, 733], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory", "ANATOMY", 129, 140], ["infection", "OBSERVATION", 141, 150], ["diseases", "OBSERVATION", 402, 410], ["severe", "OBSERVATION_MODIFIER", 513, 519], ["acute", "OBSERVATION_MODIFIER", 520, 525], ["respiratory", "ANATOMY", 526, 537], ["infections", "OBSERVATION", 538, 548], ["infection", "OBSERVATION", 634, 643], ["severe", "OBSERVATION_MODIFIER", 674, 680], ["acute", "OBSERVATION_MODIFIER", 681, 686], ["respiratory", "ANATOMY", 687, 698], ["infection", "OBSERVATION", 699, 708], ["oxygen therapy", "OBSERVATION", 719, 733]]], ["Therefore, this review's main objective was to describe the rate of health care worker severe acute respiratory infection according to the modality used to provide oxygen.MATERIALS AND METHODSThe present systematic review and meta-analysis was registered before its initiation.", [["respiratory", "ANATOMY", 100, 111], ["respiratory infection", "DISEASE", 100, 121], ["oxygen", "CHEMICAL", 164, 170], ["oxygen", "CHEMICAL", 164, 170], ["oxygen", "SIMPLE_CHEMICAL", 164, 170], ["severe acute respiratory infection", "PROBLEM", 87, 121], ["oxygen", "TREATMENT", 164, 170], ["meta-analysis", "TEST", 226, 239], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["acute", "OBSERVATION_MODIFIER", 94, 99], ["respiratory", "ANATOMY", 100, 111], ["infection", "OBSERVATION", 112, 121]]], ["Its results are presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (Table E1 , available online at http://www.annemergmed. com).", [["Systematic Reviews", "TEST", 79, 97]]], ["13Study DesignThe search strategy aimed to find both published and unpublished studies.", [["unpublished studies", "TEST", 67, 86]]], ["The references provided in the guidelines or the care of severe acute respiratory infection patients of major free openaccess medical education blogs, global, American, and European health organizations, as well as in all previously identified articles and main review articles, were reviewed in search of additional studies.", [["respiratory", "ANATOMY", 70, 81], ["acute respiratory infection", "DISEASE", 64, 91], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["severe acute respiratory infection", "PROBLEM", 57, 91], ["additional studies", "TEST", 306, 324], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory", "ANATOMY", 70, 81], ["infection", "OBSERVATION", 82, 91]]], ["The authors of included articles were also contacted to assess whether they had access to pertinent unpublished data.Study DesignA 3-stage selection process was used.", [["Study DesignA 3-stage selection process", "TREATMENT", 117, 156]]], ["In the first stage, after automatic removal of duplicates, each citation title was screened to exclude obviously unrelated studies.", [["automatic removal", "TREATMENT", 26, 43]]], ["In the second stage, the titles and abstracts of the remaining citations were screened for potential relevance by Inclusion criteria were original studies of all designs describing the risk (rate and total number) of infection for health care workers caring for adult patients with severe acute respiratory infection (COVID-19, severe acute respiratory syndrome, Middle East respiratory syndrome, and emerging or pandemic influenza) according to the modality of oxygen therapy provided (intubation, noninvasive ventilation [bilevel positive airway pressure {BiPAP} or continuous positive airway pressure], high-flow nasal cannula, bag-valve-mask ventilation, and face mask with or without reservoir and nasal cannula).", [["respiratory", "ANATOMY", 295, 306], ["airway", "ANATOMY", 541, 547], ["airway", "ANATOMY", 588, 594], ["nasal", "ANATOMY", 616, 621], ["face", "ANATOMY", 663, 667], ["nasal", "ANATOMY", 703, 708], ["infection", "DISEASE", 217, 226], ["acute respiratory infection", "DISEASE", 289, 316], ["COVID", "DISEASE", 318, 323], ["acute respiratory syndrome", "DISEASE", 335, 361], ["Middle East respiratory syndrome", "DISEASE", 363, 395], ["influenza", "DISEASE", 422, 431], ["oxygen", "CHEMICAL", 462, 468], ["oxygen", "CHEMICAL", 462, 468], ["patients", "ORGANISM", 268, 276], ["oxygen", "SIMPLE_CHEMICAL", 462, 468], ["airway", "MULTI-TISSUE_STRUCTURE", 541, 547], ["airway", "MULTI-TISSUE_STRUCTURE", 588, 594], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 703, 716], ["patients", "SPECIES", 268, 276], ["original studies", "TEST", 138, 154], ["infection", "PROBLEM", 217, 226], ["severe acute respiratory infection", "PROBLEM", 282, 316], ["COVID", "TEST", 318, 323], ["severe acute respiratory syndrome", "PROBLEM", 328, 361], ["Middle East respiratory syndrome", "PROBLEM", 363, 395], ["pandemic influenza)", "PROBLEM", 413, 432], ["oxygen therapy", "TREATMENT", 462, 476], ["intubation", "TREATMENT", 487, 497], ["noninvasive ventilation", "TREATMENT", 499, 522], ["bilevel positive airway pressure", "TREATMENT", 524, 556], ["BiPAP", "TREATMENT", 558, 563], ["continuous positive airway pressure", "TREATMENT", 568, 603], ["high-flow nasal cannula", "TREATMENT", 606, 629], ["bag-valve", "TREATMENT", 631, 640], ["mask ventilation", "TREATMENT", 641, 657], ["face mask", "TREATMENT", 663, 672], ["reservoir", "TREATMENT", 689, 698], ["nasal cannula", "TREATMENT", 703, 716], ["second stage", "OBSERVATION_MODIFIER", 7, 19], ["infection", "OBSERVATION", 217, 226], ["severe", "OBSERVATION_MODIFIER", 282, 288], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["respiratory", "ANATOMY", 295, 306], ["infection", "OBSERVATION", 307, 316], ["severe", "OBSERVATION_MODIFIER", 328, 334], ["acute", "OBSERVATION_MODIFIER", 335, 340], ["respiratory syndrome", "OBSERVATION", 341, 361], ["Middle", "ANATOMY_MODIFIER", 363, 369], ["respiratory syndrome", "OBSERVATION", 375, 395], ["oxygen therapy", "OBSERVATION", 462, 476], ["airway pressure", "OBSERVATION", 588, 603], ["valve", "ANATOMY", 635, 640]]], ["Because it was anticipated that limited clinical data would be available for some modalities of oxygen therapy, studies on aerosol generation and droplet dispersion were also considered for inclusion.", [["oxygen", "CHEMICAL", 96, 102], ["oxygen", "CHEMICAL", 96, 102], ["oxygen", "SIMPLE_CHEMICAL", 96, 102], ["oxygen therapy", "TREATMENT", 96, 110], ["aerosol generation", "TREATMENT", 123, 141], ["droplet dispersion", "TREATMENT", 146, 164], ["oxygen therapy", "OBSERVATION", 96, 110]]], ["Studies describing only patients already receiving mechanical ventilation were excluded as outside the scope of this review, which focused on the oxygen therapy initially provided and also because the nature of care these patients frequently receive (eg, tracheal suctioning) is often different.", [["tracheal", "ANATOMY", 255, 263], ["oxygen", "CHEMICAL", 146, 152], ["oxygen", "CHEMICAL", 146, 152], ["patients", "ORGANISM", 24, 32], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["patients", "ORGANISM", 222, 230], ["tracheal", "MULTI-TISSUE_STRUCTURE", 255, 263], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 222, 230], ["Studies", "TEST", 0, 7], ["mechanical ventilation", "TREATMENT", 51, 73], ["the oxygen therapy", "TREATMENT", 142, 160], ["tracheal suctioning", "TREATMENT", 255, 274], ["oxygen therapy", "OBSERVATION", 146, 160], ["tracheal", "ANATOMY", 255, 263]]], ["Animal studies were also excluded.", [["Animal studies", "TEST", 0, 14]]], ["There were no language restrictions, but studies published before January 1, 2000, were excluded because they were published before the first modern-day severe acute respiratory infection pandemic (severe acute respiratory syndrome 2002 to 2003).", [["respiratory", "ANATOMY", 166, 177], ["respiratory infection", "DISEASE", 166, 187], ["acute respiratory syndrome", "DISEASE", 205, 231], ["language restrictions", "PROBLEM", 14, 35], ["severe acute respiratory infection pandemic (severe acute respiratory syndrome", "PROBLEM", 153, 231], ["no", "UNCERTAINTY", 11, 13], ["language restrictions", "OBSERVATION", 14, 35], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["respiratory", "ANATOMY", 166, 177], ["infection", "OBSERVATION", 178, 187], ["severe", "OBSERVATION_MODIFIER", 198, 204], ["acute", "OBSERVATION_MODIFIER", 205, 210], ["respiratory syndrome", "OBSERVATION", 211, 231]]], ["14Data Collection and ProcessingThe data (summary estimates) for all pertinent variables (eg, first author, publication year, study design, disease treated, number of health care workers exposed, number of patients treated, modality of oxygen therapy evaluated, health care worker infection) were extracted independently by 2 reviewers (A.C. and S.G.M.) using a standardized electronic form, with conflicts resolved through consensus.", [["oxygen", "CHEMICAL", 236, 242], ["infection", "DISEASE", 281, 290], ["oxygen", "CHEMICAL", 236, 242], ["patients", "ORGANISM", 206, 214], ["oxygen", "SIMPLE_CHEMICAL", 236, 242], ["patients", "SPECIES", 206, 214], ["oxygen therapy", "TREATMENT", 236, 250]]], ["For each modality of oxygen therapy, an exposed health care worker had to have been in the room in which the oxygen therapy was provided.", [["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 109, 115], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 109, 115], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 109, 115], ["oxygen therapy", "TREATMENT", 21, 35], ["the oxygen therapy", "TREATMENT", 105, 123], ["oxygen therapy", "OBSERVATION", 21, 35], ["oxygen therapy", "OBSERVATION", 109, 123]]], ["An unexposed health care worker had to have cared for patients with severe acute respiratory infection but must not have been present in the room while the studied modality of oxygen therapy was administered.", [["respiratory", "ANATOMY", 81, 92], ["acute respiratory infection", "DISEASE", 75, 102], ["oxygen", "CHEMICAL", 176, 182], ["oxygen", "CHEMICAL", 176, 182], ["patients", "ORGANISM", 54, 62], ["oxygen", "SIMPLE_CHEMICAL", 176, 182], ["patients", "SPECIES", 54, 62], ["severe acute respiratory infection", "PROBLEM", 68, 102], ["oxygen therapy", "TREATMENT", 176, 190], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory", "ANATOMY", 81, 92], ["infection", "OBSERVATION", 93, 102], ["oxygen therapy", "OBSERVATION", 176, 190]]], ["An attempt was made to contact the authors of the included articles to ensure that the abstraction and interpretation of their data were accurate and to certify that there were no duplicate data.Outcome MeasuresThe primary outcome measure was the development of a severe acute respiratory infection for health care workers.", [["respiratory", "ANATOMY", 277, 288], ["respiratory infection", "DISEASE", 277, 298], ["the abstraction", "TEST", 83, 98], ["duplicate data", "TEST", 180, 194], ["a severe acute respiratory infection", "PROBLEM", 262, 298], ["severe", "OBSERVATION_MODIFIER", 264, 270], ["acute", "OBSERVATION_MODIFIER", 271, 276], ["respiratory", "ANATOMY", 277, 288], ["infection", "OBSERVATION", 289, 298]]], ["The preferred timing of measurement was at 14 days postexposure, given the incubation period of the diseases of interest.", [["diseases", "OBSERVATION", 100, 108]]], ["2, 15 The secondary outcome measure, used for aerosol-generation models, was aerosol or exhaled air dispersion during oxygen therapy.", [["oxygen", "CHEMICAL", 118, 124], ["2, 15", "CHEMICAL", 0, 5], ["oxygen", "CHEMICAL", 118, 124], ["oxygen", "SIMPLE_CHEMICAL", 118, 124], ["aerosol-generation models", "TREATMENT", 46, 71], ["aerosol", "TREATMENT", 77, 84], ["exhaled air dispersion", "TREATMENT", 88, 110], ["oxygen therapy", "TREATMENT", 118, 132], ["air dispersion", "OBSERVATION", 96, 110], ["oxygen therapy", "OBSERVATION", 118, 132]]], ["When multiple results were presented for the same modality of oxygen therapy, the maximal dispersion distance was reported.", [["oxygen", "CHEMICAL", 62, 68], ["oxygen", "CHEMICAL", 62, 68], ["oxygen", "SIMPLE_CHEMICAL", 62, 68], ["oxygen therapy", "TREATMENT", 62, 76], ["oxygen therapy", "OBSERVATION", 62, 76]]], ["For case reports and case series, the proportion or number of health care workers infected was described separately.Outcome MeasuresThe quality assessment of all retained articles was performed by 2 independent reviewers (A.C. and S.G.M.), with conflicts resolved through consensus.", [["The quality assessment", "TEST", 132, 154]]], ["16 Articles with a score of 8 or more were considered at low risk of bias, 6 or 7 at moderate risk, and 5 or less at high risk.", [["bias", "TEST", 69, 73]]], ["Abstracts, case reports, case series, and models were considered at high risk of bias.Primary Data AnalysisFor outcomes reported in at least 3 clinical studies, results were pooled in a meta-analysis.", [["Primary Data Analysis", "TEST", 86, 107], ["clinical studies", "TEST", 143, 159], ["a meta-analysis", "TEST", 184, 199]]], ["If the I 2 was greater than 75%, the results were described only qualitatively, without a meta-analysis.", [["the I 2", "TEST", 3, 10], ["a meta-analysis", "TEST", 88, 103]]], ["A random-effect model was used to better account for the expected differences in design among the included studies.", [["A random-effect model", "TEST", 0, 21], ["studies", "TEST", 107, 114]]], ["The results are presented according to the modality of oxygen therapy provided.", [["oxygen", "CHEMICAL", 55, 61], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["oxygen therapy", "TREATMENT", 55, 69], ["oxygen therapy", "OBSERVATION", 55, 69]]], ["Results from case series, case reports, and models were not meta-analyzed and are presented after clinical results, in the appropriate subgroup of oxygen therapy.", [["oxygen", "CHEMICAL", 147, 153], ["oxygen", "CHEMICAL", 147, 153], ["oxygen", "SIMPLE_CHEMICAL", 147, 153], ["oxygen therapy", "TREATMENT", 147, 161], ["oxygen therapy", "OBSERVATION", 147, 161]]], ["Studies in which risks for different modalities of oxygen therapy or another high-risk intervention were combined were evaluated separately (mixed exposure).", [["oxygen", "CHEMICAL", 51, 57], ["oxygen", "CHEMICAL", 51, 57], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["Studies", "TEST", 0, 7], ["oxygen therapy", "TREATMENT", 51, 65], ["another high-risk intervention", "TREATMENT", 69, 99], ["oxygen therapy", "OBSERVATION", 51, 65]]], ["All results are presented with their 95% confidence intervals (CIs).Primary Data AnalysisFor each analysis in which more than 10 articles would be included, a funnel plot was constructed to assess for a publication bias.", [["Primary Data Analysis", "TEST", 68, 89], ["each analysis", "TEST", 93, 106], ["a funnel plot", "TEST", 157, 170], ["a publication bias", "TEST", 201, 219]]], ["17 When fewer than 10 articles were available, the reporting bias was assessed qualitatively.Primary Data AnalysisIn addition, 2 sets of sensitivity analyses were performed: 1 excluding articles at high risk of bias and 1 excluding studies with an n of less than 50.Primary Data AnalysisAll analyses were performed with RevMan (version 5.3; Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen, Denmark).Characteristics of Study SubjectsOf 22,123 unique citations, 50 studies were included ( Figure 1 ).", [["sensitivity analyses", "TEST", 137, 157], ["bias", "TEST", 211, 215], ["studies", "TEST", 232, 239], ["an n", "TEST", 245, 249], ["Primary Data Analysis", "TEST", 266, 287], ["All analyses", "TEST", 287, 299], ["Study", "TEST", 429, 434]]], ["A total of 16 observational studies (either cohort studies or case-control studies) reported clinical outcomes and were included in the meta-analysis (cohort studies 8; case-control studies 8).", [["16 observational studies", "TEST", 11, 35], ["cohort studies", "TEST", 44, 58], ["the meta-analysis", "TEST", 132, 149], ["cohort studies", "TEST", 151, 165]]], ["An additional 14 case reports or series and 20 studies reporting on aerosol or droplet dispersion were included in the systematic review.", [["20 studies", "TEST", 44, 54], ["aerosol or droplet dispersion", "TREATMENT", 68, 97]]], ["Most of the 30 clinical studies described the risk of transmission of severe acute respiratory syndrome (n\u00bc18; 60%) or influenza virus (n\u00bc7; 23%).", [["acute respiratory syndrome", "DISEASE", 77, 103], ["influenza virus", "DISEASE", 119, 134], ["influenza virus", "ORGANISM", 119, 134], ["influenza virus", "SPECIES", 119, 134], ["clinical studies", "TEST", 15, 31], ["severe acute respiratory syndrome", "PROBLEM", 70, 103], ["influenza virus", "PROBLEM", 119, 134], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["respiratory syndrome", "OBSERVATION", 83, 103]]], ["Given the recent emergence of COVID-19, only 3 studies (10%) evaluated the infection of health care workers by the virus.", [["infection", "DISEASE", 75, 84], ["COVID", "TEST", 30, 35], ["infection", "OBSERVATION", 75, 84]]], ["A total of 16 studies presented results regarding intubation, 5 for bag-valvemask manual ventilation, 22 for noninvasive ventilation, 9 for high-flow nasal cannula, 11 for face mask with or without reservoir, and 4 for nasal cannula.", [["nasal", "ANATOMY", 150, 155], ["face", "ANATOMY", 172, 176], ["nasal", "ANATOMY", 219, 224], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 150, 163], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 219, 232], ["16 studies", "TEST", 11, 21], ["intubation", "TREATMENT", 50, 60], ["bag-valvemask manual ventilation", "TREATMENT", 68, 100], ["noninvasive ventilation", "TREATMENT", 109, 132], ["high-flow nasal cannula", "TREATMENT", 140, 163], ["face mask", "TREATMENT", 172, 181], ["reservoir", "TREATMENT", 198, 207], ["nasal cannula", "TREATMENT", 219, 232], ["nasal cannula", "ANATOMY", 219, 232]]], ["Three studies reported outcomes with the use of more than one modality of oxygen therapy or in combination with another high-risk intervention.", [["oxygen", "CHEMICAL", 74, 80], ["oxygen", "CHEMICAL", 74, 80], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["Three studies", "TEST", 0, 13], ["oxygen therapy", "TREATMENT", 74, 88], ["another high-risk intervention", "TREATMENT", 112, 142]]], ["The individual characteristics of the 50 studies included are presented in the Table.", [["the 50 studies", "TEST", 34, 48]]], ["All included studies were considered at moderate (n\u00bc4) or high (n\u00bc46) risk of bias and globally provided a very low certainty of evidence (Table E2 , available online at http://www. annemergmed.com).", [["All included studies", "TEST", 0, 20], ["high (n\u00bc46) risk of bias", "PROBLEM", 58, 82]]], ["One article described the odds of having a superspreading event (3 nosocomial cases or more) in a hospital.", [["a superspreading event", "PROBLEM", 41, 63]]], ["[19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30]Main ResultsA total of 2,675 health care workers (10% exposed, 14% infected) were included in the 12 observational studies in the meta-analysis assessing the risk of intubation (Table E3 , available online at http://www.annemergmed. com).", [["[19] [20] [21] [22", "CHEMICAL", 0, 18], ["[19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29", "SIMPLE_CHEMICAL", 0, 53], ["E3", "PROTEIN", 243, 245], ["the meta-analysis", "TEST", 185, 202]]], ["18, 24, 27, 28, [31] [32] [33] [34] [35] [36] [37] [38] In these studies, there was an association between being present at the intubation and the risk of infection among health care workers.", [["infection", "DISEASE", 155, 164], ["24, 27, 28, [31] [32] [33] [34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 4, 55], ["these studies", "TEST", 59, 72], ["the intubation", "TREATMENT", 124, 138], ["infection", "PROBLEM", 155, 164], ["infection", "OBSERVATION", 155, 164]]], ["The summary estimate for these studies yielded an OR of 5.34 (95% CI 2.44 to 11.68), with high statistical heterogeneity (I 2 \u00bc 71%) ( Figure E1 , available online at http://www. annemergmed.com).", [["these studies", "TEST", 25, 38], ["CI", "TEST", 66, 68], ["high statistical heterogeneity", "PROBLEM", 90, 120], ["Figure E1", "TEST", 135, 144]]], ["The results presented in the study by Teleman et al 38 , and no answer was received from the authors to explain that difference.", [["the study", "TEST", 25, 34]]], ["The summary estimate for the 11 remaining studies yielded an OR of 6.48 (95% CI 2.90 to 14.44), with high statistical heterogeneity (I 2 \u00bc 71%) (Figure 2 ).", [["CI", "TEST", 77, 79], ["high statistical heterogeneity", "PROBLEM", 101, 131]]], ["The results of one aerosol dispersion model pertaining to the performance of an intubation are presented in Appendix E2 and Table E3 , available online at http://www.annemergmed.com.Main ResultsA total of 693 health care workers (18% exposed, 5% infected) were included in the 3 observational studies in the meta-analysis assessing the risk of bag-valve-mask ventilation (Table E4 , available online at http://www. annemergmed.com).", [["E3", "PROTEIN", 130, 132], ["one aerosol dispersion", "TREATMENT", 15, 37], ["an intubation", "TREATMENT", 77, 90], ["bag-valve", "TREATMENT", 344, 353], ["mask ventilation", "TREATMENT", 354, 370], ["Appendix", "ANATOMY", 108, 116], ["valve", "ANATOMY", 348, 353]]], ["24, 27, 33 In these studies, there was an association between bag-valve-mask ventilation and the risk of infection among health care workers.", [["infection", "DISEASE", 105, 114], ["these studies", "TEST", 14, 27], ["bag-valve", "TREATMENT", 62, 71], ["mask ventilation", "TREATMENT", 72, 88], ["infection", "PROBLEM", 105, 114], ["valve", "ANATOMY", 66, 71], ["mask ventilation", "OBSERVATION", 72, 88], ["infection", "OBSERVATION", 105, 114]]], ["The summary estimate for these studies yielded an OR of 2.70 (95% CI 1.31 to 5.56), with no statistical heterogeneity (I 2 \u00bc 0%) Figure 3 ).", [["these studies", "TEST", 25, 38], ["CI", "TEST", 66, 68], ["statistical heterogeneity", "PROBLEM", 92, 117], ["no", "UNCERTAINTY", 89, 91], ["heterogeneity", "OBSERVATION", 104, 117]]], ["The results of 2 aerosol dispersion models pertaining to the use of bag-valve-mask ventilation are presented in Appendix E2 and Table E4 , available online at http://www.annemergmed.com.", [["2 aerosol dispersion models", "TREATMENT", 15, 42], ["bag-valve", "TREATMENT", 68, 77], ["mask ventilation", "TREATMENT", 78, 94], ["valve", "ANATOMY", 72, 77], ["Appendix", "ANATOMY", 112, 120]]], ["A total of 942 health care workers (25% exposed, 5% infected) were included in the 9 observational studies in the meta-analysis assessing the risk of being exposed to noninvasive ventilation (Table E5 , available online at http://www.annemergmed.com).", [["noninvasive ventilation", "TREATMENT", 167, 190]]], ["18, 24, 27, 28, 32, 33, 35, 37, 39 Subgroups were created depending on the specific exposure of health care workers (BiPAP, noninvasive ventilation [undefined] , and BiPAP mask manipulation).", [["BiPAP", "TREATMENT", 117, 122], ["noninvasive ventilation", "TREATMENT", 124, 147], ["BiPAP mask manipulation", "TREATMENT", 166, 189]]], ["Overall, there was an association between being exposed to noninvasive ventilation and the infection risk among health care workers.", [["infection", "DISEASE", 91, 100], ["noninvasive ventilation", "TREATMENT", 59, 82], ["infection", "OBSERVATION", 91, 100]]], ["The summary estimate for these studies yielded an OR of 3.96 (95% CI 2.12 to 7.40), with no statistical heterogeneity (I 2 \u00bc 0%) (Figure 4 ).", [["these studies", "TEST", 25, 38], ["CI", "TEST", 66, 68], ["statistical heterogeneity", "PROBLEM", 92, 117], ["no", "UNCERTAINTY", 89, 91], ["heterogeneity", "OBSERVATION", 104, 117]]], ["The results of 6 case series and 6 aerosol or droplet dispersion models pertaining to the use of noninvasive ventilation are presented in Appendix E2 and Table E5 , available online at http://www.annemergmed.com.Main ResultsNo observational studies reported on the use of highflow nasal cannula.", [["nasal", "ANATOMY", 281, 286], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 281, 294], ["6 aerosol", "TREATMENT", 33, 42], ["droplet dispersion models", "TREATMENT", 46, 71], ["noninvasive ventilation", "TREATMENT", 97, 120], ["observational studies", "TEST", 227, 248], ["highflow nasal cannula", "TREATMENT", 272, 294], ["Appendix", "ANATOMY", 138, 146]]], ["The results of 2 case series and 7 aerosol or droplet dispersion models pertaining to the use of highflow nasal cannula are presented in Appendix E2 and Table E6 , available online at http://www.annemergmed. com.Main ResultsSeven observational studies reported on the use of conventional oxygen therapy (Table E7 , available online at http://www.annemergmed.com).", [["nasal", "ANATOMY", 106, 111], ["oxygen", "CHEMICAL", 288, 294], ["oxygen", "CHEMICAL", 288, 294], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 106, 119], ["oxygen", "SIMPLE_CHEMICAL", 288, 294], ["7 aerosol or droplet dispersion models", "TREATMENT", 33, 71], ["highflow nasal cannula", "TREATMENT", 97, 119], ["observational studies", "TEST", 230, 251], ["conventional oxygen therapy", "TREATMENT", 275, 302], ["nasal cannula", "ANATOMY", 106, 119], ["Appendix", "ANATOMY", 137, 145]]], ["18, 24, 27, 33, 38, 40, 41 It was decided not to perform a meta-analysis because of the uncertainty of the specific exposure for most of these studies and the overlapping data.", [["a meta-analysis", "TEST", 57, 72], ["these studies", "TEST", 137, 150], ["the overlapping data", "TEST", 155, 175]]], ["In one study, Yu et al 18 observed an increased risk of a superspreading event in a ward when oxygen was administered with a face mask at more than 6 L/min (OR\u00bc7.08 [95% CI 1.30 to 38.42] ).", [["oxygen", "CHEMICAL", 94, 100], ["oxygen", "CHEMICAL", 94, 100], ["oxygen", "SIMPLE_CHEMICAL", 94, 100], ["one study", "TEST", 3, 12], ["oxygen", "TREATMENT", 94, 100], ["a face mask", "TREATMENT", 123, 134], ["CI", "TEST", 170, 172], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["In the studies by Heinzerling et al 33 and Raboud et al, 24 there was no statistically significant association between being exposed to high-flow oxygen and infection among health care workers (OR\u00bc1.", [["oxygen", "CHEMICAL", 146, 152], ["infection", "DISEASE", 157, 166], ["oxygen", "CHEMICAL", 146, 152], ["oxygen", "SIMPLE_CHEMICAL", 146, 152], ["the studies", "TEST", 3, 14], ["high-flow oxygen", "TREATMENT", 136, 152], ["no", "UNCERTAINTY", 70, 72], ["flow oxygen", "OBSERVATION", 141, 152]]], ["39 24 The results of 9 aerosol dispersion models pertaining to the administration of conventional oxygen therapy are presented in Appendix E2 and Table E7 , available online at http://www. annemergmed.com.Main ResultsNo observational studies reported on the use of highflow nasal cannula.", [["nasal", "ANATOMY", 274, 279], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["E7", "ORGANISM", 152, 154], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 274, 287], ["9 aerosol dispersion models", "TREATMENT", 21, 48], ["conventional oxygen therapy", "TREATMENT", 85, 112], ["observational studies", "TEST", 220, 241], ["highflow nasal cannula", "TREATMENT", 265, 287], ["oxygen therapy", "OBSERVATION", 98, 112], ["Appendix", "ANATOMY", 130, 138]]], ["The results of 3 case series in which a mixed exposure was observed are presented in Appendix E2 and Table E8 , available online at http://www. annemergmed.com.Sensitivity AnalysesSensitivity analyses yielded no additional information.", [["a mixed exposure", "PROBLEM", 38, 54], ["Sensitivity AnalysesSensitivity analyses", "TEST", 160, 200], ["Appendix", "ANATOMY", 85, 93]]], ["The exclusion of articles at high risk of bias did not significantly influence the results regarding the exposure to intubation ( Figure E2 , available online at http://www. annemergmed.com).", [["intubation", "TREATMENT", 117, 127]]], ["Only one article remained available for the exposure to bag-valve-mask ventilation and noninvasive ventilation (Figures E3 and E4 , available online at http://www.annemergmed.com).", [["E3", "PROTEIN", 120, 122], ["E4", "PROTEIN", 127, 129], ["bag-valve", "TREATMENT", 56, 65], ["mask ventilation", "TREATMENT", 66, 82], ["noninvasive ventilation", "TREATMENT", 87, 110], ["valve", "ANATOMY", 60, 65]]], ["A publication bias might have prevented small studies without significant results regarding the exposure to intubation from being published ( Figure E5 , available online at http://www. annemergmed.com).", [["A publication bias", "TEST", 0, 18], ["small studies", "TEST", 40, 53], ["intubation", "TREATMENT", 108, 118]]], ["A publication bias might also have prevented case series with an intermediate rate of infection from being published because only 3 of the 14 case reports and series included did not report a risk of infection of either 0% or 100%.", [["infection", "DISEASE", 86, 95], ["infection", "DISEASE", 200, 209], ["A publication bias", "PROBLEM", 0, 18], ["infection", "PROBLEM", 86, 95], ["infection", "PROBLEM", 200, 209], ["infection", "OBSERVATION", 86, 95], ["infection", "OBSERVATION", 200, 209]]], ["No other evidence of a publication bias was found.LIMITATIONSThe main limitation of the present review is the quality of the studies included.", [["a publication bias", "PROBLEM", 21, 39], ["the studies", "TEST", 121, 132], ["other evidence of", "UNCERTAINTY", 3, 20], ["publication bias", "OBSERVATION", 23, 39]]], ["Most studies had significant limitations in their design and included only a small number of health care workers, of whom only a few were infected.", [["Most studies", "TEST", 0, 12], ["small", "OBSERVATION_MODIFIER", 77, 82], ["infected", "OBSERVATION", 138, 146]]], ["However, the results were consistent in the sensitivity analyses in which articles at high risk of bias were excluded.", [["the sensitivity analyses", "TEST", 40, 64], ["bias", "PROBLEM", 99, 103]]], ["Some studies did not report any infection, which prevented the calculation of an OR.", [["infection", "DISEASE", 32, 41], ["Some studies", "TEST", 0, 12], ["any infection", "PROBLEM", 28, 41], ["infection", "OBSERVATION", 32, 41]]], ["Most of the clinical studies that were included described the risk of severe acute respiratory syndrome transmission.", [["respiratory", "ANATOMY", 83, 94], ["acute respiratory syndrome transmission", "DISEASE", 77, 116], ["the clinical studies", "TEST", 8, 28], ["severe acute respiratory syndrome transmission", "PROBLEM", 70, 116], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["respiratory syndrome", "OBSERVATION", 83, 103]]], ["Other severe acute respiratory infections might have a different predisposition of transmission and this limits the generalizability of the presented results to the current COVID-19 pandemic.", [["respiratory", "ANATOMY", 19, 30], ["acute respiratory infections", "DISEASE", 13, 41], ["Other severe acute respiratory infections", "PROBLEM", 0, 41], ["the current COVID", "TEST", 161, 178], ["pandemic", "PROBLEM", 182, 190], ["severe", "OBSERVATION_MODIFIER", 6, 12], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["respiratory", "ANATOMY", 19, 30], ["infections", "OBSERVATION", 31, 41]]], ["In addition, it is possible that improvement in technical aspects of oxygen therapy (eg, video-assisted rapid sequence intubation, double-limb circuit noninvasive ventilation) could decrease the risk of contamination.", [["limb", "ANATOMY", 138, 142], ["oxygen", "CHEMICAL", 69, 75], ["oxygen", "CHEMICAL", 69, 75], ["oxygen", "SIMPLE_CHEMICAL", 69, 75], ["limb", "ORGANISM_SUBDIVISION", 138, 142], ["oxygen therapy", "TREATMENT", 69, 83], ["video-assisted rapid sequence intubation", "TREATMENT", 89, 129], ["double-limb circuit noninvasive ventilation", "TREATMENT", 131, 174], ["contamination", "PROBLEM", 203, 216], ["is possible", "UNCERTAINTY", 16, 27], ["improvement", "OBSERVATION_MODIFIER", 33, 44], ["oxygen therapy", "OBSERVATION", 69, 83], ["contamination", "OBSERVATION", 203, 216]]], ["Although every author was contacted to validate that there were no repeated data, it remains possible that some health care workers were included in multiple studies that were conducted at the same site.", [["multiple studies", "TEST", 149, 165]]], ["There were no clinical data for some modalities of oxygen therapy, which prevented the realization of a meta-analysis and left some conclusions relying on indirect data.", [["oxygen", "CHEMICAL", 51, 57], ["oxygen", "CHEMICAL", 51, 57], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["clinical data", "TEST", 14, 27], ["oxygen therapy", "TREATMENT", 51, 65], ["a meta-analysis", "TEST", 102, 117], ["indirect data", "TEST", 155, 168], ["no", "UNCERTAINTY", 11, 13], ["oxygen therapy", "OBSERVATION", 51, 65]]], ["Finally, it is probable that the presented results were confounded to some extent by the increased disease severity and contagiousness of the patients requiring oxygen therapy, the type of personal protective equipment used by health care workers, and the infection control training they received.DISCUSSIONIn this systematic review and meta-analysis, it was observed that exposure to intubation, bag-valve-mask ventilation, and noninvasive ventilation was associated with an increased risk of severe acute respiratory infection for health care workers.", [["respiratory", "ANATOMY", 507, 518], ["oxygen", "CHEMICAL", 161, 167], ["infection", "DISEASE", 256, 265], ["acute respiratory infection", "DISEASE", 501, 528], ["oxygen", "CHEMICAL", 161, 167], ["patients", "ORGANISM", 142, 150], ["oxygen", "SIMPLE_CHEMICAL", 161, 167], ["patients", "SPECIES", 142, 150], ["the increased disease severity", "PROBLEM", 85, 115], ["oxygen therapy", "TREATMENT", 161, 175], ["personal protective equipment", "TREATMENT", 189, 218], ["the infection control training", "TREATMENT", 252, 282], ["intubation", "TREATMENT", 385, 395], ["bag-valve", "TREATMENT", 397, 406], ["mask ventilation", "TREATMENT", 407, 423], ["noninvasive ventilation", "TREATMENT", 429, 452], ["severe acute respiratory infection", "PROBLEM", 494, 528], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["disease", "OBSERVATION", 99, 106], ["oxygen therapy", "OBSERVATION", 161, 175], ["valve", "ANATOMY", 401, 406], ["mask ventilation", "OBSERVATION", 407, 423], ["increased", "OBSERVATION_MODIFIER", 476, 485], ["severe", "OBSERVATION_MODIFIER", 494, 500], ["acute", "OBSERVATION_MODIFIER", 501, 506], ["respiratory", "ANATOMY", 507, 518], ["infection", "OBSERVATION", 519, 528]]], ["No clinical studies assessed the risk associated with the use of high-flow nasal cannula.", [["nasal", "ANATOMY", 75, 80], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 75, 88], ["clinical studies", "TEST", 3, 19], ["high-flow nasal cannula", "TREATMENT", 65, 88], ["nasal cannula", "OBSERVATION", 75, 88]]], ["The provision of conventional oxygen therapy was generally associated with an increased risk of infection even though no meta-analysis was performed, given the uncertainty of the specific exposure, the overlapping data between some studies, and the various study designs.", [["oxygen", "CHEMICAL", 30, 36], ["infection", "DISEASE", 96, 105], ["oxygen", "CHEMICAL", 30, 36], ["oxygen", "SIMPLE_CHEMICAL", 30, 36], ["conventional oxygen therapy", "TREATMENT", 17, 44], ["infection", "PROBLEM", 96, 105], ["meta-analysis", "TEST", 121, 134], ["some studies", "TEST", 227, 239], ["the various study", "TEST", 245, 262], ["oxygen therapy", "OBSERVATION", 30, 44], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["infection", "OBSERVATION", 96, 105]]], ["Most models described significant air or droplet dispersion for all modalities of oxygen therapy.", [["oxygen", "CHEMICAL", 82, 88], ["oxygen", "CHEMICAL", 82, 88], ["oxygen", "SIMPLE_CHEMICAL", 82, 88], ["significant air", "PROBLEM", 22, 37], ["droplet dispersion", "TREATMENT", 41, 59], ["oxygen therapy", "TREATMENT", 82, 96], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["air", "OBSERVATION", 34, 37], ["droplet dispersion", "OBSERVATION", 41, 59], ["oxygen therapy", "OBSERVATION", 82, 96]]], ["However, most models measuring specifically the quantity of aerosol generated did not observe a significant increase.DISCUSSIONThe greatest risk factor for contracting a severe acute respiratory infection is probably performing or being exposed to an intubation.", [["respiratory", "ANATOMY", 183, 194], ["respiratory infection", "DISEASE", 183, 204], ["a significant increase", "PROBLEM", 94, 116], ["a severe acute respiratory infection", "PROBLEM", 168, 204], ["an intubation", "TREATMENT", 248, 261], ["most models", "OBSERVATION_MODIFIER", 9, 20], ["quantity", "OBSERVATION_MODIFIER", 48, 56], ["significant", "OBSERVATION_MODIFIER", 96, 107], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["greatest", "OBSERVATION_MODIFIER", 131, 139], ["severe", "OBSERVATION_MODIFIER", 170, 176], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["respiratory", "ANATOMY", 183, 194], ["infection", "OBSERVATION", 195, 204], ["intubation", "OBSERVATION", 251, 261]]], ["8 Despite the high heterogeneity in the analysis, the consistency of this finding throughout studies that observed at least some infections, with the exception of the study by Teleman et al, 38 adds some strength to that observation.", [["infections", "DISEASE", 129, 139], ["the high heterogeneity", "PROBLEM", 10, 32], ["the analysis", "TEST", 36, 48], ["some infections", "PROBLEM", 124, 139], ["the study", "TEST", 163, 172], ["high heterogeneity", "OBSERVATION_MODIFIER", 14, 32], ["infections", "OBSERVATION", 129, 139]]], ["As described earlier, it is possible that there was a statistical error in that study, given the discrepancy in the OR that was presented by the authors and the OR calculated from their results.", [["that study", "TEST", 75, 85]]], ["The observed association is likely caused by the fact that intubation requires some proximity to the patient's airway.", [["airway", "ANATOMY", 111, 117], ["patient", "ORGANISM", 101, 108], ["airway", "MULTI-TISSUE_STRUCTURE", 111, 117], ["patient", "SPECIES", 101, 108], ["intubation", "TREATMENT", 59, 69], ["is likely caused", "UNCERTAINTY", 25, 41], ["intubation", "OBSERVATION", 59, 69], ["airway", "ANATOMY", 111, 117]]], ["Other interventions putting health care workers at risk (high-flow oxygen, airway suctioning, bag-valve-mask ventilation, chest compressions, etc) are also often performed in the context of intubation and might not have been reported while still contributing to the burden of infection associated with this procedure.", [["airway", "ANATOMY", 75, 81], ["chest", "ANATOMY", 122, 127], ["oxygen", "CHEMICAL", 67, 73], ["infection", "DISEASE", 276, 285], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["airway", "MULTI-TISSUE_STRUCTURE", 75, 81], ["high-flow oxygen", "TREATMENT", 57, 73], ["airway suctioning", "TREATMENT", 75, 92], ["bag-valve", "TREATMENT", 94, 103], ["mask ventilation", "TREATMENT", 104, 120], ["chest compressions", "TREATMENT", 122, 140], ["intubation", "TREATMENT", 190, 200], ["infection", "PROBLEM", 276, 285], ["this procedure", "TREATMENT", 302, 316], ["airway", "ANATOMY", 75, 81], ["valve", "ANATOMY", 98, 103], ["chest", "ANATOMY", 122, 127], ["infection", "OBSERVATION", 276, 285]]], ["42, 43 Intubation is also frequently provided urgently for acutely ill patients, who might have higher contagiousness than their counterparts with milder symptoms.", [["acutely ill", "DISEASE", 59, 70], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Intubation", "TREATMENT", 7, 17], ["higher contagiousness", "PROBLEM", 96, 117], ["milder symptoms", "PROBLEM", 147, 162]]], ["Likewise, the mental burden and stress associated with performing the intubation could increase the odds of self-contaminating during or after the procedure.DISCUSSIONBag-valve-mask ventilation or noninvasive ventilation was also associated with a significantly higher risk of contagion.", [["the mental burden", "PROBLEM", 10, 27], ["stress", "PROBLEM", 32, 38], ["the intubation", "TREATMENT", 66, 80], ["the procedure", "TREATMENT", 143, 156], ["valve-mask ventilation", "TREATMENT", 171, 193], ["noninvasive ventilation", "TREATMENT", 197, 220], ["valve", "ANATOMY", 171, 176], ["mask ventilation", "OBSERVATION", 177, 193], ["contagion", "OBSERVATION", 277, 286]]], ["There was less evidence to support these findings than for intubation.", [["intubation", "TREATMENT", 59, 69]]], ["The same factors as those involved in intubation support these associations.", [["intubation", "TREATMENT", 38, 48]]], ["In addition, for noninvasive ventilation, the high flow and pressure of the oxygen delivered can generate jets of air and droplets, which could easily facilitate transmission of the disease.", [["oxygen", "CHEMICAL", 76, 82], ["oxygen", "CHEMICAL", 76, 82], ["oxygen", "SIMPLE_CHEMICAL", 76, 82], ["noninvasive ventilation", "TREATMENT", 17, 40], ["the high flow", "TREATMENT", 42, 55], ["the oxygen", "TREATMENT", 72, 82], ["jets of air and droplets", "PROBLEM", 106, 130], ["the disease", "PROBLEM", 178, 189], ["high flow", "OBSERVATION", 46, 55], ["air", "OBSERVATION", 114, 117], ["disease", "OBSERVATION", 182, 189]]], ["44 No clinical evidence was available for the use of high-flow nasal cannula.", [["nasal", "ANATOMY", 63, 68], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 63, 76], ["high-flow nasal cannula", "TREATMENT", 53, 76], ["nasal cannula", "OBSERVATION", 63, 76]]], ["One case report and one case series reported no health care worker infection with the use of this modality while patients with severe acute respiratory infection were treated.", [["respiratory", "ANATOMY", 140, 151], ["infection", "DISEASE", 67, 76], ["acute respiratory infection", "DISEASE", 134, 161], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["this modality", "TREATMENT", 93, 106], ["severe acute respiratory infection", "PROBLEM", 127, 161], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory", "ANATOMY", 140, 151], ["infection", "OBSERVATION", 152, 161]]], ["21, 45 However, the air and droplet dispersion observed in some studies was similar to that observed for BiPAP, which is generally accepted as an aerosol-generating procedure.", [["BiPAP", "CHEMICAL", 105, 110], ["BiPAP", "CHEMICAL", 105, 110], ["BiPAP", "SIMPLE_CHEMICAL", 105, 110], ["the air and droplet dispersion", "PROBLEM", 16, 46], ["some studies", "TEST", 59, 71], ["BiPAP", "TREATMENT", 105, 110], ["an aerosol-generating procedure", "TREATMENT", 143, 174], ["air", "OBSERVATION", 20, 23], ["droplet dispersion", "OBSERVATION", 28, 46]]], ["20, 22, 44 Given the observed results for other oxygenation modalities, it remains possible that contamination risk is significant when patients with severe acute respiratory infection are treated with high-flow nasal cannula.DISCUSSIONThere was also no clinical evidence, except for higher flows of oxygen, for infection with the use of conventional oxygen therapy by face mask or nasal cannula.", [["respiratory", "ANATOMY", 163, 174], ["nasal", "ANATOMY", 212, 217], ["face", "ANATOMY", 369, 373], ["nasal", "ANATOMY", 382, 387], ["acute respiratory infection", "DISEASE", 157, 184], ["oxygen", "CHEMICAL", 300, 306], ["infection", "DISEASE", 312, 321], ["oxygen", "CHEMICAL", 351, 357], ["oxygen", "CHEMICAL", 300, 306], ["oxygen", "CHEMICAL", 351, 357], ["patients", "ORGANISM", 136, 144], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 212, 225], ["oxygen", "SIMPLE_CHEMICAL", 300, 306], ["oxygen", "SIMPLE_CHEMICAL", 351, 357], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 382, 395], ["patients", "SPECIES", 136, 144], ["other oxygenation modalities", "TREATMENT", 42, 70], ["contamination risk", "PROBLEM", 97, 115], ["severe acute respiratory infection", "PROBLEM", 150, 184], ["high-flow nasal cannula", "TREATMENT", 202, 225], ["higher flows of oxygen", "TREATMENT", 284, 306], ["infection", "PROBLEM", 312, 321], ["conventional oxygen therapy", "TREATMENT", 338, 365], ["face mask", "TREATMENT", 369, 378], ["nasal cannula", "TREATMENT", 382, 395], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["respiratory", "ANATOMY", 163, 174], ["infection", "OBSERVATION", 175, 184], ["nasal cannula", "OBSERVATION", 212, 225], ["infection", "OBSERVATION", 312, 321], ["nasal cannula", "OBSERVATION", 382, 395]]], ["Air dispersion distance observed for nasal cannula at 5 L/min was, on some occasions, as high as the distance observed for BiPAP.", [["nasal", "ANATOMY", 37, 42], ["BiPAP", "CHEMICAL", 123, 128], ["BiPAP", "CHEMICAL", 123, 128], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 37, 50], ["BiPAP", "PROTEIN", 123, 128], ["Air dispersion distance", "PROBLEM", 0, 23], ["nasal cannula", "TREATMENT", 37, 50], ["BiPAP", "TREATMENT", 123, 128], ["nasal", "ANATOMY", 37, 42], ["cannula", "ANATOMY_MODIFIER", 43, 50]]], ["22, 44, 46 The various air dispersion distances observed at the same flow were likely caused by a complex interaction between the patient's physiognomy, the precise positioning of the nasal cannula, and the room configuration and ventilation.", [["nasal", "ANATOMY", 184, 189], ["patient", "ORGANISM", 130, 137], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 184, 197], ["patient", "SPECIES", 130, 137], ["The various air dispersion distances", "PROBLEM", 11, 47], ["a complex interaction between the patient's physiognomy", "PROBLEM", 96, 151], ["the nasal cannula", "TREATMENT", 180, 197], ["ventilation", "TREATMENT", 230, 241], ["various", "OBSERVATION_MODIFIER", 15, 22], ["air dispersion", "OBSERVATION", 23, 37], ["flow", "OBSERVATION_MODIFIER", 69, 73], ["likely caused", "UNCERTAINTY", 79, 92], ["complex", "OBSERVATION_MODIFIER", 98, 105], ["interaction", "OBSERVATION", 106, 117], ["nasal cannula", "ANATOMY", 184, 197]]], ["22, 44, 46 Nasal cannulae, especially at higher flows, have the potential to at least disperse naturally occurring aerosols and could even generate some aerosols in particular settings.", [["Nasal cannulae", "MULTI-TISSUE_STRUCTURE", 11, 25], ["Nasal cannulae", "TREATMENT", 11, 25]]], ["At a similar flow, air dispersion distances were generally lower when a face mask was used rather than a nasal cannula.", [["face", "ANATOMY", 72, 76], ["nasal", "ANATOMY", 105, 110], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 105, 118], ["air dispersion distances", "PROBLEM", 19, 43], ["a face mask", "TREATMENT", 70, 81], ["a nasal cannula", "TREATMENT", 103, 118], ["similar", "OBSERVATION_MODIFIER", 5, 12], ["flow", "OBSERVATION", 13, 17], ["air dispersion", "OBSERVATION", 19, 33], ["lower", "OBSERVATION_MODIFIER", 59, 64], ["nasal cannula", "OBSERVATION", 105, 118]]], ["At a similar oxygen flow, these distances also seemed to be higher with venturi masks in comparison with simple or nonrebreather masks.", [["oxygen", "CHEMICAL", 13, 19], ["oxygen", "CHEMICAL", 13, 19], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["venturi masks", "TREATMENT", 72, 85], ["simple or nonrebreather masks", "TREATMENT", 105, 134], ["oxygen flow", "OBSERVATION", 13, 24], ["higher", "OBSERVATION_MODIFIER", 60, 66], ["venturi masks", "OBSERVATION", 72, 85]]], ["44, 47 This is likely explained by the air entrainment that increase the total air flow for venturi masks.", [["venturi masks", "TREATMENT", 92, 105], ["likely explained", "UNCERTAINTY", 15, 31], ["air entrainment", "OBSERVATION", 39, 54], ["total", "OBSERVATION_MODIFIER", 73, 78], ["air flow", "OBSERVATION", 79, 87]]], ["The air dispersion distances observed for all types of face masks increased along with the oxygen flow.", [["oxygen", "CHEMICAL", 91, 97], ["oxygen", "CHEMICAL", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 91, 97], ["The air dispersion distances", "PROBLEM", 0, 28], ["face masks", "TREATMENT", 55, 65], ["the oxygen flow", "TREATMENT", 87, 102], ["air dispersion", "OBSERVATION", 4, 18], ["all", "OBSERVATION_MODIFIER", 42, 45], ["types", "OBSERVATION_MODIFIER", 46, 51], ["face masks", "OBSERVATION", 55, 65], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["oxygen flow", "OBSERVATION", 91, 102]]], ["44, 47 It is difficult to identify a precise cutoff that would cause aerosol generation.", [["aerosol generation", "TREATMENT", 69, 87], ["aerosol generation", "OBSERVATION", 69, 87]]], ["Yu et al 18 identified an increased risk of superspreading events when flows higher than 6 L/min were used.", [["superspreading events", "PROBLEM", 44, 65], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["superspreading events", "OBSERVATION", 44, 65]]], ["In addition, in some circumstances, with oxygen flows of 8 to 10 L/min air dispersion distances were in the range of those observed with some BiPAP settings.", [["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 41, 47], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["oxygen flows", "TEST", 41, 53], ["some BiPAP settings", "TREATMENT", 137, 156], ["oxygen flows", "OBSERVATION", 41, 53]]], ["44, 47 Because air dispersion distances are also likely affected by complex mask-patient-room interactions, oxygen flows higher than 6 L/min should be used with more caution by health care workers.", [["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 108, 114], ["patient", "ORGANISM", 81, 88], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["patient", "SPECIES", 81, 88], ["air dispersion distances", "PROBLEM", 15, 39], ["oxygen flows", "TREATMENT", 108, 120], ["air dispersion", "OBSERVATION", 15, 29], ["also likely", "UNCERTAINTY", 44, 55], ["complex", "OBSERVATION_MODIFIER", 68, 75], ["mask", "OBSERVATION", 76, 80]]], ["Oxygen delivery with a face mask could also be preferred to the use of a nasal cannula.DISCUSSIONIt remains hypothetical that any of the increased risk observed was caused by \"aerosol generation.\" 25, 48 Although some studies have reported probable aerosol transmission in wards, the main route of transmission for severe acute respiratory infection might be droplets and fomites, which are spread out when these modalities of oxygen therapy are used.", [["face", "ANATOMY", 23, 27], ["nasal", "ANATOMY", 73, 78], ["respiratory", "ANATOMY", 328, 339], ["Oxygen", "CHEMICAL", 0, 6], ["acute respiratory infection", "DISEASE", 322, 349], ["oxygen", "CHEMICAL", 427, 433], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 427, 433], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 73, 86], ["oxygen", "SIMPLE_CHEMICAL", 427, 433], ["Oxygen delivery", "TREATMENT", 0, 15], ["a face mask", "TREATMENT", 21, 32], ["a nasal cannula", "TREATMENT", 71, 86], ["some studies", "TEST", 213, 225], ["aerosol transmission", "TREATMENT", 249, 269], ["severe acute respiratory infection", "PROBLEM", 315, 349], ["fomites", "PROBLEM", 372, 379], ["oxygen therapy", "TREATMENT", 427, 441], ["severe", "OBSERVATION_MODIFIER", 315, 321], ["acute", "OBSERVATION_MODIFIER", 322, 327], ["respiratory", "ANATOMY", 328, 339], ["infection", "OBSERVATION", 340, 349], ["oxygen therapy", "OBSERVATION", 427, 441]]], ["20, 22, 23, 49, 50 It is also possible that naturally occurring aerosols can be dispersed by the flow of oxygen and contaminate health care workers more easily.", [["oxygen", "CHEMICAL", 105, 111], ["oxygen", "CHEMICAL", 105, 111], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["the flow of oxygen", "TREATMENT", 93, 111], ["also possible", "UNCERTAINTY", 25, 38]]], ["[51] [52] [53] [54] [55] The precautionary principle would suggest maximizing health care worker training and protection to the extent possible when patients with severe acute respiratory infection are treated, keeping in mind the limited quantities of such specialized equipment and the hierarchy of risk described previously.", [["respiratory", "ANATOMY", 176, 187], ["acute respiratory infection", "DISEASE", 170, 197], ["[51] [52] [53] [54] [55]", "CHEMICAL", 0, 24], ["[51] [52] [53] [54] [55]", "SIMPLE_CHEMICAL", 0, 24], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["protection", "TREATMENT", 110, 120], ["severe acute respiratory infection", "PROBLEM", 163, 197], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory", "ANATOMY", 176, 187], ["infection", "OBSERVATION", 188, 197]]], ["The present review can contribute to the complex decision facing clinicians regarding the optimal modality of oxygen therapy for patients with severe acute respiratory infection by providing a better understanding of the risk involved, which can improve health care worker safety and contribute to preserving health care system capacity, thus reducing the global morbidity associated with severe acute respiratory infection.", [["respiratory", "ANATOMY", 156, 167], ["respiratory", "ANATOMY", 402, 413], ["oxygen", "CHEMICAL", 110, 116], ["acute respiratory infection", "DISEASE", 150, 177], ["acute respiratory infection", "DISEASE", 396, 423], ["oxygen", "CHEMICAL", 110, 116], ["oxygen", "SIMPLE_CHEMICAL", 110, 116], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["oxygen therapy", "TREATMENT", 110, 124], ["severe acute respiratory infection", "PROBLEM", 143, 177], ["the global morbidity", "PROBLEM", 352, 372], ["severe acute respiratory infection", "PROBLEM", 389, 423], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["respiratory", "ANATOMY", 156, 167], ["infection", "OBSERVATION", 168, 177], ["severe", "OBSERVATION_MODIFIER", 389, 395], ["acute", "OBSERVATION_MODIFIER", 396, 401], ["respiratory", "ANATOMY", 402, 413], ["infection", "OBSERVATION", 414, 423]]], ["In general, the lowest flow of oxygen should be used to maintain an adequate oxygen saturation for patients with severe acute respiratory infection, and manipulation of oxygen delivery equipment should be minimized to limit the risk of infection among health care workers.DISCUSSIONIn summary, most modalities of oxygen therapy are associated with an increased risk of infection in health care workers and none are demonstrated as safe.", [["respiratory", "ANATOMY", 126, 137], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 77, 83], ["acute respiratory infection", "DISEASE", 120, 147], ["oxygen", "CHEMICAL", 169, 175], ["infection", "DISEASE", 236, 245], ["oxygen", "CHEMICAL", 313, 319], ["infection", "DISEASE", 369, 378], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 169, 175], ["oxygen", "CHEMICAL", 313, 319], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["oxygen", "SIMPLE_CHEMICAL", 77, 83], ["patients", "ORGANISM", 99, 107], ["oxygen", "SIMPLE_CHEMICAL", 169, 175], ["oxygen", "SIMPLE_CHEMICAL", 313, 319], ["patients", "SPECIES", 99, 107], ["oxygen", "TREATMENT", 31, 37], ["severe acute respiratory infection", "PROBLEM", 113, 147], ["manipulation of oxygen delivery equipment", "TREATMENT", 153, 194], ["infection", "PROBLEM", 236, 245], ["oxygen therapy", "TREATMENT", 313, 327], ["infection", "PROBLEM", 369, 378], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["respiratory", "ANATOMY", 126, 137], ["infection", "OBSERVATION", 138, 147], ["infection", "OBSERVATION", 236, 245], ["oxygen therapy", "OBSERVATION", 313, 327], ["increased", "OBSERVATION_MODIFIER", 351, 360], ["infection", "OBSERVATION", 369, 378]]], ["Betterdesigned studies would improve the certainty of these observations, particularly for the modalities for which clinical data were lacking.", [["these observations", "TEST", 54, 72], ["clinical data", "TEST", 116, 129]]], ["Future studies should also evaluate whether adequate protection and training can mitigate the increased risks of transmission described in the present review.", [["Future studies", "TEST", 0, 14], ["training", "TREATMENT", 68, 76], ["increased", "OBSERVATION_MODIFIER", 94, 103]]], ["All authors attest to meeting the four ICMJE.org authorship criteria: (1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND (2) Drafting the work or revising it critically for important intellectual content; AND (3) Final approval of the version to be published; AND (4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.DISCUSSIONFunding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org).", [["the acquisition", "TEST", 144, 159], ["the version", "TREATMENT", 325, 336]]], ["Accepted for publication June 17, 2020.Trial registration number: CRD42020175256The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the article; and decision to submit the article for publication.", [["CRD", "PROBLEM", 66, 69], ["the study", "TEST", 133, 142], ["analysis", "TEST", 168, 176], ["the data", "TEST", 200, 208], ["no role", "UNCERTAINTY", 96, 103]]]]}